

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
28 August 2003 (28.08.2003)

PCT


(10) International Publication Number
WO 03/070193 A2

(51) International Patent Classification ⁷ :	A61K	60/440,129	15 January 2003 (15.01.2003)	US
(21) International Application Number:	PCT/US03/05190	(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications:		
(22) International Filing Date:	20 February 2003 (20.02.2003)	US	60/398,036 (CON)	
(25) Filing Language:	English	Filed on	23 July 2002 (23.07.2002)	
(26) Publication Language:	English	US	10/225,023 (CON)	
(30) Priority Data:		Filed on	21 August 2002 (21.08.2002)	
60/358,580	20 February 2002 (20.02.2002)	US	10/157,580 (CON)	
60/363,124	11 March 2002 (11.03.2002)	US	Filed on	22 April 2002 (22.04.2002)
60/374,722	22 April 2002 (22.04.2002)	US	US	60/358,580 (CON)
10/157,580	29 May 2002 (29.05.2002)	US	Filed on	20 February 2002 (20.02.2002)
60/386,782	6 June 2002 (06.06.2002)	US	US	60/363,124 (CON)
60/398,036	23 July 2002 (23.07.2002)	US	Filed on	11 March 2002 (11.03.2002)
10/225,023	21 August 2002 (21.08.2002)	US	US	60/386,782 (CON)
60/406,784	29 August 2002 (29.08.2002)	US	Filed on	6 June 2002 (06.06.2002)
60/408,378	5 September 2002 (05.09.2002)	US	US	60/406,784 (CON)
60/409,293	9 September 2002 (09.09.2002)	US	Filed on	29 August 2002 (29.08.2002)

[Continued on next page]

(54) Title: RNA INTERFERENCE MEDIATED INHIBITION OF HIV GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)

WO 03/070193 A2



(57) Abstract: The present invention concerns methods and reagents useful in modulating human immunodeficiency virus (HIV) gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against HIV gene expression and/or activity. The small nucleic acid molecules are useful in the treatment and diagnosis of HIV infection, AIDS, and any other disease or condition that responds to modulation of HIV expression or activity.



US	60/408,378 (CON)
Filed on	5 September 2002 (05.09.2002)
US	60/409,293 (CON)
Filed on	9 September 2002 (09.09.2002)
US	60/440,129 (CON)
Filed on	15 January 2003 (15.01.2003)

(71) Applicant (for all designated States except US): **SIRNA THERAPEUTICS, INC** [US/US]; 2950 Wilderness Place, Boulder, CO 80301 (US).

(71) Applicant and

(72) Inventor (for US only): **MCSWIGGEN, James** [US/US]; 4866 Franklin Drive, Boulder, CO 80301 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BEIGELMAN, Leonid** [US/US]; 5530 Colt Drive, Longmont, CO 80503 (US). **MACEJAK, Dennis** [US/US]; 6595 Union Street, Arvada, CO 80004 (US).

(74) Agent: **TERPSTRA, Anita, J.**; McDonnell Boehnen Hulbert & Berghoff, 300 South Wacker Drive, Suite 3200, Chicago, IL 60606 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

**RNA INTERFERENCE MEDIATED INHIBITION OF HIV GENE EXPRESSION
USING SHORT INTERFERING NUCLEIC ACID (siNA)**

This invention claims the benefit of McSwiggen, USSN 60/398,036 filed July 23, 2002, of McSwiggen, USSN 10/225,023 filed August 21, 2002, of McSwiggen, USSN 5 10/157,580 filed May 29, 2002, which claims the benefit of McSwiggen USSN 60/294,140 filed May 29, 2001, of McSwiggen USSN 60/374,722 filed April 22, 2002, of Beigelman USSN 60/358,580 filed February 20, 2002, of Beigelman USSN 60/363,124 filed March 11, 2002, of Beigelman USSN 60/386,782 filed June 6, 2002, of Beigelman USSN 60/406,784 filed August 29, 2002, of Beigelman USSN 60/408,378 10 filed September 5, 2002, of Beigelman USSN 60/409,293 filed September 9, 2002, and of Beigelman USSN 60/440,129 filed January 15, 2003. These applications are hereby incorporated by reference herein in their entireties, including the drawings.

Field Of The Invention

The present invention concerns compounds, compositions, and methods for the 15 study, diagnosis, and treatment of conditions and diseases that respond to the modulation of human immunodeficiency virus (HIV) gene expression and/or activity. The present invention also concerns compounds, compositions, and methods relating to conditions and diseases that respond to the modulation of expression and/or activity of genes involved in human immunodeficiency virus (HIV) expression and activity pathways. 20 Specifically, the invention relates to small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against HIV gene expression.

Background Of The Invention

25 The following is a discussion of relevant art pertaining to RNAi. The discussion is provided only for understanding of the invention that follows. The summary is not an admission that any of the work described below is prior art to the claimed invention.

RNA interference refers to the process of sequence-specific post-transcriptional 30 gene silencing in animals mediated by short interfering RNAs (siRNAs) (Fire *et al.*, 1998, *Nature*, 391, 806). The corresponding process in plants is commonly referred to as

post-transcriptional gene silencing or RNA silencing and is also referred to as quelling in fungi. The process of post-transcriptional gene silencing is thought to be an evolutionarily-conserved cellular defense mechanism used to prevent the expression of foreign genes and is commonly shared by diverse flora and phyla (Fire *et al.*, 1999, 5 *Trends Genet.*, 15, 358). Such protection from foreign gene expression may have evolved in response to the production of double-stranded RNAs (dsRNAs) derived from viral infection or from the random integration of transposon elements into a host genome via a cellular response that specifically destroys homologous single-stranded RNA or viral genomic RNA. The presence of dsRNA in cells triggers the RNAi response 10 though a mechanism that has yet to be fully characterized. This mechanism appears to be different from the interferon response that results from dsRNA-mediated activation of protein kinase PKR and 2',5'-oligoadenylate synthetase resulting in non-specific cleavage of mRNA by ribonuclease L.

The presence of long dsRNAs in cells stimulates the activity of a ribonuclease III 15 enzyme referred to as dicer. Dicer is involved in the processing of the dsRNA into short pieces of dsRNA known as short interfering RNAs (siRNAs) (Berstein *et al.*, 2001, *Nature*, 409, 363). Short interfering RNAs derived from dicer activity are typically about 21 to about 23 nucleotides in length and comprise about 19 base pair duplexes (Elbashir *et al.*, 2001, *Genes Dev.*, 15, 188). Dicer has also been implicated in the 20 excision of 21- and 22-nucleotide small temporal RNAs (stRNAs) from precursor RNA of conserved structure that are implicated in translational control (Hutvagner *et al.*, 2001, *Science*, 293, 834). The RNAi response also features an endonuclease complex, commonly referred to as an RNA-induced silencing complex (RISC), which mediates 25 cleavage of single-stranded RNA having sequence complementary to the antisense strand of the siRNA duplex. Cleavage of the target RNA takes place in the middle of the region complementary to the antisense strand of the siRNA duplex (Elbashir *et al.*, 2001, *Genes Dev.*, 15, 188).

RNAi has been studied in a variety of systems. Fire *et al.*, 1998, *Nature*, 391, 806, were the first to observe RNAi in *C. elegans*. Wianny and Goetz, 1999, *Nature Cell 30 Biol.*, 2, 70, describe RNAi mediated by dsRNA in mouse embryos. Hammond *et al.*, 2000, *Nature*, 404, 293, describe RNAi in *Drosophila* cells transfected with dsRNA. Elbashir *et al.*, 2001, *Nature*, 411, 494, describe RNAi induced by introduction of

duplexes of synthetic 21-nucleotide RNAs in cultured mammalian cells including human embryonic kidney and HeLa cells. Recent work in *Drosophila* embryonic lysates (Elbashir *et al.*, 2001, *EMBO J.*, 20, 6877) has revealed certain requirements for siRNA length, structure, chemical composition, and sequence that are essential to mediate 5 efficient RNAi activity. These studies have shown that 21-nucleotide siRNA duplexes are most active when containing 3'-terminal dinucleotide overhangs. Furthermore, complete substitution of one or both siRNA strands with 2'-deoxy (2'-H) or 2'-O-methyl nucleotides abolishes RNAi activity, whereas substitution of the 3'-terminal siRNA overhang nucleotides with 2'-deoxy nucleotides (2'-H) was shown to be tolerated. Single 10 mismatch sequences in the center of the siRNA duplex were also shown to abolish RNAi activity. In addition, these studies also indicate that the position of the cleavage site in the target RNA is defined by the 5'-end of the siRNA guide sequence rather than the 3'-end of the guide sequence (Elbashir *et al.*, 2001, *EMBO J.*, 20, 6877). Other studies have indicated that a 5'-phosphate on the target-complementary strand of a siRNA duplex is 15 required for siRNA activity and that ATP is utilized to maintain the 5'-phosphate moiety on the siRNA (Nykanen *et al.*, 2001, *Cell*, 107, 309).

Studies have shown that replacing the 3'-terminal nucleotide overhanging segments of a 21-mer siRNA duplex having two -nucleotide 3'-overhangs with deoxyribonucleotides does not have an adverse effect on RNAi activity. Replacing up to 20 four nucleotides on each end of the siRNA with deoxyribonucleotides has been reported to be well tolerated, whereas complete substitution with deoxyribonucleotides results in no RNAi activity (Elbashir *et al.*, 2001, *EMBO J.*, 20, 6877). In addition, Elbashir *et al.*, *supra*, also report that substitution of siRNA with 2'-O-methyl nucleotides completely abolishes RNAi activity. Li *et al.*, International PCT Publication No. WO 00/44914, and 25 Beach *et al.*, International PCT Publication No. WO 01/68836 preliminarily suggest that siRNA may include modifications to either the phosphate-sugar backbone or the nucleoside to include at least one of a nitrogen or sulfur heteroatom, however, neither application postulates to what extent such modifications would be tolerated in siRNA molecules, nor provides any further guidance or examples of such modified siRNA. 30 Kreutzer *et al.*, Canadian Patent Application No. 2,359,180, also describe certain chemical modifications for use in dsRNA constructs in order to counteract activation of double-stranded RNA-dependent protein kinase PKR, specifically 2'-amino or 2'-O-methyl nucleotides, and nucleotides containing a 2'-O or 4'-C methylene bridge.

However, Kreutzer *et al.* similarly fails to provide examples or guidance as to what extent these modifications would be tolerated in siRNA molecules.

Parrish *et al.*, 2000, *Molecular Cell*, 6, 1977-1087, tested certain chemical modifications targeting the unc-22 gene in *C. elegans* using long (>25 nt) siRNA transcripts. The authors describe the introduction of thiophosphate residues into these siRNA transcripts by incorporating thiophosphate nucleotide analogs with T7 and T3 RNA polymerase and observed that RNAs with two phosphorothioate modified bases also had substantial decreases in effectiveness as RNAi. Further, Parrish *et al.* reported that phosphorothioate modification of more than two residues greatly destabilized the RNAs *in vitro* such that interference activities could not be assayed. *Id.* at 1081. The authors also tested certain modifications at the 2'-position of the nucleotide sugar in the long siRNA transcripts and found that substituting deoxynucleotides for ribonucleotides produced a substantial decrease in interference activity, especially in the case of Uridine to Thymidine and/or Cytidine to deoxy-Cytidine substitutions. *Id.* In addition, the authors tested certain base modifications, including substituting, in sense and antisense strands of the siRNA, 4-thiouracil, 5-bromouracil, 5-iodouracil, and 3-(aminoallyl)uracil for uracil, and inosine for guanosine. Whereas 4-thiouracil and 5-bromouracil substitution appeared to be tolerated, Parrish reported that inosine produced a substantial decrease in interference activity when incorporated in either strand. Parrish also reported that incorporation of 5-iodouracil and 3-(aminoallyl)uracil in the antisense strand resulted in a substantial decrease in RNAi activity as well.

The use of longer dsRNA has been described. For example, Beach *et al.*, International PCT Publication No. WO 01/68836, describes specific methods for attenuating gene expression using endogenously-derived dsRNA. Tuschl *et al.*, International PCT Publication No. WO 01/75164, describe a *Drosophila in vitro* RNAi system and the use of specific siRNA molecules for certain functional genomic and certain therapeutic applications; although Tuschl, 2001, *Chem. Biochem.*, 2, 239-245, doubts that RNAi can be used to cure genetic diseases or viral infection due to the danger of activating interferon response. Li *et al.*, International PCT Publication No. WO 00/44914, describe the use of specific dsRNAs for attenuating the expression of certain target genes. Zernicka-Goetz *et al.*, International PCT Publication No. WO 01/36646, describe certain methods for inhibiting the expression of particular genes in mammalian

cells using certain dsRNA molecules. Fire *et al.*, International PCT Publication No. WO 99/32619, describe particular methods for introducing certain dsRNA molecules into cells for use in inhibiting gene expression. Plaetinck *et al.*, International PCT Publication No. WO 00/01846, describe certain methods for identifying specific genes 5 responsible for conferring a particular phenotype in a cell using specific dsRNA molecules. Mello *et al.*, International PCT Publication No. WO 01/29058, describe the identification of specific genes involved in dsRNA-mediated RNAi. Deschamps Depaillette *et al.*, International PCT Publication No. WO 99/07409, describe specific 10 compositions consisting of particular dsRNA molecules combined with certain anti-viral agents. Waterhouse *et al.*, International PCT Publication No. 99/53050, describe certain methods for decreasing the phenotypic expression of a nucleic acid in plant cells using certain dsRNAs. Driscoll *et al.*, International PCT Publication No. WO 01/49844, describe specific DNA constructs for use in facilitating gene silencing in targeted 15 organisms.

15 Others have reported on various RNAi and gene-silencing systems. For example, Parrish *et al.*, 2000, *Molecular Cell*, 6, 1977-1087, describe specific chemically-modified siRNA constructs targeting the unc-22 gene of *C. elegans*. Grossniklaus, International PCT Publication No. WO 01/38551, describes certain methods for regulating polycomb 20 gene expression in plants using certain dsRNAs. Churikov *et al.*, International PCT Publication No. WO 01/42443, describe certain methods for modifying genetic characteristics of an organism using certain dsRNAs. Cogoni *et al.*, International PCT Publication No. WO 01/53475, describe certain methods for isolating a *Neurospora* silencing gene and uses thereof. Reed *et al.*, International PCT Publication No. WO 01/68836, describe certain methods for gene silencing in plants. Honer *et al.*, 25 International PCT Publication No. WO 01/70944, describe certain methods of drug screening using transgenic nematodes as Parkinson's Disease models using certain dsRNAs. Deak *et al.*, International PCT Publication No. WO 01/72774, describe certain *Drosophila*-derived gene products that may be related to RNAi in *Drosophila*. Arndt *et al.*, International PCT Publication No. WO 01/92513 describe certain methods for 30 mediating gene suppression by using factors that enhance RNAi. Tuschl *et al.*, International PCT Publication No. WO 02/44321, describe certain synthetic siRNA constructs. Pachuk *et al.*, International PCT Publication No. WO 00/63364, and Satishchandran *et al.*, International PCT Publication No. WO 01/04313, describe certain

methods and compositions for inhibiting the function of certain polynucleotide sequences using certain dsRNAs. Echeverri *et al.*, International PCT Publication No. WO 02/38805, describe certain *C. elegans* genes identified via RNAi. Kreutzer *et al.*, International PCT Publications Nos. WO 02/055692, WO 02/055693, and EP 1144623 5 B1 describes certain methods for inhibiting gene expression using RNAi. Graham *et al.*, International PCT Publications Nos. WO 99/49029 and WO 01/70949, and AU 4037501 describe certain vector expressed siRNA molecules. Fire *et al.*, US 6,506,559, describe certain methods for inhibiting gene expression in vitro using certain long dsRNA (greater than 25 nucleotide) constructs that mediate RNAi.

10 Acquired immunodeficiency syndrome (AIDS) is thought to be caused by infection with the human immunodeficiency virus, for example, HIV-1. Draper *et al.*, U.S. Patent Nos. 6,159,692, 5,972,704, 5,693,535, and International PCT Publication Nos. WO 93/23569 and WO 95/04818, describes enzymatic nucleic acid molecules targeting HIV. Novina *et al.*, 2002, *Nature Medicine*, 8, 681-686, describes certain siRNA constructs 15 targeting HIV-1 infection. Lee *et al.*, 2002, *Nature Biotechnology*, 19, 500-505, describes certain siRNA targeted against HIV-1 rev.

SUMMARY OF THE INVENTION

This invention relates to compounds, compositions, and methods useful for modulating the expression of genes, such as those genes associated with the development 20 or maintenance of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS), by RNA interference (RNAi), using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of HIV genes, or genes involved in HIV pathways or genes involved in HIV activity by RNA 25 interference (RNAi) using small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA 30 (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of HIV genes. A siNA of the invention can be unmodified or chemically-

modified. A siNA of the instant invention can be chemically synthesized, expressed from a vector or enzymatically synthesized. The instant invention also features various chemically-modified synthetic short interfering nucleic acid (siNA) molecules capable of modulating HIV gene expression or activity in cells by RNA interference (RNAi). The 5 use of chemically-modified siNA improves various properties of native siNA molecules through increased resistance to nuclease degradation *in vivo* and/or through improved cellular uptake. Further, contrary to earlier published studies, siNA having multiple chemical modifications retains its RNAi activity. The siNA molecules of the instant invention provide useful reagents and methods for a variety of therapeutic, diagnostic, 10 target validation, genomic discovery, genetic engineering, and pharmacogenomic applications.

In one embodiment, the invention features a double-stranded short interfering nucleic acid (siNA) molecule that inhibits replication of a human immunodeficiency virus (HIV), wherein one of the strands of the double-stranded siNA molecule is an 15 antisense strand which comprises a nucleotide sequence that is complementary to the nucleotide sequence of an HIV RNA or a portion thereof and the other strand is a sense strand which comprises a nucleotide sequence that is complementary to the nucleotide sequence of the antisense strand. In one embodiment, the HIV RNA comprises HIV-1RNA. In another embodiment, the HIV RNA comprises HIV-2 RNA.

20 In one embodiment, the invention features a double-stranded short interfering nucleic acid (siNA) molecule that inhibits replication of a human immunodeficiency virus (HIV), wherein one of the strands of the double-stranded siNA molecule is an antisense strand which comprises a nucleotide sequence that is complementary to the nucleotide sequence of an HIV RNA or a portion thereof, and the other strand is a sense 25 strand which comprises a nucleotide sequence that is complementary to the nucleotide sequence of the antisense strand, wherein a majority of the pyrimidine nucleotides present in the double-stranded siNA molecule comprises a sugar modification. In one embodiment, all of the pyrimidine nucleotides present in the double-stranded siNA molecule comprise a sugar modification. In one embodiment, each strand of the double- 30 stranded siNA molecule comprises about 19 to about 29 nucleotides and each strand comprises at least about 19 nucleotides that are complementary to the nucleotides of the other strand. In another embodiment, the double-stranded siNA molecule is assembled

from two oligonucleotide fragments, wherein one fragment comprises nucleotide sequence of the antisense strand of the siNA molecule and the second fragment comprises nucleotide sequence of the sense strand of the siNA molecule. In yet another embodiment, the sense strand of the double-stranded siNA molecule is connected to the 5 antisense strand via a linker molecule, such as a polynucleotide linker or a non-nucleotide linker. In another embodiment, any pyrimidine nucleotides (i.e., one or more or all) present in the sense strand of the double-stranded siNA molecule are 2'-deoxy-2'-fluoro pyrimidine nucleotides and any purine nucleotides (i.e., one or more or all) present in the sense region are 2'-deoxy purine nucleotides. In yet another embodiment, 10 the sense strand of the double-stranded siNA molecule comprises a 3'-end and a 5'-end, wherein a terminal cap moiety (e.g., an inverted deoxy abasic moiety) is present at the 5'-end, the 3'-end, or both of the 5' and 3' ends of the sense strand. In another embodiment, the antisense strand of the double-stranded siNA molecule comprises one or more 2'-deoxy-2'-fluoro pyrimidine nucleotides and one or more 2'-O-methyl purine nucleotides. 15 In yet another embodiment, any pyrimidine nucleotides present in the antisense strand of the double-stranded siNA molecule are 2'-deoxy-2'-fluoro pyrimidine nucleotides and any purine nucleotides present in the antisense strand are 2'-O-methyl purine nucleotides. In another embodiment, the antisense strand of the double-stranded siNA molecule comprises a phosphorothioate internucleotide linkage at the 3' end of the antisense 20 strand. In yet another embodiment, the antisense strand comprises a glyceryl modification at the 3' end of the antisense strand. In still another embodiment, the 5'-end of the antisense strand optionally includes a phosphate group.

In one embodiment, the invention features a double-stranded short interfering nucleic acid (siNA) molecule that inhibits replication of a human immunodeficiency 25 virus (HIV), wherein one of the strands of the double-stranded siNA molecule is an antisense strand which comprises a nucleotide sequence that is complementary to the nucleotide sequence of an HIV RNA or a portion thereof and the other strand is a sense strand which comprises a nucleotide sequence that is complementary to the nucleotide sequence of the antisense strand, wherein a majority of the pyrimidine nucleotides 30 present in the double-stranded siNA molecule comprises a sugar modification, and wherein each of the two strands of said siNA molecule comprises 21 nucleotides. In one embodiment, 21 nucleotides of the antisense strand are base-paired to the nucleotide sequence of the HIV RNA or a portion thereof. In another embodiment, about 19

nucleotides of the antisense strand are base-paired to the nucleotide sequence of the HIV RNA or a portion thereof. In one embodiment, each strand of the siNA molecule is base-paired to the complementary nucleotides of the other strand of the siNA molecule. In another embodiment, about 19 nucleotides of each strand of the siNA molecule are base-paired to the complementary nucleotides of the other strand of the siNA molecule and at least two 3' terminal nucleotides of each strand of the siNA molecule are not base-paired to the nucleotides of the other strand of the siNA molecule. In one embodiment, each of the two 3' terminal nucleotides of each strand of the siNA molecule that are not base-paired are 2'-deoxy-pyrimidines, such as 2'-deoxy-thymidine.

In one embodiment, the invention features a double-stranded short interfering nucleic acid (siNA) molecule that inhibits replication of a human immunodeficiency virus (HIV), wherein one of the strands of the double-stranded siNA molecule is an antisense strand which comprises a nucleotide sequence that is complementary to the nucleotide sequence of an HIV RNA or a portion thereof and the other strand is a sense strand which comprises a nucleotide sequence that is complementary to the nucleotide sequence of the antisense strand, wherein a majority of the pyrimidine nucleotides present in the double-stranded siNA molecule comprises a sugar modification and wherein the nucleotide sequence of the antisense strand or a portion thereof is complementary to a nucleotide sequence of the 5'-untranslated region of an HIV RNA or a portion thereof.

In another embodiment, the invention features a double-stranded short interfering nucleic acid (siNA) molecule that inhibits replication of a human immunodeficiency virus (HIV), wherein one of the strands of the double-stranded siNA molecule is an antisense strand which comprises a nucleotide sequence that is complementary to the nucleotide sequence of an HIV RNA or a portion thereof, and the other strand is a sense strand which comprises a nucleotide sequence that is complementary to the nucleotide sequence of the antisense strand, wherein a majority of the pyrimidine nucleotides present in the double-stranded siNA molecule comprises a sugar modification and wherein the nucleotide sequence of the antisense strand or a portion thereof is complementary to a nucleotide sequence of an HIV RNA that is present in the RNA of all HIV.

In one embodiment, the invention features a double-stranded short interfering nucleic acid (siNA) molecule that inhibits replication of a human immunodeficiency virus (HIV), wherein one of the strands of the double-stranded siNA molecule is an antisense strand which comprises nucleotide sequence that is complementary to the nucleotide sequence of an RNA encoding an HIV protein or a fragment thereof and the other strand is a sense strand which comprises a nucleotide sequence that is complementary to the nucleotide sequence of the antisense strand. In one embodiment, a majority of the pyrimidine nucleotides present in the double-stranded siNA molecule comprises a sugar modification.

In one embodiment, the nucleotide sequence of the antisense strand or a portion thereof of a siNA molecule of the invention is complementary to the nucleotide sequence of an HIV RNA or a portion thereof that is present in the RNA of all HIV strains.

In one embodiment, the invention features a pharmaceutical composition comprising a siNA molecule of the invention in an acceptable carrier or diluent.

In one embodiment, the invention features a medicament comprising an siNA molecule of the invention.

In one embodiment, the invention features an active ingredient comprising an siNA molecule of the invention.

In one embodiment, the invention features the use of a double-stranded short interfering nucleic acid (siNA) molecule that inhibits replication of a human immunodeficiency virus (HIV), wherein one of the strands of said double-stranded siNA molecule is an antisense strand which comprises a nucleotide sequence that is complementary to the nucleotide sequence of an HIV RNA or a portion thereof and the other strand is a sense strand which comprises a nucleotide sequence that is complementary to the nucleotide sequence of the antisense strand, wherein a majority of the pyrimidine nucleotides present in said double-stranded siNA molecule comprises a sugar modification.

In one embodiment, the invention features one or more siNA molecules and methods that independently or in combination modulate the expression of gene(s) encoding HIV and/or HIV polypeptides. Specifically, the present invention features

siNA molecules that modulate the expression of HIV, for example, HIV-1, HIV-2, and related viruses such as FIV-1 and SIV-1; or a specific HIV gene, for example, LTR, nef, vif, tat, or rev. In particular embodiments, the invention features nucleic acid-based molecules and methods that modulate the expression of HIV-1 encoded genes, for example Genbank Accession No. AJ302647; HIV-2 gene, for example Genbank Accession No. NC_001722; FIV-1, for example Genbank Accession No. NC_001482; SIV-1, for example Genbank Accession No. M66437; *LTR*, for example included in Genbank Accession No. AJ302647; *nef*, for example included in Genbank Accession No. AJ302647; *vif*, for example included in Genbank Accession No. AJ302647; *tat*, for example included in Genbank Accession No. AJ302647; and *rev*, for example included in Genbank Accession No. AJ302647.

In another embodiment, the invention features one or more siNA molecules and methods that independently or in combination modulate the expression of gene(s) encoding the HIV-1 envelope glycoprotein (*env*, for example, Genbank accession number NC_001802), such as to inhibit CD4 receptor mediated fusion of HIV-1. In particular, the present invention describes the selection and function of siNA molecules capable of modulating HIV-1 envelope glycoprotein expression, for example, expression of the gp120 and gp41 subunits of HIV-1 envelope glycoprotein. These siNA molecules can be used to treat diseases and disorders associated with HIV infection, or as a prophylactic measure to prevent HIV-1 infection.

In one embodiment, the invention features one or more siNA molecules and methods that independently or in combination modulate the expression of genes representing cellular targets for HIV infection, such as cellular receptors, cell surface molecules, cellular enzymes, cellular transcription factors, and/or cytokines, second messengers, and cellular accessory molecules.

Examples of such cellular receptors involved in HIV infection contemplated by the instant invention include, but are not limited to, CD4 receptors, CXCR4 (also known as Fusin; LESTR; NPY3R, e.g., Genbank Accession No. NM_003467); CCR5 (also known as CKR-5, CMKRB5, e.g., Genbank Accession No. NM_000579); CCR3 (also known as CC-CKR-3, CKR-3, CMKBR3, e.g., Genbank Accession No. NM_001837); CCR2 (also known as CCR2b, CMKBR2, e.g., Genbank Accession Nos. NM_000647 and

NM_000648); CCR1 (also known as CKR1, CMKBR1, e.g., Genbank Accession No. NM_001295); CCR4 (also known as CKR-4, e.g., Genbank Accession No. NM_005508); CCR8 (also known as ChemR1, TER1, CMKBR8, e.g., Genbank Accession No. NM_005201); CCR9 (also known as D6, e.g. Genbank Accession Nos. NM_006641 and NM_031200); CXCR2 (also known as IL-8RB, e.g., Genbank Accession No. NM_001557); STRL33 (also known as Bonzo; TYMSTR, e.g., Genbank Accession No. NM_006564); US28; V28 (also known as CMKBRL1, CX3CR1, GPR13, e.g., Genbank Accession No. NM_001337); gpr1 (also known as GPR1, e.g., Genbank Accession No. NM_005279); gpr15 (also known as BOB, GPR15, e.g., Genbank Accession No. NM_005290); Apj (also known as angiotensin-receptor-like, AGTRL1, e.g., Genbank Accession No. NM_005161); and ChemR23 receptors (e.g., Genbank Accession No. NM_004072).

Examples of cell surface molecules involved in HIV infection contemplated by the instant invention include, but are not limited to, Heparan Sulfate Proteoglycans, HSPG2 (e.g., Genbank Accession No. NM_005529); SDC2 (e.g., Genbank Accession Nos. AK025488, J04621, J04621); SDC4 (e.g., Genbank Accession No. NM_002999); GPC1 (e.g., Genbank Accession No. NM_002081); SDC3 (e.g., Genbank Accession No. NM_014654); SDC1 (e.g., Genbank Accession No. NM_002997); Galactoceramides (e.g., Genbank Accession Nos. NM_000153, NM_003360, NM_001478.2, NM_004775, and NM_004861); and Erythrocyte-expressed Glycolipids (e.g., Genbank Accession Nos. NM_003778, NM_003779, NM_003780, NM_030587, and NM_001497).

Examples of cellular enzymes involved in HIV infection contemplated by the invention include, but are not limited to, N-myristoyltransferase (NMT1, e.g., Genbank Accession No. NM_021079 and NMT2, e.g., Genbank Accession No. NM_004808); Glycosylation Enzymes (e.g., Genbank Accession Nos. NM_000303, NM_013339, NM_003358, NM_005787, NM_002408, NM_002676, NM_002435), NM_002409, NM_006122, NM_002372, NM_006699, NM_005907, NM_004479, NM_000150, NM_005216 and NM_005668); gp-160 Processing Enzymes (such as PCSK5, e.g., Genbank Accession No. NM_006200); Ribonucleotide Reductase (e.g., Genbank Accession Nos. NM_001034, NM_001033, AB036063, AB036063, AB036532, AK001965, AK001965, AK023605, AL137348, and AL137348); and Polyamine

Biosynthesis enzymes (e.g., Genbank Accession Nos. NM_002539, NM_003132 and NM_001634).

Examples of cellular transcription factors involved in HIV infection contemplated by the invention include, but are not limited to, SP-1 and NF-kappa B (such as NFKB2, 5 e.g., Genbank Accession No. NM_002502; RELA, e.g., Genbank Accession No. NM_021975; and NFKB1, e.g., Genbank Accession No. NM_003998).

Examples of cytokines and second messengers involved in HIV infection contemplated by the invention include, but are not limited to, Tumor Necrosis Factor-a (TNF-a, e.g., Genbank Accession No. NM_000594); Interleukin 1a (IL-1a, e.g., Genbank 10 Accession No. NM_000575); Interleukin 6 (IL-6, e.g., Genbank Accession No. NM_000600); Phospholipase C (PLC, e.g., Genbank Accession No. NM_000933); and Protein Kinase C (PKC, e.g., Genbank Accession No. NM_006255).

Examples of cellular accessory molecules involved in HIV infection contemplated by the invention include, but are not limited to, Cyclophilins, (such as PPID, e.g., 15 Genbank Accession No. NM_005038; PPIA, e.g., Genbank Accession No. NM_021130; PPIE, e.g., Genbank Accession No. NM_006112; PPIB, e.g., Genbank Accession No. NM_000942; PPIF, e.g., Genbank Accession No. NM_005729; PPIG, e.g., Genbank Accession No. NM_004792; and PPIC, e.g., Genbank Accession No. NM_000943); Mitogen Activated Protein Kinase (MAP-Kinase, such as MAPK1, e.g., Genbank 20 Accession Nos. NM_002745 and NM_138957); and Extracellular Signal-Regulated Kinase (ERK-Kinase).

A siNA molecule can be adapted for use to treat HIV infection or acquired immunodeficiency syndrome (AIDS). A siNA molecule can comprise a sense region and an antisense region and wherein said antisense region comprises sequence 25 complementary to a HIV RNA sequence and the sense region comprises sequence complementary to the antisense region. A siNA molecule can be assembled from two nucleic acid fragments wherein one fragment comprises the sense region and the second fragment comprises the antisense region of said siNA molecule. The sense region and antisense region can be connected via a linker molecule, including covalently connected 30 via the linker molecule. The linker molecule can be a polynucleotide linker or a non-nucleotide linker.

In one embodiment, the invention features a siNA molecule having RNAi activity against HIV-1 RNA, wherein the siNA molecule comprises a sequence complementary to any RNA having HIV-1 encoding sequence, for example, Genbank Accession No. AJ302647. In another embodiment, the invention features a siNA molecule having RNAi activity against HIV-2 RNA, wherein the siNA molecule comprises a sequence complementary to any RNA having HIV-2 encoding sequence, for example Genbank Accession No. NC_001722. In another embodiment, the invention features a siNA molecule having RNAi activity against FIV-1 RNA, wherein the siNA molecule comprises a sequence complementary to any RNA having FIV-1 encoding sequence, for example, Genbank Accession No. NC_001482. In another embodiment, the invention features a siNA molecule having RNAi activity against SIV-1 RNA, wherein the siNA molecule comprises a sequence complementary to any RNA having SIV-1 encoding sequence, for example, Genbank Accession No. M66437.

In yet another embodiment, the invention features a siNA molecule comprising a sequence complementary to a sequence comprising Genbank Accession Nos. AJ302647 (HIV-1), NC_001722 (HIV-2), NC_001482 (FIV-1) and/or M66437 (SIV-1).

The description below of the various aspects and embodiments is provided with reference to the exemplary HIV-1 gene, referred to as HIV. However, such reference is meant to be exemplary only and the various aspects and embodiments described herein are also directed to other genes which encode HIV polypeptides and/or polypeptides of similar viruses to HIV, as well as cellular targets for HIV, such as those described herein. The various aspects and embodiments are also directed to other genes that are involved in the progression, development, or maintenance of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS). Those additional genes can be analyzed for target sites using the methods described for HIV herein. Thus, the inhibition and the effects of such inhibition of the other genes can be performed as described herein. In other words, the term "HIV" as it is defined herein below and recited in the described embodiments, is meant to encompass genes associated with the development or maintenance of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS), such as genes which encode HIV polypeptides and/or polypeptides of similar viruses to HIV genes, as well as cellular genes involved in HIV pathways of gene expression and/or HIV activity. Also, the term

“HIV” as it is defined herein below and recited in the described embodiments, is meant to encompass HIV viral gene products and cellular gene products involved in HIV infection, such as those described herein. Thus, each of the embodiments described herein with reference to the term “HIV” are applicable to all of the virus, cellular and 5 viral protein, peptide, polypeptide, and/or polynucleotide molecules covered by the term “HIV”, as that term is defined herein.

Due to the high sequence variability of the HIV genome, selection of nucleic acid molecules for broad therapeutic applications would likely involve the conserved regions of the HIV genome. Specifically, the present invention describes nucleic acid molecules 10 that cleave the conserved regions of the HIV genome. Therefore, one nucleic acid molecule can be designed to target all the different isolates of HIV. Nucleic acid molecules designed to target conserved regions of various HIV isolates can enable efficient inhibition of HIV replication in diverse subject populations and can ensure the effectiveness of the nucleic acid molecules against HIV quasi species which evolve due 15 to mutations in the non-conserved regions of the HIV genome. Therefore a single siNA molecule can be targeted against all isolates of HIV by designing the siNA molecule to interact with conserved nucleotide sequences of HIV (such conserved sequences are expected to be present in the RNA of all HIV isolates).

In one embodiment, the invention features a siNA molecule that down-regulates 20 expression of a HIV gene, for example, wherein the HIV gene comprises HIV encoding sequence.

In one embodiment, the invention features a siNA molecule having RNAi activity against HIV RNA, wherein the siNA molecule comprises a sequence complementary to any RNA having HIV or other encoding sequence, such as the exemplary sequences 25 having GenBank Accession Nos. disclosed herein. Chemical modifications as shown in **Tables III and IV** or otherwise described herein can be applied to any siNA construct of the invention.

In another embodiment, the invention features a siNA molecule having RNAi activity against a HIV gene or related genes involved in HIV infection and AIDS, 30 wherein the siNA molecule comprises nucleotide sequence complementary to the nucleotide sequence of such genes, such as the exemplary sequences having GenBank

Accession Nos. disclosed herein. In another embodiment, a siNA molecule of the invention includes nucleotide sequence that can interact with nucleotide sequence of a HIV gene and thereby mediate silencing of HIV gene expression, for example, wherein the siNA mediates regulation of HIV gene expression by cellular processes that modulate the chromatin structure of the HIV gene and prevent transcription of the HIV gene.

5 In another embodiment, the invention features a siNA molecule comprising nucleotide sequence, for example, nucleotide sequence in the antisense region of the siNA molecule that is complementary to a nucleotide sequence or portion of sequence of a HIV gene. In another embodiment, the invention features a siNA molecule comprising 10 a region, for example, the antisense region of the siNA construct, complementary to a sequence or portion of sequence comprising a HIV gene sequence.

In one embodiment, the antisense region of HIV siNA constructs can comprise a sequence complementary to sequence having any of SEQ ID NOs. 1-738 or 1477-1482. In one embodiment, the antisense region can also comprise sequence having any of SEQ 15 ID NOs. 739-1476, 1491-1498, 1507-1514, 1523-1530, 1535-1538, 1547-1554, 1557- 1558, 1567-1574, 1595, 1597, 1599, 1601, 1603, or 1604. In another embodiment, the sense region of HIV constructs can comprise sequence having any of SEQ ID NOs. 1- 738, 1477-1490, 1499-1506, 1515-1522, 1531-1534, 1539-1546, 1555-1556, 1559-1566, 1575-1576, 1594, 1596, 1598, 1600, or 1602. The sense region can comprise a sequence 20 of SEQ ID NO. 1583 and the antisense region can comprise a sequence of SEQ ID NO. 1584. The sense region can comprise a sequence of SEQ ID NO. 1585 and the antisense region can comprise a sequence of SEQ ID NO. 1586. The sense region can comprise a sequence of SEQ ID NO. 1587 and the antisense region can comprise a sequence of SEQ ID NO. 1588. The sense region can comprise a sequence of SEQ ID NO. 1589 and the 25 antisense region can comprise a sequence of SEQ ID NO. 1590. The sense region can comprise a sequence of SEQ ID NO. 1591 and the antisense region can comprise a sequence of SEQ ID NO. 1592. The sense region can comprise a sequence of SEQ ID NO. 1589 and the antisense region can comprise a sequence of SEQ ID NO. 1593.

In one embodiment, a siNA molecule of the invention comprises any of SEQ ID 30 NOs. 1-1604. The sequences shown in SEQ ID NOs: 1-1604 are not limiting. A siNA

molecule of the invention can comprise any contiguous HIV sequence (e.g., about 19 to about 25, or about 19, 20, 21, 22, 23, 24 or 25 contiguous HIV nucleotides).

In yet another embodiment, the invention features a siNA molecule comprising a sequence, for example, the antisense sequence of the siNA construct, complementary to a sequence or portion of sequence comprising sequence represented by GenBank Accession Nos. disclosed herein. Chemical modifications in **Tables III and IV** and described herein can be applied to any siRNA construct of the invention.

In one embodiment of the invention a siNA molecule comprises an antisense strand having about 19 to about 29 nucleotides, wherein the antisense strand is complementary to a RNA sequence encoding a HIV protein, and wherein said siNA further comprises a sense strand having about 19 to about 29 (e.g., about 19, 20, 21, 22, 23, 24, 25, 26, 27, 28 or 29) nucleotides, and wherein said sense strand and said antisense strand are distinct nucleotide sequences with at least about 19 complementary nucleotides.

In another embodiment of the invention a siNA molecule of the invention comprises an antisense region having about 19 to about 29 (e.g., about 19, 20, 21, 22, 23, 24, 25, 26, 27, 28 or 29) nucleotides, wherein the antisense region is complementary to a RNA sequence encoding a HIV protein, and wherein said siNA further comprises a sense region having about 19 to about 29 nucleotides, wherein said sense region and said antisense region comprise a linear molecule with at least about 19 complementary nucleotides.

In one embodiment of the invention a siNA molecule comprises an antisense strand comprising a nucleotide sequence that is complementary to a nucleotide sequence or a portion thereof encoding a HIV protein. The siNA further comprises a sense strand, wherein said sense strand comprises a nucleotide sequence of a HIV gene or a portion thereof.

In another embodiment, a siNA molecule comprises an antisense region comprising a nucleotide sequence that is complementary to a nucleotide sequence or a portion thereof encoding a HIV protein. The siNA molecule further comprises a sense

region, wherein said sense region comprises a nucleotide sequence of a HIV gene or a portion thereof.

In one embodiment, a siNA molecule of the invention has RNAi activity that modulates expression of RNA encoded by a HIV gene. Because HIV genes can share some degree of sequence homology with each other, siNA molecules can be designed to target a class of HIV genes (and associated receptor or ligand genes) or alternately specific HIV genes by selecting sequences that are either shared amongst different HIV targets or alternatively that are unique for a specific HIV target. Therefore, in one embodiment, the siNA molecule can be designed to target conserved regions of HIV RNA sequence having homology between several HIV genes so as to target several HIV genes (e.g., different HIV strains, splice variants, mutant genes etc.) with one siNA molecule. In another embodiment, the siNA molecule can be designed to target a sequence that is unique to a specific HIV RNA sequence due to the high degree of specificity that the siNA molecule requires to mediate RNAi activity.

In one embodiment, nucleic acid molecules of the invention that act as mediators of the RNA interference gene silencing response are double-stranded nucleic acid molecules. In another embodiment, the siNA molecules of the invention consist of duplexes containing about 19 base pairs between oligonucleotides comprising about 19 to about 25 (e.g., about 19, 20, 21, 22, 23, 24 or 25) nucleotides. In yet another embodiment, siNA molecules of the invention comprise duplexes with overhanging ends of about 1 to about 3 (e.g., about 1, 2, or 3) nucleotides, for example about 21-nucleotide duplexes with about 19 base pairs and 3'-terminal mononucleotide, dinucleotide, or trinucleotide overhangs.

In one embodiment, the invention features one or more chemically-modified siNA constructs having specificity for HIV expressing nucleic acid molecules, such as RNA encoding a HIV protein. Non-limiting examples of such chemical modifications include without limitation phosphorothioate internucleotide linkages, 2'-deoxyribonucleotides, 2'-O-methyl ribonucleotides, 2'-deoxy-2'-fluoro ribonucleotides, "universal base" nucleotides, "acyclic" nucleotides, 5-C-methyl nucleotides, and terminal glyceryl and/or inverted deoxy abasic residue incorporation. These chemical modifications, when used in various siNA constructs, are shown to preserve RNAi activity in cells while at the

same time, dramatically increasing the serum stability of these compounds. Furthermore, contrary to the data published by Parrish *et al.*, *supra*, applicant demonstrates that multiple (greater than one) phosphorothioate substitutions are well-tolerated and confer substantial increases in serum stability for modified siNA 5 constructs.

In one embodiment, a siNA molecule of the invention comprises modified nucleotides while maintaining the ability to mediate RNAi. The modified nucleotides can be used to improve *in vitro* or *in vivo* characteristics such as stability, activity, and/or bioavailability. For example, a siNA molecule of the invention can comprise modified 10 nucleotides as a percentage of the total number of nucleotides present in the siNA molecule. As such, a siNA molecule of the invention can generally comprise about 5% to 100% modified nucleotides (e.g., 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100% modified nucleotides). The actual percentage of modified nucleotides present in a given siNA molecule will 15 depend on the total number of nucleotides present in the siNA. If the siNA molecule is single stranded, the percent modification can be based upon the total number of nucleotides present in the single stranded siNA molecules. Likewise, if the siNA molecule is double stranded, the percent modification can be based upon the total number of nucleotides present in the sense strand, antisense strand, or both the sense and 20 antisense strands.


In a non-limiting example, the introduction of chemically-modified nucleotides into nucleic acid molecules provides a powerful tool in overcoming potential limitations of *in vivo* stability and bioavailability inherent to native RNA molecules that are delivered exogenously. For example, the use of chemically-modified nucleic acid 25 molecules can enable a lower dose of a particular nucleic acid molecule for a given therapeutic effect since chemically-modified nucleic acid molecules tend to have a longer half-life in serum. Furthermore, certain chemical modifications can improve the bioavailability of nucleic acid molecules by targeting particular cells or tissues and/or improving cellular uptake of the nucleic acid molecule. Therefore, even if the activity of 30 a chemically-modified nucleic acid molecule is reduced as compared to a native nucleic acid molecule, for example, when compared to an all-RNA nucleic acid molecule, the overall activity of the modified nucleic acid molecule can be greater than that of the

native molecule due to improved stability and/or delivery of the molecule. Unlike native unmodified siNA, chemically-modified siNA can also minimize the possibility of activating interferon activity in humans.

The antisense region of a siNA molecule of the invention can comprise a phosphorothioate internucleotide linkage at the 3'-end of said antisense region. The antisense region can comprise about one to about five phosphorothioate internucleotide linkages at the 5'-end of said antisense region. The 3'-terminal nucleotide overhangs of a siNA molecule of the invention can comprise ribonucleotides or deoxyribonucleotides that are chemically-modified at a nucleic acid sugar, base, or backbone. The 3'-terminal nucleotide overhangs can comprise one or more universal base ribonucleotides. The 3'-terminal nucleotide overhangs can comprise one or more acyclic nucleotides.

One embodiment of the invention provides an expression vector comprising a nucleic acid sequence encoding at least one siNA molecule of the invention in a manner that allows expression of the nucleic acid molecule. Another embodiment of the invention provides a mammalian cell comprising such an expression vector. The mammalian cell can be a human cell. The siNA molecule of the expression vector can comprise a sense region and an antisense region. The antisense region can comprise sequence complementary to a RNA or DNA sequence encoding HIV and the sense region can comprise sequence complementary to the antisense region. The siNA molecule can comprise two distinct strands having complementary sense and antisense regions. The siNA molecule can comprise a single strand having complementary sense and antisense regions.


In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule capable of mediating RNA interference (RNAi) against a HIV inside a cell or reconstituted *in vitro* system, wherein the chemical modification comprises one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) nucleotides comprising a backbone modified internucleotide linkage having Formula I:



wherein each R1 and R2 is independently any nucleotide, non-nucleotide, or polynucleotide which can be naturally-occurring or chemically-modified, each X and Y is independently O, S, N, alkyl, or substituted alkyl, each Z and W is independently O, S, N, alkyl, substituted alkyl, O-alkyl, S-alkyl, alkaryl, or aralkyl, and wherein W, X, Y, and Z are optionally not all O.

The chemically-modified internucleotide linkages having Formula I, for example, wherein any Z, W, X, and/or Y independently comprises a sulphur atom, can be present in one or both oligonucleotide strands of the siNA duplex, for example, in the sense strand, the antisense strand, or both strands. The siNA molecules of the invention can 10 comprise one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) chemically-modified internucleotide linkages having Formula I at the 3'-end, the 5'-end, or both of the 3' and 5'-ends of the sense strand, the antisense strand, or both strands. For example, an exemplary siNA molecule of the invention can comprise about 1 to about 5 or more (e.g., about 1, 2, 3, 4, 5, or more) chemically-modified internucleotide linkages having 15 Formula I at the 5'-end of the sense strand, the antisense strand, or both strands. In another non-limiting example, an exemplary siNA molecule of the invention can comprise one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) pyrimidine nucleotides with chemically-modified internucleotide linkages having Formula I in the sense strand, the antisense strand, or both strands. In yet another non-limiting example, 20 an exemplary siNA molecule of the invention can comprise one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) purine nucleotides with chemically-modified internucleotide linkages having Formula I in the sense strand, the antisense strand, or both strands. In another embodiment, a siNA molecule of the invention having 25 internucleotide linkage(s) of Formula I also comprises a chemically-modified nucleotide or non-nucleotide having any of Formulae I-VII.


In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule capable of mediating RNA interference (RNAi) against a HIV inside a cell or reconstituted *in vitro* system, wherein the chemical modification comprises one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) nucleotides or 30 non-nucleotides having Formula II:



wherein each R3, R4, R5, R6, R7, R8, R10, R11 and R12 is independently H, OH, alkyl, substituted alkyl, alkaryl or aralkyl, F, Cl, Br, CN, CF₃, OCF₃, OCN, O-alkyl, S-alkyl, N-alkyl, O-alkenyl, S-alkenyl, N-alkenyl, SO-alkyl, alkyl-OSH, alkyl-OH, O-alkyl-OH, O-alkyl-SH, S-alkyl-OH, S-alkyl-SH, alkyl-S-alkyl, alkyl-O-alkyl, ONO₂, NO₂, N₃, NH₂, aminoalkyl, aminoacid, aminoacyl, ONH₂, O-aminoalkyl, O-aminoacid, O-aminoacyl, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, or group having Formula I; R9 is O, S, CH₂, S=O, CHF, or CF₂, and B is a nucleosidic base such as adenine, guanine, uracil, cytosine, thymine, 2-aminoadenosine, 5-methylcytosine, 2,6-diaminopurine, or any other non-naturally occurring base that can be complementary or non-complementary to target RNA or a non-nucleosidic base such as phenyl, naphthyl, 3-nitropyrrole, 5-nitroindole, nebularine, pyridone, pyridinone, or any other non-naturally occurring universal base that can be complementary or non-complementary to target RNA.

The chemically-modified nucleotide or non-nucleotide of Formula II can be present in one or both oligonucleotide strands of the siNA duplex, for example in the sense strand, the antisense strand, or both strands. The siNA molecules of the invention can comprise one or more chemically-modified nucleotide or non-nucleotide of Formula II at the 3'-end, the 5'-end, or both of the 3' and 5'-ends of the sense strand, the antisense strand, or both strands. For example, an exemplary siNA molecule of the invention can comprise about 1 to about 5 or more (e.g., about 1, 2, 3, 4, 5, or more) chemically-modified nucleotides or non-nucleotides of Formula II at the 5'-end of the sense strand, the antisense strand, or both strands. In another non-limiting example, an exemplary siNA molecule of the invention can comprise about 1 to about 5 or more (e.g., about 1, 2, 3, 4, 5, or more) chemically-modified nucleotides or non-nucleotides of Formula II at the 3'-end of the sense strand, the antisense strand, or both strands.

In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule capable of mediating RNA interference (RNAi) against a HIV inside a cell or reconstituted *in vitro* system, wherein the chemical modification comprises one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) nucleotides or 5 non-nucleotides having Formula III:




wherein each R3, R4, R5, R6, R7, R8, R10, R11 and R12 is independently H, OH, alkyl, substituted alkyl, alkaryl or aralkyl, F, Cl, Br, CN, CF₃, OCF₃, OCN, O-alkyl, S-alkyl, N-alkyl, O-alkenyl, S-alkenyl, N-alkenyl, SO-alkyl, alkyl-OSH, alkyl-OH, O-alkyl-OH, 10 O-alkyl-SH, S-alkyl-OH, S-alkyl-SH, alkyl-S-alkyl, alkyl-O-alkyl, ONO₂, NO₂, N₃, NH₂, aminoalkyl, aminoacid, aminoacyl, ONH₂, O-aminoalkyl, O-aminoacid, O-aminoacyl, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, 15 substituted silyl, or group having Formula I; R9 is O, S, CH₂, S=O, CHF, or CF₂, and B is a nucleosidic base such as adenine, guanine, uracil, cytosine, thymine, 2-aminoadenosine, 5-methylcytosine, 2,6-diaminopurine, or any other non-naturally occurring base that can be employed to be complementary or non-complementary to target RNA or a non-nucleosidic base such as phenyl, naphthyl, 3-nitropyrrole, 5-nitroindole, nebularine, pyridone, pyridinone, or any other non-naturally occurring 20 universal base that can be complementary or non-complementary to target RNA.

20 The chemically-modified nucleotide or non-nucleotide of Formula III can be present in one or both oligonucleotide strands of the siNA duplex, for example, in the sense strand, the antisense strand, or both strands. The siNA molecules of the invention can comprise one or more chemically-modified nucleotide or non-nucleotide of Formula III at the 3'-end, the 5'-end, or both of the 3' and 5'-ends of the sense strand, the antisense 25 strand, or both strands. For example, an exemplary siNA molecule of the invention can comprise about 1 to about 5 or more (e.g., about 1, 2, 3, 4, 5, or more) chemically-

modified nucleotide(s) or non-nucleotide(s) of Formula III at the 5'-end of the sense strand, the antisense strand, or both strands. In another non-limiting example, an exemplary siNA molecule of the invention can comprise about 1 to about 5 or more (e.g., about 1, 2, 3, 4, 5, or more) chemically-modified nucleotide or non-nucleotide of Formula III at the 3'-end of the sense strand, the antisense strand, or both strands.

In another embodiment, a siNA molecule of the invention comprises a nucleotide having Formula II or III, wherein the nucleotide having Formula II or III is in an inverted configuration. For example, the nucleotide having Formula II or III is connected to the siNA construct in a 3'-3', 3'-2', 2'-3', or 5'-5' configuration, such as at the 3'-end, the 5'-end, or both of the 3' and 5'-ends of one or both siNA strands.

In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule capable of mediating RNA interference (RNAi) against a HIV inside a cell or reconstituted *in vitro* system, wherein the chemical modification comprises a 5'-terminal phosphate group having Formula IV:



wherein each X and Y is independently O, S, N, alkyl, substituted alkyl, or alkylhalo; wherein each Z and W is independently O, S, N, alkyl, substituted alkyl, O-alkyl, S-alkyl, alkaryl, aralkyl, or alkylhalo; and wherein W, X, Y and Z are not all O.

In one embodiment, the invention features a siNA molecule having a 5'-terminal phosphate group having Formula IV on the target-complementary strand, for example, a strand complementary to a target RNA, wherein the siNA molecule comprises an all RNA siNA molecule. In another embodiment, the invention features a siNA molecule having a 5'-terminal phosphate group having Formula IV on the target-complementary strand wherein the siNA molecule also comprises about 1 to about 3 (e.g., about 1, 2, or 3) nucleotide 3'-terminal nucleotide overhangs having about 1 to about 4 (e.g., about 1, 2, 3, or 4) deoxyribonucleotides on the 3'-end of one or both strands. In another embodiment, a 5'-terminal phosphate group having Formula IV is present on the target-

complementary strand of a siNA molecule of the invention, for example a siNA molecule having chemical modifications having any of Formulae I-VII.

In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule capable of mediating RNA interference (RNAi) against a 5 HIV inside a cell or reconstituted *in vitro* system, wherein the chemical modification comprises one or more phosphorothioate internucleotide linkages. For example, in a non-limiting example, the invention features a chemically-modified short interfering nucleic acid (siNA) having about 1, 2, 3, 4, 5, 6, 7, 8 or more phosphorothioate internucleotide linkages in one siNA strand. In yet another embodiment, the invention 10 features a chemically-modified short interfering nucleic acid (siNA) individually having about 1, 2, 3, 4, 5, 6, 7, 8 or more phosphorothioate internucleotide linkages in both siNA strands. The phosphorothioate internucleotide linkages can be present in one or both oligonucleotide strands of the siNA duplex, for example in the sense strand, the antisense strand, or both strands. The siNA molecules of the invention can comprise one or more 15 phosphorothioate internucleotide linkages at the 3'-end, the 5'-end, or both of the 3'- and 5'-ends of the sense strand, the antisense strand, or both strands. For example, an exemplary siNA molecule of the invention can comprise about 1 to about 5 or more (e.g., about 1, 2, 3, 4, 5, or more) consecutive phosphorothioate internucleotide linkages at the 5'-end of the sense strand, the antisense strand, or both strands. In another non-limiting 20 example, an exemplary siNA molecule of the invention can comprise one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) pyrimidine phosphorothioate internucleotide linkages in the sense strand, the antisense strand, or both strands. In yet another non-limiting example, an exemplary siNA molecule of the invention can comprise one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) purine phosphorothioate 25 internucleotide linkages in the sense strand, the antisense strand, or both strands.

In one embodiment, the invention features a siNA molecule, wherein the sense strand comprises one or more, for example, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more phosphorothioate internucleotide linkages, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) 2'-deoxy, 2'-O-methyl, 2'-deoxy-2'-fluoro, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) universal base modified nucleotides, and optionally a terminal cap molecule at the 3'-end, the 5'-end, or both of the 3'- and 5'-ends 30 of the sense strand; and wherein the antisense strand comprises about 1 to about 10 or

more, specifically about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more phosphorothioate internucleotide linkages, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) 2'-deoxy, 2'-O-methyl, 2'-deoxy-2'-fluoro, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) universal base modified nucleotides, and optionally a 5 terminal cap molecule at the 3'-end, the 5'-end, or both of the 3'- and 5'-ends of the antisense strand. In another embodiment, one or more, for example about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more, pyrimidine nucleotides of the sense and/or antisense siNA strand are chemically-modified with 2'-deoxy, 2'-O-methyl and/or 2'-deoxy-2'-fluoro nucleotides, with or without one or more, for example about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more, 10 phosphorothioate internucleotide linkages and/or a terminal cap molecule at the 3'-end, the 5'-end, or both of the 3'- and 5'-ends, being present in the same or different strand.

In another embodiment, the invention features a siNA molecule, wherein the sense strand comprises about 1 to about 5, specifically about 1, 2, 3, 4, or 5 phosphorothioate internucleotide linkages, and/or one or more (e.g., about 1, 2, 3, 4, 5, or more) 2'-deoxy, 15 2'-O-methyl, 2'-deoxy-2'-fluoro, and/or one or more (e.g., about 1, 2, 3, 4, 5, or more) universal base modified nucleotides, and optionally a terminal cap molecule at the 3-end, the 5'-end, or both of the 3'- and 5'-ends of the sense strand; and wherein the antisense strand comprises about 1 to about 5 or more, specifically about 1, 2, 3, 4, 5, or more phosphorothioate internucleotide linkages, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 20 7, 8, 9, 10 or more) 2'-deoxy, 2'-O-methyl, 2'-deoxy-2'-fluoro, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) universal base modified nucleotides, and optionally a terminal cap molecule at the 3'-end, the 5'-end, or both of the 3'- and 5'-ends of the antisense strand. In another embodiment, one or more, for example, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more, pyrimidine nucleotides of the sense and/or antisense siNA 25 strand are chemically-modified with 2'-deoxy, 2'-O-methyl and/or 2'-deoxy-2'-fluoro nucleotides, with or without about 1 to about 5 or more, for example about 1, 2, 3, 4, 5, or more phosphorothioate internucleotide linkages and/or a terminal cap molecule at the 3'-end, the 5'-end, or both of the 3'- and 5'-ends, being present in the same or different strand.

30 In one embodiment, the invention features a siNA molecule, wherein the antisense strand comprises one or more, for example, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more phosphorothioate internucleotide linkages, and/or about one or more (e.g., about 1, 2, 3,

4, 5, 6, 7, 8, 9, 10 or more) 2'-deoxy, 2'-O-methyl, 2'-deoxy-2'-fluoro, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) universal base modified nucleotides, and optionally a terminal cap molecule at the 3'-end, the 5'-end, or both of the 3'- and 5'-ends of the sense strand; and wherein the antisense strand comprises about 1 to about 10 or 5 more, specifically about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more phosphorothioate internucleotide linkages, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) 2'-deoxy, 2'-O-methyl, 2'-deoxy-2'-fluoro, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) 2'-deoxy, 2'-O-methyl, 2'-deoxy-2'-fluoro, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) universal base modified nucleotides, and optionally a terminal cap molecule at the 3'-end, the 5'-end, or both of the 3'- and 5'-ends of the 10 antisense strand. In another embodiment, one or more, for example about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more pyrimidine nucleotides of the sense and/or antisense siNA strand are chemically-modified with 2'-deoxy, 2'-O-methyl and/or 2'-deoxy-2'-fluoro nucleotides, with or without one or more, for example about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more phosphorothioate internucleotide linkages and/or a terminal cap molecule at the 3'-end, 15 the 5'-end, or both of the 3' and 5'-ends, being present in the same or different strand.

In another embodiment, the invention features a siNA molecule, wherein the antisense strand comprises about 1 to about 5 or more, specifically about 1, 2, 3, 4, 5 or more phosphorothioate internucleotide linkages, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) 2'-deoxy, 2'-O-methyl, 2'-deoxy-2'-fluoro, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) universal base modified nucleotides, and optionally a terminal cap molecule at the 3'-end, the 5'-end, or both of the 3'- and 5'-ends of the sense strand; and wherein the antisense strand comprises about 1 to about 5 or more, specifically about 1, 2, 3, 4, 5 or more phosphorothioate internucleotide linkages, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) 2'-deoxy, 2'-O-methyl, 20 2'-deoxy-2'-fluoro, and/or one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) universal base modified nucleotides, and optionally a terminal cap molecule at the 3'- and 5'-ends of the antisense strand. In another embodiment, one or more, for example about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more pyrimidine nucleotides of the sense and/or antisense siNA strand are chemically- 25 modified with 2'-deoxy, 2'-O-methyl and/or 2'-deoxy-2'-fluoro nucleotides, with or without about 1 to about 5, for example about 1, 2, 3, 4, 5 or more phosphorothioate internucleotide linkages and/or a terminal cap molecule at the 3'-end, the 5'-end, or both of the 3'- and 5'-ends, being present in the same or different strand.

In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule having about 1 to about 5, specifically about 1, 2, 3, 4, 5 or more phosphorothioate internucleotide linkages in each strand of the siNA molecule.

In another embodiment, the invention features a siNA molecule comprising 2'-5' internucleotide linkages. The 2'-5' internucleotide linkage(s) can be at the 3'-end, the 5'-end, or both of the 3'- and 5'-ends of one or both siNA sequence strands. In addition, the 2'-5' internucleotide linkage(s) can be present at various other positions within one or both siNA sequence strands, for example, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more including every internucleotide linkage of a pyrimidine nucleotide in one or both strands of the siNA molecule can comprise a 2'-5' internucleotide linkage, or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more including every internucleotide linkage of a purine nucleotide in one or both strands of the siNA molecule can comprise a 2'-5' internucleotide linkage.


In another embodiment, a chemically-modified siNA molecule of the invention comprises a duplex having two strands, one or both of which can be chemically-modified, wherein each strand is about 18 to about 27 (e.g., about 18, 19, 20, 21, 22, 23, 24, 25, 26, or 27) nucleotides in length, wherein the duplex has about 18 to about 23 (e.g., about 18, 19, 20, 21, 22, or 23) base pairs, and wherein the chemical modification comprises a structure having any of Formulae I-VII. For example, an exemplary chemically-modified siNA molecule of the invention comprises a duplex having two strands, one or both of which can be chemically-modified with a chemical modification having any of Formulae I-VII or any combination thereof, wherein each strand consists of about 21 nucleotides, each having a 2-nucleotide 3'-terminal nucleotide overhang, and wherein the duplex has about 19 base pairs. In another embodiment, a siNA molecule of the invention comprises a single stranded hairpin structure, wherein the siNA is about 36 to about 70 (e.g., about 36, 40, 45, 50, 55, 60, 65, or 70) nucleotides in length having about 18 to about 23 (e.g., about 18, 19, 20, 21, 22, or 23) base pairs, and wherein the siNA can include a chemical modification comprising a structure having any of Formulae I-VII or any combination thereof. For example, an exemplary chemically-modified siNA molecule of the invention comprises a linear oligonucleotide having about 42 to about 50 (e.g., about 42, 43, 44, 45, 46, 47, 48, 49, or 50) nucleotides that is chemically-modified with a chemical modification having any of Formulae I-VII or any combination thereof, wherein the linear oligonucleotide forms a hairpin structure having

about 19 base pairs and a 2-nucleotide 3'-terminal nucleotide overhang. In another embodiment, a linear hairpin siNA molecule of the invention contains a stem loop motif, wherein the loop portion of the siNA molecule is biodegradable. For example, a linear hairpin siNA molecule of the invention is designed such that degradation of the loop portion of the siNA molecule *in vivo* can generate a double-stranded siNA molecule with 3'-terminal overhangs, such as 3'-terminal nucleotide overhangs comprising about 2 nucleotides.

5 In another embodiment, a siNA molecule of the invention comprises a circular nucleic acid molecule, wherein the siNA is about 38 to about 70 (e.g., about 38, 40, 45, 10 50, 55, 60, 65, or 70) nucleotides in length having about 18 to about 23 (e.g., about 18, 19, 20, 21, 22, or 23) base pairs, and wherein the siNA can include a chemical modification, which comprises a structure having any of Formulae I-VII or any combination thereof. For example, an exemplary chemically-modified siNA molecule of 15 the invention comprises a circular oligonucleotide having about 42 to about 50 (e.g., about 42, 43, 44, 45, 46, 47, 48, 49, or 50) nucleotides that is chemically-modified with a chemical modification having any of Formulae I-VII or any combination thereof, wherein the circular oligonucleotide forms a dumbbell shaped structure having about 19 base pairs and 2 loops.


20 In another embodiment, a circular siNA molecule of the invention contains two loop motifs, wherein one or both loop portions of the siNA molecule is biodegradable. For example, a circular siNA molecule of the invention is designed such that degradation of the loop portions of the siNA molecule *in vivo* can generate a double-stranded siNA molecule with 3'-terminal overhangs, such as 3'-terminal nucleotide overhangs comprising about 2 nucleotides.

25 In one embodiment, a siNA molecule of the invention comprises at least one (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) abasic moiety, for example a compound having Formula V:



wherein each R3, R4, R5, R6, R7, R8, R10, R11, R12, and R13 is independently H, OH, alkyl, substituted alkyl, alkaryl or aralkyl, F, Cl, Br, CN, CF₃, OCF₃, OCN, O-alkyl, S-alkyl, N-alkyl, O-alkenyl, S-alkenyl, N-alkenyl, SO-alkyl, alkyl-OSH, alkyl-OH, O-alkyl-OH, O-alkyl-SH, S-alkyl-OH, S-alkyl-SH, alkyl-S-alkyl, alkyl-O-alkyl, ONO₂, NO₂, N₃, NH₂, aminoalkyl, aminoacid, aminoacyl, ONH₂, O-aminoalkyl, O-aminoacid, O-aminoacyl, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, or group having Formula I; R9 is O, S, CH₂, S=O, CHF, or CF₂.


In one embodiment, a siNA molecule of the invention comprises at least one (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) inverted abasic moiety, for example a compound having Formula VI:



wherein each R3, R4, R5, R6, R7, R8, R10, R11, R12, and R13 is independently H, OH, alkyl, substituted alkyl, alkaryl or aralkyl, F, Cl, Br, CN, CF₃, OCF₃, OCN, O-alkyl, S-alkyl, N-alkyl, O-alkenyl, S-alkenyl, N-alkenyl, SO-alkyl, alkyl-OSH, alkyl-OH, O-alkyl-OH, O-alkyl-SH, S-alkyl-OH, S-alkyl-SH, alkyl-S-alkyl, alkyl-O-alkyl, ONO₂, NO₂, N₃, NH₂, aminoalkyl, aminoacid, aminoacyl, ONH₂, O-aminoalkyl, O-aminoacid, O-aminoacyl, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, or group having Formula I; R9 is O, S, CH₂, S=O, CHF, or CF₂, and

either R2, R3, R8 or R13 serve as points of attachment to the siNA molecule of the invention.

In another embodiment, a siNA molecule of the invention comprises at least one (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) substituted polyalkyl moieties, for example a compound having Formula VII:



wherein each n is independently an integer from 1 to 12, each R1, R2 and R3 is independently H, OH, alkyl, substituted alkyl, alkaryl or aralkyl, F, Cl, Br, CN, CF3, OCF3, OCN, O-alkyl, S-alkyl, N-alkyl, O-alkenyl, S-alkenyl, N-alkenyl, SO-alkyl, alkyl-OSH, alkyl-OH, O-alkyl-OH, O-alkyl-SH, S-alkyl-OH, S-alkyl-SH, alkyl-S-alkyl, alkyl-O-alkyl, ONO2, NO2, N3, NH2, aminoalkyl, aminoacid, aminoacyl, ONH2, O-aminoalkyl, O-aminoacid, O-aminoacyl, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, or a group having Formula I, and R1, R2 or R3 serves as points of attachment to the siNA molecule of the invention.

In another embodiment, the invention features a compound having Formula VII, wherein R1 and R2 are hydroxyl (OH) groups, n = 1, and R3 comprises O and is the point of attachment to the 3'-end, the 5'-end, or both of the 3' and 5'-ends of one or both strands of a double-stranded siNA molecule of the invention or to a single-stranded siNA molecule of the invention. This modification is referred to herein as "glyceryl" (for example modification 6 in **Figure 10**).

In another embodiment, a moiety having any of Formula V, VI or VII of the invention is at the 3'-end, the 5'-end, or both of the 3' and 5'-ends of a siNA molecule of the invention. For example, a moiety having Formula V, VI or VII can be present at the 3'-end, the 5'-end, or both of the 3' and 5'-ends of the antisense strand, the sense strand, or both antisense and sense strands of the siNA molecule. In addition, a moiety having Formula VII can be present at the 3'-end or the 5'-end of a hairpin siNA molecule as described herein.

In another embodiment, a siNA molecule of the invention comprises an abasic residue having Formula V or VI, wherein the abasic residue having Formula VI or VI is connected to the siNA construct in a 3'-3', 3'-2', 2'-3', or 5'-5' configuration, such as at the 3'-end, the 5'-end, or both of the 3' and 5'-ends of one or both siNA strands.

5 In one embodiment, a siNA molecule of the invention comprises one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) locked nucleic acid (LNA) nucleotides, for example at the 5'-end, the 3'-end, both of the 5' and 3'-ends, or any combination thereof, of the siNA molecule.

10 In another embodiment, a siNA molecule of the invention comprises one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) acyclic nucleotides, for example at the 5'-end, the 3'-end, both of the 5' and 3'-ends, or any combination thereof, of the siNA molecule.

15 In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule of the invention, wherein the chemically-modified siNA comprises a sense region, where any (e.g., one or more or all) pyrimidine nucleotides present in the sense region are 2'-deoxy-2'-fluoro pyrimidine nucleotides (e.g., wherein all pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides), and where any (e.g., one or more or all) purine nucleotides present in the sense region are 2'-
20 deoxy purine nucleotides (e.g., wherein all purine nucleotides are 2'-deoxy purine nucleotides or alternately a plurality of purine nucleotides are 2'-deoxy purine nucleotides).

25 In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule of the invention, wherein the chemically-modified siNA comprises a sense region, where any (e.g., one or more or all) pyrimidine nucleotides present in the sense region are 2'-deoxy-2'-fluoro pyrimidine nucleotides (e.g., wherein all pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides), and where any (e.g., one or more or all) purine nucleotides present in the sense region are 2'-
30 deoxy purine nucleotides (e.g., wherein all purine nucleotides are 2'-deoxy purine nucleotides or alternately a plurality of purine nucleotides are 2'-deoxy purine

nucleotides), wherein any nucleotides comprising a 3'-terminal nucleotide overhang that are present in said sense region are 2'-deoxy nucleotides.

In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule of the invention, wherein the chemically-modified siNA comprises an antisense region, where any (e.g., one or more or all) pyrimidine nucleotides present in the antisense region are 2'-deoxy-2'-fluoro pyrimidine nucleotides (e.g., wherein all pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides), and wherein any (e.g., one or more or all) purine nucleotides present in the antisense region are 2'-O-methyl purine nucleotides (e.g., wherein all purine nucleotides are 2'-O-methyl purine nucleotides or alternately a plurality of purine nucleotides are 2'-O-methyl purine nucleotides).

In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule of the invention, wherein the chemically-modified siNA comprises an antisense region, where any (e.g., one or more or all) pyrimidine nucleotides present in the antisense region are 2'-deoxy-2'-fluoro pyrimidine nucleotides (e.g., wherein all pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides), and wherein any (e.g., one or more or all) purine nucleotides present in the antisense region are 2'-O-methyl purine nucleotides (e.g., wherein all purine nucleotides are 2'-O-methyl purine nucleotides or alternately a plurality of purine nucleotides are 2'-O-methyl purine nucleotides), wherein any nucleotides comprising a 3'-terminal nucleotide overhang that are present in said antisense region are 2'-deoxy nucleotides.

In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule of the invention, wherein the chemically-modified siNA comprises an antisense region, where any (e.g., one or more or all) pyrimidine nucleotides present in the antisense region are 2'-deoxy-2'-fluoro pyrimidine nucleotides (e.g., wherein all pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides), and where any (e.g., one or more or all) purine nucleotides present in the antisense region are 2'-deoxy purine nucleotides (e.g., wherein all purine nucleotides are

2'-deoxy purine nucleotides or alternately a plurality of purine nucleotides are 2'-deoxy purine nucleotides).

In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule of the invention capable of mediating RNA interference (RNAi) against a HIV inside a cell or reconstituted *in vitro* system, wherein the chemically-modified siNA comprises a sense region, where one or more pyrimidine nucleotides present in the sense region are 2'-deoxy-2'-fluoro pyrimidine nucleotides (e.g., wherein all pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides), and where one or more purine nucleotides present in the sense region are 2'-deoxy purine nucleotides (e.g., wherein all purine nucleotides are 2'-deoxy purine nucleotides or alternately a plurality of purine nucleotides are 2'-deoxy purine nucleotides), and inverted deoxy abasic modifications that are optionally present at the 3'-end, the 5'-end, or both of the 3' and 5'-ends of the sense region, the sense region optionally further comprising a 3'-terminal overhang having about 1 to about 4 (e.g., about 1, 2, 3, or 4) 2'-deoxyribonucleotides; and wherein the chemically-modified short interfering nucleic acid molecule comprises an antisense region, where one or more pyrimidine nucleotides present in the antisense region are 2'-deoxy-2'-fluoro pyrimidine nucleotides (e.g., wherein all pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides), and wherein one or more purine nucleotides present in the antisense region are 2'-O-methyl purine nucleotides (e.g., wherein all purine nucleotides are 2'-O-methyl purine nucleotides or alternately a plurality of purine nucleotides are 2'-O-methyl purine nucleotides), and a terminal cap modification, such as any modification described herein or shown in **Figure 10**, that is optionally present at the 3'-end, the 5'-end, or both of the 3' and 5'-ends of the antisense sequence, the antisense region optionally further comprising a 3'-terminal nucleotide overhang having about 1 to about 4 (e.g., about 1, 2, 3, or 4) 2'-deoxynucleotides, wherein the overhang nucleotides can further comprise one or more (e.g., 1, 2, 3, or 4) phosphorothioate internucleotide linkages. Non-limiting examples of these chemically-modified siNAs are shown in **Figures 4 and 5 and Tables III and IV** herein.

In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule of the invention capable of mediating RNA interference (RNAi) against a HIV inside a cell or reconstituted *in vitro* system, wherein the siNA comprises a sense region, where one or more pyrimidine nucleotides present in the sense region are 2'-deoxy-2'-fluoro pyrimidine nucleotides (e.g., wherein all pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides), and where one or more purine nucleotides present in the sense region are purine ribonucleotides (e.g., wherein all purine nucleotides are purine ribonucleotides or alternately a plurality of purine nucleotides are purine ribonucleotides), and inverted deoxy abasic modifications that are optionally present at the 3'-end, the 5'-end, or both of the 3' and 5'-ends of the sense region, the sense region optionally further comprising a 3'-terminal overhang having about 1 to about 4 (e.g., about 1, 2, 3, or 4) 2'-deoxyribonucleotides; and wherein the siNA comprises an antisense region, where one or more pyrimidine nucleotides present in the antisense region are 2'-deoxy-2'-fluoro pyrimidine nucleotides (e.g., wherein all pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides), and wherein any purine nucleotides present in the antisense region are 2'-O-methyl purine nucleotides (e.g., wherein all purine nucleotides are 2'-O-methyl purine nucleotides or alternately a plurality of purine nucleotides are 2'-O-methyl purine nucleotides), and a terminal cap modification, such as any modification described herein or shown in **Figure 10**, that is optionally present at the 3'-end, the 5'-end, or both of the 3' and 5'-ends of the antisense sequence, the antisense region optionally further comprising a 3'-terminal nucleotide overhang having about 1 to about 4 (e.g., about 1, 2, 3, or 4) 2'-deoxynucleotides, wherein the overhang nucleotides can further comprise one or more (e.g., 1, 2, 3, or 4) phosphorothioate internucleotide linkages. Non-limiting examples of these chemically-modified siNAs are shown in **Figures 4 and 5 and Tables III and IV** herein.

In one embodiment, the invention features a chemically-modified short interfering nucleic acid (siNA) molecule of the invention capable of mediating RNA interference (RNAi) against a HIV inside a cell or reconstituted *in vitro* system, wherein the chemically-modified siNA comprises a sense region, where one or more pyrimidine nucleotides present in the sense region are 2'-deoxy-2'-fluoro pyrimidine nucleotides

(e.g., wherein all pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides), and for example where one or more purine nucleotides present in the sense region are selected from the group consisting of 2'-deoxy nucleotides, locked nucleic acid (LNA) nucleotides, 2'-methoxyethyl nucleotides, 4'-thionucleotides, and 2'-O-methyl nucleotides (e.g., wherein all purine nucleotides are selected from the group consisting of 2'-deoxy nucleotides, locked nucleic acid (LNA) nucleotides, 2'-methoxyethyl nucleotides, 4'-thionucleotides, and 2'-O-methyl nucleotides or alternately a plurality of purine nucleotides are selected from the group consisting of 2'-deoxy nucleotides, locked nucleic acid (LNA) nucleotides, 2'-methoxyethyl nucleotides, 4'-thionucleotides, and 2'-O-methyl nucleotides), and wherein inverted deoxy abasic modifications are optionally present at the 3'-end, the 5'-end, or both of the 3' and 5'-ends of the sense region, the sense region optionally further comprising a 3'-terminal overhang having about 1 to about 4 (e.g., about 1, 2, 3, or 4) 2'-deoxyribonucleotides; and wherein the chemically-modified short interfering nucleic acid molecule comprises an antisense region, where one or more pyrimidine nucleotides present in the antisense region are 2'-deoxy-2'-fluoro pyrimidine nucleotides (e.g., wherein all pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides), and wherein one or more purine nucleotides present in the antisense region are selected from the group consisting of 2'-deoxy nucleotides, locked nucleic acid (LNA) nucleotides, 2'-methoxyethyl nucleotides, 4'-thionucleotides, and 2'-O-methyl nucleotides (e.g., wherein all purine nucleotides are selected from the group consisting of 2'-deoxy nucleotides, locked nucleic acid (LNA) nucleotides, 2'-methoxyethyl nucleotides, 4'-thionucleotides, and 2'-O-methyl nucleotides or alternately a plurality of purine nucleotides are selected from the group consisting of 2'-deoxy nucleotides, locked nucleic acid (LNA) nucleotides, 2'-methoxyethyl nucleotides, 4'-thionucleotides, and 2'-O-methyl nucleotides), and a terminal cap modification, such as any modification described herein or shown in **Figure 10**, that is optionally present at the 3'-end, the 5'-end, or both of the 3' and 5'-ends of the antisense sequence, the antisense region optionally further comprising a 3'-terminal nucleotide overhang having about 1 to about 4 (e.g., about 1, 2, 3, or 4) 2'-deoxynucleotides, wherein the overhang nucleotides can further comprise one or more (e.g., 1, 2, 3, or 4) phosphorothioate internucleotide linkages.

In another embodiment, any modified nucleotides present in the siNA molecules of the invention, preferably in the antisense strand of the siNA molecules of the invention, but also optionally in the sense and/or both antisense and sense strands, comprise modified nucleotides having properties or characteristics similar to naturally occurring ribonucleotides. For example, the invention features siNA molecules including modified nucleotides having a Northern conformation (e.g., Northern pseudorotation cycle, see for example Saenger, *Principles of Nucleic Acid Structure*, Springer-Verlag ed., 1984). As such, chemically modified nucleotides present in the siNA molecules of the invention, preferably in the antisense strand of the siNA molecules of the invention, but also optionally in the sense and/or both antisense and sense strands, are resistant to nuclease degradation while at the same time maintaining the capacity to mediate RNAi. Non-limiting examples of nucleotides having a northern configuration include locked nucleic acid (LNA) nucleotides (e.g., 2'-O,4'-C-methylene-(D-ribofuranosyl) nucleotides); 2'-methoxyethoxy (MOE) nucleotides; 2'-methyl-thio-ethyl, 2'-deoxy-2'-fluoro nucleotides, 2'-deoxy-2'-chloro nucleotides, 2'-azido nucleotides, and 2'-O-methyl nucleotides.

In one embodiment, the invention features a chemically-modified short interfering nucleic acid molecule (siNA) capable of mediating RNA interference (RNAi) against a HIV inside a cell or reconstituted *in vitro* system, wherein the chemical modification comprises a conjugate covalently attached to the chemically-modified siNA molecule. In another embodiment, the conjugate is covalently attached to the chemically-modified siNA molecule via a biodegradable linker. In one embodiment, the conjugate molecule is attached at the 3'-end of either the sense strand, the antisense strand, or both strands of the chemically-modified siNA molecule. In another embodiment, the conjugate molecule is attached at the 5'-end of either the sense strand, the antisense strand, or both strands of the chemically-modified siNA molecule. In yet another embodiment, the conjugate molecule is attached both the 3'-end and 5'-end of either the sense strand, the antisense strand, or both strands of the chemically-modified siNA molecule, or any combination thereof. In one embodiment, a conjugate molecule of the invention comprises a molecule that facilitates delivery of a chemically-modified siNA molecule into a biological system, such as a cell. In another embodiment, the conjugate molecule attached to the chemically-modified siNA molecule is a poly ethylene glycol, human serum albumin, or a ligand for a cellular receptor that can mediate cellular uptake.

Examples of specific conjugate molecules contemplated by the instant invention that can be attached to chemically-modified siNA molecules are described in Vargeese *et al.*, U.S. Serial No. 10/201,394, incorporated by reference herein. The type of conjugates used and the extent of conjugation of siNA molecules of the invention can be evaluated for improved pharmacokinetic profiles, bioavailability, and/or stability of siNA constructs while at the same time maintaining the ability of the siNA to mediate RNAi activity. As such, one skilled in the art can screen siNA constructs that are modified with various conjugates to determine whether the siNA conjugate complex possesses improved properties while maintaining the ability to mediate RNAi, for example in animal models as are generally known in the art.

In one embodiment, the invention features a short interfering nucleic acid (siNA) molecule of the invention, wherein the siNA further comprises a nucleotide, non-nucleotide, or mixed nucleotide/non-nucleotide linker that joins the sense region of the siNA to the antisense region of the siNA. In one embodiment, a nucleotide linker of the invention can be a linker of ≥ 2 nucleotides in length, for example 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides in length. In another embodiment, the nucleotide linker can be a nucleic acid aptamer. By “aptamer” or “nucleic acid aptamer” as used herein is meant a nucleic acid molecule that binds specifically to a target molecule wherein the nucleic acid molecule has sequence that comprises a sequence recognized by the target molecule in its natural setting. Alternately, an aptamer can be a nucleic acid molecule that binds to a target molecule where the target molecule does not naturally bind to a nucleic acid. The target molecule can be any molecule of interest. For example, the aptamer can be used to bind to a ligand-binding domain of a protein, thereby preventing interaction of the naturally occurring ligand with the protein. This is a non-limiting example and those in the art will recognize that other embodiments can be readily generated using techniques generally known in the art. (See, for example, Gold *et al.*, 1995, *Annu. Rev. Biochem.*, 64, 763; Brody and Gold, 2000, *J. Biotechnol.*, 74, 5; Sun, 2000, *Curr. Opin. Mol. Ther.*, 2, 100; Kusser, 2000, *J. Biotechnol.*, 74, 27; Hermann and Patel, 2000, *Science*, 287, 820; and Jayasena, 1999, *Clinical Chemistry*, 45, 1628.)

In yet another embodiment, a non-nucleotide linker of the invention comprises abasic nucleotide, polyether, polyamine, polyamide, peptide, carbohydrate, lipid, polyhydrocarbon, or other polymeric compounds (e.g. polyethylene glycols such as those

having between 2 and 100 ethylene glycol units). Specific examples include those described by Seela and Kaiser, *Nucleic Acids Res.* 1990, 18:6353 and *Nucleic Acids Res.* 1987, 15:3113; Cload and Schepartz, *J. Am. Chem. Soc.* 1991, 113:6324; Richardson and Schepartz, *J. Am. Chem. Soc.* 1991, 113:5109; Ma *et al.*, *Nucleic Acids Res.* 1993, 21:2585 and *Biochemistry* 1993, 32:1751; Durand *et al.*, *Nucleic Acids Res.* 1990, 18:6353; McCurdy *et al.*, *Nucleosides & Nucleotides* 1991, 10:287; Jschke *et al.*, *Tetrahedron Lett.* 1993, 34:301; Ono *et al.*, *Biochemistry* 1991, 30:9914; Arnold *et al.*, International Publication No. WO 89/02439; Usman *et al.*, International Publication No. WO 95/06731; Dudycz *et al.*, International Publication No. WO 95/11910 and Ferentz and Verdine, *J. Am. Chem. Soc.* 1991, 113:4000, all hereby incorporated by reference herein. A "non-nucleotide" further means any group or compound that can be incorporated into a nucleic acid chain in the place of one or more nucleotide units, including either sugar and/or phosphate substitutions, and allows the remaining bases to exhibit their enzymatic activity. The group or compound can be abasic in that it does not contain a commonly recognized nucleotide base, such as adenosine, guanine, cytosine, uracil or thymine, for example at the C1 position of the sugar.

In one embodiment, the invention features a short interfering nucleic acid (siNA) molecule capable of mediating RNA interference (RNAi) inside a cell or reconstituted in vitro system, wherein one or both strands of the siNA molecule that are assembled from two separate oligonucleotides do not comprise any ribonucleotides. For example, a siNA molecule can be assembled from a single oligonucleotide where the sense and antisense regions of the siNA comprise separate oligonucleotides not having any ribonucleotides (e.g., nucleotides having a 2'-OH group) present in the oligonucleotides. In another example, a siNA molecule can be assembled from a single oligonucleotide where the sense and antisense regions of the siNA are linked or circularized by a nucleotide or non-nucleotide linker as described herein, wherein the oligonucleotide does not have any ribonucleotides (e.g., nucleotides having a 2'-OH group) present in the oligonucleotide. Applicant has surprisingly found that the presence of ribonucleotides (e.g., nucleotides having a 2'-hydroxyl group) within the siNA molecule is not required or essential to support RNAi activity. As such, in one embodiment, all positions within the siNA can include chemically modified nucleotides and/or non-nucleotides such as nucleotides and/or non-nucleotides having Formula I, II, III, IV, V, VI, or VII or any combination thereof.

to the extent that the ability of the siNA molecule to support RNAi activity in a cell is maintained.

In one embodiment, a siNA molecule of the invention is a single stranded siNA molecule that mediates RNAi activity in a cell or reconstituted in vitro system, wherein 5 the siNA molecule comprises a single stranded polynucleotide having complementarity to a target nucleic acid sequence. In another embodiment, the single stranded siNA molecule of the invention comprises a 5'-terminal phosphate group. In another embodiment, the single stranded siNA molecule of the invention comprises a 5'-terminal phosphate group and a 3'-terminal phosphate group (e.g., a 2',3'-cyclic phosphate). In 10 another embodiment, the single stranded siNA molecule of the invention comprises about 19 to about 29 nucleotides. In yet another embodiment, the single stranded siNA molecule of the invention comprises one or more chemically modified nucleotides or non-nucleotides described herein. For example, all the positions within the siNA molecule can include chemically-modified nucleotides such as nucleotides having any 15 of Formulae I-VII, or any combination thereof to the extent that the ability of the siNA molecule to support RNAi activity in a cell is maintained.

In one embodiment, a siNA molecule of the invention is a single stranded siNA molecule that mediates RNAi activity in a cell or reconstituted in vitro system, wherein the siNA molecule comprises a single stranded polynucleotide having complementarity 20 to a target nucleic acid sequence, and wherein one or more pyrimidine nucleotides present in the siNA are 2'-deoxy-2'-fluoro pyrimidine nucleotides (e.g., wherein all pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides), and wherein any purine nucleotides present in the antisense region are 2'-O-methyl purine 25 nucleotides (e.g., wherein all purine nucleotides are 2'-O-methyl purine nucleotides or alternately a plurality of purine nucleotides are 2'-O-methyl purine nucleotides), and a terminal cap modification, such as any modification described herein or shown in **Figure 10**, that is optionally present at the 3'-end, the 5'-end, or both of the 3' and 5'-ends of the antisense sequence, the siNA optionally further comprising about 1 to about 4 (e.g., 30 about 1, 2, 3, or 4) terminal 2'-deoxynucleotides at the 3'-end of the siNA molecule, wherein the terminal nucleotides can further comprise one or more (e.g., 1, 2, 3, or 4)

phosphorothioate internucleotide linkages, and wherein the siNA optionally further comprises a terminal phosphate group, such as a 5'-terminal phosphate group.

In one embodiment, a siNA molecule of the invention is a single stranded siNA molecule that mediates RNAi activity in a cell or reconstituted in vitro system, wherein 5 the siNA molecule comprises a single stranded polynucleotide having complementarity to a target nucleic acid sequence, and wherein one or more pyrimidine nucleotides present in the siNA are 2'-deoxy-2'-fluoro pyrimidine nucleotides (e.g., wherein all pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides), and 10 wherein any purine nucleotides present in the antisense region are 2'-deoxy purine nucleotides (e.g., wherein all purine nucleotides are 2'-deoxy purine nucleotides or alternately a plurality of purine nucleotides are 2'-deoxy purine nucleotides), and a terminal cap modification, such as any modification described herein or shown in **Figure 10**, that is optionally present at the 3'-end, the 5'-end, or both of the 3' and 5'-ends of the 15 antisense sequence, the siNA optionally further comprising about 1 to about 4 (e.g., about 1, 2, 3, or 4) terminal 2'-deoxynucleotides at the 3'-end of the siNA molecule, wherein the terminal nucleotides can further comprise one or more (e.g., 1, 2, 3, or 4) phosphorothioate internucleotide linkages, and wherein the siNA optionally further comprises a terminal phosphate group, such as a 5'-terminal phosphate group.

20 In one embodiment, a siNA molecule of the invention is a single stranded siNA molecule that mediates RNAi activity in a cell or reconstituted in vitro system, wherein the siNA molecule comprises a single stranded polynucleotide having complementarity to a target nucleic acid sequence, and wherein one or more pyrimidine nucleotides present in the siNA are 2'-deoxy-2'-fluoro pyrimidine nucleotides (e.g., wherein all 25 pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides), and wherein any purine nucleotides present in the antisense region are locked nucleic acid (LNA) nucleotides (e.g., wherein all purine nucleotides are LNA nucleotides or alternately a plurality of purine nucleotides are LNA nucleotides), and a terminal cap 30 modification, such as any modification described herein or shown in **Figure 10**, that is optionally present at the 3'-end, the 5'-end, or both of the 3' and 5'-ends of the antisense sequence, the siNA optionally further comprising about 1 to about 4 (e.g., about 1, 2, 3,

or 4) terminal 2'-deoxynucleotides at the 3'-end of the siNA molecule, wherein the terminal nucleotides can further comprise one or more (e.g., 1, 2, 3, or 4) phosphorothioate internucleotide linkages, and wherein the siNA optionally further comprises a terminal phosphate group, such as a 5'-terminal phosphate group.

5 In one embodiment, a siNA molecule of the invention is a single stranded siNA molecule that mediates RNAi activity in a cell or reconstituted in vitro system, wherein the siNA molecule comprises a single stranded polynucleotide having complementarity to a target nucleic acid sequence, and wherein one or more pyrimidine nucleotides present in the siNA are 2'-deoxy-2'-fluoro pyrimidine nucleotides (e.g., wherein all 10 pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides or alternately a plurality of pyrimidine nucleotides are 2'-deoxy-2'-fluoro pyrimidine nucleotides), and wherein any purine nucleotides present in the antisense region are 2'-methoxyethyl purine nucleotides (e.g., wherein all purine nucleotides are 2'-methoxyethyl purine nucleotides or alternately a plurality of purine nucleotides are 2'-methoxyethyl purine 15 nucleotides), and a terminal cap modification, such as any modification described herein or shown in **Figure 10**, that is optionally present at the 3'-end, the 5'-end, or both of the 3' and 5'-ends of the antisense sequence, the siNA optionally further comprising about 1 to about 4 (e.g., about 1, 2, 3, or 4) terminal 2'-deoxynucleotides at the 3'-end of the siNA molecule, wherein the terminal nucleotides can further comprise one or more (e.g., 20 1, 2, 3, or 4) phosphorothioate internucleotide linkages, and wherein the siNA optionally further comprises a terminal phosphate group, such as a 5'-terminal phosphate group.

In another embodiment, any modified nucleotides present in the single stranded siNA molecules of the invention comprise modified nucleotides having properties or characteristics similar to naturally occurring ribonucleotides. For example, the invention 25 features siNA molecules including modified nucleotides having a Northern conformation (e.g., Northern pseudorotation cycle, see for example Saenger, *Principles of Nucleic Acid Structure*, Springer-Verlag ed., 1984). As such, chemically modified nucleotides present in the single stranded siNA molecules of the invention are preferably resistant to nuclelease degradation while at the same time maintaining the capacity to mediate RNAi.

30 In one embodiment, the invention features a method for modulating the expression of a HIV gene within a cell comprising: (a) synthesizing a siNA molecule of the

invention, which can be chemically-modified, wherein one of the siNA strands comprises a sequence complementary to RNA of the HIV gene; and (b) introducing the siNA molecule into a cell under conditions suitable to modulate the expression of the HIV gene in the cell.

5 In one embodiment, the invention features a method for modulating the expression of a HIV gene within a cell comprising: (a) synthesizing a siNA molecule of the invention, which can be chemically-modified, wherein one of the siNA strands comprises a sequence complementary to RNA of the HIV gene and wherein the sense strand sequence of the siNA comprises a sequence identical to the sequence of the target 10 RNA; and (b) introducing the siNA molecule into a cell under conditions suitable to modulate the expression of the HIV gene in the cell.

15 In another embodiment, the invention features a method for modulating the expression of more than one HIV gene within a cell comprising: (a) synthesizing siNA molecules of the invention, which can be chemically-modified, wherein one of the siNA strands comprises a sequence complementary to RNA of the HIV genes; and (b) introducing the siNA molecules into a cell under conditions suitable to modulate the expression of the HIV genes in the cell.

20 In another embodiment, the invention features a method for modulating the expression of more than one HIV gene within a cell comprising: (a) synthesizing a siNA molecule of the invention, which can be chemically-modified, wherein one of the siNA strands comprises a sequence complementary to RNA of the HIV gene and wherein the sense strand sequence of the siNA comprises a sequence identical to the sequence of the target RNA; and (b) introducing the siNA molecules into a cell under conditions suitable to modulate the expression of the HIV genes in the cell.

25 In one embodiment, siNA molecules of the invention are used as reagents in ex vivo applications. For example, siNA reagents are introduced into tissue or cells that are transplanted into a subject for therapeutic effect. The cells and/or tissue can be derived from an organism or subject that later receives the explant, or can be derived from another organism or subject prior to transplantation. The siNA molecules can be used to 30 modulate the expression of one or more genes in the cells or tissue, such that the cells or tissue obtain a desired phenotype or are able to perform a function when transplanted in

vivo. In one embodiment, certain target cells from a patient are extracted. These extracted cells are contacted with siRNAs targeting a specific nucleotide sequence within the cells under conditions suitable for uptake of the siRNAs by these cells (e.g. using delivery reagents such as cationic lipids, liposomes and the like or using techniques such 5 as electroporation to facilitate the delivery of siRNAs into cells). The cells are then reintroduced back into the same patient or other patients.

In one embodiment, the invention features a method of modulating the expression of a HIV gene in a tissue explant comprising: (a) synthesizing a siRNA molecule of the invention, which can be chemically-modified, wherein one of the siRNA strands 10 comprises a sequence complementary to RNA of the HIV gene; and (b) introducing the siRNA molecule into a cell of the tissue explant derived from a particular organism under conditions suitable to modulate the expression of the HIV gene in the tissue explant. In another embodiment, the method further comprises introducing the tissue explant back into the organism the tissue was derived from or into another organism under conditions 15 suitable to modulate the expression of the HIV gene in that organism.

In one embodiment, the invention features a method of modulating the expression of a HIV gene in a tissue explant comprising: (a) synthesizing a siRNA molecule of the invention, which can be chemically-modified, wherein one of the siRNA strands comprises a sequence complementary to RNA of the HIV gene and wherein the sense 20 strand sequence of the siRNA comprises a sequence identical to the sequence of the target RNA; and (b) introducing the siRNA molecule into a cell of the tissue explant derived from a particular organism under conditions suitable to modulate the expression of the HIV gene in the tissue explant. In another embodiment, the method further comprises introducing the tissue explant back into the organism the tissue was derived from or into 25 another organism under conditions suitable to modulate the expression of the HIV gene in that organism.

In another embodiment, the invention features a method of modulating the expression of more than one HIV gene in a tissue explant comprising: (a) synthesizing siRNA molecules of the invention, which can be chemically-modified, wherein one of the 30 siRNA strands comprises a sequence complementary to RNA of the HIV genes; and (b) introducing the siRNA molecules into a cell of the tissue explant derived from a particular

organism under conditions suitable to modulate the expression of the HIV genes in the tissue explant. In another embodiment, the method further comprises introducing the tissue explant back into the organism the tissue was derived from or into another organism under conditions suitable to modulate the expression of the HIV genes in that 5 organism.

In one embodiment, the invention features a method of modulating the expression of a HIV gene in an organism comprising: (a) synthesizing a siNA molecule of the invention, which can be chemically-modified, wherein one of the siNA strands comprises a sequence complementary to RNA of the HIV gene; and (b) introducing the 10 siNA molecule into the organism under conditions suitable to modulate the expression of the HIV gene in the organism.

In another embodiment, the invention features a method of modulating the expression of more than one HIV gene in an organism comprising: (a) synthesizing siNA molecules of the invention, which can be chemically-modified, wherein one of the 15 siNA strands comprises a sequence complementary to RNA of the HIV genes; and (b) introducing the siNA molecules into the organism under conditions suitable to modulate the expression of the HIV genes in the organism.

In one embodiment, the invention features a method for modulating the expression of a HIV gene within a cell comprising: (a) synthesizing a siNA molecule of the 20 invention, which can be chemically-modified, wherein the siNA comprises a single stranded sequence having complementarity to RNA of the HIV gene; and (b) introducing the siNA molecule into a cell under conditions suitable to modulate the expression of the HIV gene in the cell.

In another embodiment, the invention features a method for modulating the 25 expression of more than one HIV gene within a cell comprising: (a) synthesizing siNA molecules of the invention, which can be chemically-modified, wherein the siNA comprises a single stranded sequence having complementarity to RNA of the HIV gene; and (b) contacting the siNA molecule with a cell in vitro or in vivo under conditions suitable to modulate the expression of the HIV genes in the cell.

5 In one embodiment, the invention features a method of modulating the expression of a HIV gene in a tissue explant comprising: (a) synthesizing a siNA molecule of the invention, which can be chemically-modified, wherein the siNA comprises a single stranded sequence having complementarity to RNA of the HIV gene; and (b) contacting the siNA molecule with a cell of the tissue explant derived from a particular organism under conditions suitable to modulate the expression of the HIV gene in the tissue explant. In another embodiment, the method further comprises introducing the tissue explant back into the organism the tissue was derived from or into another organism under conditions suitable to modulate the expression of the HIV gene in that organism.

10 15 In another embodiment, the invention features a method of modulating the expression of more than one HIV gene in a tissue explant comprising: (a) synthesizing siNA molecules of the invention, which can be chemically-modified, wherein the siNA comprises a single stranded sequence having complementarity to RNA of the HIV gene; and (b) introducing the siNA molecules into a cell of the tissue explant derived from a particular organism under conditions suitable to modulate the expression of the HIV genes in the tissue explant. In another embodiment, the method further comprises introducing the tissue explant back into the organism the tissue was derived from or into another organism under conditions suitable to modulate the expression of the HIV genes in that organism.

20 25 In one embodiment, the invention features a method of modulating the expression of a HIV gene in an organism comprising: (a) synthesizing a siNA molecule of the invention, which can be chemically-modified, wherein the siNA comprises a single stranded sequence having complementarity to RNA of the HIV gene; and (b) introducing the siNA molecule into the organism under conditions suitable to modulate the expression of the HIV gene in the organism.

30 In another embodiment, the invention features a method of modulating the expression of more than one HIV gene in an organism comprising: (a) synthesizing siNA molecules of the invention, which can be chemically-modified, wherein the siNA comprises a single stranded sequence having complementarity to RNA of the HIV gene; and (b) introducing the siNA molecules into the organism under conditions suitable to modulate the expression of the HIV genes in the organism.

In one embodiment, the invention features a method of modulating the expression of a HIV gene in an organism comprising contacting the organism with a siNA molecule of the invention under conditions suitable to modulate the expression of the HIV gene in the organism.

5 In another embodiment, the invention features a method of modulating the expression of more than one HIV gene in an organism comprising contacting the organism with one or more siNA molecules of the invention under conditions suitable to modulate the expression of the HIV genes in the organism.

The siNA molecules of the invention can be designed to inhibit target (HIV) gene expression through RNAi targeting of a variety of RNA molecules. In one embodiment, the siNA molecules of the invention are used to target various RNAs corresponding to a target gene. Non-limiting examples of such RNAs include messenger RNA (mRNA), alternate RNA splice variants of target gene(s), post-transcriptionally modified RNA of target gene(s), pre-mRNA of target gene(s), and/or RNA templates. If alternate splicing produces a family of transcripts that are distinguished by usage of appropriate exons, the instant invention can be used to inhibit gene expression through the appropriate exons to specifically inhibit or to distinguish among the functions of gene family members. For example, a protein that contains an alternatively spliced transmembrane domain can be expressed in both membrane bound and secreted forms. Use of the invention to target the exon containing the transmembrane domain can be used to determine the functional consequences of pharmaceutical targeting of membrane bound as opposed to the secreted form of the protein. Non-limiting examples of applications of the invention relating to targeting these RNA molecules include therapeutic pharmaceutical applications, pharmaceutical discovery applications, molecular diagnostic and gene function applications, and gene mapping, for example using single nucleotide polymorphism mapping with siNA molecules of the invention. Such applications can be implemented using known gene sequences or from partial sequences available from an expressed sequence tag (EST).

In another embodiment, the siNA molecules of the invention are used to target 30 conserved sequences corresponding to a gene family or gene families such as HIV family genes. As such, siNA molecules targeting multiple HIV targets can provide increased

therapeutic effect. In addition, siNA can be used to characterize pathways of gene function in a variety of applications. For example, the present invention can be used to inhibit the activity of target gene(s) in a pathway to determine the function of uncharacterized gene(s) in gene function analysis, mRNA function analysis, or 5 translational analysis. The invention can be used to determine potential target gene pathways involved in various diseases and conditions toward pharmaceutical development. The invention can be used to understand pathways of gene expression involved in, for example, the progression and/or maintenance of cancer.

10 In one embodiment, siNA molecule(s) and/or methods of the invention are used to inhibit the expression of gene(s) that encode RNA referred to by Genbank Accession, for example HIV genes encoding RNA sequence(s) referred to herein by Genbank Accession number, for example Genbank Accession Nos. disclosed herein.

15 In one embodiment, the invention features a method comprising: (a) generating a library of siNA constructs having a predetermined complexity; and (b) assaying the siNA constructs of (a) above, under conditions suitable to determine RNAi target sites within the target RNA sequence. In another embodiment, the siNA molecules of (a) have strands of a fixed length, for example, about 23 nucleotides in length. In yet another embodiment, the siNA molecules of (a) are of differing length, for example having strands of about 19 to about 25 (e.g., about 19, 20, 21, 22, 23, 24, or 25) nucleotides in 20 length. In one embodiment, the assay can comprise a reconstituted *in vitro* siNA assay as described herein. In another embodiment, the assay can comprise a cell culture system in which target RNA is expressed. In another embodiment, fragments of target RNA are analyzed for detectable levels of cleavage, for example by gel electrophoresis, northern blot analysis, or RNase protection assays, to determine the most suitable target 25 site(s) within the target RNA sequence. The target RNA sequence can be obtained as is known in the art, for example, by cloning and/or transcription for *in vitro* systems, and by cellular expression in *in vivo* systems.

30 In one embodiment, the invention features a method comprising: (a) generating a randomized library of siNA constructs having a predetermined complexity, such as of 4^N , where N represents the number of base paired nucleotides in each of the siNA construct strands (eg. for a siNA construct having 21 nucleotide sense and antisense strands with

19 base pairs, the complexity would be 4¹⁹); and (b) assaying the siNA constructs of (a) above, under conditions suitable to determine RNAi target sites within the target HIV RNA sequence. In another embodiment, the siNA molecules of (a) have strands of a fixed length, for example about 23 nucleotides in length. In yet another embodiment, the 5 siNA molecules of (a) are of differing length, for example having strands of about 19 to about 25 (e.g., about 19, 20, 21, 22, 23, 24, or 25) nucleotides in length. In one embodiment, the assay can comprise a reconstituted *in vitro* siNA assay as described in Example 7 herein. In another embodiment, the assay can comprise a cell culture system in which target RNA is expressed. In another embodiment, fragments of HIV RNA are 10 analyzed for detectable levels of cleavage, for example by gel electrophoresis, northern blot analysis, or RNase protection assays, to determine the most suitable target site(s) within the target HIV RNA sequence. The target HIV RNA sequence can be obtained as is known in the art, for example, by cloning and/or transcription for *in vitro* systems, and by cellular expression in *in vivo* systems.

15 In another embodiment, the invention features a method comprising: (a) analyzing the sequence of a RNA target encoded by a target gene; (b) synthesizing one or more sets of siNA molecules having sequence complementary to one or more regions of the RNA of (a); and (c) assaying the siNA molecules of (b) under conditions suitable to determine RNAi targets within the target RNA sequence. In one embodiment, the siNA molecules 20 of (b) have strands of a fixed length, for example about 23 nucleotides in length. In another embodiment, the siNA molecules of (b) are of differing length, for example having strands of about 19 to about 25 (e.g., about 19, 20, 21, 22, 23, 24, or 25) nucleotides in length. In one embodiment, the assay can comprise a reconstituted *in vitro* siNA assay as described herein. In another embodiment, the assay can comprise a 25 cell culture system in which target RNA is expressed. Fragments of target RNA are analyzed for detectable levels of cleavage, for example by gel electrophoresis, northern blot analysis, or RNase protection assays, to determine the most suitable target site(s) within the target RNA sequence. The target RNA sequence can be obtained as is known in the art, for example, by cloning and/or transcription for *in vitro* systems, and by 30 expression in *in vivo* systems.

By "target site" is meant a sequence within a target RNA that is "targeted" for cleavage mediated by a siNA construct which contains sequences within its antisense region that are complementary to the target sequence.

By "detectable level of cleavage" is meant cleavage of target RNA (and formation 5 of cleaved product RNAs) to an extent sufficient to discern cleavage products above the background of RNAs produced by random degradation of the target RNA. Production of cleavage products from 1-5% of the target RNA is sufficient to detect above the background for most methods of detection.

In one embodiment, the invention features a composition comprising a siNA 10 molecule of the invention, which can be chemically-modified, in a pharmaceutically acceptable carrier or diluent. In another embodiment, the invention features a pharmaceutical composition comprising siNA molecules of the invention, which can be chemically-modified, targeting one or more genes in a pharmaceutically acceptable carrier or diluent. In another embodiment, the invention features a method for treating 15 or preventing a disease or condition in a subject, comprising administering to the subject a composition of the invention under conditions suitable for the treatment or prevention of the disease or condition in the subject, alone or in conjunction with one or more other therapeutic compounds. In yet another embodiment, the invention features a method for reducing or preventing tissue rejection in a subject comprising administering to the 20 subject a composition of the invention under conditions suitable for the reduction or prevention of tissue rejection in the subject.

In another embodiment, the invention features a method for validating a HIV gene 25 target comprising: (a) synthesizing a siNA molecule of the invention, which can be chemically-modified, wherein one of the siNA strands includes a sequence complementary to RNA of a HIV target gene; (b) introducing the siNA molecule into a cell, tissue, or organism under conditions suitable for modulating expression of the HIV target gene in the cell, tissue, or organism; and (c) determining the function of the gene by assaying for any phenotypic change in the cell, tissue, or organism.

In another embodiment, the invention features a method for validating a HIV target 30 comprising: (a) synthesizing a siNA molecule of the invention, which can be chemically-modified, wherein one of the siNA strands includes a sequence

complementary to RNA of a HIV target gene; (b) introducing the siNA molecule into a biological system under conditions suitable for modulating expression of the HIV target gene in the biological system; and (c) determining the function of the gene by assaying for any phenotypic change in the biological system.

5 By "biological system" is meant, material, in a purified or unpurified form, from biological sources, including but not limited to human, animal, plant, insect, bacterial, viral or other sources, wherein the system comprises the components required for RNAi activity. The term "biological system" includes, for example, a cell, tissue, or organism, or extract thereof. The term biological system also includes reconstituted RNAi systems
10 that can be used in an *in vitro* setting.

By "phenotypic change" is meant any detectable change to a cell that occurs in response to contact or treatment with a nucleic acid molecule of the invention (e.g., siNA). Such detectable changes include, but are not limited to, changes in shape, size, proliferation, motility, protein expression or RNA expression or other physical or
15 chemical changes as can be assayed by methods known in the art. The detectable change can also include expression of reporter genes/molecules such as Green Fluorescent Protein (GFP) or various tags that are used to identify an expressed protein or any other cellular component that can be assayed.

20 In one embodiment, the invention features a kit containing a siNA molecule of the invention, which can be chemically-modified, that can be used to modulate the expression of a HIV target gene in a cell, tissue, or organism. In another embodiment, the invention features a kit containing more than one siNA molecule of the invention, which can be chemically-modified, that can be used to modulate the expression of more than one HIV target gene in a cell, tissue, or organism.

25 In one embodiment, the invention features a cell containing one or more siNA molecules of the invention, which can be chemically-modified. In another embodiment, the cell containing a siNA molecule of the invention is a mammalian cell. In yet another embodiment, the cell containing a siNA molecule of the invention is a human cell.

30 In one embodiment, the synthesis of a siNA molecule of the invention, which can be chemically-modified, comprises: (a) synthesis of two complementary strands of the

5 siNA molecule; (b) annealing the two complementary strands together under conditions suitable to obtain a double-stranded siNA molecule. In another embodiment, synthesis of the two complementary strands of the siNA molecule is by solid phase oligonucleotide synthesis. In yet another embodiment, synthesis of the two complementary strands of the
10 siNA molecule is by solid phase tandem oligonucleotide synthesis.

In one embodiment, the invention features a method for synthesizing a siNA duplex molecule comprising: (a) synthesizing a first oligonucleotide sequence strand of the siNA molecule, wherein the first oligonucleotide sequence strand comprises a cleavable linker molecule that can be used as a scaffold for the synthesis of the second
15 oligonucleotide sequence strand of the siNA; (b) synthesizing the second oligonucleotide sequence strand of siNA on the scaffold of the first oligonucleotide sequence strand, wherein the second oligonucleotide sequence strand further comprises a chemical moiety
20 than can be used to purify the siNA duplex; (c) cleaving the linker molecule of (a) under conditions suitable for the two siNA oligonucleotide strands to hybridize and form a stable duplex; and (d) purifying the siNA duplex utilizing the chemical moiety of the second oligonucleotide sequence strand. In one embodiment, cleavage of the linker molecule in (c) above takes place during deprotection of the oligonucleotide, for example under hydrolysis conditions using an alkylamine base such as methylamine. In one embodiment, the method of synthesis comprises solid phase synthesis on a solid support
25 such as controlled pore glass (CPG) or polystyrene, wherein the first sequence of (a) is synthesized on a cleavable linker, such as a succinyl linker, using the solid support as a scaffold. The cleavable linker in (a) used as a scaffold for synthesizing the second strand can comprise similar reactivity as the solid support derivatized linker, such that cleavage of the solid support derivatized linker and the cleavable linker of (a) takes place
30 concomitantly. In another embodiment, the chemical moiety of (b) that can be used to isolate the attached oligonucleotide sequence comprises a trityl group, for example a dimethoxytrityl group, which can be employed in a trityl-on synthesis strategy as described herein. In yet another embodiment, the chemical moiety, such as a dimethoxytrityl group, is removed during purification, for example, using acidic conditions.

In a further embodiment, the method for siNA synthesis is a solution phase synthesis or hybrid phase synthesis wherein both strands of the siNA duplex are

synthesized in tandem using a cleavable linker attached to the first sequence which acts a scaffold for synthesis of the second sequence. Cleavage of the linker under conditions suitable for hybridization of the separate siNA sequence strands results in formation of the double-stranded siNA molecule.

5 In another embodiment, the invention features a method for synthesizing a siNA duplex molecule comprising: (a) synthesizing one oligonucleotide sequence strand of the siNA molecule, wherein the sequence comprises a cleavable linker molecule that can be used as a scaffold for the synthesis of another oligonucleotide sequence; (b) synthesizing a second oligonucleotide sequence having complementarity to the first 10 sequence strand on the scaffold of (a), wherein the second sequence comprises the other strand of the double-stranded siNA molecule and wherein the second sequence further comprises a chemical moiety than can be used to isolate the attached oligonucleotide sequence; (c) purifying the product of (b) utilizing the chemical moiety of the second oligonucleotide sequence strand under conditions suitable for isolating the full-length 15 sequence comprising both siNA oligonucleotide strands connected by the cleavable linker and under conditions suitable for the two siNA oligonucleotide strands to hybridize and form a stable duplex. In one embodiment, cleavage of the linker molecule in (c) above takes place during deprotection of the oligonucleotide, for example under hydrolysis conditions. In another embodiment, cleavage of the linker molecule in (c) 20 above takes place after deprotection of the oligonucleotide. In another embodiment, the method of synthesis comprises solid phase synthesis on a solid support such as controlled pore glass (CPG) or polystyrene, wherein the first sequence of (a) is synthesized on a cleavable linker, such as a succinyl linker, using the solid support as a scaffold. The cleavable linker in (a) used as a scaffold for synthesizing the second strand can comprise 25 similar reactivity or differing reactivity as the solid support derivatized linker, such that cleavage of the solid support derivatized linker and the cleavable linker of (a) takes place either concomitantly or sequentially. In one embodiment, the chemical moiety of (b) that can be used to isolate the attached oligonucleotide sequence comprises a trityl group, for example a dimethoxytrityl group.

30 In another embodiment, the invention features a method for making a double-stranded siNA molecule in a single synthetic process comprising: (a) synthesizing an oligonucleotide having a first and a second sequence, wherein the first sequence is

complementary to the second sequence, and the first oligonucleotide sequence is linked to the second sequence via a cleavable linker, and wherein a terminal 5'-protecting group, for example, a 5'-O-dimethoxytrityl group (5'-O-DMT) remains on the oligonucleotide having the second sequence; (b) deprotecting the oligonucleotide whereby the 5 deprotection results in the cleavage of the linker joining the two oligonucleotide sequences; and (c) purifying the product of (b) under conditions suitable for isolating the double-stranded siNA molecule, for example using a trityl-on synthesis strategy as described herein.

10 In another embodiment, the method of synthesis of siNA molecules of the invention comprises the teachings of Scaringe *et al.*, US Patent Nos. 5,889,136; 6,008,400; and 6,111,086, incorporated by reference herein in their entirety.

15 In one embodiment, the invention features siNA constructs that mediate RNAi against a HIV, wherein the siNA construct comprises one or more chemical modifications, for example, one or more chemical modifications having any of Formulae I-VII or any combination thereof that increases the nuclease resistance of the siNA construct.

20 In another embodiment, the invention features a method for generating siNA molecules with increased nuclease resistance comprising (a) introducing nucleotides having any of Formula I-VII or any combination thereof into a siNA molecule, and (b) assaying the siNA molecule of step (a) under conditions suitable for isolating siNA molecules having increased nuclease resistance.

25 In one embodiment, the invention features siNA constructs that mediate RNAi against a HIV, wherein the siNA construct comprises one or more chemical modifications described herein that modulates the binding affinity between the sense and antisense strands of the siNA construct.

In another embodiment, the invention features a method for generating siNA molecules with increased binding affinity between the sense and antisense strands of the siNA molecule comprising (a) introducing nucleotides having any of Formula I-VII or any combination thereof into a siNA molecule, and (b) assaying the siNA molecule of

step (a) under conditions suitable for isolating siNA molecules having increased binding affinity between the sense and antisense strands of the siNA molecule.

In one embodiment, the invention features siNA constructs that mediate RNAi against a HIV, wherein the siNA construct comprises one or more chemical 5 modifications described herein that modulates the binding affinity between the antisense strand of the siNA construct and a complementary target RNA sequence within a cell.

In one embodiment, the invention features siNA constructs that mediate RNAi against a HIV, wherein the siNA construct comprises one or more chemical 10 modifications described herein that modulates the binding affinity between the antisense strand of the siNA construct and a complementary target DNA sequence within a cell.

In another embodiment, the invention features a method for generating siNA molecules with increased binding affinity between the antisense strand of the siNA molecule and a complementary target RNA sequence comprising (a) introducing 15 nucleotides having any of Formula I-VII or any combination thereof into a siNA molecule, and (b) assaying the siNA molecule of step (a) under conditions suitable for isolating siNA molecules having increased binding affinity between the antisense strand of the siNA molecule and a complementary target RNA sequence.

In another embodiment, the invention features a method for generating siNA molecules with increased binding affinity between the antisense strand of the siNA 20 molecule and a complementary target DNA sequence comprising (a) introducing nucleotides having any of Formula I-VII or any combination thereof into a siNA molecule, and (b) assaying the siNA molecule of step (a) under conditions suitable for isolating siNA molecules having increased binding affinity between the antisense strand of the siNA molecule and a complementary target DNA sequence.

25 In one embodiment, the invention features siNA constructs that mediate RNAi against a HIV, wherein the siNA construct comprises one or more chemical modifications described herein that modulate the polymerase activity of a cellular polymerase capable of generating additional endogenous siNA molecules having sequence homology to the chemically-modified siNA construct.

In another embodiment, the invention features a method for generating siNA molecules capable of mediating increased polymerase activity of a cellular polymerase capable of generating additional endogenous siNA molecules having sequence homology to a chemically-modified siNA molecule comprising (a) introducing nucleotides having any of Formula I-VII or any combination thereof into a siNA molecule, and (b) assaying the siNA molecule of step (a) under conditions suitable for isolating siNA molecules capable of mediating increased polymerase activity of a cellular polymerase capable of generating additional endogenous siNA molecules having sequence homology to the chemically-modified siNA molecule.

In one embodiment, the invention features chemically-modified siNA constructs that mediate RNAi against a HIV in a cell, wherein the chemical modifications do not significantly effect the interaction of siNA with a target RNA molecule, DNA molecule and/or proteins or other factors that are essential for RNAi in a manner that would decrease the efficacy of RNAi mediated by such siNA constructs.

In another embodiment, the invention features a method for generating siNA molecules with improved RNAi activity against HIV comprising (a) introducing nucleotides having any of Formula I-VII or any combination thereof into a siNA molecule, and (b) assaying the siNA molecule of step (a) under conditions suitable for isolating siNA molecules having improved RNAi activity.

In yet another embodiment, the invention features a method for generating siNA molecules with improved RNAi activity against a HIV target RNA comprising (a) introducing nucleotides having any of Formula I-VII or any combination thereof into a siNA molecule, and (b) assaying the siNA molecule of step (a) under conditions suitable for isolating siNA molecules having improved RNAi activity against the target RNA.

In yet another embodiment, the invention features a method for generating siNA molecules with improved RNAi activity against a HIV target DNA comprising (a) introducing nucleotides having any of Formula I-VII or any combination thereof into a siNA molecule, and (b) assaying the siNA molecule of step (a) under conditions suitable for isolating siNA molecules having improved RNAi activity against the target DNA.

In one embodiment, the invention features siNA constructs that mediate RNAi against a HIV, wherein the siNA construct comprises one or more chemical modifications described herein that modulates the cellular uptake of the siNA construct.

5 In another embodiment, the invention features a method for generating siNA molecules against HIV with improved cellular uptake comprising (a) introducing nucleotides having any of Formula I-VII or any combination thereof into a siNA molecule, and (b) assaying the siNA molecule of step (a) under conditions suitable for isolating siNA molecules having improved cellular uptake.

10 In one embodiment, the invention features siNA constructs that mediate RNAi against a HIV, wherein the siNA construct comprises one or more chemical modifications described herein that increases the bioavailability of the siNA construct, for example, by attaching polymeric conjugates such as polyethyleneglycol or equivalent conjugates that improve the pharmacokinetics of the siNA construct, or by attaching conjugates that target specific tissue types or cell types *in vivo*. Non-limiting examples 15 of such conjugates are described in Vargeese *et al.*, U.S. Serial No. 10/201,394 incorporated by reference herein.

20 In one embodiment, the invention features a method for generating siNA molecules of the invention with improved bioavailability, comprising (a) introducing a conjugate into the structure of a siNA molecule, and (b) assaying the siNA molecule of step (a) under conditions suitable for isolating siNA molecules having improved bioavailability. Such conjugates can include ligands for cellular receptors, such as peptides derived from naturally occurring protein ligands; protein localization sequences, including cellular ZIP code sequences; antibodies; nucleic acid aptamers; vitamins and other co-factors, such as folate and N-acetylgalactosamine; polymers, such as 25 polyethyleneglycol (PEG); phospholipids; polyamines, such as spermine or spermidine; and others.

30 In another embodiment, the invention features a method for generating siNA molecules of the invention with improved bioavailability comprising (a) introducing an excipient formulation to a siNA molecule, and (b) assaying the siNA molecule of step (a) under conditions suitable for isolating siNA molecules having improved bioavailability.

Such excipients include polymers such as cyclodextrins, lipids, cationic lipids, polyamines, phospholipids, and others.

In another embodiment, the invention features a method for generating siNA molecules of the invention with improved bioavailability comprising (a) introducing 5 nucleotides having any of Formulae I-VII or any combination thereof into a siNA molecule, and (b) assaying the siNA molecule of step (a) under conditions suitable for isolating siNA molecules having improved bioavailability.

In another embodiment, polyethylene glycol (PEG) can be covalently attached to 10 siNA compounds of the present invention. The attached PEG can be any molecular weight, preferably from about 2,000 to about 50,000 daltons (Da).

The present invention can be used alone or as a component of a kit having at least 15 one of the reagents necessary to carry out the *in vitro* or *in vivo* introduction of RNA to test samples and/or subjects. For example, preferred components of the kit include a siNA molecule of the invention and a vehicle that promotes introduction of the siNA into 20 cells of interest as described herein (e.g., using lipids and other methods of transfection known in the art, see for example Beigelman *et al.*, US 6,395,713). The kit can be used for target validation, such as in determining gene function and/or activity, or in drug optimization, and in drug discovery (see for example Usman *et al.*, USSN 60/402,996). Such a kit can also include instructions to allow a user of the kit to practice the invention.

20 The term "short interfering nucleic acid", "siNA", "short interfering RNA", "siRNA", "short interfering nucleic acid molecule", "short interfering oligonucleotide molecule", or "chemically-modified short interfering nucleic acid molecule" as used herein refers to any nucleic acid molecule capable of inhibiting or down regulating gene expression or viral replication, for example by mediating RNA interference "RNAi" or 25 gene silencing in a sequence-specific manner; see for example Bass, 2001, *Nature*, 411, 428-429; Elbashir *et al.*, 2001, *Nature*, 411, 494-498; and Kreutzer *et al.*, International PCT Publication No. WO 00/44895; Zernicka-Goetz *et al.*, International PCT Publication No. WO 01/36646; Fire, International PCT Publication No. WO 99/32619; 30 Plaetinck *et al.*, International PCT Publication No. WO 00/01846; Mello and Fire, International PCT Publication No. WO 01/29058; Deschamps-Depaillette, International PCT Publication No. WO 99/07409; and Li *et al.*, International PCT Publication No. WO

00/44914; Allshire, 2002, *Science*, 297, 1818-1819; Volpe *et al.*, 2002, *Science*, 297, 1833-1837; Jenuwein, 2002, *Science*, 297, 2215-2218; and Hall *et al.*, 2002, *Science*, 297, 2232-2237; Hutvagner and Zamore, 2002, *Science*, 297, 2056-60; McManus *et al.*, 2002, *RNA*, 8, 842-850; Reinhart *et al.*, 2002, *Gene & Dev.*, 16, 1616-1626; and Reinhart & Bartel, 2002, *Science*, 297, 1831). Non limiting examples of siNA molecules of the invention are shown in **Figures 4-6**, and **Tables II, III, and IV** herein. For example the siNA can be a double-stranded polynucleotide molecule comprising self-complementary sense and antisense regions, wherein the antisense region comprises nucleotide sequence that is complementary to nucleotide sequence in a target nucleic acid molecule or a portion thereof and the sense region having nucleotide sequence corresponding to the target nucleic acid sequence or a portion thereof. The siNA can be assembled from two separate oligonucleotides, where one strand is the sense strand and the other is the antisense strand, wherein the antisense and sense strands are self-complementary (i.e. each strand comprises nucleotide sequence that is complementary to nucleotide sequence in the other strand; such as where the antisense strand and sense strand form a duplex or double stranded structure, for example wherein the double stranded region is about 19 base pairs); the antisense strand comprises nucleotide sequence that is complementary to nucleotide sequence in a target nucleic acid molecule or a portion thereof and the sense strand comprises nucleotide sequence corresponding to the target nucleic acid sequence or a portion thereof. Alternatively, the siNA is assembled from a single oligonucleotide, where the self-complementary sense and antisense regions of the siNA are linked by means of a nucleic acid based or non-nucleic acid-based linker(s). The siNA can be a polynucleotide with a hairpin secondary structure, having self-complementary sense and antisense regions, wherein the antisense region comprises nucleotide sequence that is complementary to nucleotide sequence in a separate target nucleic acid molecule or a portion thereof and the sense region having nucleotide sequence corresponding to the target nucleic acid sequence or a portion thereof. The siNA can be a circular single-stranded polynucleotide having two or more loop structures and a stem comprising self-complementary sense and antisense regions, wherein the antisense region comprises nucleotide sequence that is complementary to nucleotide sequence in a target nucleic acid molecule or a portion thereof and the sense region having nucleotide sequence corresponding to the target nucleic acid sequence or a portion thereof, and wherein the circular polynucleotide can be processed either *in vivo* or *in vitro* to generate an active

siNA molecule capable of mediating RNAi. The siNA can also comprise a single stranded polynucleotide having nucleotide sequence complementary to nucleotide sequence in a target nucleic acid molecule or a portion thereof (for example, where such siNA molecule does not require the presence within the siNA molecule of nucleotide sequence corresponding to the target nucleic acid sequence or a portion thereof), wherein the single stranded polynucleotide can further comprise a terminal phosphate group, such as a 5'-phosphate (see for example Martinez *et al.*, 2002, *Cell.*, 110, 563-574 and Schwarz *et al.*, 2002, *Molecular Cell*, 10, 537-568), or 5',3'-diphosphate. In certain embodiment, the siNA molecule of the invention comprises separate sense and antisense sequences or regions, wherein the sense and antisense regions are covalently linked by nucleotide or non-nucleotide linkers molecules as is known in the art, or are alternately non-covalently linked by ionic interactions, hydrogen bonding, van der waals interactions, hydrophobic intercations, and/or stacking interactions. In certain embodiments, the siNA molecules of the invention comprise nucleotide sequence that is complementary to nucleotide sequence of a target gene. In another embodiment, the siNA molecule of the invention interacts with nucleotide sequence of a target gene in a manner that causes inhibition of expression of the target gene. As used herein, siNA molecules need not be limited to those molecules containing only RNA, but further encompasses chemically-modified nucleotides and non-nucleotides. In certain embodiments, the short interfering nucleic acid molecules of the invention lack 2'-hydroxy (2'-OH) containing nucleotides. Applicant describes in certain embodiments short interfering nucleic acids that do not require the presence of nucleotides having a 2'-hydroxy group for mediating RNAi and as such, short interfering nucleic acid molecules of the invention optionally do not include any ribonucleotides (e.g., nucleotides having a 2'-OH group). Such siNA molecules that do not require the presence of ribonucleotides within the siNA molecule to support RNAi can however have an attached linker or linkers or other attached or associated groups, moieties, or chains containing one or more nucleotides with 2'-OH groups. Optionally, siNA molecules can comprise ribonucleotides at about 5, 10, 20, 30, 40, or 50% of the nucleotide positions. The modified short interfering nucleic acid molecules of the invention can also be referred to as short interfering modified oligonucleotides "siMON." As used herein, the term siNA is meant to be equivalent to other terms used to describe nucleic acid molecules that are capable of mediating sequence specific RNAi, for example short interfering RNA

(siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), short hairpin RNA (shRNA), short interfering oligonucleotide, short interfering nucleic acid, short interfering modified oligonucleotide, chemically-modified siRNA, post-transcriptional gene silencing RNA (ptgsRNA), and others. In addition, as used herein, the term RNAi 5 is meant to be equivalent to other terms used to describe sequence specific RNA interference, such as post transcriptional gene silencing, or epigenetics. For example, siNA molecules of the invention can be used to epigenetically silence genes at both the post-transcriptional level or the pre-transcriptional level. In a non-limiting example, epigenetic regulation of gene expression by siNA molecules of the invention can result 10 from siNA mediated modification of chromatin structure to alter gene expression (see, for example, Allshire, 2002, *Science*, 297, 1818-1819; Volpe *et al.*, 2002, *Science*, 297, 1833-1837; Jenuwein, 2002, *Science*, 297, 2215-2218; and Hall *et al.*, 2002, *Science*, 297, 2232-2237).

By "modulate" is meant that the expression of the gene, or level of RNA molecule 15 or equivalent RNA molecules encoding one or more proteins or protein subunits, or activity of one or more proteins or protein subunits is up regulated or down regulated, such that expression, level, or activity is greater than or less than that observed in the absence of the modulator. For example, the term "modulate" can mean "inhibit," but the use of the word "modulate" is not limited to this definition.

20 By "inhibit", "down-regulate", or "reduce", it is meant that the expression of the gene, or level of RNA molecules or equivalent RNA molecules encoding one or more proteins or protein subunits, or activity of one or more proteins or protein subunits, is reduced below that observed in the absence of the nucleic acid molecules (e.g., siNA) of the invention. In one embodiment, inhibition, down-regulation or reduction with an siNA 25 molecule is below that level observed in the presence of an inactive or attenuated molecule. In another embodiment, inhibition, down-regulation, or reduction with siNA molecules is below that level observed in the presence of, for example, an siNA molecule with scrambled sequence or with mismatches. In another embodiment, inhibition, down-regulation, or reduction of gene expression with a nucleic acid molecule 30 of the instant invention is greater in the presence of the nucleic acid molecule than in its absence.

By "gene" or "target gene" is meant, a nucleic acid that encodes an RNA, for example, nucleic acid sequences including, but not limited to, structural genes encoding a polypeptide. The target gene can be a gene derived from a cell, an endogenous gene, a transgene, or exogenous genes such as genes of a pathogen, for example a virus, which is 5 present in the cell after infection thereof. The cell containing the target gene can be derived from or contained in any organism, for example a plant, animal, protozoan, virus, bacterium, or fungus. Non-limiting examples of plants include monocots, dicots, or gymnosperms. Non-limiting examples of animals include vertebrates or invertebrates. Non-limiting examples of fungi include molds or yeasts.

10 By "HIV" as used herein is meant, any virus, protein, peptide, polypeptide, and/or polynucleotide involved in the progression, development, or maintenance of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS), including those expressed from a HIV gene or involved in HIV infection (such 15 as polynucleotides referred to by Genbank Accession numbers herein or any other HIV transcript derived from a HIV gene); for example, entire viruses such as HIV-1, HIV-2, FIV-1, SIV-1; viral components such as *nef*, *vif*, *tat*, or *rev* viral gene products; and cellular targets that are involved in HIV infection.

By "HIV protein" is meant, any HIV peptide or protein or a component thereof, wherein the peptide or protein is encoded by a HIV gene or having HIV activity.

20 By "highly conserved sequence region" is meant, a nucleotide sequence of one or more regions in a target gene does not vary significantly from one generation to the other or from one biological system to the other.

25 By "sense region" is meant a nucleotide sequence of a siNA molecule having complementarity to an antisense region of the siNA molecule. In addition, the sense region of a siNA molecule can comprise a nucleic acid sequence having homology with a target nucleic acid sequence.

30 By "antisense region" is meant a nucleotide sequence of a siNA molecule having complementarity to a target nucleic acid sequence. In addition, the antisense region of a siNA molecule can optionally comprise a nucleic acid sequence having complementarity to a sense region of the siNA molecule.

By "target nucleic acid" is meant any nucleic acid sequence whose expression or activity is to be modulated. The target nucleic acid can be DNA or RNA.

By "complementarity" is meant that a nucleic acid can form hydrogen bond(s) with another nucleic acid sequence by either traditional Watson-Crick or other non-traditional types. In reference to the nucleic molecules of the present invention, the binding free energy for a nucleic acid molecule with its complementary sequence is sufficient to allow the relevant function of the nucleic acid to proceed, e.g., RNAi activity. Determination of binding free energies for nucleic acid molecules is well known in the art (see, e.g., Turner *et al.*, 1987, *CSH Symp. Quant. Biol.* LII pp.123-133; Frier *et al.*, 1986, *Proc. Nat. Acad. Sci. USA* 83:9373-9377; Turner *et al.*, 1987, *J. Am. Chem. Soc.* 109:3783-3785). A percent complementarity indicates the percentage of contiguous residues in a nucleic acid molecule that can form hydrogen bonds (e.g., Watson-Crick base pairing) with a second nucleic acid sequence (e.g., 5, 6, 7, 8, 9, 10 out of 10 being 50%, 60%, 70%, 80%, 90%, and 100% complementary). "Perfectly complementary" means that all the contiguous residues of a nucleic acid sequence will hydrogen bond with the same number of contiguous residues in a second nucleic acid sequence.

The siNA molecules of the invention represent a novel therapeutic approach to treat a variety of pathologic indications or other conditions, such as HIV infection or acquired immunodeficiency syndrome (AIDS) and any other diseases or conditions that are related to the levels of HIV in a cell or tissue, alone or in combination with other therapies. The reduction of HIV expression (specifically HIV RNA levels) and thus reduction in the level of the respective protein(s) relieves, to some extent, the symptoms of the disease or condition.

In one embodiment of the present invention, each sequence of a siNA molecule of the invention is independently about 18 to about 24 nucleotides in length, in specific embodiments about 18, 19, 20, 21, 22, 23, or 24 nucleotides in length. In another embodiment, the siNA duplexes of the invention independently comprise about 17 to about 23 base pairs (e.g., about 17, 18, 19, 20, 21, 22 or 23). In yet another embodiment, siNA molecules of the invention comprising hairpin or circular structures are about 35 to about 55 (e.g., about 35, 40, 45, 50 or 55) nucleotides in length, or about 38 to about 44 (e.g., 38, 39, 40, 41, 42, 43 or 44) nucleotides in length and comprising about 16 to about

22 (e.g., about 16, 17, 18, 19, 20, 21 or 22) base pairs. Exemplary siNA molecules of the invention are disclosed herein^I. Exemplary synthetic siNA molecules of the invention are shown in **Tables III and IV** and/or **Figures 4-5**.

As used herein "cell" is used in its usual biological sense, and does not refer to an entire multicellular organism, e.g., specifically does not refer to a human. The cell can be present in an organism, e.g., birds, plants and mammals such as humans, cows, sheep, apes, monkeys, swine, dogs, and cats. The cell can be prokaryotic (e.g., bacterial cell) or eukaryotic (e.g., mammalian or plant cell). The cell can be of somatic or germ line origin, totipotent or pluripotent, dividing or non-dividing. The cell can also be derived from or can comprise a gamete or embryo, a stem cell, or a fully differentiated cell.

The siNA molecules of the invention are added directly, or can be complexed with cationic lipids, packaged within liposomes, or otherwise delivered to target cells or tissues. The nucleic acid or nucleic acid complexes can be locally administered to relevant tissues *ex vivo*, or *in vivo* through injection, infusion pump or stent, with or without their incorporation in biopolymers. In particular embodiments, the nucleic acid molecules of the invention comprise sequences shown in **Tables II-III** and/or **Figures 4-5**. Examples of such nucleic acid molecules consist essentially of sequences defined in these tables and figures. Furthermore, the chemically modified constructs described in **Table IV** can be applied to any siNA sequence of the invention.

In another aspect, the invention provides mammalian cells containing one or more siNA molecules of this invention. The one or more siNA molecules can independently be targeted to the same or different sites.

By "RNA" is meant a molecule comprising at least one ribonucleotide residue. By "ribonucleotide" is meant a nucleotide with a hydroxyl group at the 2' position of a β -D-ribo-furanose moiety. The terms include double-stranded RNA, single-stranded RNA, isolated RNA such as partially purified RNA, essentially pure RNA, synthetic RNA, recombinantly produced RNA, as well as altered RNA that differs from naturally occurring RNA by the addition, deletion, substitution and/or alteration of one or more nucleotides. Such alterations can include addition of non-nucleotide material, such as to the end(s) of the siNA or internally, for example at one or more nucleotides of the RNA. Nucleotides in the RNA molecules of the instant invention can also comprise non-

standard nucleotides, such as non-naturally occurring nucleotides or chemically synthesized nucleotides or deoxynucleotides. These altered RNAs can be referred to as analogs or analogs of naturally-occurring RNA.

By "subject" is meant an organism, which is a donor or recipient of explanted cells
5 or the cells themselves. "Subject" also refers to an organism to which the nucleic acid molecules of the invention can be administered. In one embodiment, a subject is a mammal or mammalian cells. In another embodiment, a subject is a human or human cells.

The term "phosphorothioate" as used herein refers to an internucleotide linkage
10 having Formula I, wherein Z and/or W comprise a sulfur atom. Hence, the term phosphorothioate refers to both phosphorothioate and phosphorodithioate internucleotide linkages.

The term "universal base" as used herein refers to nucleotide base analogs that form base pairs with each of the natural DNA/RNA bases with little discrimination
15 between them. Non-limiting examples of universal bases include C-phenyl, C-naphthyl and other aromatic derivatives, inosine, azole carboxamides, and nitroazole derivatives such as 3-nitropyrrole, 4-nitroindole, 5-nitroindole, and 6-nitroindole as known in the art (see for example Loakes, 2001, *Nucleic Acids Research*, 29, 2437-2447).

The term "acyclic nucleotide" as used herein refers to any nucleotide having an
20 acyclic ribose sugar, for example where any of the ribose carbons (C1, C2, C3, C4, or C5), are independently or in combination absent from the nucleotide.

The nucleic acid molecules of the instant invention, individually, or in combination or in conjunction with other drugs, can be used to treat diseases or conditions discussed herein (e.g., cancers and other proliferative conditions). For example, to treat a particular
25 disease or condition, the siNA molecules can be administered to a subject or can be administered to other appropriate cells evident to those skilled in the art, individually or in combination with one or more drugs under conditions suitable for the treatment.

In a further embodiment, the siNA molecules can be used in combination with other known treatments to treat conditions or diseases discussed above. For example, the
30 described molecules could be used in combination with one or more known therapeutic

agents to treat a disease or condition. Non-limiting examples of other therapeutic agents that can be readily combined with a siNA molecule of the invention are enzymatic nucleic acid molecules, allosteric nucleic acid molecules, antisense, decoy, or aptamer nucleic acid molecules, antibodies such as monoclonal antibodies, small molecules, and other organic and/or inorganic compounds including metals, salts and ions.

In one embodiment, the invention features an expression vector comprising a nucleic acid sequence encoding at least one siNA molecule of the invention in a manner which allows expression of the siNA molecule. For example, the vector can contain sequence(s) encoding both strands of a siNA molecule comprising a duplex. The vector 10 can also contain sequence(s) encoding a single nucleic acid molecule that is self-complementary and thus forms a siNA molecule. Non-limiting examples of such expression vectors are described in Paul *et al.*, 2002, *Nature Biotechnology*, 19, 505; Miyagishi and Taira, 2002, *Nature Biotechnology*, 19, 497; Lee *et al.*, 2002, *Nature Biotechnology*, 19, 500; and Novina *et al.*, 2002, *Nature Medicine*, 8, 681-686.

15 In another embodiment, the invention features a mammalian cell, for example, a human cell, including an expression vector of the invention.

In yet another embodiment, the expression vector of the invention comprises a sequence for a siNA molecule having complementarity to a RNA molecule referred to by a Genbank Accession numbers, for example Genbank Accession Nos. disclosed herein.

20 In one embodiment, an expression vector of the invention comprises a nucleic acid sequence encoding two or more siNA molecules, which can be the same or different.

In another aspect of the invention, siNA molecules that interact with target RNA molecules and down-regulate gene encoding target RNA molecules (for example target RNA molecules referred to by Genbank Accession numbers herein) are expressed from 25 transcription units inserted into DNA or RNA vectors. The recombinant vectors can be DNA plasmids or viral vectors. siNA expressing viral vectors can be constructed based on, but not limited to, adeno-associated virus, retrovirus, adenovirus, or alphavirus. The recombinant vectors capable of expressing the siNA molecules can be delivered as described herein, and persist in target cells. Alternatively, viral vectors can be used that 30 provide for transient expression of siNA molecules. Such vectors can be repeatedly

administered as necessary. Once expressed, the siNA molecules bind and down-regulate gene function or expression via RNA interference (RNAi). Delivery of siNA expressing vectors can be systemic, such as by intravenous or intramuscular administration, by administration to target cells ex-planted from a subject followed by reintroduction into the subject, or by any other means that would allow for introduction into the desired target cell.

5 By "vectors" is meant any nucleic acid- and/or viral-based technique used to deliver a desired nucleic acid.

10 Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims.

BRIEF DESCRIPTION OF THE DRAWINGS

15 **Figure 1** shows a non-limiting example of a scheme for the synthesis of siNA molecules. The complementary siNA sequence strands, strand 1 and strand 2, are synthesized in tandem and are connected by a cleavable linkage, such as a nucleotide succinate or abasic succinate, which can be the same or different from the cleavable linker used for solid phase synthesis on a solid support. The synthesis can be either solid phase or solution phase, in the example shown, the synthesis is a solid phase synthesis. The synthesis is performed such that a protecting group, such as a dimethoxytrityl group, remains intact on the terminal nucleotide of the tandem oligonucleotide. Upon cleavage 20 and deprotection of the oligonucleotide, the two siNA strands spontaneously hybridize to form a siNA duplex, which allows the purification of the duplex by utilizing the properties of the terminal protecting group, for example by applying a trityl on purification method wherein only duplexes/oligonucleotides with the terminal protecting group are isolated.

25 **Figure 2** shows a MALDI-TOV mass spectrum of a purified siNA duplex synthesized by a method of the invention. The two peaks shown correspond to the predicted mass of the separate siNA sequence strands. This result demonstrates that the siNA duplex generated from tandem synthesis can be purified as a single entity using a simple trityl-on purification methodology.

Figure 3 shows a non-limiting proposed mechanistic representation of target RNA degradation involved in RNAi. Double-stranded RNA (dsRNA), which is generated by RNA-dependent RNA polymerase (RdRP) from foreign single-stranded RNA, for example viral, transposon, or other exogenous RNA, activates the DICER enzyme that in turn generates siNA duplexes. Alternately, synthetic or expressed siNA can be introduced directly into a cell by appropriate means. An active siNA complex forms which recognizes a target RNA, resulting in degradation of the target RNA by the RISC endonuclease complex or in the synthesis of additional RNA by RNA-dependent RNA polymerase (RdRP), which can activate DICER and result in additional siNA molecules, thereby amplifying the RNAi response.

Figure 4A-F shows non-limiting examples of chemically-modified siNA constructs of the present invention. In the figure, N stands for any nucleotide (adenosine, guanosine, cytosine, uridine, or optionally thymidine, for example thymidine can be substituted in the overhanging regions designated by parenthesis (N N)). Various modifications are shown for the sense and antisense strands of the siNA constructs.

Figure 4A: The sense strand comprises 21 nucleotides having four phosphorothioate 5'- and 3'-terminal internucleotide linkages, wherein the two terminal 3'-nucleotides are optionally base paired and wherein all pyrimidine nucleotides that may be present are 2'-O-methyl or 2'-deoxy-2'-fluoro modified nucleotides except for (N N) nucleotides, which can comprise ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein. The antisense strand comprises 21 nucleotides, optionally having a 3'-terminal glyceryl moiety and wherein the two terminal 3'-nucleotides are optionally complementary to the target RNA sequence, and having one 3'-terminal phosphorothioate internucleotide linkage and four 5'-terminal phosphorothioate internucleotide linkages and wherein all pyrimidine nucleotides that may be present are 2'-deoxy-2'-fluoro modified nucleotides except for (N N) nucleotides, which can comprise ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein.

Figure 4B: The sense strand comprises 21 nucleotides wherein the two terminal 3'-nucleotides are optionally base paired and wherein all pyrimidine nucleotides that may be present are 2'-O-methyl or 2'-deoxy-2'-fluoro modified nucleotides except for (N N)

nucleotides, which can comprise ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein. The antisense strand comprises 21 nucleotides, optionally having a 3'-terminal glyceryl moiety and wherein the two terminal 3'-nucleotides are optionally complementary to the target RNA sequence, and wherein all pyrimidine nucleotides that may be present are 2'-deoxy-2'-fluoro modified nucleotides except for (N N) nucleotides, which can comprise ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein.

Figure 4C: The sense strand comprises 21 nucleotides having 5'- and 3'- terminal cap moieties wherein the two terminal 3'-nucleotides are optionally base paired and wherein all pyrimidine nucleotides that may be present are 2'-O-methyl or 2'-deoxy-2'-fluoro modified nucleotides except for (N N) nucleotides, which can comprise ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein. The antisense strand comprises 21 nucleotides, optionally having a 3'-terminal glyceryl moiety and wherein the two terminal 3'-nucleotides are optionally complementary to the target RNA sequence, and having one 3'-terminal phosphorothioate internucleotide linkage and wherein all pyrimidine nucleotides that may be present are 2'-deoxy-2'-fluoro modified nucleotides except for (N N) nucleotides, which can comprise ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein.

Figure 4D: The sense strand comprises 21 nucleotides having 5'- and 3'- terminal cap moieties wherein the two terminal 3'-nucleotides are optionally base paired and wherein all pyrimidine nucleotides that may be present are 2'-deoxy-2'-fluoro modified nucleotides except for (N N) nucleotides, which can comprise ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein and wherein all purine nucleotides that may be present are 2'-deoxy nucleotides. The antisense strand comprises 21 nucleotides, optionally having a 3'-terminal glyceryl moiety and wherein the two terminal 3'-nucleotides are optionally complementary to the target RNA sequence, and having one 3'-terminal phosphorothioate internucleotide linkage and wherein all pyrimidine nucleotides that may be present are 2'-deoxy-2'-fluoro modified nucleotides and all purine nucleotides that may be present are 2'-O-methyl modified nucleotides except for (N N) nucleotides, which can comprise ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein.

Figure 4E: The sense strand comprises 21 nucleotides having 5'- and 3'- terminal cap moieties wherein the two terminal 3'-nucleotides are optionally base paired and wherein all pyrimidine nucleotides that may be present are 2'-deoxy-2'-fluoro modified nucleotides except for (N N) nucleotides, which can comprise ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein.

5 The antisense strand comprises 21 nucleotides, optionally having a 3'-terminal glyceryl moiety and wherein the two terminal 3'-nucleotides are optionally complementary to the target RNA sequence, and wherein all pyrimidine nucleotides that may be present are 2'-deoxy-2'-fluoro modified nucleotides and all purine nucleotides that may be present are 2'-O-methyl modified nucleotides except for (N N) nucleotides, which can comprise

10 ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein.

Figure 4F: The sense strand comprises 21 nucleotides having 5'- and 3'- terminal cap moieties wherein the two terminal 3'-nucleotides are optionally base paired and wherein all pyrimidine nucleotides that may be present are 2'-deoxy-2'-fluoro modified nucleotides except for (N N) nucleotides, which can comprise ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein.

15 The antisense strand comprises 21 nucleotides, optionally having a 3'-terminal glyceryl moiety and wherein the two terminal 3'-nucleotides are optionally complementary to the target RNA sequence, and having one 3'-terminal phosphorothioate internucleotide linkage and wherein all pyrimidine nucleotides that may be present are 2'-deoxy-2'-fluoro modified nucleotides and all purine nucleotides that may be present are 2'-deoxy nucleotides except for (N N) nucleotides, which can comprise ribonucleotides, deoxynucleotides, universal bases, or other chemical modifications described herein.

20 25 The antisense strand of constructs A-F comprise sequence complementary to any target nucleic acid sequence of the invention.

Figure 5A-F shows non-limiting examples of specific chemically-modified siNA sequences of the invention. A-F applies the chemical modifications described in **Figure 4A-F** to a HIV siNA sequence.

30 **Figure 6** shows non-limiting examples of different siNA constructs of the invention. The examples shown (constructs 1, 2, and 3) have 19 representative base

pairs; however, different embodiments of the invention include any number of base pairs described herein. Bracketed regions represent nucleotide overhangs, for example comprising about 1, 2, 3, or 4 nucleotides in length, preferably about 2 nucleotides. Constructs 1 and 2 can be used independently for RNAi activity. Construct 2 can 5 comprise a polynucleotide or non-nucleotide linker, which can optionally be designed as a biodegradable linker. In one embodiment, the loop structure shown in construct 2 can comprise a biodegradable linker that results in the formation of construct 1 *in vivo* and/or *in vitro*. In another example, construct 3 can be used to generate construct 2 under the same principle wherein a linker is used to generate the active siNA construct 2 *in vivo* 10 and/or *in vitro*, which can optionally utilize another biodegradable linker to generate the active siNA construct 1 *in vivo* and/or *in vitro*. As such, the stability and/or activity of the siNA constructs can be modulated based on the design of the siNA construct for use *in vivo* or *in vitro* and/or *in vitro*.

15 **Figure 7A-C** is a diagrammatic representation of a scheme utilized in generating an expression cassette to generate siNA hairpin constructs.

20 **Figure 7A:** A DNA oligomer is synthesized with a 5'-restriction site (R1) sequence followed by a region having sequence identical (sense region of siNA) to a predetermined HIV target sequence, wherein the sense region comprises, for example, about 19, 20, 21, or 22 nucleotides (N) in length, which is followed by a loop sequence of defined sequence (X), comprising, for example, about 3 to about 10 nucleotides.

25 **Figure 7B:** The synthetic construct is then extended by DNA polymerase to generate a hairpin structure having self-complementary sequence that will result in a siNA transcript having specificity for a HIV target sequence and having self-complementary sense and antisense regions.

30 **Figure 7C:** The construct is heated (for example to about 95°C) to linearize the sequence, thus allowing extension of a complementary second DNA strand using a primer to the 3'-restriction sequence of the first strand. The double-stranded DNA is then inserted into an appropriate vector for expression in cells. The construct can be designed such that a 3'-terminal nucleotide overhang results from the transcription, for example by engineering restriction sites and/or utilizing a poly-U termination region as described in Paul *et al.*, 2002, *Nature Biotechnology*, 29, 505-508.

Figure 8A-C is a diagrammatic representation of a scheme utilized in generating an expression cassette to generate double-stranded siNA constructs.

5 **Figure 8A:** A DNA oligomer is synthesized with a 5'-restriction (R1) site sequence followed by a region having sequence identical (sense region of siNA) to a predetermined HIV target sequence, wherein the sense region comprises, for example, about 19, 20, 21, or 22 nucleotides (N) in length, and which is followed by a 3'-restriction site (R2) which is adjacent to a loop sequence of defined sequence (X).

Figure 8B: The synthetic construct is then extended by DNA polymerase to generate a hairpin structure having self-complementary sequence.

10 **Figure 8C:** The construct is processed by restriction enzymes specific to R1 and R2 to generate a double-stranded DNA which is then inserted into an appropriate vector for expression in cells. The transcription cassette is designed such that a U6 promoter region flanks each side of the dsDNA which generates the separate sense and antisense strands of the siNA. Poly T termination sequences can be added to the constructs to 15 generate U overhangs in the resulting transcript.

Figure 9A-E is a diagrammatic representation of a method used to determine target sites for siNA mediated RNAi within a particular target nucleic acid sequence, such as messenger RNA.

20 **Figure 9A:** A pool of siNA oligonucleotides are synthesized wherein the antisense region of the siNA constructs has complementarity to target sites across the target nucleic acid sequence, and wherein the sense region comprises sequence complementary to the antisense region of the siNA.

25 **Figure 9B&C:** (**Figure 9B**) The sequences are pooled and are inserted into vectors such that (**Figure 9C**) transfection of a vector into cells results in the expression of the siNA.

Figure 9D: Cells are sorted based on phenotypic change that is associated with modulation of the target nucleic acid sequence.

Figure 9E: The siNA is isolated from the sorted cells and is sequenced to identify efficacious target sites within the target nucleic acid sequence.

Figure 10 shows non-limiting examples of different stabilization chemistries (1-10) that can be used, for example, to stabilize the 3'-end of siNA sequences of the invention, including (1) [3'-3']-inverted deoxyribose; (2) deoxyribonucleotide; (3) [5'-3']-3'-deoxyribonucleotide; (4) [5'-3']-ribonucleotide; (5) [5'-3']-3'-O-methyl ribonucleotide; (6) 3'-glycetyl; (7) [3'-5']-3'-deoxyribonucleotide; (8) [3'-3']-deoxyribonucleotide; (9) [5'-2']-deoxyribonucleotide; and (10) [5-3']-dideoxyribonucleotide. In addition to modified and unmodified backbone chemistries indicated in the figure, these chemistries can be combined with different backbone modifications as described herein, for example, backbone modifications having Formula I. In addition, the 2'-deoxy nucleotide shown 5' to the terminal modifications shown can be another modified or unmodified nucleotide or non-nucleotide described herein, for example modifications having any of Formulae I-VII or any combination thereof.

Figure 11 shows a non-limiting example of a strategy used to identify chemically modified siNA constructs of the invention that are nuclease resistance while preserving the ability to mediate RNAi activity. Chemical modifications are introduced into the siNA construct based on educated design parameters (e.g. introducing 2'-mofications, base modifications, backbone modifications, terminal cap modifications etc). The modified construct is tested in an appropriate system (e.g. human serum for nuclease resistance, shown, or an animal model for PK/delivery parameters). In parallel, the siNA construct is tested for RNAi activity, for example in a cell culture system such as a luciferase reporter assay). Lead siNA constructs are then identified which possess a particular characteristic while maintaining RNAi activity, and can be further modified and assayed once again. This same approach can be used to identify siNA-conjugate molecules with improved pharmacokinetic profiles, delivery, and RNAi activity.

25

DETAILED DESCRIPTION OF THE INVENTION

Mechanism of action of Nucleic Acid Molecules of the Invention

The discussion that follows discusses the proposed mechanism of RNA interference mediated by short interfering RNA as is presently known, and is not meant to be limiting and is not an admission of prior art. Applicant demonstrates herein that 30 chemically-modified short interfering nucleic acids possess similar or improved capacity to mediate RNAi as do siRNA molecules and are expected to possess improved stability

and activity *in vivo*; therefore, this discussion is not meant to be limiting only to siRNA and can be applied to siNA as a whole. By "improved capacity to mediate RNAi" or "improved RNAi activity" is meant to include RNAi activity measured *in vitro* and/or *in vivo* where the RNAi activity is a reflection of both the ability of the siNA to mediate RNAi and the stability of the siNAs of the invention. In this invention, the product of these activities can be increased *in vitro* and/or *in vivo* compared to an all RNA siRNA or a siNA containing a plurality of ribonucleotides. In some cases, the activity or stability of the siNA molecule can be decreased (i.e., less than ten-fold), but the overall activity of the siNA molecule is enhanced *in vitro* and/or *in vivo*.

RNA interference refers to the process of sequence specific post-transcriptional gene silencing in animals mediated by short interfering RNAs (siRNAs) (Fire *et al.*, 1998, *Nature*, 391, 806). The corresponding process in plants is commonly referred to as post-transcriptional gene silencing or RNA silencing and is also referred to as quelling in fungi. The process of post-transcriptional gene silencing is thought to be an evolutionarily-conserved cellular defense mechanism used to prevent the expression of foreign genes which is commonly shared by diverse flora and phyla (Fire *et al.*, 1999, *Trends Genet.*, 15, 358). Such protection from foreign gene expression may have evolved in response to the production of double-stranded RNAs (dsRNAs) derived from viral infection or the random integration of transposon elements into a host genome via a cellular response that specifically destroys homologous single-stranded RNA or viral genomic RNA. The presence of dsRNA in cells triggers the RNAi response though a mechanism that has yet to be fully characterized. This mechanism appears to be different from the interferon response that results from dsRNA-mediated activation of protein kinase PKR and 2', 5'-oligoadenylate synthetase resulting in non-specific cleavage of mRNA by ribonuclease L.

The presence of long dsRNAs in cells stimulates the activity of a ribonuclease III enzyme referred to as Dicer. Dicer is involved in the processing of the dsRNA into short pieces of dsRNA known as short interfering RNAs (siRNAs) (Berstein *et al.*, 2001, *Nature*, 409, 363). Short interfering RNAs derived from Dicer activity are typically about 21 to about 23 nucleotides in length and comprise about 19 base pair duplexes. Dicer has also been implicated in the excision of 21- and 22-nucleotide small temporal RNAs (stRNAs) from precursor RNA of conserved structure that are implicated in

translational control (Hutvagner *et al.*, 2001, *Science*, 293, 834). The RNAi response also features an endonuclease complex containing a siRNA, commonly referred to as an RNA-induced silencing complex (RISC), which mediates cleavage of single-stranded RNA having sequence homologous to the siRNA. Cleavage of the target RNA takes 5 place in the middle of the region complementary to the guide sequence of the siRNA duplex (Elbashir *et al.*, 2001, *Genes Dev.*, 15, 188). In addition, RNA interference can also involve small RNA (e.g., micro-RNA or miRNA) mediated gene silencing, presumably through cellular mechanisms that regulate chromatin structure and thereby prevent transcription of target gene sequences (see for example Allshire, 2002, *Science*, 10 297, 1818-1819; Volpe *et al.*, 2002, *Science*, 297, 1833-1837; Jenuwein, 2002, *Science*, 297, 2215-2218; and Hall *et al.*, 2002, *Science*, 297, 2232-2237). As such, siRNA molecules of the invention can be used to mediate gene silencing via interaction with RNA transcripts or alternately by interaction with particular gene sequences, wherein 15 such interaction results in gene silencing either at the transcriptional level or post-transcriptional level.

RNAi has been studied in a variety of systems. Fire *et al.*, 1998, *Nature*, 391, 806, were the first to observe RNAi in *C. elegans*. Wianny and Goetz, 1999, *Nature Cell Biol.*, 2, 70, describe RNAi mediated by dsRNA in mouse embryos. Hammond *et al.*, 2000, *Nature*, 404, 293, describe RNAi in *Drosophila* cells transfected with dsRNA. 20 Elbashir *et al.*, 2001, *Nature*, 411, 494, describe RNAi induced by introduction of duplexes of synthetic 21-nucleotide RNAs in cultured mammalian cells including human embryonic kidney and HeLa cells. Recent work in *Drosophila* embryonic lysates has revealed certain requirements for siRNA length, structure, chemical composition, and sequence that are essential to mediate efficient RNAi activity. These studies have shown 25 that 21 nucleotide siRNA duplexes are most active when containing two 2-nucleotide 3'-terminal nucleotide overhangs. Furthermore, substitution of one or both siRNA strands with 2'-deoxy or 2'-O-methyl nucleotides abolishes RNAi activity, whereas substitution of 3'-terminal siRNA nucleotides with deoxy nucleotides was shown to be tolerated. Mismatch sequences in the center of the siRNA duplex were also shown to abolish RNAi 30 activity. In addition, these studies also indicate that the position of the cleavage site in the target RNA is defined by the 5'-end of the siRNA guide sequence rather than the 3'-end (Elbashir *et al.*, 2001, *EMBO J.*, 20, 6877). Other studies have indicated that a 5'-phosphate on the target-complementary strand of a siRNA duplex is required for siRNA

activity and that ATP is utilized to maintain the 5'-phosphate moiety on the siRNA (Nykanen *et al.*, 2001, *Cell*, 107, 309); however, siRNA molecules lacking a 5'-phosphate are active when introduced exogenously, suggesting that 5'-phosphorylation of siRNA constructs may occur *in vivo*.

5 Synthesis of Nucleic acid Molecules

Synthesis of nucleic acids greater than 100 nucleotides in length is difficult using automated methods, and the therapeutic cost of such molecules is prohibitive. In this invention, small nucleic acid motifs ("small" refers to nucleic acid motifs no more than 100 nucleotides in length, preferably no more than 80 nucleotides in length, and most 10 preferably no more than 50 nucleotides in length; *e.g.*, individual siNA oligonucleotide sequences or siNA sequences synthesized in tandem) are preferably used for exogenous delivery. The simple structure of these molecules increases the ability of the nucleic acid to invade targeted regions of protein and/or RNA structure. Exemplary molecules of the instant invention are chemically synthesized, and others can similarly be synthesized.

15 Oligonucleotides (*e.g.*, certain modified oligonucleotides or portions of oligonucleotides lacking ribonucleotides) are synthesized using protocols known in the art, for example as described in Caruthers *et al.*, 1992, *Methods in Enzymology* 211, 3-19, Thompson *et al.*, International PCT Publication No. WO 99/54459, Wincott *et al.*, 1995, *Nucleic Acids Res.* 23, 2677-2684, Wincott *et al.*, 1997, *Methods Mol. Bio.*, 74, 20 59, Brennan *et al.*, 1998, *Biotechnol Bioeng.*, 61, 33-45, and Brennan, U.S. Pat. No. 6,001,311. All of these references are incorporated herein by reference. The synthesis of oligonucleotides makes use of common nucleic acid protecting and coupling groups, such as dimethoxytrityl at the 5'-end, and phosphoramidites at the 3'-end. In a non-limiting example, small scale syntheses are conducted on a 394 Applied Biosystems, Inc. 25 synthesizer using a 0.2 μ mol scale protocol with a 2.5 min coupling step for 2'-O-methylated nucleotides and a 45 sec coupling step for 2'-deoxy nucleotides or 2'-deoxy-2'-fluoro nucleotides. **Table V** outlines the amounts and the contact times of the reagents used in the synthesis cycle. Alternatively, syntheses at the 0.2 μ mol scale can be performed on a 96-well plate synthesizer, such as the instrument produced by Protogene 30 (Palo Alto, CA) with minimal modification to the cycle. A 33-fold excess (60 μ L of 0.11 M = 6.6 μ mol) of 2'-O-methyl phosphoramidite and a 105-fold excess of S-ethyl tetrazole (60 μ L of 0.25 M = 15 μ mol) can be used in each coupling cycle of 2'-O-methyl

residues relative to polymer-bound 5'-hydroxyl. A 22-fold excess (40 μ L of 0.11 M = 4.4 μ mol) of deoxy phosphoramidite and a 70-fold excess of S-ethyl tetrazole (40 μ L of 0.25 M = 10 μ mol) can be used in each coupling cycle of deoxy residues relative to polymer-bound 5'-hydroxyl. Average coupling yields on the 394 Applied Biosystems, Inc. synthesizer, determined by colorimetric quantitation of the trityl fractions, are typically 97.5-99%. Other oligonucleotide synthesis reagents for the 394 Applied Biosystems, Inc. synthesizer include the following: detritylation solution is 3% TCA in methylene chloride (ABI); capping is performed with 16% *N*-methyl imidazole in THF (ABI) and 10% acetic anhydride/10% 2,6-lutidine in THF (ABI); and oxidation solution is 16.9 mM I_2 , 49 mM pyridine, 9% water in THF (PERSEPTIVETM). Burdick & Jackson Synthesis Grade acetonitrile is used directly from the reagent bottle. S-Ethyltetrazole solution (0.25 M in acetonitrile) is made up from the solid obtained from American International Chemical, Inc. Alternately, for the introduction of phosphorothioate linkages, Beaucage reagent (3H-1,2-Benzodithiol-3-one 1,1-dioxide, 0.05 M in acetonitrile) is used.

Deprotection of the DNA-based oligonucleotides is performed as follows: the polymer-bound trityl-on oligoribonucleotide is transferred to a 4 mL glass screw top vial and suspended in a solution of 40% aq. methylamine (1 mL) at 65 °C for 10 min. After cooling to -20 °C, the supernatant is removed from the polymer support. The support is washed three times with 1.0 mL of EtOH:MeCN:H₂O/3:1:1, vortexed and the supernatant is then added to the first supernatant. The combined supernatants, containing the oligoribonucleotide, are dried to a white powder.

The method of synthesis used for RNA including certain siNA molecules of the invention follows the procedure as described in Usman *et al.*, 1987, *J. Am. Chem. Soc.*, 109, 7845; Scaringe *et al.*, 1990, *Nucleic Acids Res.*, 18, 5433; and Wincott *et al.*, 1995, *Nucleic Acids Res.*, 23, 2677-2684 Wincott *et al.*, 1997, *Methods Mol. Bio.*, 74, 59, and makes use of common nucleic acid protecting and coupling groups, such as dimethoxytrityl at the 5'-end, and phosphoramidites at the 3'-end. In a non-limiting example, small scale syntheses are conducted on a 394 Applied Biosystems, Inc. synthesizer using a 0.2 μ mol scale protocol with a 7.5 min coupling step for alkylsilyl protected nucleotides and a 2.5 min coupling step for 2'-O-methylated nucleotides. **Table V** outlines the amounts and the contact times of the reagents used in the synthesis

cycle. Alternatively, syntheses at the 0.2 μ mol scale can be done on a 96-well plate synthesizer, such as the instrument produced by Protogene (Palo Alto, CA) with minimal modification to the cycle. A 33-fold excess (60 μ L of 0.11 M = 6.6 μ mol) of 2'-O-methyl phosphoramidite and a 75-fold excess of S-ethyl tetrazole (60 μ L of 0.25 M = 15 μ mol) can be used in each coupling cycle of 2'-O-methyl residues relative to polymer-bound 5'-hydroxyl. A 66-fold excess (120 μ L of 0.11 M = 13.2 μ mol) of alkylsilyl (ribo) protected phosphoramidite and a 150-fold excess of S-ethyl tetrazole (120 μ L of 0.25 M = 30 μ mol) can be used in each coupling cycle of ribo residues relative to polymer-bound 5'-hydroxyl. Average coupling yields on the 394 Applied Biosystems, Inc. synthesizer, determined by colorimetric quantitation of the trityl fractions, are typically 97.5-99%. Other oligonucleotide synthesis reagents for the 394 Applied Biosystems, Inc. synthesizer include the following: detritylation solution is 3% TCA in methylene chloride (ABI); capping is performed with 16% N-methyl imidazole in THF (ABI) and 10% acetic anhydride/10% 2,6-lutidine in THF (ABI); oxidation solution is 16.9 mM I₂, 15 49 mM pyridine, 9% water in THF (PERSEPTIVETM). Burdick & Jackson Synthesis Grade acetonitrile is used directly from the reagent bottle. S-Ethyltetrazole solution (0.25 M in acetonitrile) is made up from the solid obtained from American International Chemical, Inc. Alternately, for the introduction of phosphorothioate linkages, Beaucage reagent (3H-1,2-Benzodithiol-3-one 1,1-dioxide 0.05 M in acetonitrile) is used.

20 Deprotection of the RNA is performed using either a two-pot or one-pot protocol. For the two-pot protocol, the polymer-bound trityl-on oligoribonucleotide is transferred to a 4 mL glass screw top vial and suspended in a solution of 40% aq. methylamine (1 mL) at 65 °C for 10 min. After cooling to -20 °C, the supernatant is removed from the polymer support. The support is washed three times with 1.0 mL of EtOH:MeCN:H₂O/3:1:1, vortexed and the supernatant is then added to the first supernatant. The combined supernatants, containing the oligoribonucleotide, are dried to a white powder. The base deprotected oligoribonucleotide is resuspended in anhydrous TEA/HF/NMP solution (300 μ L of a solution of 1.5 mL N-methylpyrrolidinone, 750 μ L TEA and 1 mL TEA•3HF to provide a 1.4 M HF concentration) and heated to 65 °C. 25 After 1.5 h, the oligomer is quenched with 1.5 M NH₄HCO₃.

30

Alternatively, for the one-pot protocol, the polymer-bound trityl-on oligoribonucleotide is transferred to a 4 mL glass screw top vial and suspended in a

solution of 33% ethanolic methylamine/DMSO: 1/1 (0.8 mL) at 65 °C for 15 min. The vial is brought to rt. TEA•3HF (0.1 mL) is added and the vial is heated at 65 °C for 15 min. The sample is cooled at –20 °C and then quenched with 1.5 M NH₄HCO₃.

For purification of the trityl-on oligomers, the quenched NH₄HCO₃ solution is
5 loaded onto a C-18 containing cartridge that had been prewashed with acetonitrile followed by 50 mM TEAA. After washing the loaded cartridge with water, the RNA is detritylated with 0.5% TFA for 13 min. The cartridge is then washed again with water, salt exchanged with 1 M NaCl and washed with water again. The oligonucleotide is then eluted with 30% acetonitrile.

10 The average stepwise coupling yields are typically >98% (Wincott *et al.*, 1995 *Nucleic Acids Res.* 23, 2677-2684). Those of ordinary skill in the art will recognize that the scale of synthesis can be adapted to be larger or smaller than the example described above including but not limited to 96-well format.

15 Alternatively, the nucleic acid molecules of the present invention can be synthesized separately and joined together post-synthetically, for example, by ligation (Moore *et al.*, 1992, *Science* 256, 9923; Draper *et al.*, International PCT publication No. WO 93/23569; Shabarova *et al.*, 1991, *Nucleic Acids Research* 19, 4247; Bellon *et al.*, 1997, *Nucleosides & Nucleotides*, 16, 951; Bellon *et al.*, 1997, *Bioconjugate Chem.* 8, 204), or by hybridization following synthesis and/or deprotection.

20 The siNA molecules of the invention can also be synthesized via a tandem synthesis methodology as described in Example 1 herein, wherein both siNA strands are synthesized as a single contiguous oligonucleotide fragment or strand separated by a cleavable linker which is subsequently cleaved to provide separate siNA fragments or strands that hybridize and permit purification of the siNA duplex. The linker can be a polynucleotide linker or a non-nucleotide linker. The tandem synthesis of siNA as described herein can be readily adapted to both multiwell/multiplate synthesis platforms such as 96 well or similarly larger multi-well platforms. The tandem synthesis of siNA as described herein can also be readily adapted to large scale synthesis platforms employing batch reactors, synthesis columns and the like.

A siNA molecule can also be assembled from two distinct nucleic acid strands or fragments wherein one fragment includes the sense region and the second fragment includes the antisense region of the RNA molecule.

The nucleic acid molecules of the present invention can be modified extensively to 5 enhance stability by modification with nuclease resistant groups, for example, 2'-amino, 2'-C-allyl, 2'-fluoro, 2'-O-methyl, 2'-H (for a review see Usman and Cedergren, 1992, *TIBS* 17, 34; Usman *et al.*, 1994, *Nucleic Acids Symp. Ser.* 31, 163). siNA constructs can be purified by gel electrophoresis using general methods or can be purified by high pressure liquid chromatography (HPLC; see Wincott *et al.*, *supra*, the totality of which is 10 hereby incorporated herein by reference) and re-suspended in water.

In another aspect of the invention, siNA molecules of the invention are expressed from transcription units inserted into DNA or RNA vectors. The recombinant vectors can be DNA plasmids or viral vectors. siNA expressing viral vectors can be constructed based on, but not limited to, adeno-associated virus, retrovirus, adenovirus, or alphavirus. 15 The recombinant vectors capable of expressing the siNA molecules can be delivered as described herein, and persist in target cells. Alternatively, viral vectors can be used that provide for transient expression of siNA molecules.

Optimizing Activity of the nucleic acid molecule of the invention.

Chemically synthesizing nucleic acid molecules with modifications (base, sugar 20 and/or phosphate) can prevent their degradation by serum ribonucleases, which can increase their potency (see *e.g.*, Eckstein *et al.*, International Publication No. WO 92/07065; Perrault *et al.*, 1990 *Nature* 344, 565; Pieken *et al.*, 1991, *Science* 253, 314; Usman and Cedergren, 1992, *Trends in Biochem. Sci.* 17, 334; Usman *et al.*, International Publication 25 No. WO 93/15187; and Rossi *et al.*, International Publication No. WO 91/03162; Sproat, U.S. Pat. No. 5,334,711; Gold *et al.*, U.S. Pat. No. 6,300,074; and Burgin *et al.*, *supra*; all of which are incorporated by reference herein). All of the above references describe various chemical modifications that can be made to the base, phosphate and/or sugar moieties of the nucleic acid molecules described herein. Modifications that enhance their efficacy in cells, and removal of bases from nucleic acid 30 molecules to shorten oligonucleotide synthesis times and reduce chemical requirements are desired.

There are several examples in the art describing sugar, base and phosphate modifications that can be introduced into nucleic acid molecules with significant enhancement in their nuclease stability and efficacy. For example, oligonucleotides are modified to enhance stability and/or enhance biological activity by modification with 5 nuclease resistant groups, for example, 2'-amino, 2'-C-allyl, 2'-fluoro, 2'-O-methyl, 2'-O-allyl, 2'-H, nucleotide base modifications (for a review see Usman and Cedergren, 1992, *TIBS*, 17, 34; Usman *et al.*, 1994, *Nucleic Acids Symp. Ser.* 31, 163; Burgin *et al.*, 1996, *Biochemistry*, 35, 14090). Sugar modification of nucleic acid molecules have been extensively described in the art (see Eckstein *et al.*, *International Publication* PCT No. 10 WO 92/07065; Perrault *et al.* *Nature*, 1990, 344, 565-568; Pieken *et al.* *Science*, 1991, 253, 314-317; Usman and Cedergren, *Trends in Biochem. Sci.*, 1992, 17, 334-339; Usman *et al.* *International Publication* PCT No. WO 93/15187; Sproat, *U.S. Pat.* No. 5,334,711 and Beigelman *et al.*, 1995, *J. Biol. Chem.*, 270, 25702; Beigelman *et al.*, *International PCT publication* No. WO 97/26270; Beigelman *et al.*, *U.S. Pat.* No. 15 5,716,824; Usman *et al.*, *U.S. Pat.* No. 5,627,053; Woolf *et al.*, *International PCT Publication* No. WO 98/13526; Thompson *et al.*, USSN 60/082,404 which was filed on April 20, 1998; Karpeisky *et al.*, 1998, *Tetrahedron Lett.*, 39, 1131; Earnshaw and Gait, 1998, *Biopolymers (Nucleic Acid Sciences)*, 48, 39-55; Verma and Eckstein, 1998, *Annu. Rev. Biochem.*, 67, 99-134; and Burlina *et al.*, 1997, *Bioorg. Med. Chem.*, 5, 1999-2010; 20 all of the references are hereby incorporated in their totality by reference herein). Such publications describe general methods and strategies to determine the location of incorporation of sugar, base and/or phosphate modifications and the like into nucleic acid molecules without modulating catalysis, and are incorporated by reference herein. In view of such teachings, similar modifications can be used as described herein to modify 25 the siNA nucleic acid molecules of the instant invention so long as the ability of siNA to promote RNAi in cells is not significantly inhibited.

While chemical modification of oligonucleotide internucleotide linkages with phosphorothioate, phosphorodithioate, and/or 5'-methylphosphonate linkages improves 30 stability, excessive modifications can cause some toxicity or decreased activity. Therefore, when designing nucleic acid molecules, the amount of these internucleotide linkages should be minimized. The reduction in the concentration of these linkages should lower toxicity, resulting in increased efficacy and higher specificity of these molecules.

Short interfering nucleic acid (siNA) molecules having chemical modifications that maintain or enhance activity are provided. Such a nucleic acid is also generally more resistant to nucleases than an unmodified nucleic acid. Accordingly, the *in vitro* and/or *in vivo* activity should not be significantly lowered. In cases in which modulation is the 5 goal, therapeutic nucleic acid molecules delivered exogenously should optimally be stable within cells until translation of the target RNA has been modulated long enough to reduce the levels of the undesirable protein. This period of time varies between hours to days depending upon the disease state. Improvements in the chemical synthesis of RNA 10 and DNA (Wincott *et al.*, 1995, *Nucleic Acids Res.* 23, 2677; Caruthers *et al.*, 1992, *Methods in Enzymology* 211, 3-19 (incorporated by reference herein)) have expanded the ability to modify nucleic acid molecules by introducing nucleotide modifications to enhance their nuclease stability, as described above.

In one embodiment, nucleic acid molecules of the invention include one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) G-clamp nucleotides. A G-clamp 15 nucleotide is a modified cytosine analog wherein the modifications confer the ability to hydrogen bond both Watson-Crick and Hoogsteen faces of a complementary guanine within a duplex, see for example Lin and Matteucci, 1998, *J. Am. Chem. Soc.*, 120, 8531-8532. A single G-clamp analog substitution within an oligonucleotide can result in substantially enhanced helical thermal stability and mismatch discrimination when 20 hybridized to complementary oligonucleotides. The inclusion of such nucleotides in nucleic acid molecules of the invention results in both enhanced affinity and specificity to nucleic acid targets, complementary sequences, or template strands. In another embodiment, nucleic acid molecules of the invention include one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) LNA "locked nucleic acid" nucleotides such as a 2', 4'- 25 C methylene bicyclo nucleotide (see for example Wengel *et al.*, International PCT Publication No. WO 00/66604 and WO 99/14226).

In another embodiment, the invention features conjugates and/or complexes of siNA molecules of the invention. Such conjugates and/or complexes can be used to facilitate delivery of siNA molecules into a biological system, such as a cell. The 30 conjugates and complexes provided by the instant invention can impart therapeutic activity by transferring therapeutic compounds across cellular membranes, altering the pharmacokinetics, and/or modulating the localization of nucleic acid molecules of the

invention. The present invention encompasses the design and synthesis of novel conjugates and complexes for the delivery of molecules, including, but not limited to, small molecules, lipids, phospholipids, nucleosides, nucleotides, nucleic acids, antibodies, toxins, negatively charged polymers and other polymers, for example 5 proteins, peptides, hormones, carbohydrates, polyethylene glycols, or polyamines, across cellular membranes. In general, the transporters described are designed to be used either individually or as part of a multi-component system, with or without degradable linkers. These compounds are expected to improve delivery and/or localization of nucleic acid molecules of the invention into a number of cell types originating from different tissues, 10 in the presence or absence of serum (see Sullenger and Cech, U.S. Pat. No. 5,854,038). Conjugates of the molecules described herein can be attached to biologically active molecules via linkers that are biodegradable, such as biodegradable nucleic acid linker molecules.

The term "biodegradable linker" as used herein, refers to a nucleic acid or non- 15 nucleic acid linker molecule that is designed as a biodegradable linker to connect one molecule to another molecule, for example, a biologically active molecule to a siNA molecule of the invention or the sense and antisense strands of a siNA molecule of the invention. The biodegradable linker is designed such that its stability can be modulated for a particular purpose, such as delivery to a particular tissue or cell type. The stability 20 of a nucleic acid-based biodegradable linker molecule can be modulated by using various chemistries, for example combinations of ribonucleotides, deoxyribonucleotides, and chemically-modified nucleotides, such as 2'-O-methyl, 2'-fluoro, 2'-amino, 2'-O-amino, 2'-C-allyl, 2'-O-allyl, and other 2'-modified or base modified nucleotides. The biodegradable nucleic acid linker molecule can be a dimer, trimer, tetramer or longer 25 nucleic acid molecule, for example, an oligonucleotide of about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides in length, or can comprise a single nucleotide with a phosphorus-based linkage, for example, a phosphoramidate or phosphodiester linkage. The biodegradable nucleic acid linker molecule can also comprise nucleic acid backbone, nucleic acid sugar, or nucleic acid base modifications.

30 The term "biodegradable" as used herein, refers to degradation in a biological system, for example enzymatic degradation or chemical degradation.

The term "biologically active molecule" as used herein, refers to compounds or molecules that are capable of eliciting or modifying a biological response in a system. Non-limiting examples of biologically active siNA molecules either alone or in combination with other molecules contemplated by the instant invention include 5 therapeutically active molecules such as antibodies, hormones, antivirals, peptides, proteins, chemotherapeutics, small molecules, vitamins, co-factors, nucleosides, nucleotides, oligonucleotides, enzymatic nucleic acids, antisense nucleic acids, triplex forming oligonucleotides, 2,5-A chimeras, siNA, dsRNA, allozymes, aptamers, decoys and analogs thereof. Biologically active molecules of the invention also include 10 molecules capable of modulating the pharmacokinetics and/or pharmacodynamics of other biologically active molecules, for example, lipids and polymers such as polyamines, polyamides, polyethylene glycol and other polyethers.

The term "phospholipid" as used herein, refers to a hydrophobic molecule comprising at least one phosphorus group. For example, a phospholipid can comprise a 15 phosphorus-containing group and saturated or unsaturated alkyl group, optionally substituted with OH, COOH, oxo, amine, or substituted or unsubstituted aryl groups.

Therapeutic nucleic acid molecules (e.g., siNA molecules) delivered exogenously optimally are stable within cells until reverse transcription of the RNA has been modulated long enough to reduce the levels of the RNA transcript. The nucleic acid 20 molecules are resistant to nucleases in order to function as effective intracellular therapeutic agents. Improvements in the chemical synthesis of nucleic acid molecules described in the instant invention and in the art have expanded the ability to modify nucleic acid molecules by introducing nucleotide modifications to enhance their nuclease stability as described above.

25 In yet another embodiment, siNA molecules having chemical modifications that maintain or enhance enzymatic activity of proteins involved in RNAi are provided. Such nucleic acids are also generally more resistant to nucleases than unmodified nucleic acids. Thus, *in vitro* and/or *in vivo* the activity should not be significantly lowered.

30 Use of the nucleic acid-based molecules of the invention will lead to better treatment of the disease progression by affording the possibility of combination therapies (e.g., multiple siNA molecules targeted to different genes; nucleic acid molecules

coupled with known small molecule modulators; or intermittent treatment with combinations of molecules, including different motifs and/or other chemical or biological molecules). The treatment of subjects with siNA molecules can also include combinations of different types of nucleic acid molecules, such as enzymatic nucleic acid 5 molecules (ribozymes), allozymes, antisense, 2,5-A oligoadenylate, decoys, and aptamers.

In another aspect a siNA molecule of the invention comprises one or more 5' and/or a 3'- cap structure, for example on only the sense siNA strand, the antisense siNA strand, or both siNA strands.

10 By "cap structure" is meant chemical modifications, which have been incorporated at either terminus of the oligonucleotide (see, for example, Adamic *et al.*, U.S. Pat. No. 5,998,203, incorporated by reference herein). These terminal modifications protect the nucleic acid molecule from exonuclease degradation, and may help in delivery and/or localization within a cell. The cap may be present at the 5'-terminus (5'-cap) or at the 3'- 15 terminal (3'-cap) or may be present on both termini. In non-limiting examples, the 5'-cap is selected from the group consisting of glyceryl, inverted deoxy abasic residue (moiety); 4',5'-methylene nucleotide; 1-(beta-D-erythofuranosyl) nucleotide, 4'-thio nucleotide; carbocyclic nucleotide; 1,5-anhydrohexitol nucleotide; L-nucleotides; alpha-nucleotides; modified base nucleotide; phosphorodithioate linkage; *threo*-pentofuranosyl nucleotide; 20 acyclic 3',4'-seco nucleotide; acyclic 3,4-dihydroxybutyl nucleotide; acyclic 3,5-dihydroxypentyl nucleotide, 3'-3'-inverted nucleotide moiety; 3'-3'-inverted abasic moiety; 3'-2'-inverted nucleotide moiety; 3'-2'-inverted abasic moiety; 1,4-butanediol phosphate; 3'-phosphoramidate; hexylphosphate; aminohexyl phosphate; 3'-phosphate; 3'-phosphorothioate; phosphorodithioate; or bridging or non-bridging 25 methylphosphonate moiety.

In non-limiting examples, the 3'-cap is selected from the group consisting of glyceryl, inverted deoxy abasic residue (moiety), 4',5'-methylene nucleotide; 1-(beta-D-erythofuranosyl) nucleotide; 4'-thio nucleotide, carbocyclic nucleotide; 5'-amino-alkyl phosphate; 1,3-diamino-2-propyl phosphate; 3-aminopropyl phosphate; 6-aminohexyl phosphate; 1,2-aminododecyl phosphate; hydroxypropyl phosphate; 1,5-anhydrohexitol nucleotide; L-nucleotide; alpha-nucleotide; modified base nucleotide;

phosphorodithioate; *threo*-pentofuranosyl nucleotide; acyclic 3',4'-seco nucleotide; 3,4-dihydroxybutyl nucleotide; 3,5-dihydroxypentyl nucleotide, 5'-5'-inverted nucleotide moiety; 5'-5'-inverted abasic moiety; 5'-phosphoramidate; 5'-phosphorothioate; 1,4-butanediol phosphate; 5'-amino; bridging and/or non-bridging 5'-phosphoramidate, 5 phosphorothioate and/or phosphorodithioate, bridging or non bridging methylphosphonate and 5'-mercapto moieties (for more details see Beaucage and Iyer, 1993, *Tetrahedron* 49, 1925; incorporated by reference herein).

By the term "non-nucleotide" is meant any group or compound which can be incorporated into a nucleic acid chain in the place of one or more nucleotide units, including either sugar and/or phosphate substitutions, and allows the remaining bases to exhibit their enzymatic activity. The group or compound is abasic in that it does not contain a commonly recognized nucleotide base, such as adenosine, guanine, cytosine, uracil or thymine and therefore lacks a base at the 1'-position.

An "alkyl" group refers to a saturated aliphatic hydrocarbon, including straight-chain, branched-chain, and cyclic alkyl groups. Preferably, the alkyl group has 1 to 12 carbons. More preferably, it is a lower alkyl of from 1 to 7 carbons, more preferably 1 to 4 carbons. The alkyl group can be substituted or unsubstituted. When substituted the substituted group(s) is preferably, hydroxyl, cyano, alkoxy, =O, =S, NO₂ or N(CH₃)₂, amino, or SH. The term also includes alkenyl groups that are unsaturated hydrocarbon groups containing at least one carbon-carbon double bond, including straight-chain, branched-chain, and cyclic groups. Preferably, the alkenyl group has 1 to 12 carbons. More preferably, it is a lower alkenyl of from 1 to 7 carbons, more preferably 1 to 4 carbons. The alkenyl group may be substituted or unsubstituted. When substituted the substituted group(s) is preferably, hydroxyl, cyano, alkoxy, =O, =S, NO₂, halogen, N(CH₃)₂, amino, or SH. The term "alkyl" also includes alkynyl groups that have an unsaturated hydrocarbon group containing at least one carbon-carbon triple bond, including straight-chain, branched-chain, and cyclic groups. Preferably, the alkynyl group has 1 to 12 carbons. More preferably, it is a lower alkynyl of from 1 to 7 carbons, more preferably 1 to 4 carbons. The alkynyl group may be substituted or unsubstituted. When substituted the substituted group(s) is preferably, hydroxyl, cyano, alkoxy, =O, =S, NO₂ or N(CH₃)₂, amino or SH.

Such alkyl groups can also include aryl, alkylaryl, carbocyclic aryl, heterocyclic aryl, amide and ester groups. An "aryl" group refers to an aromatic group that has at least one ring having a conjugated pi electron system and includes carbocyclic aryl, heterocyclic aryl and biaryl groups, all of which may be optionally substituted. The 5 preferred substituent(s) of aryl groups are halogen, trihalomethyl, hydroxyl, SH, OH, cyano, alkoxy, alkyl, alkenyl, alkynyl, and amino groups. An "alkylaryl" group refers to an alkyl group (as described above) covalently joined to an aryl group (as described above). Carbocyclic aryl groups are groups wherein the ring atoms on the aromatic ring are all carbon atoms. The carbon atoms are optionally substituted. Heterocyclic aryl 10 groups are groups having from 1 to 3 heteroatoms as ring atoms in the aromatic ring and the remainder of the ring atoms are carbon atoms. Suitable heteroatoms include oxygen, sulfur, and nitrogen, and include furanyl, thienyl, pyridyl, pyrrolyl, N-lower alkyl pyrrolo, pyrimidyl, pyrazinyl, imidazolyl and the like, all optionally substituted. An "amide" refers to an -C(O)-NH-R, where R is either alkyl, aryl, alkylaryl or hydrogen. 15 An "ester" refers to an -C(O)-OR', where R is either alkyl, aryl, alkylaryl or hydrogen.

By "nucleotide" as used herein is as recognized in the art to include natural bases (standard), and modified bases well known in the art. Such bases are generally located at the 1' position of a nucleotide sugar moiety. Nucleotides generally comprise a base, sugar and a phosphate group. The nucleotides can be unmodified or modified at the 20 sugar, phosphate and/or base moiety, (also referred to interchangeably as nucleotide analogs, modified nucleotides, non-natural nucleotides, non-standard nucleotides and other; see, for example, Usman and McSwiggen, *supra*; Eckstein *et al.*, International PCT Publication No. WO 92/07065; Usman *et al.*, International PCT Publication No. WO 93/15187; Uhlman & Peyman, *supra*, all are hereby incorporated by reference 25 herein). There are several examples of modified nucleic acid bases known in the art as summarized by Limbach *et al.*, 1994, *Nucleic Acids Res.* 22, 2183. Some of the non-limiting examples of base modifications that can be introduced into nucleic acid molecules include, inosine, purine, pyridin-4-one, pyridin-2-one, phenyl, pseudouracil, 2, 4, 6-trimethoxy benzene, 3-methyl uracil, dihydrouridine, naphthyl, aminophenyl, 30 5-alkylcytidines (e.g., 5-methylcytidine), 5-alkyluridines (e.g., ribothymidine), 5-halouridine (e.g., 5-bromouridine) or 6-azapyrimidines or 6-alkylpyrimidines (e.g. 6-methyluridine), propyne, and others (Burgin *et al.*, 1996, *Biochemistry*, 35, 14090;

Uhlman & Peyman, *supra*). By "modified bases" in this aspect is meant nucleotide bases other than adenine, guanine, cytosine and uracil at 1' position or their equivalents.

In one embodiment, the invention features modified siNA molecules, with phosphate backbone modifications comprising one or more phosphorothioate, phosphorodithioate, methylphosphonate, phosphotriester, morpholino, amide carbamate, carboxymethyl, acetamide, polyamide, sulfonate, sulfonamide, sulfamate, formacetal, thioformacetal, and/or alkylsilyl, substitutions. For a review of oligonucleotide backbone modifications, see Hunziker and Leumann, 1995, *Nucleic Acid Analogues: Synthesis and Properties*, in *Modern Synthetic Methods*, VCH, 331-417, and Mesmaeker *et al.*, 1994, *Novel Backbone Replacements for Oligonucleotides*, in *Carbohydrate Modifications in Antisense Research*, ACS, 24-39.

By "abasic" is meant sugar moieties lacking a base or having other chemical groups in place of a base at the 1' position, see for example Adamic *et al.*, U.S. Pat. No. 5,998,203.

By "unmodified nucleoside" is meant one of the bases adenine, cytosine, guanine, thymine, or uracil joined to the 1' carbon of β -D-ribo-furanose.

By "modified nucleoside" is meant any nucleotide base which contains a modification in the chemical structure of an unmodified nucleotide base, sugar and/or phosphate. Non-limiting examples of modified nucleotides are shown by Formulae I-VII and/or other modifications described herein.

In connection with 2'-modified nucleotides as described for the present invention, by "amino" is meant 2'-NH₂ or 2'-O- NH₂, which can be modified or unmodified. Such modified groups are described, for example, in Eckstein *et al.*, U.S. Pat. No. 5,672,695 and Matulic-Adamic *et al.*, U.S. Pat. No. 6,248,878, which are both incorporated by reference in their entireties.

Various modifications to nucleic acid siNA structure can be made to enhance the utility of these molecules. Such modifications will enhance shelf-life, half-life *in vitro*, stability, and ease of introduction of such oligonucleotides to the target site, *e.g.*, to enhance penetration of cellular membranes, and confer the ability to recognize and bind to targeted cells.

Administration of Nucleic Acid Molecules

A siRNA molecule of the invention can be adapted for use to treat, for example conditions related to HIV infection and/or AIDS, alone or in combination with other therapies. For example, a siNA molecule can comprise a delivery vehicle, including 5 liposomes, for administration to a subject, carriers and diluents and their salts, and/or can be present in pharmaceutically acceptable formulations. Methods for the delivery of nucleic acid molecules are described in Akhtar *et al.*, 1992, *Trends Cell Bio.*, 2, 139; *Delivery Strategies for Antisense Oligonucleotide Therapeutics*, ed. Akhtar, 1995, Maurer *et al.*, 1999, *Mol. Membr. Biol.*, 16, 129-140; Hofland and Huang, 1999, *Handb. 10 Exp. Pharmacol.*, 137, 165-192; and Lee *et al.*, 2000, *ACS Symp. Ser.*, 752, 184-192, all of which are incorporated herein by reference. Beigelman *et al.*, U.S. Pat. No. 6,395,713 and Sullivan *et al.*, PCT WO 94/02595 further describe the general methods for delivery 15 of nucleic acid molecules. These protocols can be utilized for the delivery of virtually any nucleic acid molecule. Nucleic acid molecules can be administered to cells by a variety of methods known to those of skill in the art, including, but not restricted to, encapsulation in liposomes, by iontophoresis, or by incorporation into other vehicles, such as hydrogels, cyclodextrins (see for example Gonzalez *et al.*, 1999, *Bioconjugate 20 Chem.*, 10, 1068-1074), biodegradable nanocapsules, and bioadhesive microspheres, or by proteinaceous vectors (O'Hare and Normand, International PCT Publication No. WO 00/53722). Alternatively, the nucleic acid/vehicle combination is locally delivered by direct injection or by use of an infusion pump. Direct injection of the nucleic acid 25 molecules of the invention, whether subcutaneous, intramuscular, or intradermal, can take place using standard needle and syringe methodologies, or by needle-free technologies such as those described in Conry *et al.*, 1999, *Clin. Cancer Res.*, 5, 2330-2337 and Barry *et al.*, International PCT Publication No. WO 99/31262. The molecules of the instant invention can be used as pharmaceutical agents. Pharmaceutical agents prevent, modulate the occurrence, or treat (alleviate a symptom to some extent, preferably all of the symptoms) of a disease state in a subject.

Thus, the invention features a pharmaceutical composition comprising one or more 30 nucleic acid(s) of the invention in an acceptable carrier, such as a stabilizer, buffer, and the like. The polynucleotides of the invention can be administered (e.g., RNA, DNA or protein) and introduced into a subject by any standard means, with or without stabilizers,

buffers, and the like, to form a pharmaceutical composition. When it is desired to use a liposome delivery mechanism, standard protocols for formation of liposomes can be followed. The compositions of the present invention can also be formulated and used as tablets, capsules or elixirs for oral administration, suppositories for rectal administration, 5 sterile solutions, suspensions for injectable administration, and the other compositions known in the art.

The present invention also includes pharmaceutically acceptable formulations of the compounds described. These formulations include salts of the above compounds, *e.g.*, acid addition salts, for example, salts of hydrochloric, hydrobromic, acetic acid, and 10 benzene sulfonic acid.

A pharmacological composition or formulation refers to a composition or formulation in a form suitable for administration, *e.g.*, systemic administration, into a cell or subject, including for example a human. Suitable forms, in part, depend upon the use or the route of entry, for example oral, transdermal, or by injection. Such forms 15 should not prevent the composition or formulation from reaching a target cell (*i.e.*, a cell to which the negatively charged nucleic acid is desirable for delivery). For example, pharmacological compositions injected into the blood stream should be soluble. Other factors are known in the art, and include considerations such as toxicity and forms that prevent the composition or formulation from exerting its effect.

20 By "systemic administration" is meant *in vivo* systemic absorption or accumulation of drugs in the blood stream followed by distribution throughout the entire body. Administration routes that lead to systemic absorption include, without limitation: intravenous, subcutaneous, intraperitoneal, inhalation, oral, intrapulmonary and intramuscular. Each of these administration routes exposes the siNA molecules of the 25 invention to an accessible diseased tissue. The rate of entry of a drug into the circulation has been shown to be a function of molecular weight or size. The use of a liposome or other drug carrier comprising the compounds of the instant invention can potentially localize the drug, for example, in certain tissue types, such as the tissues of the reticular endothelial system (RES). A liposome formulation that can facilitate the 30 association of drug with the surface of cells, such as, lymphocytes and macrophages is also useful. This approach can provide enhanced delivery of the drug to target cells by

taking advantage of the specificity of macrophage and lymphocyte immune recognition of abnormal cells, such as cells producing excess HIV.

By "pharmaceutically acceptable formulation" is meant, a composition or formulation that allows for the effective distribution of the nucleic acid molecules of the instant invention in the physical location most suitable for their desired activity. Non-limiting examples of agents suitable for formulation with the nucleic acid molecules of the instant invention include: P-glycoprotein inhibitors (such as Pluronic P85), which can enhance entry of drugs into the CNS (Jollet-Riant and Tillement, 1999, *Fundam. Clin. Pharmacol.*, 13, 16-26); biodegradable polymers, such as poly (DL-lactide-coglycolide) microspheres for sustained release delivery after intracerebral implantation (Emerich, DF *et al*, 1999, *Cell Transplant*, 8, 47-58) (Alkermes, Inc. Cambridge, MA); and loaded nanoparticles, such as those made of polybutylcyanoacrylate, which can deliver drugs across the blood brain barrier and can alter neuronal uptake mechanisms (*Prog Neuropsychopharmacol Biol Psychiatry*, 23, 941-949, 1999). Other non-limiting examples of delivery strategies for the nucleic acid molecules of the instant invention include material described in Boado *et al.*, 1998, *J. Pharm. Sci.*, 87, 1308-1315; Tyler *et al.*, 1999, *FEBS Lett.*, 421, 280-284; Pardridge *et al.*, 1995, *PNAS USA.*, 92, 5592-5596; Boado, 1995, *Adv. Drug Delivery Rev.*, 15, 73-107; Aldrian-Herrada *et al.*, 1998, *Nucleic Acids Res.*, 26, 4910-4916; and Tyler *et al.*, 1999, *PNAS USA.*, 96, 7053-7058.

The invention also features the use of the composition comprising surface-modified liposomes containing poly (ethylene glycol) lipids (PEG-modified, or long-circulating liposomes or stealth liposomes). These formulations offer a method for increasing the accumulation of drugs in target tissues. This class of drug carriers resists opsonization and elimination by the mononuclear phagocytic system (MPS or RES), thereby enabling longer blood circulation times and enhanced tissue exposure for the encapsulated drug (Lasic *et al.* *Chem. Rev.* 1995, 95, 2601-2627; Ishiwata *et al.*, *Chem. Pharm. Bull.* 1995, 43, 1005-1011). Such liposomes have been shown to accumulate selectively in tumors, presumably by extravasation and capture in the neovascularized target tissues (Lasic *et al.*, *Science* 1995, 267, 1275-1276; Oku *et al.*, 1995, *Biochim. Biophys. Acta*, 1238, 86-90). The long-circulating liposomes enhance the pharmacokinetics and pharmacodynamics of DNA and RNA, particularly compared to conventional cationic liposomes which are known to accumulate in tissues of the MPS

(Liu *et al.*, *J. Biol. Chem.* 1995, 42, 24864-24870; Choi *et al.*, International PCT Publication No. WO 96/10391; Ansell *et al.*, International PCT Publication No. WO 96/10390; Holland *et al.*, International PCT Publication No. WO 96/10392). Long-circulating liposomes are also likely to protect drugs from nuclease degradation to a greater extent compared to cationic liposomes, based on their ability to avoid accumulation in metabolically aggressive MPS tissues such as the liver and spleen.

The present invention also includes compositions prepared for storage or administration that include a pharmaceutically effective amount of the desired compounds in a pharmaceutically acceptable carrier or diluent. Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical art, and are described, for example, in *Remington's Pharmaceutical Sciences*, Mack Publishing Co. (A.R. Gennaro edit. 1985), hereby incorporated by reference herein. For example, preservatives, stabilizers, dyes and flavoring agents can be provided. These include sodium benzoate, sorbic acid and esters of *p*-hydroxybenzoic acid. In addition, 15 antioxidants and suspending agents can be used.

A pharmaceutically effective dose is that dose required to prevent, inhibit the occurrence, or treat (alleviate a symptom to some extent, preferably all of the symptoms) of a disease state. The pharmaceutically effective dose depends on the type of disease, the composition used, the route of administration, the type of mammal being treated, the 20 physical characteristics of the specific mammal under consideration, concurrent medication, and other factors that those skilled in the medical arts will recognize. Generally, an amount between 0.1 mg/kg and 100 mg/kg body weight/day of active ingredients is administered dependent upon potency of the negatively charged polymer.

The nucleic acid molecules of the invention and formulations thereof can be 25 administered orally, topically, parenterally, by inhalation or spray, or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and/or vehicles. The term parenteral as used herein includes percutaneous, subcutaneous, intravascular (e.g., intravenous), intramuscular, or intrathecal injection or infusion techniques and the like. In addition, there is provided a 30 pharmaceutical formulation comprising a nucleic acid molecule of the invention and a pharmaceutically acceptable carrier. One or more nucleic acid molecules of the

invention can be present in association with one or more non-toxic pharmaceutically acceptable carriers and/or diluents and/or adjuvants, and if desired other active ingredients. The pharmaceutical compositions containing nucleic acid molecules of the invention can be in a form suitable for oral use, for example, as tablets, troches, 5 lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion, hard or soft capsules, or syrups or elixirs.

Compositions intended for oral use can be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions can contain one or more such sweetening agents, flavoring agents, coloring 10 agents or preservative agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients that are suitable for the manufacture of tablets. These excipients can be, for example, inert diluents; such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and 15 disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia; and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets can be uncoated or they can be coated by known techniques. In some cases such coatings can be prepared by known techniques to delay 20 disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate can be employed.

Formulations for oral use can also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is 25 mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.

Aqueous suspensions contain the active materials in a mixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydropropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; 30 dispersing or wetting agents can be a naturally-occurring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example

polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions can also contain one or more preservatives, for example ethyl, or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.

10 Oily suspensions can be formulated by suspending the active ingredients in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oily suspensions can contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents and flavoring agents can be added to provide palatable oral preparations. These compositions can be
15 preserved by the addition of an anti-oxidant such as ascorbic acid

20 Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents or suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, can also be present.

25 Pharmaceutical compositions of the invention can also be in the form of oil-in-water emulsions. The oily phase can be a vegetable oil or a mineral oil or mixtures of these. Suitable emulsifying agents can be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol, anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions can also contain sweetening and flavoring agents.

30 Syrups and elixirs can be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol, glucose or sucrose. Such formulations can also contain a

demulcent, a preservative and flavoring and coloring agents. The pharmaceutical compositions can be in the form of a sterile injectable aqueous or oleaginous suspension. This suspension can be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents that have been mentioned above.

5 The sterile injectable preparation can also be a sterile injectable solution or suspension in a non-toxic parentally acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that can be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any

10 bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

The nucleic acid molecules of the invention can also be administered in the form of suppositories, *e.g.*, for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient that is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials include cocoa butter and polyethylene glycols.

15 Nucleic acid molecules of the invention can be administered parenterally in a sterile medium. The drug, depending on the vehicle and concentration used, can either be suspended or dissolved in the vehicle. Advantageously, adjuvants such as local anesthetics, preservatives and buffering agents can be dissolved in the vehicle.

20 Dosage levels of the order of from about 0.1 mg to about 140 mg per kilogram of body weight per day are useful in the treatment of the above-indicated conditions (about 0.5 mg to about 7 g per subject per day). The amount of active ingredient that can be combined with the carrier materials to produce a single dosage form varies depending upon the host treated and the particular mode of administration. Dosage unit forms generally contain between from about 1 mg to about 500 mg of an active ingredient.

25 It is understood that the specific dose level for any particular subject depends upon a variety of factors including the activity of the specific compound employed, the age, 30 body weight, general health, sex, diet, time of administration, route of administration,

and rate of excretion, drug combination and the severity of the particular disease undergoing therapy.

For administration to non-human animals, the composition can also be added to the animal feed or drinking water. It can be convenient to formulate the animal feed and 5 drinking water compositions so that the animal takes in a therapeutically appropriate quantity of the composition along with its diet. It can also be convenient to present the composition as a premix for addition to the feed or drinking water.

The nucleic acid molecules of the present invention can also be administered to a subject in combination with other therapeutic compounds to increase the overall 10 therapeutic effect. The use of multiple compounds to treat an indication can increase the beneficial effects while reducing the presence of side effects.

In one embodiment, the invention comprises compositions suitable for administering nucleic acid molecules of the invention to specific cell types. For example, the asialoglycoprotein receptor (ASGPr) (Wu and Wu, 1987, *J. Biol. Chem.* 15 262, 4429-4432) is unique to hepatocytes and binds branched galactose-terminal glycoproteins, such as asialoorosomucoid (ASOR). In another example, the folate receptor is overexpressed in many cancer cells. Binding of such glycoproteins, synthetic glycoconjugates, or folates to the receptor takes place with an affinity that strongly depends on the degree of branching of the oligosaccharide chain, for example, 20 triantennary structures are bound with greater affinity than biantennary or monoantennary chains (Baenziger and Fiete, 1980, *Cell*, 22, 611-620; Connolly *et al.*, 1982, *J. Biol. Chem.*, 257, 939-945). Lee and Lee, 1987, *Glycoconjugate J.*, 4, 317-328, obtained this high specificity through the use of N-acetyl-D-galactosamine as the carbohydrate moiety, which has higher affinity for the receptor, compared to galactose. This "clustering effect" 25 has also been described for the binding and uptake of mannose-terminating glycoproteins or glycoconjugates (Ponpipom *et al.*, 1981, *J. Med. Chem.*, 24, 1388-1395). The use of galactose, galactosamine, or folate based conjugates to transport exogenous compounds across cell membranes can provide a targeted delivery approach to, for example, the treatment of liver disease, cancers of the liver, or other cancers. The 30 use of bioconjugates can also provide a reduction in the required dose of therapeutic compounds required for treatment. Furthermore, therapeutic bioavailability,

pharmacodynamics, and pharmacokinetic parameters can be modulated through the use of nucleic acid bioconjugates of the invention. Non-limiting examples of such bioconjugates are described in Vargeese *et al.*, USSN 10/201,394, filed August 13, 2001; and Matulic-Adamic *et al.*, USSN 60/362,016, filed March 6, 2002.

5 Alternatively, certain siNA molecules of the instant invention can be expressed within cells from eukaryotic promoters (e.g., Izant and Weintraub, 1985, *Science*, 229, 345; McGarry and Lindquist, 1986, *Proc. Natl. Acad. Sci. USA* 83, 399; Scanlon *et al.*, 1991, *Proc. Natl. Acad. Sci. USA*, 88, 10591-5; Kashani-Sabet *et al.*, 1992, *Antisense Res. Dev.*, 2, 3-15; Dropulic *et al.*, 1992, *J. Virol.*, 66, 1432-41; Weerasinghe *et al.*, 10 1991, *J. Virol.*, 65, 5531-4; Ojwang *et al.*, 1992, *Proc. Natl. Acad. Sci. USA*, 89, 10802-6; Chen *et al.*, 1992, *Nucleic Acids Res.*, 20, 4581-9; Sarver *et al.*, 1990 *Science*, 247, 1222-1225; Thompson *et al.*, 1995, *Nucleic Acids Res.*, 23, 2259; Good *et al.*, 1997, *Gene Therapy*, 4, 45. Those skilled in the art realize that any nucleic acid can be expressed in eukaryotic cells from the appropriate DNA/RNA vector. The activity of 15 such nucleic acids can be augmented by their release from the primary transcript by a enzymatic nucleic acid (Draper *et al.*, PCT WO 93/23569, and Sullivan *et al.*, PCT WO 94/02595; Ohkawa *et al.*, 1992, *Nucleic Acids Symp. Ser.*, 27, 15-6; Taira *et al.*, 1991, *Nucleic Acids Res.*, 19, 5125-30; Ventura *et al.*, 1993, *Nucleic Acids Res.*, 21, 3249-55; Chowrira *et al.*, 1994, *J. Biol. Chem.*, 269, 25856.

20 In another aspect of the invention, RNA molecules of the present invention can be expressed from transcription units (see for example Couture *et al.*, 1996, *TIG*, 12, 510) inserted into DNA or RNA vectors. The recombinant vectors can be DNA plasmids or viral vectors. siNA expressing viral vectors can be constructed based on, but not limited to, adeno-associated virus, retrovirus, adenovirus, or alphavirus. In another embodiment, 25 pol III based constructs are used to express nucleic acid molecules of the invention (see for example Thompson, U.S. Pats. Nos. 5,902,880 and 6,146,886). The recombinant vectors capable of expressing the siNA molecules can be delivered as described above, and persist in target cells. Alternatively, viral vectors can be used that provide for transient expression of nucleic acid molecules. Such vectors can be repeatedly 30 administered as necessary. Once expressed, the siNA molecule interacts with the target mRNA and generates an RNAi response. Delivery of siNA molecule expressing vectors can be systemic, such as by intravenous or intra-muscular administration, by

administration to target cells ex-planted from a subject followed by reintroduction into the subject, or by any other means that would allow for introduction into the desired target cell (for a review see Couture *et al.*, 1996, *TIG.*, 12, 510).

In one aspect the invention features an expression vector comprising a nucleic acid sequence encoding at least one siNA molecule of the instant invention. The expression vector can encode one or both strands of a siNA duplex, or a single self-complementary strand that self hybridizes into a siNA duplex. The nucleic acid sequences encoding the siNA molecules of the instant invention can be operably linked in a manner that allows expression of the siNA molecule (see for example Paul *et al.*, 2002, *Nature Biotechnology*, 19, 505; Miyagishi and Taira, 2002, *Nature Biotechnology*, 19, 497; Lee *et al.*, 2002, *Nature Biotechnology*, 19, 500; and Novina *et al.*, 2002, *Nature Medicine*, 8, 681-686.

In another aspect, the invention features an expression vector comprising: a) a transcription initiation region (e.g., eukaryotic pol I, II or III initiation region); b) a transcription termination region (e.g., eukaryotic pol I, II or III termination region); and c) a nucleic acid sequence encoding at least one of the siNA molecules of the instant invention, wherein said sequence is operably linked to said initiation region and said termination region in a manner that allows expression and/or delivery of the siNA molecule. The vector can optionally include an open reading frame (ORF) for a protein operably linked on the 5' side or the 3'-side of the sequence encoding the siNA of the invention and/or an intron (intervening sequences).

Transcription of the siNA molecule sequences can be driven from a promoter for eukaryotic RNA polymerase I (pol I), RNA polymerase II (pol II), or RNA polymerase III (pol III). Transcripts from pol II or pol III promoters are expressed at high levels in all cells; the levels of a given pol II promoter in a given cell type depends on the nature of the gene regulatory sequences (enhancers, silencers, etc.) present nearby. Prokaryotic RNA polymerase promoters are also used, providing that the prokaryotic RNA polymerase enzyme is expressed in the appropriate cells (Elroy-Stein and Moss, 1990, *Proc. Natl. Acad. Sci. U S A*, 87, 6743-7; Gao and Huang 1993, *Nucleic Acids Res.*, 21, 2867-72; Lieber *et al.*, 1993, *Methods Enzymol.*, 217, 47-66; Zhou *et al.*, 1990, *Mol. Cell. Biol.*, 10, 4529-37). Several investigators have demonstrated that nucleic acid

molecules expressed from such promoters can function in mammalian cells (e.g. Kashani-Sabet *et al.*, 1992, *Antisense Res. Dev.*, 2, 3-15; Ojwang *et al.*, 1992, *Proc. Natl. Acad. Sci. U S A*, 89, 10802-6; Chen *et al.*, 1992, *Nucleic Acids Res.*, 20, 4581-9; Yu *et al.*, 1993, *Proc. Natl. Acad. Sci. U S A*, 90, 6340-4; L'Huillier *et al.*, 1992, *EMBO J.*, 11, 4411-8; Lisziewicz *et al.*, 1993, *Proc. Natl. Acad. Sci. U. S. A.*, 90, 8000-4; Thompson *et al.*, 1995, *Nucleic Acids Res.*, 23, 2259; Sullenger & Cech, 1993, *Science*, 262, 1566). More specifically, transcription units such as the ones derived from genes encoding U6 small nuclear (snRNA), transfer RNA (tRNA) and adenovirus VA RNA are useful in generating high concentrations of desired RNA molecules such as siNA in cells (Thompson *et al.*, *supra*; Couture and Stinchcomb, 1996, *supra*; Noonberg *et al.*, 1994, *Nucleic Acid Res.*, 22, 2830; Noonberg *et al.*, U.S. Pat. No. 5,624,803; Good *et al.*, 1997, *Gene Ther.*, 4, 45; Beigelman *et al.*, International PCT Publication No. WO 96/18736. The above siNA transcription units can be incorporated into a variety of vectors for introduction into mammalian cells, including but not restricted to, plasmid DNA vectors, viral DNA vectors (such as adenovirus or adeno-associated virus vectors), or viral RNA vectors (such as retroviral or alphavirus vectors) (for a review see Couture and Stinchcomb, 1996, *supra*).

In another aspect the invention features an expression vector comprising a nucleic acid sequence encoding at least one of the siNA molecules of the invention in a manner that allows expression of that siNA molecule. The expression vector comprises in one embodiment: a) a transcription initiation region; b) a transcription termination region; and c) a nucleic acid sequence encoding at least one strand of the siNA molecule, wherein the sequence is operably linked to the initiation region and the termination region in a manner that allows expression and/or delivery of the siNA molecule.

In another embodiment the expression vector comprises: a) a transcription initiation region; b) a transcription termination region; c) an open reading frame; and d) a nucleic acid sequence encoding at least one strand of a siNA molecule, wherein the sequence is operably linked to the 3'-end of the open reading frame and wherein the sequence is operably linked to the initiation region, the open reading frame and the termination region in a manner that allows expression and/or delivery of the siNA molecule. In yet another embodiment, the expression vector comprises: a) a transcription initiation region; b) a transcription termination region; c) an intron; and d) a

nucleic acid sequence encoding at least one siNA molecule, wherein the sequence is operably linked to the initiation region, the intron and the termination region in a manner which allows expression and/or delivery of the nucleic acid molecule.

In another embodiment, the expression vector comprises: a) a transcription initiation region; b) a transcription termination region; c) an intron; d) an open reading frame; and e) a nucleic acid sequence encoding at least one strand of a siNA molecule, wherein the sequence is operably linked to the 3'-end of the open reading frame and wherein the sequence is operably linked to the initiation region, the intron, the open reading frame and the termination region in a manner which allows expression and/or delivery of the siNA molecule.

HIV overview

AIDS (acquired immunodeficiency syndrome) was first reported in the United States in 1981 and has since become a major worldwide epidemic. AIDS is caused by the human immunodeficiency virus (HIV). By killing or damaging cells of the body's immune system, HIV progressively destroys the body's ability to fight infections and certain cancers. People diagnosed with AIDS may get life-threatening diseases called opportunistic infections, which are caused by microbes such as viruses or bacteria that usually do not make healthy people sick. More than 790,000 cases of AIDS have been reported in the United States since 1981, and as many as 900,000 Americans may be infected with HIV.

HIV infection results in a chronic, progressive illness. Its course is marked by increasing levels of viral replication and the emergence of more virulent viral strains. This process causes the destruction of the immune system. HIV infection is staged by CD4 cell counts and clinical symptoms. Not all people progress through all stages and the time frames may also vary greatly from person to person. After infection with HIV, there is usually a seroconversion illness followed by an asymptomatic stage which lasts months to years (up to 18, but 10 years is the average). This is followed by symptomatic phases which correlate with progressive immunodeficiency. The progression of HIV disease varies from person to person and depends on a number of factors, including genetics and mode of transmission. Viral load is an important surrogate marker which measures the quantity of virus in plasma and predicts the rate of progression. It is a

measured in RNA copies/ml. It is also used to assess response to drug therapy and may predict the development of drug resistance. After seroconversion, each person develops a viral load set point. The lower the viral load the slower the progression of HIV disease (i.e. immune system destruction) and eventually clinical symptoms and opportunistic conditions. Between 50-90% of people infected with HIV have an acute clinical illness which typically occurs 2-4 weeks after the infecting exposure to HIV. Very often these seroconversion illnesses are recognized in retrospect since the symptoms may be non specific (viral or flu-like). Many develop a mononucleosis-like illness which begins acutely and lasts up to two weeks. Symptoms may include: fever, headache, lymphadenopathy, myalgia, rash, and mucocutaneous ulceration. Laboratory tests may indicate a viral infection. HIV p24 antigen may be detected at this stage even if antibodies to the HIV have not yet formed. Viral load is very high at this stage and CD4 counts drop transiently during seroconversion.

HIV is a retrovirus member of the Lentivirinae family. Retroviruses are enveloped RNA viruses characteristically possessing an RNA-dependent DNA polymerase termed reverse transcriptase. Two types of virus are known to affect humans; HIV-1 causes AIDS and is found worldwide, and HIV-2 has been isolated from some African cases of AIDS.

In its extracellular form, the virus exists as a lipid-encoated cylindrical nucleocapsid of approximately 100 nm in diameter. Inserted within its lipid envelope are glycoproteins, a portion of which (glycoprotein [gp] 120) forms the binding region that attaches to the CD4 receptor on host cells (T-lymphocyte helper cells, activated monocytes and macrophages, and glial cells). After fusing with the cell membrane and entering the cytoplasm, the virus loses its envelope, and reverse transcription of RNA to DNA occurs.

Viral DNA integrates into host cell DNA as a latent provirus by a viral endonuclease. If the host cell is latently infected, no infection develops. If the host is actively infected, the proviral DNA is transcribed and translated, producing viral proteins and RNA. The viral proteins assemble and bud (by reverse endocytosis) through the host cell plasma membrane as new virions. The virus disseminates by budding or by cell-to-cell transfer.

Abnormalities in all components of the immune system can be seen as the severity of HIV disease progresses. The most profound consequence of HIV infection is impairment of cell-mediated (T cell) immunity. HIV binds directly to the CD4 receptor of the T helper cell, resulting in progressive depletion of this T-cell population. As a 5 result, the immune system is less able to (1) mount cytotoxic T-cell responses to virally infected cells or cancers, (2) to form delayed-type hypersensitivity reactions, and (3) to process new foreign substances presenting to the immune system. Significant impairment of the humoral immune system occurs in most persons infected with HIV. HIV also can infect monocytes and macrophages.

10 The use of small interfering nucleic acid molecules targeting HIV genes therefore provides a class of novel therapeutic agents that can be used in the treatment HIV infection and AIDS, as well as immunological disorders or any other disease or condition that responds to modulation of HIV genes.

Examples:

15 The following are non-limiting examples showing the selection, isolation, synthesis and activity of nucleic acids of the instant invention.

Example 1: Tandem synthesis of siNA constructs

Exemplary siNA molecules of the invention are synthesized in tandem using a cleavable linker, for example, a succinyl-based linker. Tandem synthesis as described 20 herein is followed by a one-step purification process that provides RNAi molecules in high yield. This approach is highly amenable to siNA synthesis in support of high throughput RNAi screening, and can be readily adapted to multi-column or multi-well synthesis platforms.

After completing a tandem synthesis of a siNA oligo and its complement in which 25 the 5'-terminal dimethoxytrityl (5'-O-DMT) group remains intact (trityl on synthesis), the oligonucleotides are deprotected as described above. Following deprotection, the siNA sequence strands are allowed to spontaneously hybridize. This hybridization yields a duplex in which one strand has retained the 5'-O-DMT group while the complementary strand comprises a terminal 5'-hydroxyl. The newly formed duplex behaves as a single 30 molecule during routine solid-phase extraction purification (Trityl-On purification) even

though only one molecule has a dimethoxytrityl group. Because the strands form a stable duplex, this dimethoxytrityl group (or an equivalent group, such as other trityl groups or other hydrophobic moieties) is all that is required to purify the pair of oligos, for example by using a C18 cartridge.

5 Standard phosphoramidite synthesis chemistry is used up to the point of introducing a tandem linker, such as an inverted deoxy abasic succinate or glyceryl succinate linker (see **Figure 1**) or an equivalent cleavable linker. A non-limiting example of linker coupling conditions that can be used includes a hindered base such as diisopropylethylamine (DIPA) and/or DMAP in the presence of an activator reagent such
10 as Bromotripyrrolidinophosphoniumhexafluorophosphate (PyBrOP). After the linker is coupled, standard synthesis chemistry is utilized to complete synthesis of the second sequence leaving the terminal the 5'-O-DMT intact. Following synthesis, the resulting oligonucleotide is deprotected according to the procedures described herein and quenched with a suitable buffer, for example with 50mM NaOAc or 1.5M NH₄H₂CO₃.

15 Purification of the siNA duplex can be readily accomplished using solid phase extraction, for example using a Waters C18 SepPak 1g cartridge conditioned with 1 column volume (CV) of acetonitrile, 2 CV H₂O, and 2 CV 50mM NaOAc. The sample is loaded and then washed with 1 CV H₂O or 50mM NaOAc. Failure sequences are eluted with 1 CV 14% ACN (Aqueous with 50mM NaOAc and 50mM NaCl). The
20 column is then washed, for example with 1 CV H₂O followed by on-column detritylation, for example by passing 1 CV of 1% aqueous trifluoroacetic acid (TFA) over the column, then adding a second CV of 1% aqueous TFA to the column and allowing to stand for approximately 10 minutes. The remaining TFA solution is removed and the column washed with H₂O followed by 1 CV 1M NaCl and additional
25 H₂O. The siNA duplex product is then eluted, for example using 1 CV 20% aqueous CAN.

Figure 2 provides an example of MALDI-TOF mass spectrometry analysis of a purified siNA construct in which each peak corresponds to the calculated mass of an individual siNA strand of the siNA duplex. The same purified siNA provides three
30 peaks when analyzed by capillary gel electrophoresis (CGE), one peak presumably corresponding to the duplex siNA, and two peaks presumably corresponding to the

separate siNA sequence strands. Ion exchange HPLC analysis of the same siNA construct only shows a single peak. Testing of the purified siNA construct using a luciferase reporter assay described below demonstrated the same RNAi activity compared to siNA constructs generated from separately synthesized oligonucleotide sequence strands.

5 Example 2: Identification of potential siNA target sites in any RNA sequence

The sequence of an RNA target of interest, such as a viral or human mRNA transcript, is screened for target sites, for example by using a computer folding algorithm. In a non-limiting example, the sequence of a gene or RNA gene transcript derived from a database, such as Genbank, is used to generate siNA targets having complementarity to the target. Such sequences can be obtained from a database, or can be determined experimentally as known in the art. Target sites that are known, for example, those target sites determined to be effective target sites based on studies with other nucleic acid molecules, for example ribozymes or antisense, or those targets known to be associated with a disease or condition such as those sites containing mutations or 10 deletions, can be used to design siNA molecules targeting those sites. Various parameters can be used to determine which sites are the most suitable target sites within the target RNA sequence. These parameters include but are not limited to secondary or tertiary RNA structure, the nucleotide base composition of the target sequence, the degree of homology between various regions of the target sequence, or the relative 15 position of the target sequence within the RNA transcript. Based on these determinations, any number of target sites within the RNA transcript can be chosen to screen siNA molecules for efficacy, for example by using *in vitro* RNA cleavage assays, cell culture, or animal models. In a non-limiting example, anywhere from 1 to 1000 target sites are chosen within the transcript based on the size of the siNA construct to be 20 used. High throughput screening assays can be developed for screening siNA molecules using methods known in the art, such as with multi-well or multi-plate assays to determine efficient reduction in target gene expression.

Example 3: Selection of siNA molecule target sites in a RNA

The following non-limiting steps can be used to carry out the selection of siNAs 30 targeting a given gene sequence or transcript.

1. The target sequence is parsed *in silico* into a list of all fragments or subsequences of a particular length, for example 23 nucleotide fragments, contained within the target sequence. This step is typically carried out using a custom Perl script, but commercial sequence analysis programs such as Oligo, MacVector, or the GCG Wisconsin Package can be employed as well.
5
2. In some instances the siNAAs correspond to more than one target sequence; such would be the case for example in targeting different transcripts of the same gene, targeting different transcripts of more than one gene, or for targeting both the human gene and an animal homolog. In this case, a subsequence list of a particular length is
10 generated for each of the targets, and then the lists are compared to find matching sequences in each list. The subsequences are then ranked according to the number of target sequences that contain the given subsequence; the goal is to find subsequences that are present in most or all of the target sequences. Alternately, the ranking can identify subsequences that are unique to a target sequence, such as a mutant target
15 sequence. Such an approach would enable the use of siNA to target specifically the mutant sequence and not effect the expression of the normal sequence.
3. In some instances the siNA subsequences are absent in one or more sequences while present in the desired target sequence; such would be the case if the siNA targets a gene with a paralogous family member that is to remain untargeted. As in case 2
20 above, a subsequence list of a particular length is generated for each of the targets, and then the lists are compared to find sequences that are present in the target gene but are absent in the untargeted paralog.
4. The ranked siNA subsequences can be further analyzed and ranked according to GC content. A preference can be given to sites containing 30-70% GC, with a further
25 preference to sites containing 40-60% GC.
5. The ranked siNA subsequences can be further analyzed and ranked according to self-folding and internal hairpins. Weaker internal folds are preferred; strong hairpin structures are to be avoided.
6. The ranked siNA subsequences can be further analyzed and ranked according to
30 whether they have runs of GGG or CCC in the sequence. GGG (or even more Gs) in

either strand can make oligonucleotide synthesis problematic and can potentially interfere with RNAi activity, so it is avoided whenever better sequences are available. CCC is searched in the target strand because that will place GGG in the antisense strand.

- 5 7. The ranked siNA subsequences can be further analyzed and ranked according to whether they have the dinucleotide UU (uridine dinucleotide) on the 3'-end of the sequence, and/or AA on the 5'-end of the sequence (to yield 3' UU on the antisense sequence). These sequences allow one to design siNA molecules with terminal TT thymidine dinucleotides.
- 10 8. Four or five target sites are chosen from the ranked list of subsequences as described above. For example, in subsequences having 23 nucleotides, the right 21 nucleotides of each chosen 23-mer subsequence are then designed and synthesized for the upper (sense) strand of the siNA duplex, while the reverse complement of the left 21 nucleotides of each chosen 23-mer subsequence are then designed and synthesized for the lower (antisense) strand of the siNA duplex (see **Tables II and III**). If terminal TT residues are desired for the sequence (as described in paragraph 7), then the two 3' terminal nucleotides of both the sense and antisense strands are replaced by TT prior to synthesizing the oligos.
- 15 9. The siNA molecules are screened in an *in vitro*, cell culture or animal model system to identify the most active siNA molecule or the most preferred target site within the target RNA sequence.
- 20

In an alternate approach, a pool of siNA constructs specific to a HIV target sequence is used to screen for target sites in cells expressing HIV RNA, such as in B cell, T cell, macrophage and endothelial cell culture systems. The general strategy used in 25 this approach is shown in **Figure 9**. A non-limiting example of such is a pool comprising sequences having sense sequences comprising SEQ ID NOs. 1-738, 1477-1490, 1499-1506, 1515-1522, 1531-1534, 1539-1546, 1555-1556, 1559-1566, and 1575-1576 and antisense sequences comprising SEQ ID NOs. 739-1476, 1491-1498, 1507-1514, 1523-1530, 1535-1538, 1547-1554, 1557-1558, and 1567-1574 respectively. Cells 30 expressing HIV (e.g., A549 or Caco-2 cells) are transfected with the pool of siNA constructs and cells that demonstrate a phenotype associated with HIV inhibition are

sorted. The pool of siNA constructs can be expressed from transcription cassettes inserted into appropriate vectors (see for example **Figure 7** and **Figure 8**). The siNA from cells demonstrating a positive phenotypic change (e.g., decreased proliferation, decreased HIV mRNA levels or decreased HIV protein expression), are sequenced to 5 determine the most suitable target site(s) within the target HIV RNA sequence.

Example 4: HIV targeted siNA design

siNA target sites were chosen by analyzing sequences of the HIV RNA target and optionally prioritizing the target sites on the basis of folding (structure of any given sequence analyzed to determine siNA accessibility to the target), by using a library of 10 siNA molecules as described in Example 3, or alternately by using an *in vitro* siNA system as described in Example 6 herein. siNA target sites were chosen by analyzing sequences of the HIV-1 RNA target (for example Genbank Accession Nos. shown in **Table III**) and optionally prioritizing the target sites on the basis of folding (structure of any given sequence analyzed to determine siNA accessibility to the target). The 15 sequence alignments of all known A and B strains of HIV were screened for homology and siNA molecules were designed to target conserved sequences across these strains since the A and B strains are currently the most prevalent strains. Alternately, all known strains or other subclasses of HIV can be similarly screened for homology (see **Table IV**) and homologous sequences used as targets. A cutoff for % homology between the 20 different strains can be used to increase or decrease the number of targets considered, for example 70%, 75%, 80%, 85%, 90% or 95% homology. The sequences shown in **Table I** represent 80% homology between the HIV strains shown in **Table III**. siNA molecules were designed that could bind each target sequence and are optionally individually analyzed by computer folding to assess whether the siNA molecule can interact with the 25 target sequence. Varying the length of the siNA molecules can be chosen to optimize activity. The siNA sense (upper sequence) and antisense (lower sequence) sequences shown in **Table I** comprise 19 nucleotides in length, with the sense strand comprising the same sequence as the target sequence and the antisense strand comprising a complementary sequence to the sense/target sequence. The sense and antisense strands 30 can further comprise nucleotide 3'-overhangs as described herein, preferably the overhangs comprise about 2 nucleotides which can optionally be complementary to the target sequence in the antisense siNA strand, and/or optionally analogous to the adjacent

nucleotides in the target sequence when present in the sense siNA strand. Generally, a sufficient number of complementary nucleotide bases are chosen to bind to, or otherwise interact with, the target RNA, but the degree of complementarity can be modulated to accommodate siNA duplexes or varying length or base composition. By using such 5 methodologies, siNA molecules can be designed to target sites within any known RNA sequence, for example those RNA sequences corresponding to the any gene transcript.

Chemically modified siNA constructs are designed to provide nuclease stability for systemic administration *in vivo* and/or improved pharmacokinetic, localization, and delivery properties while preserving the ability to mediate RNAi activity. Chemical 10 modifications as described herein are introduced synthetically using synthetic methods described herein and those generally known in the art. The synthetic siNA constructs are then assayed for nuclease stability in serum and/or cellular/tissue extracts (e.g. liver extracts). The synthetic siNA constructs are also tested in parallel for RNAi activity using an appropriate assay, such as a luciferase reporter assay as described herein or 15 another suitable assay that can quantity RNAi activity. Synthetic siNA constructs that possess both nuclease stability and RNAi activity can be further modified and re-evaluated in stability and activity assays. The chemical modifications of the stabilized active siNA constructs can then be applied to any siNA sequence targeting any chosen RNA and used, for example, in target screening assays to pick lead siNA compounds for 20 therapeutic development (see for example **Figure 11**).

Example 5: Chemical Synthesis and Purification of siNA

siNA molecules can be designed to interact with various sites in the RNA message, for example, target sequences within the RNA sequences described herein. The sequence of one strand of the siNA molecule(s) is complementary to the target site 25 sequences described above. The siNA molecules can be chemically synthesized using methods described herein. Inactive siNA molecules that are used as control sequences can be synthesized by scrambling the sequence of the siNA molecules such that it is not complementary to the target sequence. Generally, siNA constructs can be synthesized using solid phase oligonucleotide synthesis methods as described herein (see for example 30 Usman *et al.*, US Patent Nos. 5,804,683; 5,831,071; 5,998,203; 6,117,657; 6,353,098; 6,362,323; 6,437,117; 6,469,158; Scaringe *et al.*, US Patent Nos. 6,111,086; 6,008,400; 6,111,086 all incorporated by reference herein in their entirety).

In a non-limiting example, RNA oligonucleotides are synthesized in a stepwise fashion using the phosphoramidite chemistry as is known in the art. Standard phosphoramidite chemistry involves the use of nucleosides comprising any of 5'-O-dimethoxytrityl, 2'-O-tert-butyldimethylsilyl, 3'-O-2-Cyanoethyl N,N-diisopropylphosphoramidite groups, and exocyclic amine protecting groups (e.g. N6-benzoyl adenosine, N4 acetyl cytidine, and N2-isobutyryl guanosine). Alternately, 2'-O-Silyl Ethers can be used in conjunction with acid-labile 2'-O-orthoester protecting groups in the synthesis of RNA as described by Scaringe *supra*. Differing 2' chemistries can require different protecting groups, for example 2'-deoxy-2'-amino nucleosides can utilize N-phthaloyl protection as described by Usman *et al.*, US Patent 5,631,360, incorporated by reference herein in its entirety).

During solid phase synthesis, each nucleotide is added sequentially (3' - to 5' - direction) to the solid support-bound oligonucleotide. The first nucleoside at the 3'-end of the chain is covalently attached to a solid support (e.g., controlled pore glass or 15 polystyrene) using various linkers. The nucleotide precursor, a ribonucleoside phosphoramidite, and activator are combined resulting in the coupling of the second nucleoside phosphoramidite onto the 5'-end of the first nucleoside. The support is then washed and any unreacted 5'-hydroxyl groups are capped with a capping reagent such as acetic anhydride to yield inactive 5'-acetyl moieties. The trivalent phosphorus linkage is 20 then oxidized to a more stable phosphate linkage. At the end of the nucleotide addition cycle, the 5'-O-protecting group is cleaved under suitable conditions (e.g., acidic conditions for trityl-based groups and Fluoride for silyl-based groups). The cycle is repeated for each subsequent nucleotide.

Modification of synthesis conditions can be used to optimize coupling efficiency, 25 for example by using differing coupling times, differing reagent/phosphoramidite concentrations, differing contact times, differing solid supports and solid support linker chemistries depending on the particular chemical composition of the siNA to be synthesized. Deprotection and purification of the siNA can be performed as is generally described in Usman *et al.*, US 5,831,071, US 6,353,098, US 6,437,117, and Bellon *et al.*, 30 US 6,054,576, US 6,162,909, US 6,303,773, incorporated by reference herein in their entirety or Scaringe *supra*. Additionally, deprotection conditions can be modified to provide the best possible yield and purity of siNA constructs. For example, applicant has

observed that oligonucleotides comprising 2'-deoxy-2'-fluoro nucleotides can degrade under inappropriate deprotection conditions. Such oligonucleotides are deprotected using aqueous methylamine at about 35°C for 30 minutes. If the 2'-deoxy-2'-fluoro containing oligonucleotide also comprises ribonucleotides, after deprotection with 5 aqueous methylamine at about 35°C for 30 minutes, TEA-HF is added and the reaction maintained at about 65°C for an additional 15 minutes.

Example 6: RNAi *in vitro* assay to assess siNA activity

An *in vitro* assay that recapitulates RNAi in a cell-free system is used to evaluate siNA constructs targeting HIV RNA targets. The assay comprises the system described 10 by Tuschl *et al.*, 1999, *Genes and Development*, 13, 3191-3197 and Zamore *et al.*, 2000, *Cell*, 101, 25-33 adapted for use with HIV target RNA. A Drosophila extract derived from syncytial blastoderm is used to reconstitute RNAi activity *in vitro*. Target RNA is generated via *in vitro* transcription from an appropriate HIV expressing plasmid using T7 15 RNA polymerase or via chemical synthesis as described herein. Sense and antisense siNA strands (for example 20 uM each) are annealed by incubation in buffer (such as 100 mM potassium acetate, 30 mM HEPES-KOH, pH 7.4, 2 mM magnesium acetate) for 1 min. at 90°C followed by 1 hour at 37°C, then diluted in lysis buffer (for example 100 mM potassium acetate, 30 mM HEPES-KOH at pH 7.4, 2mM magnesium acetate). Annealing can be monitored by gel electrophoresis on an agarose gel in TBE buffer and 20 stained with ethidium bromide. The Drosophila lysate is prepared using zero to two-hour-old embryos from Oregon R flies collected on yeasted molasses agar that are dechorionated and lysed. The lysate is centrifuged and the supernatant isolated. The assay comprises a reaction mixture containing 50% lysate [vol/vol], RNA (10-50 pM final concentration), and 10% [vol/vol] lysis buffer containing siNA (10 nM final 25 concentration). The reaction mixture also contains 10 mM creatine phosphate, 10 ug.ml creatine phosphokinase, 100 um GTP, 100 uM UTP, 100 uM CTP, 500 uM ATP, 5 mM DTT, 0.1 U/uL RNasin (Promega), and 100 uM of each amino acid. The final concentration of potassium acetate is adjusted to 100 mM. The reactions are pre-assembled on ice and preincubated at 25° C for 10 minutes before adding RNA, then 30 incubated at 25° C for an additional 60 minutes. Reactions are quenched with 4 volumes of 1.25 x Passive Lysis Buffer (Promega). Target RNA cleavage is assayed by RT-PCR

analysis or other methods known in the art and are compared to control reactions in which siNA is omitted from the reaction.

Alternately, internally-labeled target RNA for the assay is prepared by *in vitro* transcription in the presence of [alpha-³²P] CTP, passed over a G 50 Sephadex column 5 by spin chromatography and used as target RNA without further purification. Optionally, target RNA is 5'-³²P-end labeled using T4 polynucleotide kinase enzyme. Assays are performed as described above and target RNA and the specific RNA cleavage products generated by RNAi are visualized on an autoradiograph of a gel. The 10 percentage of cleavage is determined by Phosphor Imager[®] quantitation of bands representing intact control RNA or RNA from control reactions without siNA and the cleavage products generated by the assay.

In one embodiment, this assay is used to determine target sites the HIV RNA target for siNA mediated RNAi cleavage, wherein a plurality of siNA constructs are screened for RNAi mediated cleavage of the HIV RNA target, for example, by analyzing the assay 15 reaction by electrophoresis of labeled target RNA, or by northern blotting, as well as by other methodology well known in the art.

Example 7: Nucleic acid inhibition of HIV target RNA *in vivo*

siNA molecules targeted to the huma HIV RNA are designed and synthesized as described above. These nucleic acid molecules can be tested for cleavage activity *in* 20 *vivo*, for example, using the following procedure. The target sequences and the nucleotide location within the HIV RNA are given in **Table II and III**.

Two formats are used to test the efficacy of siNAAs targeting HIV. First, the reagents are tested in cell culture using, for example, B cell, T cell, macrophage or endothelial cell culture systems to determine the extent of RNA and protein inhibition. 25 siNA reagents (*e.g.*; see **Tables II and III**) are selected against the HIV target as described herein. RNA inhibition is measured after delivery of these reagents by a suitable transfection agent to, for example, B cell, T cell, macrophage or endothelial cells. Relative amounts of target RNA are measured versus actin using real-time PCR monitoring of amplification (*eg.*, ABI 7700 Taqman[®]). A comparison is made to a 30 mixture of oligonucleotide sequences made to unrelated targets or to a randomized siNA

control with the same overall length and chemistry, but randomly substituted at each position. Primary and secondary lead reagents are chosen for the target and optimization performed. After an optimal transfection agent concentration is chosen, a RNA time-course of inhibition is performed with the lead siNA molecule. In addition, a cell-plating format can be used to determine RNA inhibition.

Delivery of siNA to Cells

Cells (e.g., B cell, T cell, macrophage or endothelial cells) are seeded, for example, at 1×10^5 cells per well of a six-well dish in EGM-2 (BioWhittaker) the day before transfection. siNA (final concentration, for example 20nM) and cationic lipid (e.g., final concentration 2 μ g/ml) are complexed in EGM basal media (Biowhittaker) at 37°C for 30 minutes in polystyrene tubes. Following vortexing, the complexed siNA is added to each well and incubated for the times indicated. For initial optimization experiments, cells are seeded, for example, at 1×10^3 in 96 well plates and siNA complex added as described. Efficiency of delivery of siNA to cells is determined using a fluorescent siNA complexed with lipid. Cells in 6-well dishes are incubated with siNA for 24 hours, rinsed with PBS and fixed in 2% paraformaldehyde for 15 minutes at room temperature. Uptake of siNA is visualized using a fluorescent microscope.

Taqman and Lightcycler quantification of mRNA

Total RNA is prepared from cells following siNA delivery, for example, using 20 Qiagen RNA purification kits for 6-well or Rneasy extraction kits for 96-well assays. For Taqman analysis, dual-labeled probes are synthesized with the reporter dye, FAM or JOE, covalently linked at the 5'-end and the quencher dye TAMRA conjugated to the 3'-end. One-step RT-PCR amplifications are performed on, for example, an ABI PRISM 7700 Sequence Detector using 50 μ l reactions consisting of 10 μ l total RNA, 100 nM forward primer, 900 nM reverse primer, 100 nM probe, 1X TaqMan PCR reaction buffer (PE-Applied Biosystems), 5.5 mM MgCl₂, 300 μ M each dATP, dCTP, dGTP, and dTTP, 10U RNase Inhibitor (Promega), 1.25U AmpliTaq Gold (PE-Applied Biosystems) and 10U M-MLV Reverse Transcriptase (Promega). The thermal cycling conditions can consist of 30 min at 48°C, 10 min at 95°C, followed by 40 cycles of 15 sec at 95°C and 1 25 min at 60°C. Quantitation of mRNA levels is determined relative to standards generated from serially diluted total cellular RNA (300, 100, 33, 11 ng/rxn) and normalizing to β -

actin or GAPDH mRNA in parallel TaqMan reactions. For each gene of interest an upper and lower primer and a fluorescently labeled probe are designed. Real time incorporation of SYBR Green I dye into a specific PCR product can be measured in glass capillary tubes using a lightcyler. A standard curve is generated for each primer pair using control cRNA. Values are represented as relative expression to GAPDH in each sample.

Western blotting

Nuclear extracts can be prepared using a standard micro preparation technique (see for example Andrews and Faller, 1991, *Nucleic Acids Research*, 19, 2499). Protein extracts from supernatants are prepared, for example using TCA precipitation. An equal volume of 20% TCA is added to the cell supernatant, incubated on ice for 1 hour and pelleted by centrifugation for 5 minutes. Pellets are washed in acetone, dried and resuspended in water. Cellular protein extracts are run on a 10% Bis-Tris NuPage (nuclear extracts) or 4-12% Tris-Glycine (supernatant extracts) polyacrylamide gel and transferred onto nitro-cellulose membranes. Non-specific binding can be blocked by incubation, for example, with 5% non-fat milk for 1 hour followed by primary antibody for 16 hour at 4°C. Following washes, the secondary antibody is applied, for example (1:10,000 dilution) for 1 hour at room temperature and the signal detected with SuperSignal reagent (Pierce).

20 Example 8: Models useful to evaluate the down-regulation of HIV gene expression

Cell Culture

The siNA constructs of the invention can be used in various cell culture systems as are commonly known in the art to screen for compounds having anti-HIV activity. B cell, T cell, macrophage and endothelial cell culture systems are non-limiting examples of cell culture systems that can be readily adapted for screening siNA molecules of the invention. In a non-limiting example, siNA molecules of the invention are co-transfected with HIV-1 pNL4-3 proviral DNA into 293/EcR cells as described by Lee *et al.*, 2002, *Nature Biotechnology*, 19, 500-505, using a U6 snRNA promoter driven expression system.

In a non-limiting example, the siNA expression vectors are prepared using the pTZ U6+1 vector described in Lee *et al. supra.* as follows. One cassette harbors the 21-nucleotide sense sequences and the other a 21-nucleotide antisense sequence (Table I). These sequences are designed to target HIV-1 RNA targets described herein. As a control to verify a siNA mechanism, irrelevant sense and antisense (S/AS) sequences lacking complementarity to HIV-1 (S/AS (IR)) are subcloned in pTZ U6+1. RNA samples are prepared from 293/EcR cells transiently co-transfected with siNA or control constructs, and subjected to Ponasterone A induction. RNAs are also prepared from 293 cells co-transfected with HIV-1 pNL4-3 proviral DNA and siNA or control constructs.

5 For determination of anti-HIV-1 activity of the siNAs, transient assays are done by co-transfection of siNA constructs and infectious HIV-1 proviral DNA, pNL4-3 into 293 cells as described above, followed by Northern analysis as known in the art. The p24 values are calculated with the aid of, for example, a Dynatech MR5000 ELISA plate reader (Dynatech Labs Inc., Chantilly, VA). Cell viability can also be assessed using a

10 Trypan Blue dye exclusion count at four days after transfection.

15

Other cell culture model systems for screening compounds having anti-HIV activity are generally known in the art. For example, Duzgunes *et al.*, 2001, Nucleosides, *Nucleotides & Nucleic Acids*, 20(4-7), 515-523; Cagnun *et al.*, 2000, *Antisense Nucleic Acid Drug Dev.*, 10, 251; Ho *et al.*, 1995, *Stem Cells*, 13 supp 3, 100; and Baur *et al.*, 20

1997, *Blood*, 89, 2259 describe cell culture systems that can be readily adapted for use with the compositions of the instant invention and the assays described herein.

Animal Models

Evaluating the efficacy of anti-HIV agents in animal models is an important prerequisite to human clinical trials. The siNA constructs of the invention can be 25 evaluated in a variety of animal models including, for example, a hollow fiber HIV model (see, for example, Gruenberg, US 5,627,070), mouse models for AIDS using transgenic mice expressing HIV-1 genes from CD4 promoters and enhancers (see, for example, Jolicoeur, International PCT Publication No. WO 98/50535) and/or the HIV/SIV/SHIV non-human primate models (see, for example, Narayan, US 5,849,994).
30 The siNA compounds and virus can be administered by a variety of methods and routes as described herein and as known in the art. Quantitation of results in these models can

be performed by a variety of methods, including quantitative PCR, quantitative and bulk co-cultivation assays, plasma co-cultivation assays, antigen and antibody detection assays, lymphocyte proliferation, intracellular cytokines, flow cytometry, as well as hematology and CBC evaluation. Additional animal models are generally known in the art, see for example Bai *et al.*, 2000, *Mol. Ther.*, 1, 244.

Example 9: RNAi mediated inhibition of HIV RNA expression

siNA constructs (**Table III**) are tested for efficacy in reducing HIV RNA expression in, for example, 293 cells. Cells are plated approximately 24h before transfection in 96-well plates at 5,000-7,500 cells/well, 100 μ l/well, such that at the time 10 of transfection cells are 70-90% confluent. For transfection, annealed siRNAs are mixed with the transfection reagent in a volume of 50 μ l/well and incubated for 20 minutes at room temperature and are cotransfected with HIV-1 pNL4-3 proviral DNA into 293 cells. The siNA transfection mixtures are added to cells to give a final siNA concentration of 25 nM in a volume of 150 μ l. Each siNA transfection mixture is added 15 to 3 wells for triplicate siNA treatments. Cells are incubated at 37° for 24h in the continued presence of the siNA transfection mixture. At 24h, RNA is prepared from each well of treated cells. The supernatants with the transfection mixtures are first removed and discarded, then the cells are lysed and RNA prepared from each well. Target gene expression following treatment is evaluated by RT-PCR for the target gene 20 and for a control gene (36B4, an RNA polymerase subunit) for normalization. In addition, ELISA can be used to determine HIV-1 p24 viral antigen levels. The triplicate data is averaged and the standard deviations determined for each treatment. Normalized data are graphed and the percent reduction of target mRNA by active siRNAs in comparison to their respective inverted control siRNAs is determined (see for example Lee 25 *et al.*, 2002, *Nature Biotechnology*, 20, 500-505).

In a non-limiting example, a siNA construct comprising ribonucleotides and 3'-terminal dithymidine caps is assayed along with a chemically modified siNA construct comprising 2'-deoxy-2'-fluoro pyrimidine nucleotides and purine ribonucleotides in which the sense strand of the siNA is further modified with 5' and 3'-terminal inverted 30 deoxyabasic caps and the antisense strand comprises a 3'-terminal phosphorothioate internucleotide linkage. Additional stabilization chemistries as described in Table IV are

similarly assayed for activity. These siNA constructs are compared to appropriate matched chemistry inverted controls. In addition, the siNA constructs are also compared to untreated cells, cells transfected with lipid and scrambled siNA constructs, and cells transfected with lipid alone (transfection control).

5 Example 10: Indications

The present body of knowledge in HIV research indicates the need for methods to assay HIV activity and for compounds that can regulate HIV expression for research, diagnostic, and therapeutic use. As described herein, the nucleic acid molecules of the present invention can be used in assays to diagnose disease state related of HIV levels.

10 In addition, the nucleic acid molecules can be used to treat disease state related to HIV levels.

Particular degenerative and disease states that can be associated with HIV expression modulation include, but are not limited to, acquired immunodeficiency disease (AIDS) and related diseases and conditions including, but not limited to,

15 Kaposi's sarcoma, lymphoma, cervical cancer, squamous cell carcinoma, cardiac myopathy, rheumatic diseases, and opportunistic infection, for example Pneumocystis carinii, Cytomegalovirus, Herpes simplex, Mycobacteria, Cryptococcus, Toxoplasma, Progressive multifocal leuco-encephalopathy (Papovavirus), Mycobacteria, Aspergillus, Cryptococcus, Candida, Cryptosporidium, Isospora belli, Microsporidia and any other
20 diseases or conditions that are related to or will respond to the levels of HIV in a cell or tissue, alone or in combination with other therapies.

The present body of knowledge in HIV research indicates the need for methods to assay HIV activity and for compounds that can regulate HIV expression for research, diagnostic, and therapeutic use.

25 The use of antiviral compounds, monoclonal antibodies, chemotherapy, radiation therapy, analgesics, and/or anti-inflammatory compounds, are all non-limiting examples of a methods that can be combined with or used in conjunction with the nucleic acid molecules (e.g. ribozymes and antisense molecules) of the instant invention. Examples of antiviral compounds that can be used in conjunction with the nucleic acid molecules of
30 the invention include, but are not limited to, AZT (also known as zidovudine or ZDV),

ddC (zalcitabine), dDI (dideoxyinosine), d4T (stavudine), and 3TC (lamivudine) Ribavirin, delvaridine (ReSCRIPTOR), nevirapine (Viramune), efravirenz (Sustiva), ritonavir (Norvir), saquinavir (Invirase), indinavir (Crixivan), amprenavir (Agenerase), nelfinavir (Viracept), and/or lopinavir (Kaletra). Common chemotherapies that can be
5 combined with nucleic acid molecules of the instant invention include various combinations of cytotoxic drugs to kill cancer cells. These drugs include, but are not limited to, paclitaxel (Taxol), docetaxel, cisplatin, methotrexate, cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate, gemcitabine, and vinorelbine. Those skilled in the art will recognize that other drug compounds and therapies can be similarly
10 be readily combined with the nucleic acid molecules of the instant invention (e.g. ribozymes, siRNA and antisense molecules) are hence within the scope of the instant invention.

Example 11: Diagnostic uses

The siNA molecules of the invention can be used in a variety of diagnostic
15 applications, such as in the identification of molecular targets (e.g., RNA) in a variety of applications, for example, in clinical, industrial, environmental, agricultural and/or research settings. Such diagnostic use of siNA molecules involves utilizing reconstituted RNAi systems, for example, using cellular lysates or partially purified cellular lysates. siNA molecules of this invention can be used as diagnostic tools to examine genetic drift
20 and mutations within diseased cells or to detect the presence of endogenous or exogenous, for example viral, RNA in a cell. The close relationship between siNA activity and the structure of the target RNA allows the detection of mutations in any region of the molecule, which alters the base-pairing and three-dimensional structure of the target RNA. By using multiple siNA molecules described in this invention, one can
25 map nucleotide changes, which are important to RNA structure and function *in vitro*, as well as in cells and tissues. Cleavage of target RNAs with siNA molecules can be used to inhibit gene expression and define the role of specified gene products in the progression of disease or infection. In this manner, other genetic targets can be defined as important mediators of the disease. These experiments will lead to better treatment of
30 the disease progression by affording the possibility of combination therapies (e.g., multiple siNA molecules targeted to different genes, siNA molecules coupled with known small molecule inhibitors, or intermittent treatment with combinations siNA

molecules and/or other chemical or biological molecules). Other *in vitro* uses of siNA molecules of this invention are well known in the art, and include detection of the presence of mRNAs associated with a disease, infection, or related condition. Such RNA is detected by determining the presence of a cleavage product after treatment with a 5 siNA using standard methodologies, for example, fluorescence resonance emission transfer (FRET).

In a specific example, siNA molecules that cleave only wild-type or mutant forms of the target RNA are used for the assay. The first siNA molecules (*i.e.*, those that cleave only wild-type forms of target RNA) are used to identify wild-type RNA present 10 in the sample and the second siNA molecules (*i.e.*, those that cleave only mutant forms of target RNA) are used to identify mutant RNA in the sample. As reaction controls, synthetic substrates of both wild-type and mutant RNA are cleaved by both siNA molecules to demonstrate the relative siNA efficiencies in the reactions and the absence 15 of cleavage of the "non-targeted" RNA species. The cleavage products from the synthetic substrates also serve to generate size markers for the analysis of wild-type and mutant RNAs in the sample population. Thus, each analysis requires two siNA molecules, two substrates and one unknown sample, which is combined into six 20 reactions. The presence of cleavage products is determined using an RNase protection assay so that full-length and cleavage fragments of each RNA can be analyzed in one lane of a polyacrylamide gel. It is not absolutely required to quantify the results to gain 25 insight into the expression of mutant RNAs and putative risk of the desired phenotypic changes in target cells. The expression of mRNA whose protein product is implicated in the development of the phenotype (*i.e.*, disease related or infection related) is adequate to establish risk. If probes of comparable specific activity are used for both transcripts, then a qualitative comparison of RNA levels is adequate and decreases the cost of the 30 initial diagnosis. Higher mutant form to wild-type ratios are correlated with higher risk whether RNA levels are compared qualitatively or quantitatively.

All patents and publications mentioned in the specification are indicative of the levels of skill of those skilled in the art to which the invention pertains. All references 30 cited in this disclosure are incorporated by reference to the same extent as if each reference had been incorporated by reference in its entirety individually.

One skilled in the art would readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The methods and compositions described herein as presently representative of preferred embodiments are exemplary and are not intended as 5 limitations on the scope of the invention. Changes therein and other uses will occur to those skilled in the art, which are encompassed within the spirit of the invention, are defined by the scope of the claims.

It will be readily apparent to one skilled in the art that varying substitutions and modifications can be made to the invention disclosed herein without departing from the 10 scope and spirit of the invention. Thus, such additional embodiments are within the scope of the present invention and the following claims. The present invention teaches one skilled in the art to test various combinations and/or substitutions of chemical modifications described herein toward generating nucleic acid constructs with improved activity for mediating RNAi activity. Such improved activity can comprise improved 15 stability, improved bioavailability, and/or improved activation of cellular responses mediating RNAi. Therefore, the specific embodiments described herein are not limiting and one skilled in the art can readily appreciate that specific combinations of the modifications described herein can be tested without undue experimentation toward identifying siNA molecules with improved RNAi activity.

20 The invention illustratively described herein suitably can be practiced in the absence of any element or elements, limitation or limitations that are not specifically disclosed herein. Thus, for example, in each instance herein any of the terms "comprising", "consisting essentially of", and "consisting of" may be replaced with either of the other two terms. The terms and expressions which have been employed are used 25 as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments, optional 30 features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the description and the appended claims.

In addition, where features or aspects of the invention are described in terms of Markush groups or other grouping of alternatives, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group or other group.

Table I: HIV Accession Numbers

Accession	Name	Subtype
AB032740	95TNIH022	01_AE
AB032741	95TNIH047	01_AE
AB052995	93JPNH1	01_AE
AB070352	NH25 93JPNH25T 93JP-NH2.5T	01_AE
AB070353	NH2 93JPNH2ENV	01_AE
AF164485	93TH9021	01_AE
AF197338	93TH057	01_AE
AF197339	93TH065	01_AE
AF197340	90CF11697 AF197340	01_AE
AF197341	90CF4071 AF197341	01_AE
AF259954	CM235-2	01_AE
AF259955	CM235-4	01_AE
AY008714	97CNGX2F 97CNGX-2F	01_AE
AY008718	97CNGX11F	01_AE
U51188	90CF402 90CR402 CAR-E 4002	01_AE
U51189	93TH253	01_AE
U54771	CM240	01_AE
AF362994	NP1623	01B
AY082968	TH1326 AY082968	01B
AJ404325	97DCKTB49 97CDKTB49 HIM404325	01GHJKU
AB049811	97GHAG1 AB049811	02_AG
AB052867	AB052867	02_AG
AF063223	DJ263	02_AG
AF063224	DJ264	02_AG
AF107770	SE7812	02_AG
AF184155	G829	02_AG
AF377954	CM52885 AF377954	02_AG
AF377955	CM53658 AF377955	02_AG
AJ251056	MP1211 98SE-MP1211	02_AG
AJ251057	MP1213 98SEMP1213 HIM251057	02_AG
AJ286133	97CM-MP807	02_AG
L39106	IBNG	02_AG
AF193276	KAL153-2	03_AB
AF193277	RU98001 98RU001	03_AB
AF414006	98BY10443 AF414006	03-AB
AF049337	94CY032-3 CY032.3	04_cpx
AF119819	97PVMY GR84	04_cpx
AF119820	97PVCH GR11	04_cpx
AF076998	VI961	05_DF
AF193253	VI1310 AF193253	05_DF
AF064699	BFP90	06_cpx
AJ245481	95ML84	06_cpx
AJ288981	97SE1078	06_cpx
AJ288982	95ML127	06_cpx
AF286226	97CN001 C54	07_BC
AF286230	98CN009	07_BC
AX149647	C54A C54	07_BC
AX149672	C54D AX149672	07_BC
AX149771	CN54b	07_BC
AX149898	C54C	07_BC

AF286229	98CN006	08 BC
AY008715	97CNGX6F	08 BC
AY008716	97CNGX7F	08 BC
AY008717	97CNGX9F	08 BC
AF289548	96TZBF061	10 CD
AF289549	96TZBF071	10 CD
AF289550	96TZBF110	10 CD
AF179368	GR17	11 cpx
AJ291718	MP818	11 cpx
AJ291719	MP1298	11 cpx
AJ291720	MP1307	11 cpx
AF385934	URTR23	12 BF
AF385935	URTR35	12 BF
AF385936	ARMA159	12 BF
AF408629	A32879 AF408629	12 BF
AF408630	A32989 AF408630	12 BF
AY037279	ARMA185	12 BF
AF423756	X397 AF423756	14 BG
AF423757	X421 AF423757	14 BG
AF423758	X475 AF423758	14 BG
AF423759	X477 AF423759	14 BG
AF450096	X605 AF450096	14 BG
AF450097	X623 AF450097	14 BG
AF069669	SE8538	A
AF069671	SE7535	A
AF069673	SE8891	A
AF107771	UGSE8131	A
AF193275	97BL006 AF193275	A
AF361872	97TZ02 AF361872	A
AF361873	97TZ03 AF361873	A
AF413987	98UA0116 AF413987	A
AF004885	Q23-17	A1
AF069670	SE7253	A1
M62320	U455 U455A	A1
U51190	92UG037	A1
AF286237	94CY017.41	A2
AF286238	97CDKTB48	A2
U86780	ZAM184	A2C
AF286239	97KR004	A2D
AF316544	97CDKP58	A2G
AF067156	95IN21301	AC
AF071474	SE9488	AC
AF361871	97TZ01 AF361871	AC
AF361876	97TZ06 AF361876	AC
AF361878	97TZ08 AF361878	AC
AF361879	97TZ09 AF361879	AC
U88823	92RW009	AC
AF075702	SE8603	ACD
AJ276595	VI1035	ACG
AF071473	SE7108	AD
AF075701	SE6954	AD
AJ237565	97NOGIL3	ADHK
X04415	MAL MALCG	ADK
AF377959	CM53379 AF377959	AFGHJU
AF377957	CM53392 AF377957	AG

AJ276596	VI1197	AG
U88825	92NG003	AG
AF076474	VI354	AGHU
AF192135	BW2117	AGJ
AJ293865	B76 HIM293865	AGJ
AF069672	SE6594	AU
A04321	IIIB LAI	B
AB078005	ARES2 AB078005	B
AF003887	WC001	B
AF003888	NL43WC001	B
AF004394	AD87 ADA	B
AF033819	HXB2-copy LAI	B
AF042100	MBC200	B
AF042101	MBC925	B
AF042102	MBC18 MBCC18	B
AF042103	MBCC54	B
AF042104	MBCC98	B
AF042105	MBCD36	B
AF042106	MBCC18R01 C18R01	B
AF049494	499JC16	B
AF049495	NC7	B
AF069140	DH12-3	B
AF070521	NL43E9 LAI IIIB/NY5	B
AF075719	MNTQ MNcloneTQ	B
AF086817	TWCYS LM49	B
AF146728	VH	B
AF224507	WK	B
AF256204	S6111 AF256204	B
AF256205	S61D15 AF256205	B
AF256206	S61G1 AF256206	B
AF256207	S61G7 AF256207	B
AF256208	S61I15 AF256208	B
AF256209	S61K1 AF256209	B
AF256210	S61K15 AF256210	B
AF256211	S61D1	B
AF286365	WR27	B
AJ006287	89SP061 89ES061	B
AJ271445	GB8 GB8-46R HIM271445	B
AX078307	BH10	B
AY037268	ARCH054	B
AY037269	ARMS008	B
AY037270	BOL122	B
AY037274	ARMA173	B
AY037282	ARMA132	B
D10112	CAM1	B
D86068	MCK1	B
D86069	PM213	B
K02007	SF2 LAV2 ARV2	B
K02013	LAI BRU	B
K02083	PV22	B
K03455	HXB2 HXB2CG HXB2R LAI	B
L02317	BC BCSG3	B
L31963	TH475A LAI	B
M15654	BH102 BH10	B
M17449	MNCG MN	B

M17451	RF HAT3	B
M19921	NL43 pNL43 NL43	B
M26727	OYI, 397	B
M38429	JRCSF JR-CSF	B
M38431	NY5CG	B
M93258	YU2 YU2X	B
M93259	YU10	B
NC_001802	HXB2R	B
U12055	LW123	B
U21135	WEAU160 GHOSH	B
U23487	contaminant MANC	B
U26546	WR27	B
U26942	NL4-3 LAI/NY5 pNL43 NL43	B
U34603	H0320-2A12 ACH3202A12	B
U34604	3202A21 ACH3202A21	B
U37270	C18MBC	B
U39362	P896 89.6	B
U43096	D31	B
U43141	HAN	B
U63632	JRFL JR-FL	B
U69584	85WCIPR54	B
U69585	WCIPR854	B
U69586	WCIPR8546	B
U69587	WCIPR8552	B
U69588	WCIPR855	B
U69589	WCIPR9011	B
U69590	WCIPR9012	B
U69591	WCIPR9018	B
U69592	WCIPR9031	B
U69593	WCIPR9032	B
U71182	RL42	B
X01762	REHTLV3 LAI IIIB	B
Z11530	F12CG	B
AF332867	A027 AF332867	BF
AF408626	A025 AF408626	BF
AF408627	A047 AF408627	BF
AF408628	A063 AF408628	BF
AF408631	A050 AF408631	BF
AF408632	A32878 AF408632	BF
AY037266	ARCH014	BF
AY037267	ARCH003	BF
AY037271	BOL137	BF
AY037272	URTR17	BF
AY037273	ARMA062	BF
AY037275	ARMA036	BF
AY037276	ARMA070	BF
AY037277	ARMA037	BF
AY037278	ARMA006	BF
AY037280	ARMA097	BF
AY037281	ARMA038	BF
AY037283	ARMA029	BF
AF005495	93BR029.4	BF1
AF423755	X254 AF423755	BG
AB023804	93IN101	C
AF067154	93IN999 301999	C

AF067155	95IN21068	C
AF067157	93IN904 301904	C
AF067158	93IN905 301905	C
AF067159	94IN11246	C
AF110959	96BW01B03 96BW01B03	C
AF110960	96BW01B21	C
AF110961	96BW01B22	C
AF110962	96BW0402	C
AF110963	96BW0407	C
AF110964	96BW0408	C
AF110965	96BW0409	C
AF110966	96BW0410	C
AF110967	96BW0502	C
AF110968	96BW0504	C
AF110969	96BW1104	C
AF110970	96BW1106	C
AF110971	96BW11B01	C
AF110972	96BW1210	C
AF110973	96BW15B03	C
AF110974	96BW15C02	C
AF110975	96BW15C05	C
AF110976	96BW16B01	C
AF110977	96BW16D14	C
AF110978	96BW1626	C
AF110979	96BW17A09	C
AF110980	96BW17B03	C
AF110981	96BW17B05	C
AF286223	94IN476	C
AF286224	96ZM651	C
AF286225	96ZM751	C
AF286227	97ZA012	C
AF286228	98BR004	C
AF286231	98IN012	C
AF286232	98IN022	C
AF286233	98IS002	C
AF286234	98TZ013	C
AF286235	98TZ017	C
AF290027	96BW06H51 96BW06-H51	C
AF290028	96BW06J4	C
AF290029	96BW06J7 AF290029	C
AF290030	96BW06K18 AF290030	C
AF321523	MJ4	C
AF361874	97TZ04 AF361874	C
AF361875	97TZ05 AF361875	C
AF443074	96BWM015	C
AF443075	96BWM032 AF443075	C
AF443076	98BWMC122 AF443076	C
AF443077	98BWMC134 AF443077	C
AF443078	98BWMC14A3 AF443078	C
AF443079	98BWM01410 AF443079	C
AF443080	98BWM018D5 AF443080	C
AF443081	98BWM036A5 AF443081	C
AF443082	98BWM037D5 AF443082	C
AF443083	99BW393212 AF443083	C
AF443084	99BW46424 AF443084	C

AF443085	99BW47458 AF443085	C
AF443086	99BW47547 AF443086	C
AF443087	99BWMC168 AF443087	C
AF443088	00BW07621 AF443088	C
AF443089	00BW076820 AF443089	C
AF443090	00BW087421 AF443090	C
AF443091	00BW147127 AF443091	C
AF443092	00BW16162 AF443092	C
AF443093	00BW1686. 00BW16868 AF443093	C
AF443094	00BW17593 AF443094	C
AF443095	00BW17732 AF443095	C
AF443096	00BW17835 AF443096	C
AF443097	00BW17956 AF443097	C
AF443098	00BW18113 AF443098	C
AF443099	00BW18595 AF443099	C
AF443100	00BW18802 AF443100	C
AF443101	00BW192113 AF443101	C
AF443102	00BW20361 AF443102	C
AF443103	00BW20636 AF443103	C
AF443104	00BW20872 AF443104	C
AF443105	00BW2127214 AF443105	C
AF443106	00BW21283 AF443106	C
AF443107	00BW22767 AF443107	C
AF443108	00BW38193 AF443108	C
AF443109	00BW38428 AF443109	C
AF443110	00BW38713 AF443110	C
AF443111	00BW38769	C
AF443112	00BW38868	C
AF443113	00BW38916	C
AF443114	00BW39702	C
AF443115	00BW50311	C
AY043173	DU151 AY043173	C
AY043174	DU179 AY043174	C
AY043175	DU422 AY043175	C
AY043176	CTSC2 AY043176	C
U46016	ETH2220 C2220	C
U52953	92BR025	C
AF361877	97TZ07 AF361877	CD
AY074891	00BWM0351 AY074891	CD
AF133821	MB2059	D
AJ320484	HIM320484	D
K03454	ELI	D
M22639	Z2Z6 Z2 CDC-Z34	D
M27323	NDK	D
U88822	84ZR085	D
U88824	94UG1141	D
AF005494	93BR020.1	F1
AF075703	FIN9363	F1
AF077336	VI850	F1
AJ249238	MP411 96FRMP411	F1
AF377956	CM53657 AF377956	F2
AJ249236	MP255 95CMMP255	F2
AJ249237	MP257 95CM-MP257C	F2
AF076475	VI1126	F2KU
AF061640	HH8793-1.1	G

AF061641	HH8793-12.1	G
AF061642	SE6165 G6165	G
AF084936	DRCBL	G
AF423760	X558 AF423760	G
AF450098	X138 AF450098	G
U88826	92NG083 JV10832	G
AF005496	90CF056 90CR056	H
AF190127	VI991	H
AF190128	VI997	H
AF082394	SE7887 SE92809	J
AF082395	SE7022 SE9173	J
AJ249235	EQTB11C 97ZR-EQTB11C	K
AJ249239	MP535 96CM-MP535C	K
AJ239083	97CA-MP645M/O	MO
AJ006022	YBF30	N
AJ271370	YBF106	N
AF407418	VAU AF407418	O
AF407419	VAU AF407419	O
AJ302646	SEMP1299 HIM302646	O
AJ302647	SEMP1300 HIM302647	O
L20571	MVP5180	O
L20587	ANT70	O
NC_002787	SEMP1299 NC_002787	O
AF286236	83CD003 Z3 AF286236	U
AF457101	90CD121E12 AF457101	U
AY046058	GR303 99GR303 AY046058	U

(+)uuuuuuuu

Table II: HIV siNA and Target Sequences

Target Sequence	SeqID	Upper seq	Seq ID	Lower seq
UUUGAAAAAGGACCAGCAA	1	UUUGGAAAAGGACCAGCAA	1	UUUGCUGGUCCUUUCCAAA
CAGGAGCAGAUGAUACAGU	2	CAGGAGCAGAUGAUACAGU	2	ACUGUAUCAUCUGCUCCUG
AGAAAAGGGGGAUUGGGG	3	AGAAAAGGGGGAUUGGGG	3	CCCCAAUCCCCCUUUCU
GUAGACAGGAUGAGGAUUA	4	GUAGACAGGAUGAGGAUUA	4	UAUCCUCAUCUGCUUCAC
ACAGGAGCAGAUGAUACAG	5	ACAGGAGCAGAUGAUACAG	5	CUGUAUCAUCUGCUCCUGU
AAAAAGGGGGAUUGGGG	6	AAAAAGGGGGAUUGGGG	6	CCCCCAAUCCCCCUUUCU
UUAGAUACAGGAGCAGAUG	7	UUAGAUACAGGAGCAGAUG	7	CAUCUGCUCCUGUAUCUA
UAGAUACAGGAGCAGAUGA	8	UAGAUACAGGAGCAGAUGA	8	UCAUCUGCUCCUGUAUCUA
AGCAGAAAGACAGUGCAAU	9	AGCAGAAAGACAGUGGCAAU	9	AUJGCCACUGCUUCUGCU
AUUAGAUACAGGAGCAGAU	10	AUUAGAUACAGGAGCAGAU	10	AUCUGCUCCUGUAUCUAU
AUACAGGAGCAGAUAC	11	AUACAGGAGCAGAUAC	11	GUUAUCAUCUGCUCCUGUAU
GAAGCAGAAAGACAGUGGCAA	12	GAAGCAGAAAGACAGUGGCAA	12	UJGCCACUGCUUCUGCU
AGAGCAGAAAGACAGUGGCA	13	AGAGCAGAAAGACAGUGGCA	13	UGCCACUGCUUCUGCU
GCAGAAAGACAGUGGCAAUG	14	GCAGAAAGACAGUGGCAAUG	14	CAUUGCCACUGCUUCUGC
AGAUACAGGAGCAGAUGAU	15	AGAUACAGGAGCAGAUGAU	15	AUCAUCUGCUCCUGUAUCU
UACAGGAGCAGAUGAUACA	16	UACAGGAGCAGAUGAUACA	16	UGUAUCAUCUGCUCCUGUA
UUUUAGAUACAGGAGCAGA	17	UUUUAGAUACAGGAGCAGA	17	UCUGCUCCUGUAUCUAUA
GAUACAGGAGCAGAUGAU	18	GAUACAGGAGCAGAUGAU	18	UAUCAUCUGCUCCUGUAUC
AUGGAAAAACAGAUGGCAGG	19	AUGGAAAAACAGAUGGCAGG	19	CCUGCCACUGUUUCCAU
GUCAACAUUUUGGAAGAA	20	GUCAACAUUUUGGAAGAA	20	UUCUUCCAAUUAUGGUUGAC
UAGGGAAAACAGAUGGCAG	21	UAGGGAAAACAGAUGGCAG	21	CUGCCACUCUGUUUCCAU
AUGAUAGGGGAAUUGGAG	22	AUGAUAGGGGAAUUGGAG	22	CUCCAAUUUCCCCAUCAU
CAGAAGACAGUGGCAAUGA	23	CAGAAGACAGUGGCAAUGA	23	UCAUUGGCCACUGCUUCUG
CAAUGGCCAUUGACAGAAAG	24	CAAUGGCCAUUGACAGAAAG	24	CUUCUGCUCAUGGCCAUUG
UCAACAUUUUGGAAGAAA	25	UCAACAUUUUGGAAGAAA	25	UUUCUCCAAUUAUGGUUGA
AAUGGCCAUUGACAGAAAG	26	AAUGGCCAUUGACAGAAAG	26	UCUUCUUGCUAAUGGCCAU
UGAUAGGGAAUUGGAGG	27	UGAUAGGGAAUUGGAGG	27	CCUCCAAUUCCCCUCAUCA
GACAGGGCUUUUUUJUAGG	28	GACAGGGCUUUUUUJUAGG	28	CCUAAAUAUUAGGCCUGUC
AUUUUCGGGUUUUUJUACAG	29	AUUUUCGGGUUUUUJUACAG	29	CUGJAAAUAACCCGAAAU
CUAUUAGAUACAGGAGCAG	30	CUAUUAGAUACAGGAGCAG	30	CUGGUCCUGUAUCUUAAUAG

AGACAGGGCUAUUUUUAG	31	AGACAGGGCUAUUUUUAG	31	CUAAAAAUUAGCCUGUCU	769
AAAUGAUAGGGGAAUUGG	32	AAAUGAUAGGGGAAUUGG	32	CCAAUUCCCCUCAUUU	770
UAUGGGCAAGCAGGAGCU	33	UAUGGGCAAGCAGGAGCU	33	AGCUUCCUGCUUGCCCAUA	771
UAGUAUGGGCAAGGGGA	34	UAGUAUGGGCAAGGGGA	34	UCCUJGCUJGCCAUACUA	772
GAAACAGAUGGCAGGUGA	35	GAAACAGAUGGCAGGUGA	35	UCACCUGCCAUUCGUUUUC	773
ACCAUCAAUGGAGGCGUG	36	ACCAUCAAUGGAGGCGUG	36	CAGCJUCCUCAUUAGGUGU	774
AUGAUAGGGGAAUUGGA	37	AUGAUAGGGGAAUUGGA	37	UCCAAUUCCCCUCAUCAUU	775
UGGAAAACAGAUGGCAGGU	38	UGGAAAACAGAUGGCAGGU	38	ACCUGCCAUUCGUUUUC	776
GGAAAACAGAUGGCAGGUG	39	GGAAAACAGAUGGCAGGUG	39	CACCGGCCAUUCGUUUUC	777
GAUUAUGGAAAACAGAUGG	40	GAUUAUGGAAAACAGAUGG	40	CCAUCUGUIUUUCAUAAUC	778
AAAUGAUAGGGGAAUUG	41	AAAUGAUAGGGGAAUUG	41	CAAUUCCCCUCAUCAUUUU	779
UGGAAAGGUGAAGGGCAG	42	UGGAAAGGUGAAGGGCAG	42	CUGCCCUUCACCUUUCC	780
AUCAAUAGGGAAGCUGCAG	43	AUCAAUAGGGAAGCUGCAG	43	CUGCAGCUUCCUCAUJGAU	781
UGGAAAACCAAAAUGAUAG	44	UGGAAAACCAAAAUGAUAG	44	CUAUCAUUUJGUUUCC	782
CCAUCAUAGGGAAGCUGC	45	CCAUCAUAGGGAAGCUGC	45	GCAGCUUCCUCAUJGUGG	783
AGGGAUUAUGGAAAACAGA	46	AGGGAUUAUGGAAAACAGA	46	UCUGUUUCCUAUAUCCU	784
GGAAACCAAAAUGAUAGG	47	GGAAACCAAAAUGAUAGG	47	CCUAUCAUUUJGUUUCC	785
UAGGGGAAUUGGGUUU	48	UAGGGGAAUUGGGUUU	48	AAACCCUCAAUUCCCC	786
UACAGUGCCAGGGAAAGAA	49	UACAGUGCCAGGGAAAGAA	49	UUCUJUUCCCUGCACUGUA	787
CUCUAAUAGAUACAGGAGC	50	CUCUAAUAGAUACAGGAGC	50	GCUCUCGUUAUCUAUAGAG	788
GGAUUAUGGAAAACAGAUG	51	GGAUUAUGGAAAACAGAUG	51	CAUCGUUUCCUAUAUCC	789
CAAAAAAUGAUAGGGAA	52	CAAAAAAUGAUAGGGAA	52	UUCCCCUCAUCAUJUJGG	790
AUGGAAAACCAAAAUGAU	53	AUGGAAAACCAAAAUGAU	53	UAUCAUUUUJGUUUCCAU	791
CAGUGCAGGGAAAGAAUA	54	CAGUGCAGGGAAAGAAUA	54	UAUUCUUUCCUCUGCACUG	792
ACAAUUGGCCAUUGACAGAA	55	ACAAUUGGCCAUUGACAGAA	55	UUCUGCUUAUGGCCAUJGU	793
CCAUGCAUGGACAAGUAGA	56	CCAUGCAUGGACAAGUAGA	56	UCUACUGGUCCAUJGCAUG	794
AUUAUGGAAAACAGAUGGC	57	AUUAUGGAAAACAGAUGGC	57	GCCAUJGUUUCCAUAAU	795
AACAUUGGCCAUUGACAGA	58	AACAUUGGCCAUUGACAGA	58	UCUGCUAUJGGCCAUJGU	796
AAAAAUGAUAGGGAAUU	59	AAAAAUGAUAGGGAAUU	59	AAUUCCCCUCAUCAUUUU	797
GCCAUUGCAUGGACAAGUAG	60	GCCAUUGCAUGGACAAGUAG	60	CUACUJGUCCAUJGCAUGGC	798
UAGCAGGAAGAUGGCCAGU	61	UAGCAGGAAGAUGGCCAGU	61	ACUGGCCAUUCUCCUGCU	799
AAAAAAUGAUAGGGGAAU	62	AAAAAAUGAUAGGGGAAU	62	AUUCCCCUCAUCAUUUU	800
AGAAAAAUGAUAGACAGCAUG	63	AGAAAAAUGAUAGACAGCAUG	63	CAUGCUGCUAUCAUUUCU	801
UCUAAUAGAUACAGGAGCA	64	UCUAAUAGAUACAGGAGCA	64	UGCUCUCGUUAUCUAUAGA	802
GCUCUAAUAGAUACAGGAG	65	GCUCUAAUAGAUACAGGAG	65	CUCCUGUAUCUAUAGAGC	803
CAGGCUAAUUUUUAGGGA	66	CAGGCUAAUUUUUAGGGA	66	UCCCUAAUUUUUAGCCUG	804

AGGAGCAAGAUGAUACAGUA	67	AGGAGCAGAUGAUACAGUA	67	UACUGUAUCAUCUGCUCCU	805
AAACAAUGGCCAUUGACAG	68	AAACAAUGGCCAUUGACAG	68	CUGUCAUGGCCAUUGUUU	806
CGGGUUUAAUACAGGGACA	69	CGGGUUUAAUACAGGGACA	69	UGUCCUCGUAAAUAACCCG	807
CAACAUAAUJGGAAAGAAAAU	70	CAACAUAAUJGGAAAGAAAAU	70	AUUUCUJCCAUUUAGUUG	808
UCAAUAGGGAAGCUGCAGA	71	UCAAUAGGGAAGCUGCAGA	71	UCUGCAGCUUCUCAUUGA	809
GGAAAGGGUAGGGCAGU	72	GGAAAGGGUAGGGCAGU	72	ACUGCCCCUACACUUUCC	810
UUUCGGGUUAAUACAGGG	73	UUUCGGGUUAAUACAGGG	73	CCUGUAAAACCCGAAA	811
UCGGGUUAAUACAGGGAC	74	UCGGGUUAAUACAGGGAC	74	GUCCUGUAAAACCCGGA	812
ACAGUGCGGGGAAAGAAU	75	ACAGUGCGGGGAAAGAAU	75	AUUCUUCCCCUGACUGU	813
AUGCAUGGACAAGUAGACU	76	AUGCAUGGACAAGUAGACU	76	AGUCUACUUGGUCAUGCAU	814
AAGCCAUGGCAUGGACAAGU	77	AAGCCAUGGCAUGGACAAGU	77	ACUUGGUCAUGGUAGGCUU	815
AGCCAUGGCAUGGACAAGU	78	AGCCAUGGCAUGGACAAGU	78	UACUUGGUCCAUAGGUAGCU	816
GCAUUAUCAGAAGGAGCCA	79	GCAUUAUCAGAAGGAGCCA	79	UGGCUCUUCUCAUAAAUGC	817
AUUUGGAGAAGUGAAUUAU	80	AUUUGGAGAAGUGAAUUAU	80	AUAAUUCACUUCUCCAAUU	818
AGAAAAAAUCAUAAACAGU	81	AGAAAAAAUCAUAAACAGU	81	ACUGUACUGAUUUUUUCU	819
GAAGCCAUGGCAUGGACAAG	82	GAAGCCAUGGCAUGGACAAG	82	CIUGUCCAUUGGUCCUUC	820
ACAGGCCUAUUUUUJAGGG	83	ACAGGCCUAUUUUUJAGGG	83	CCCUAAAAAUJAGCCUGU	821
GAAGAAAUGAUGACGCAU	84	GAAGAAAUGAUGACGCAU	84	AUGCUGUACUAUUCUUC	822
UUUUCGGGUUAAUACAGG	85	UUUUCGGGUUAAUACAGG	85	CCUGUAAAACCCGAAAA	823
ACCAAAAAGAUAGGGGA	86	ACCAAAAAGAUAGGGGA	86	UCCCCCUAUCAUUUJUGGU	824
GAAGUGACAUAGCAGGAAC	87	GAAGUGACAUAGCAGGAAC	87	GUUCCUGCIAUGGUCAUCU	825
UUCGGGUUAAUACAGGG	88	UUCGGGUUAAUACAGGG	88	UCCUGUAAAACCCGAA	826
AUAGGGGGAAUJGGGGUU	89	AUAGGGGGAAUJGGGGUU	89	AACCUCCAAUCCCCUAU	827
AGAAGAAAUGAUGACAGCA	90	AGAAGAAAUGAUGACAGCA	90	UGCUGUCAUCAUUUCUUCU	828
AUJGGGAAAGUGAAUUAUA	91	AUJGGGAAAGUGAAUUAUA	91	UAAAUAUCACUUCUCCAAU	829
GGAAGUGACAUAGCAGGAA	92	GGAAGUGACAUAGCAGGAA	92	UCCUGGUAGGUACUUCU	830
AGGCCUAUUUUUJAGGGAA	93	AGGCCUAUUUUUJAGGGAA	93	UCCCCUAAAAAUJAGCCU	831
UUAUGGAAAACAGAUGGCA	94	UUAUGGAAAACAGAUGGCA	94	UGCCAUUCUGUUUUCCAAU	832
GGGAUUAUJGGAAAACAGAU	95	GGGAUUAUJGGAAAACAGAU	95	AUCUGUUUCAUAAUCC	833
UAGAAGAAAUGAUGACAGC	96	UAGAAGAAAUGAUGACAGC	96	GCUGUCAUCAUUUCUUCUA	834
AGCUCUAAUJAGAUACAGGA	97	AGCUCUAAUJAGAUACAGGA	97	UCCUGUAAUCUAAAAGAGCU	835
GUAUUGGGCAAGCAGGGAGC	98	GUAUUGGGCAAGCAGGGAGC	98	GUCCCCUGGUUGCCCAUAC	836
CUUAGGCAUCUCCUAGGC	99	CUUAGGCAUCUCCUAGGC	99	GCCAUAGGGAGAUGCCUAAG	837
GCAGGAACCUACUQUACCC	100	GCAGGAACCUACUQUACCC	100	GGGUACUACUAGGUCCUGC	838
GGGGAAAGUGACAUAGCAGG	101	GGGGAAAGUGACAUAGCAGG	101	CCUGGUAAUGGUCAUCUCC	839
UACAAUCCCCAAAGUCAAG	102	UACAAUCCCCAAAGUCAAG	102	CUUGACUUUJGGGGAUUGUA	840

UUCCCUAACAUCCCCAAAG	103	UUCCCUAACAUCCCCAAAG	103	CUJUGGGGAUUGUAGGGAA	841
AAGCCUCUACAUAGAACAGG	104	AAGCCUCUACAUAGAACAGG	104	CCUGUAUCUAAUAGAGCUU	842
CCUAGGGCAGGAAGAACCG	105	CCUAGGGCAGGAAGAACCG	105	CGCUUCUUCGCCAUAGG	843
AGGGGAAGGACAUAGCAG	106	AGGGGAAGGACAUAGCAG	106	CUGCUAUGUCACUUCCCC	844
UCCUAUGGCAGGAAGAACG	107	UCCUAUGGCAGGAAGAACG	107	GUUCUUCGCCAUAGGA	845
CAGCAUUAUCAGAAGGAGC	108	CAGCAUUAUCAGAAGGAGC	108	GUCCUCUCUGAUAAUGCUG	846
AUCUCCUAUGGCAGGAAGA	109	AUCUCCUAUGGCAGGAAGA	109	UCUUCUCCGCAUAGGAGAU	847
AGCAGGAACUACUAGUACC	110	AGCAGGAACUACUAGUACC	110	GGUACUAGUAGUCCUGCU	848
GAAACCAAAAUGAUAGGG	111	GAAACCAAAAUGAUAGGG	111	CCCUAUCAUUUUGGUUUC	849
AAACCAAAAUGAUAGGG	112	AAACCAAAAUGAUAGGG	112	CCCCUAUCAUUUUGGUUUI	850
CAGAAGGAGCCACCCACA	113	CAGAAGGAGCCACCCACA	113	UGGGGUUGGCCUUCUUCUG	851
UAGCAGGAACUACUAGUAC	114	UAGCAGGAACUACUAGUAC	114	GUACUAGUAGUCCUGCUA	852
UGCAUGGACAAGUAGACUG	115	UGCAUGGACAAGUAGACUG	115	CAGUCUACUUGUCCAUUGCA	853
UAGGGCAUCUCCUAGGCA	116	UAGGGCAUCUCCUAGGCA	116	UGCCAUAGGAGAUCCUAA	854
UAGGGCAGGAAGAGCGGA	117	UAGGGCAGGAAGAGCGGA	117	UCCGCUUCUCCUGCCAU	855
AUAGCAGGAACUACUAGUA	118	AUAGCAGGAACUACUAGUA	118	UACUAGUAGUCCUGCUAU	856
UAGACAUAAUAGCAACAGA	119	UAGACAUAAUAGCAACAGA	119	UCUGUUGCUAUUAGUCUA	857
CAUUAUCAGAACGGGCCAC	120	CAUUAUCAGAACGGGCCAC	120	GUGGCCUCCUUCUGAUAAUG	858
CUAUGGCAGGAAGAACCGG	121	CUAUGGCAGGAAGAACCGG	121	CCGCUUCUCCUGCCAUAG	859
GAUAGGGGGAAUUGGAGGU	122	GAUAGGGGGAAUUGGAGGU	122	ACCUCCAAUCCCCCUAUC	860
ACAAUCCCCAAAGUCAAGG	123	ACAAUCCCCAAAGUCAAGG	123	CCUUGACUUUGGGAUUGU	861
AUUCCCUACAAUCCCCAA	124	AUUCCCUACAAUCCCCAA	124	UJUGGGAUJUGGGAAU	862
AACCAAAAUGAUAGGGG	125	AACCAAAAUGAUAGGGG	125	CCCCCUAUCAUUUUUGGUU	863
UCUCCUACUCCGAGGAAGAA	126	UCUCCUACUCCGAGGAAGAA	126	UUCUUCUGCCAUAGGAGA	864
CAUGCAUGGACAAGUAGAC	127	CAUGCAUGGACAAGUAGAC	127	GUCUACUUCUCCUGGAUG	865
CCUGUGUACCCACAGACCC	128	CCUGUGUACCCACAGACCC	128	GGGUCUUGGGGUACACAGG	866
CAUCAAAUGGAGGAAGCUGCA	129	CAUCAAAUGGAGGAAGCUGCA	129	UGCAGCUUCUCCUUAUGAUG	867
GAACAUAGCAGGAACUACUA	130	GAACAUAGCAGGAACUACUA	130	UAGUAGUUCUGCUAUUGUC	868
GAAAGGGUGAAGGGCAGUA	131	GAAAGGGUGAAGGGCAGUA	131	UACUGCCCUUCACCUUUC	869
AGUGACAUAGCAGGAACUA	132	AGUGACAUAGCAGGAACUA	132	UAGUUCUCUGCUAUUGUCACU	870
GCAGAUGAUACGUUUAG	133	GCAGAUGAUACGUUUAG	133	CUAAUACUGUAUCAUUCUGC	871
GGAGGAGAGAUACAGUAU	134	GGAGGAGAGAUACAGUAU	134	AUACUGUAUCUUCUGCUCC	872
CCAAGGGGAAGGUGACAUAG	135	CCAAGGGGAAGGUGACAUAG	135	CJAUGUUCACUUCUCCUJGG	873
GAAGCUCUACUUAUGAUACAG	136	GAAGCUCUACUUAUGAUACAG	136	CUGUAUCUAAUAGAGCUUC	874
GGGAAGGUGACAUAGCAGGA	137	GGGAAGGUGACAUAGCAGGA	137	UCCUGCUAUGUCACUUCUCC	875
CAUGCCUGGUACCCACAG	138	CAUGCCUGGUACCCACAG	138	CUGUGGGGUACACGGCAUG	876

GAAAGAGCAGAAGCAGUG	139	GAAAGAGCAGAAGCAGUG	139	CACUGUCUUUCUGUCUUUC	877
ACAUAGCAGGAACUACUAG	140	ACAUAGCAGGAACUACUAG	140	CUAGUAGGUUCCUGCUAUGU	878
CAUCUCCUAGGCAAGGAAG	141	CAUCUCCUAGGCAAGGAAG	141	CUUCCUGCCAUAGGAGAUG	879
GAAGCAGAUGAUACGUAAU	142	GAAGCAGAUGAUACGUAAU	142	AAUACUGUAUCAUUCGCU	880
AGCAUUAUCAGAAGGCC	143	AGCAUUAUCAGAAGGCC	143	GGCUCCUUCUGAUAAUGCU	881
CACCAGGCCAGAUGGAGA	144	CACCAGGCCAGAUGGAGA	144	UCUCUCUAUCUGGCCUGGUG	882
GUGACAUAGCAGGAACUAC	145	GUGACAUAGCAGGAACUAC	145	GUAGUUCUCGUUAUGUCAC	883
AGCAGGAAGAUGGCCAGUA	146	AGCAGGAAGAUGGCCAGUA	146	UACUGGCCCAUCUCCUGCU	884
GAGAACCAAGGGGAAGUGA	147	GAGAACCAAGGGGAAGUGA	147	UCACUUCUCCUUGGUUCUC	885
AGUAUAGGGCAAGCAGGGAG	148	AGUAUAGGGCAAGCAGGGAG	148	CUCCCUUGCUUGCCCAUACU	886
CCUACAAUCCCCAAAGUCA	149	CCUACAAUCCCCAAAGUCA	149	UGACUUIUGGGAUUGUAGG	887
CUACAAUCCCCAAAGUCA	150	CUACAAUCCCCAAAGUCA	150	UGACUUIUGGGAUUGUAG	888
GCCUGUGUACCCACAGACC	151	GCCUGUGUACCCACAGACC	151	GGUCUGUGGGUACACAGGC	889
AGCAGAUGAUACGUAAUA	152	AGCAGAUGAUACGUAAUA	152	UAAAUCUGUAUCAUUCGCU	890
AGAGAACCAAGGGGAAGUG	153	AGAGAACCAAGGGGAAGUG	153	CACUUCCCCUUGGUUCUCU	891
CCCUACAAUCCCCAAAGUC	154	CCCUACAAUCCCCAAAGUC	154	GACUUUGGGAUUGUAGGG	892
UGACAUAGCAGGAACUACU	155	UGACAUAGCAGGAACUACU	155	AGUAGUUCUCGUUAUGUCA	893
UUAUCAGAAGGGCACCC	156	UUAUCAGAAGGGCACCC	156	GGGUGGUCCUUUCUGUAUA	894
AAGUGACAUAGCAGGAACU	157	AAGUGACAUAGCAGGAACU	157	AGUUCCUGCUUAUGUCACUU	895
GCAGGAAGAUGGCCAGUA	158	GCAGGAAGAUGGCCAGUA	158	UUAUCUGGCCCAUCUCCUGC	896
UAGGCAUCUCCUAGGCCAG	159	UAGGCAUCUCCUAGGCCAG	159	CUGCCAUAGGGAGAUGGCCUA	897
CAAGGGGAAGGACAUAGC	160	CAAGGGGAAGGACAUAGC	160	GCUAUGUCACUUCCCUUG	898
AAAGAGCAGGAAGACAGUGG	161	AAAGAGCAGGAAGACAGUGG	161	CCACUGUCUUCUGCUUUU	899
CUCCUAUGGAGGAAGAAG	162	CUCCUAUGGAGGAAGAAG	162	CUUCUUCUGCCAUAGGAG	900
UAUCAAGGGAGGCCACCC	163	UAUCAAGGGAGGCCACCC	163	GGGGUGGCUCCUUCUGCUA	901
AUUAUCAGAAGGCCACC	164	AUUAUCAGAAGGCCACC	164	GGGGUCUCCUUCUGCUAAU	902
AUGCCUGUGUACCCACAGA	165	AUGCCUGUGUACCCACAGA	165	UCUGUGGGUACACAGGCAU	903
AAAUUAGUAGAUUUUCAGAG	166	AAAUUAGUAGAUUUUCAGAG	166	CUCUGAAAUCUACUAAUU	904
UGCAUUAAGCAGCU	167	UGCAUUAAGCAGCU	167	AAGCAGCUGCUUAUGCA	905
AUUUAGUAGAUUUUCAGAG	168	AUUUAGUAGAUUUUCAGAG	168	UCUCUGAAAUCUACUAAUU	906
GCAUCUCCUAGGCCAGAA	169	GCAUCUCCUAGGCCAGAA	169	UICUCUGCCAUAGGAGAUGC	907
AGAACCCAAGGGGAAGUGAC	170	AGAACCCAAGGGGAAGUGAC	170	GUACUUCUCCUUGGUUCU	908
UCAAAAAUUUUCGGGUUUAU	171	UCAAAAAUUUUCGGGUUUAU	171	AUAAAACCGAAAAUUUUGA	909
CAGGGGAUGGAAAGGAUCAC	172	CAGGGGAUGGAAAGGAUCAC	172	GUGAUCCUUUCUCCAUUC	910
GAAGGGAGCCACCCACAAG	173	GAAGGGAGCCACCCACAAG	173	CUUUGGGGGGUUCGUCCUUC	911
AUUUUUCGGGUUUUUUACAC	174	AUUUUUCGGGUUUUUUACAC	174	UGUAAAACCCGGAAAAAUU	912

AGCAGGAAGCACUAGGGC	175	AGCAGGAAGCACUAGGGC	175	GCCCAUAGUGCUUCCUGCU	913
AUCAGAAGGGAGCCACCCA	176	AUCAGAAGGGAGCCACCCA	176	UGGGUGGGCUUCCUCUGAU	914
UGAGAGAACCAAGGGGAAG	177	UGAGAGAACCAAGGGGAAG	177	CUUCCCUGGUUCUCUCA	915
AGGUGAAGGGCAGUAGU	178	AAGGUGAAGGGCAGUAGU	178	ACUACUGCCCCUUCACCUU	916
AAAAAAUUCAGAACAGUA	179	AAAAAAUUCAGAACAGUA	179	UACUGUACUGAUUUUUUC	917
CAAUGAGGAAGCUGCAGAA	180	CAAUGAGGAAGCUGCAGAA	180	UUCUGCAGCUUCCUCAUUG	918
AGAUGAUACGUAUAGAA	181	AGAUGAUACGUAUAGAA	181	UUCUAAUACUGUAUCACU	919
UGAGGAAGCUGCAGAAUGG	182	UGAGGAAGCUGCAGAAUGG	182	CCAUUCUGCAGCUUCCUCA	920
UAUUAUGACCCAUAAAG	183	UAUUAUGACCCAUAAAG	183	CUUUUGAUGGGGUCAUAAA	921
UCACUCUJUGGCAACGACC	184	UCACUCUJUGGCAACGACC	184	GGUCGUUGCCAAAGAGUGA	922
UGGAGAAAUUUAGUAGAUU	185	UGGAGAAAUUUAGUAGAUU	185	AAUCUACUAAUUUUCUCCA	923
AGACAGGAUGGAAUAGA	186	AGACAGGAUGGAAUAGA	186	UCUAUCCUCAUCUGUCU	924
AAAGGUGAAGGGCAGUAG	187	AAAGGUGAAGGGCAGUAG	187	CUACUGCCCCUUCACCUU	925
GGCAUCUCCUUAUGGCAGGA	188	GGCAUCUCCUUAUGGCAGGA	188	UCCUGCAGAUAGGAUGGCC	926
AGGAGGCCACCCACAAGA	189	AGGAGGCCACCCACAAGA	189	UCUUGUGGGUGGGCUUCCU	927
UAAAGGCCAGGAUUGGAUGG	190	UAAAGGCCAGGAUUGGAUGG	190	CCAUCCAUUCCUGGGCUUUA	928
GGGAGAAAUUUAGUAGAUUU	191	GGGAGAAAUUUAGUAGAUUU	191	AAAUUCUACUAAUUUUCUCC	929
AAGAGCAAGGAGACAGUGGC	192	AAGAGCAAGGAGACAGUGGC	192	GCCACUGUCUUCUGCUCU	930
UCAGAAGGGAGCCACCCAC	193	UCAGAAGGGAGCCACCCAC	193	GUGGGUGGGCUUCCUCUGA	931
AGGCAUCUCCUUAUGGCAGG	194	AGGCAUCUCCUUAUGGCAGG	194	CCUGCCAUAGGAGAUGGCC	932
AGGAUGGAAAGGAUCACC	195	AGGAUGGAAAGGAUCACC	195	GGUGAUCCUUCCUACUCCU	933
AGGAAGCUGCAGAAUGGGA	196	AGGAAGCUGCAGAAUGGGA	196	UCCCAUUCUGCAGCUUCCU	934
CUGCAUUAUAGCAGCUGCU	197	CUGCAUUAUAGCAGCUGCU	197	AGCAGCUGCUUUAUGCAG	935
AAGGGGCAGUAGUAUACA	198	AAGGGGCAGUAGUAUACA	198	UGUAUUACUACUGCCCCU	936
UGACUAGGGAGGCUJAGA	199	UGACUAGGGAGGCUJAGA	199	UCUAGCCUCCCGUAGUCAA	937
UAAAAGACACCAAGGAAGC	200	UAAAAGACACCAAGGAAGC	200	GUUUCUUCUGGUUCUUUA	938
GAGGAAGCUGCAGAAUGGG	201	GAGGAAGCUGCAGAAUGGG	201	CCCAUUCUGCAGCUCCUC	939
CAGCAGGAAGGCACUAGGG	202	CAGCAGGAAGGCACUAGGG	202	CCCAUAGUGCUUCCUGCUG	940
GGAGGCCACCCACAAGAUU	203	GGAGGCCACCCACAAGAUU	203	AAUCUUCUGGGGUUCUCC	941
AUUAUGACCCAUAAAAGA	204	AUUAUGACCCAUAAAAGA	204	UCUUUGAUGGGGUCAUAAU	942
CAGAUGAUACGUAUUAGA	205	CAGAUGAUACGUAUUAGA	205	UCUAAUACUGUAUCACUG	943
AUGAGAGAACCAAGGGAA	206	AUGAGAGAACCAAGGGAA	206	UUCCCUUCUGGUUCUCUCAU	944
AUGAGGAAGCUGCAGAAUG	207	AUGAGGAAGCUGCAGAAUG	207	CAUUCUGCAGCUCCUCAU	945
UGCCUGUGUACCCACAGAC	208	UGCCUGUGUACCCACAGAC	208	GUCUGUGGGUACACAGGCA	946
GAAGGGGCAGUAAUAC	209	GAAGGGGCAGUAAUAC	209	GUAAUACUACUGCCCCUUC	947
UCAGCAUUAUCAGAAGGG	210	UCAGCAUUAUCAGAAGGG	210	CUCCUUCUGUAUAGCUGA	948

UUCAAAUJJUUCGGGUUUA	211	UUCAAAUIUUCGGGUUUA	211	UAAACCCGAAAUUUGGAA	949
UCUGGAAAGGUGAAGGGGC	212	UCUGGAAAGGUGAAGGGGC	212	GCCCCUUCACCUUCCAGA	950
UAGCAGGAAGGAAGGCCAG	213	UAGCAGGAAGGAAGGCCAG	213	CUGGCCAUCUCCUGCUAA	951
GAACCAAGGGAAAGUGACA	214	GAACCAAGGGAAAGUGACA	214	UGUCACUUCCCUUGGUUC	952
AGAAGGAGGCCACCAA	215	AGAAGGAGGCCACCAA	215	UGUGGGGGGGCUUCUUCU	953
AAUGAGGAAGCUGCAGAAU	216	AAUGAGGAAGCUGCAGAAU	216	AUCUGCAGCUUCUCCUCAU	954
AGAAAAAAUCAGUAAACAG	217	AGAAAAAAUCAGUAAACAG	217	CUGUUACUGAUUUUUUCU	955
GGAAUUGGAGGUUUAUCA	218	GGAAUUGGAGGUUUAUCA	218	UGAUAAAACCUCCAAUUC	956
UACAGUAAUAGUAGGACCU	219	UACAGUAAUAGUAGGACCU	219	AGGUCCUACUAAUACUGUA	957
CCAGGAAUUGGAUGGCCAA	220	CCAGGAAUUGGAUGGCCAA	220	UGGGGCAUCCAUUCUGG	958
UUCUAUUGUAGAUGGGCAG	221	UUCUAUUGUAGAUGGGCAG	221	CUGCCOCACUACAUAGAA	959
CAAAAUUUCGGGUUUAU	222	CAAAAUUUCGGGUUUAU	222	AAUAAAACCCGAAAUUJJUG	960
UAGACAGGAUGAGGAUJAG	223	UAGACAGGAUGAGGAUJAG	223	CUAAUCUCAUCCUGUCUA	961
UGACAGAAAGAAAAAAUAAA	224	UGACAGAAAGAAAAAAUAAA	224	UUUAAAIIUUCUUCUGUCUA	962
UUUAAUACAGGGACAGCAG	225	UUUAAUACAGGGACAGCAG	225	CUGCUGUCCUGUAAUAAA	963
GGGUUUAAUACAGGGACAG	226	GGGUUUAAUACAGGGACAG	226	CUGUCCUGUAAUAAAACCC	964
AGAUGGAACAAGCCCCAGA	227	AGAUGGAACAAGCCCCAGA	227	UCUGGGGCUUGUCCAU	965
CUAGGGGAGGGCUAGAAGGA	228	CUAGGGGAGGGCUAGAAGGA	228	UCCUUUCAAGCCUCCGCUAG	966
UGACUAGGGGGGGCUJAGAA	229	UGACUAGGGGGGGCUJAGAA	229	UUCUAGCCUCCGCUAGUCA	967
GACAUAAUAGCAACAGACA	230	GACAUAAUAGCAACAGACA	230	UGUCUGUUGCUAUUAUGUC	968
GGUUUAAUACAGGGACAGC	231	GGUUUAAUACAGGGACAGC	231	GCUGUCCUGUAAUAAAACC	969
GCAGGUGAUGUGUGGG	232	GCAGGUGAUGUGUGGG	232	CCACACAAUCAUACCUGC	970
AUGGCAGGAAGAAGGGAG	233	AUGGCAGGAAGAAGGGAG	233	CUCCGCUUCUCCUGCCAU	971
AGGUGAUGAUUGUGGGCA	234	AGGUGAUGAUUGUGGGCA	234	UGCCACACAAUCAUACCU	972
CCACCCCAACAAGAUUAAA	235	CCACCCCAACAAGAUUAAA	235	UUUAAAUCUUGUGGGUGG	973
GUAAAAAAUUGGAUGACAG	236	GUAAAAAAUUGGAUGACAG	236	CUGUCAUCCAAUUUUUUAC	974
AUAAAUAAGCAACAGACAU	237	AUAAAUAAGCAACAGACAU	237	GUAGUCUGUUGUCUAUUAU	975
GCAUUAAGGAGCGUJUUU	238	GCAUUAAGGAGCGUJUUU	238	AAAGGAGCUCJGUUAUGC	976
GCGAGGUGAUGAUUGUGUG	239	GCGAGGUGAUGAUUGUGUG	239	CACACAAUCAUCACCUGCC	977
AUGAUACAGUAUJAGAAAGA	240	AUGAUACAGUAUJAGAAAGA	240	UCUUCUAAUACUGUAUCAU	978
GAUGGCAGGUGAUGAUUGU	241	GAUGGCAGGUGAUGAUUGU	241	ACAAUCAUCACCUGCCAU	979
CAUAAUAGCAACAGACAU	242	CAUAAUAGCAACAGACAU	242	UAUGUCUGUUGCUAUUAG	980
AAAUUUUUCGGGUUUAUUA	243	AAAUUUUUCGGGUUUAUUA	243	UAAUAAAACCCGAAAUUUU	981
ACAUAAAAGCAACAGACAU	244	ACAUAAAAGCAACAGACAU	244	AUGUCUGUUGCUAUUAGU	982
AUUUCAAAAUUUGGGCCUG	245	AUUUCAAAAUUUGGGCCUG	245	CAGGCCCAAUUUUUGAAAU	983
CUGGAAAGGUGAAGGGCA	246	CUGGAAAGGUGAAGGGCA	246	UGCCCCUUCACCUUCCAG	984

AAAACAGAUGGCGAGGUGAU	247	AAAACAGAUGGCGAGGUGAU	247	AUCACCUUGCCAUCUGUUUU	985
UUUCAAAAAAUUGGCCUGA	248	UUUCAAAAAAUUGGCCUGA	248	UCAGGGCCCAAUUUUGAAA	986
GAGAGAACCAAGGGGAAGU	249	GAGAGAACCAAGGGGAAGU	249	ACUUCCCCUGGUUCUCUC	987
CUCUGGAAAGGUGAAGGGG	250	CUCUGGAAAGGUGAAGGGG	250	CCCCUUACCUUUCAGAG	988
AUUAGCAGGAAGAUGGCCA	251	AUUAGCAGGAAGAUGGCCA	251	UGGCCAUUCUCCUGCUAAU	989
GAGCCACCCCACAAGAUUU	252	GAGCCACCCCACAAGAUUU	252	AAAUCUUGGGGGUGGCUC	990
CAUAGCAGGAACUACUAGU	253	CAUAGCAGGAACUACUAGU	253	ACUAGUAGUUCUGCUAUG	991
UUUUAAAAGAAAAAGGGGG	254	UUUUAAAAGAAAAAGGGGG	254	CCCCCCCUCUUUUUUUUAAA	992
GCGGAGGGCUAGAGGAGAG	255	GCGGAGGGCUAGAGGAGAG	255	CUCUCCUUCUAGGCCUCGG	993
CAGUAUUAGUAGGACCUAC	256	CAGUAUUAGUAGGACCUAC	256	GUAGGUCCUACUAAUACUG	994
AGGGGAAUUGGAGGUUUU	257	AGGGGAAUUGGAGGUUUU	257	AAAACCUCCAAUUCCCCCU	995
ACAGUAUUAGUAGGACCUA	258	ACAGUAUUAGUAGGACCUA	258	UAGGUCCUACUAAUACUGU	996
GACUAGGGGGGGCUAGAAG	259	GACUAGGGGGGGCUAGAAG	259	CUUCUAGGCCUCGGCUAUGC	997
GUUUAUUACAGGGACAGCA	260	GUUUAUUACAGGGACAGCA	260	UGCUGUICCCUGUAAAAC	998
CAGGUGAUGAUUGUGGGC	261	CAGGUGAUGAUUGUGGGC	261	GCCACACAAUCAUACCCUG	999
AGGGGAGGCUAGAGGAGA	262	AGGGGAGGCUAGAGGAGA	262	UCUCCUUCUAGGCCUCGGCU	1000
UCUAUGUAGAUGGGCAGC	263	UCUAUGUAGAUGGGCAGC	263	GCUGCCCCAUCAUAGA	1001
UAAAAAAAUUUGGAUGACAGA	264	UAAAAAAUUUGGAUGACAGA	264	UCUGUCAUCCAAUUUUUUA	1002
GCAGCAGGAAGGCACUAUG	265	GCAGCAGGAAGGCACUAUG	265	CCAUAGUGCUUCCUGCUGC	1003
UUAUUAUACAGGGACAGCAGA	266	UUAUUAUACAGGGACAGCAGA	266	UCUGGUUCUCCUGUAAAUA	1004
AAACAGAUGGCGAGGUGAUG	267	AAACAGAUGGCGAGGUGAUG	267	CAUCACUGCCAUUCUGUUU	1005
AUUCAAAAUUUUCGGGUUU	268	AUUCAAAAUUUUCGGGUUU	268	AAACCCGAAAAUUUUGAAU	1006
GGGGAAUUGGAGGUUUUA	269	GGGGAAUUGGAGGUUUUA	269	AUAAAACCUCCAAUCCCC	1007
GCCACCCACAAAGAUUUAA	270	GCCACCCACAAAGAUUUAA	270	UAAAACUUCUGGGGGGGC	1008
GAUGAUACAGAUUAGAAG	271	GAUGAUACAGAUUAGAAG	271	CIUCUAAUACUGUAUC	1009
UAAUAGCAACAGACAUACA	272	UAAUAGCAACAGACAUACA	272	UGUAUGUCUGUUGCUAUA	1010
GAGGGCUAGGAAGGAGAGA	273	GAGGGCUAGGAAGGAGAGA	273	UCUCUCUCCUUUJAGCCUC	1011
GUACAGUAAUAGUAGGAC	274	GUACAGUAAUAGUAGGAC	274	GUCCUACUAAUACUGUAC	1012
UAGGGGAGGCUAGAAGGAG	275	UAGGGGAGGCUAGAAGGAG	275	CUCCUUCUAGGCCUCGGCUA	1013
CGGAGGCUAGAAGGAGAGA	276	CGGAGGCUAGAAGGAGAGA	276	UCUCUCUUCUAGGCCUCGG	1014
GGUACAGUAAUAGUAGGAC	277	GGUACAGUAAUAGUAGGAC	277	GUCCUACUAAUACUGUAC	1015
AAAUUUUUCGGGUUUUAUC	278	AAAUUUUUCGGGUUUUAUC	278	GUAAAUAACCCGAAAAUUU	1016
AGCAGCAGGAAGCACUAUG	279	AGCAGCAGGAAGCACUAUG	279	CAUAGUGCUUCCUGCUGC	1017
AGCCACCCACAAAGAUUA	280	AGCCACCCACAAAGAUUA	280	UAAAUCUUGGGGGGGCU	1018
AACCAAGGGGAAGUGACAU	281	AACCAAGGGGAAGUGACAU	281	AUGUCACUUCCCCCUUGGUU	1019
AAGGGGAAGUGACAUAGCA	282	AAGGGGAAGUGACAUAGCA	282	UGCUAUGUCACUCCCCUU	1020

UUAAAGCAGGAUUGGAUG	283	UUAAAGCAGGAUUGGAUG	283	CAUCCAUUCCUGGCCUUUA	1021
ACUAGCGGAGGCCUAGAAGG	284	ACUAGCGGAGGCCUAGAAGG	284	CCUUCUAGCCUCCGCCUAGU	1022
UAGGUACAGUAAUUGUAGG	285	UAGGUACAGUAAUUGUAGG	285	CCUACUAAUACGUACCUA	1023
GGGGAAUJUGGGUUUUA	286	GGGGAAUJUGGGUUUUA	286	UAAAACUCUCAAUUCCCCC	1024
AGAUGGCAGGUGAUGAUUG	287	AGAUGGCAGGUGAUGAUUG	287	CAAUCUACCCUGCCAUUCU	1025
UUAACAAUAGGCCAUUGAC	288	UUAACAAUAGGCCAUUGAC	288	GUCAUAGGCCAUUGUUUA	1026
UGGCAGGUGAUGAUUGUGU	289	UGGCAGGUGAUGAUUGUGU	289	ACACAAUCAUCACUGCCA	1027
UAAAAAUUAGCAGGAAGAUG	290	UAAAAAUUAGCAGGAAGAUG	290	CAUCUUCUGCUAAUUUA	1028
AGGAGCCACCCACAAAGAU	291	AGGAGCCACCCACAAAGAU	291	AUCUUGGGGGGGGUCCU	1029
GUAUUAGUAGGACCUACAC	292	GUAUUAGUAGGACCUACAC	292	GUGUAGGUCCUACUAAUAC	1030
AAUCCCCAAAGUCAAGGAG	293	AAUCCCCAAAGUCAAGGAG	293	CUCCUJGACUUUJGGGAUU	1031
CCAGGCCAGAUGAGAAC	294	CCAGGCCAGAUGAGAAC	294	GUUCUCUCAUCUGGCCUGG	1032
CCAUUAGACAGAAAGAAAAA	295	CCAUUAGACAGAAAGAAAAA	295	UUUUUUUCUUCGUCAUUGG	1033
CAGAUGGCAGGUGAUGAUU	296	CAGAUGGCAGGUGAUGAUU	296	AAUCAUCACCGGCCAUUCUG	1034
CAGAUGAGAACCAAGGG	297	CAGAUGAGAACCAAGGG	297	CCUUGGUUCUCUCAUCUG	1035
GCCAUUAGACAGAAAGAAAAA	298	GCCAUUAGACAGAAAGAAAAA	298	UUUUUUUCUUCGUCAUUGG	1036
UAUUAGUAGGCCUACACC	299	UAUUAGUAGGCCUACACC	299	GGUGUAGGUCCUACUAAUA	1037
UCUCGACGCCAGGACUCGGC	300	UCUCGACGCCAGGACUCGGC	300	GCCGAGUCCUGCCUGCGAGA	1038
AGAUGAGAACCAAGGGG	301	AGAUGAGAACCAAGGGG	301	CCCCUUGGUUCUCUCAUCU	1039
AUCCCCAAAGUCAAGGAGU	302	AUCCCCAAAGUCAAGGAGU	302	ACUCCUGACUUUJGGGAU	1040
AUUIUGCAGGAAGAUGGCC	303	AUUIUGCAGGAAGAUGGCC	303	GGCCACUUCUCCUGCUAAU	1041
GGAAUUGGAGGUUUAUC	304	GGAAUUGGAGGUUUAUC	304	GAUAAAACCUCCAUUCCC	1042
CUCGACGCCAGGACUCGGC	305	CUCGACGCCAGGACUCGGC	305	AGCCGAGUCCUGCGUCGAG	1043
AUGGCCAUUAGACAGAAAGA	306	AUGGCCAUUAGACAGAAAGA	306	UUCUUCGUCAUGGCCAU	1044
AAAAUUAGCAGGAAGAUGG	307	AAAAUUAGCAGGAAGAUGG	307	CCAUUCUCCUGCUAAUUUU	1045
ACGCAGGACUCGGCUUGCU	308	ACGCAGGACUCGGCUUGCU	308	AGCAAGCCGAGUCCUGCGU	1046
UAAAACAAUGGCCAUGGACA	309	UAAAACAAUGGCCAUGGACA	309	UGUCAUAGGCCCAUUGUUUA	1047
GAUGGAACAAAGCCCCAGAA	310	GAUGGAACAAAGCCCCAGAA	310	UUCUGGGGGCUUJGUCCAU	1048
AAUGAACAAAGUAGAAUAAA	311	AAUGAACAAAGUAGAAUAAA	311	AUUUAUCUACUJGUUCAU	1049
AUUGGAGGUUUAUCAAAAG	312	AUUGGAGGUUUAUCAAAAG	312	CUUJGAAUAAAACCUCCAAU	1050
AGGCCUAGAAGGAGAGAU	313	AGGCCUAGAAGGAGAGAU	313	AUCUCUCUCCUUCUAGGCCU	1051
AGAUGGGGUUGCGAGGCUC	314	AGAUGGGGUUGCGAGGCUC	314	GACGCUCUCUGCCACCAUCU	1052
AGGUACAGUAAUAGUAGGA	315	AGGUACAGUAAUAGUAGGA	315	UCCUACUAAUACGUACCU	1053
GGAGGCCUAGAAGGAGAG	316	GGAGGCCUAGAAGGAGAG	316	CUCUCUCCUUCUAGGCCUC	1054
CAGGACAUAAACAAGGUAGG	317	CAGGACAUAAACAAGGUAGG	317	CCUACCUUJGUUAUGUCCUG	1055
AGUAAUAGGACCUACAUCA	318	AGUAAUAGGACCUACAUCA	318	UGUAGGGUCCUACUAAUACU	1056

UUGACAGAAGAAAAUAA	319	UUGACAGAAGAAAAUAA	319	UUUUUUUUUUUUCUGUCAA	1057
UGGAGAAGUGAAUUAUA	320	UGGAGAAGUGAAUUAUA	320	UUAUAUAUUCACUUCUCCA	1058
CUCUCGACCGCAGGACUCGG	321	CUCUCGACCGCAGGACUCGG	321	CCGAGUCCUGCGUUCGAGAG	1059
AUGAACAGUAGAUAAAUAU	322	AUGAACAGUAGAUAAAUAU	322	AUUUAUCAUCUUGUUCAU	1060
UGGCCAUJUGACAGAAGAAA	323	UGGCCAUJUGACAGAAGAAA	323	UUUCUUCUGUCAAUGGCCA	1061
AUCCCCAUGUUUCAGCAU	324	AUCCCCAUGUUUCAGCAU	324	AUGCUGAAAACAUUGGUAU	1062
UUUUAAAAGAAAAGGGGG	325	UUUUAAAAGAAAAGGGGG	325	UCCCCCUUUUUUUUUAAA	1063
CGACGCAGGACUCGGCUUG	326	CGACGCAGGACUCGGCUUG	326	CAAGCCAGUCCUGCGUCG	1064
AUUGACAGAAGAAAAUAA	327	AUUGACAGAAGAAAAUAA	327	UAUUUUUUUUCUGUCAAU	1065
CUAGAAGGGAGGAUGGG	328	CUAGAAGGGAGGAUGGG	328	CCCAUCUCUCUUCUUAUG	1066
UGGCAGGAAGAAGGGAGA	329	UGGCAGGAAGAAGGGAGA	329	UCUCCGCUUUCUGGCCA	1067
CAAUCCCCAAAGUCAAGGA	330	CAAUCCCCAAAGUCAAGGA	330	UCCUUGACUUUGGGAUUG	1068
AAAUCAAAUUUUUCCGGU	331	AAAUCAAAUUUUUCCGGU	331	ACCCGAAAAAUUUGAAUUU	1069
GAAUUGGAGGUUUUAUCAA	332	GAAUUGGAGGUUUUAUCAA	332	UUGAUAAAACCUCAAUUC	1070
GACGCAGGACUCGGCUUGC	333	GACGCAGGACUCGGCUUGC	333	GCAAGCCAGUCCUGCGUC	1071
UUUGACUAGGGAGGCUAG	334	UUUGACUAGGGAGGCUAG	334	CIAGCCUCCGCUAGUCAA	1072
AUAGGUACAGUAUAGUAG	335	AUAGGUACAGUAUAGUAG	335	CUACUAAUACGUACCUAU	1073
GCUUAGAAGGAGAGAUG	336	GCUUAGAAGGAGAGAUG	336	CAUCUCUCCUUCUAGGCC	1074
ACCAGGCCAGAUGAGAA	337	ACCAGGCCAGAUGAGAA	337	UUCUCUCAUCUGGCCUGGU	1075
GAUGAGAGAACCAAGGGGA	338	GAUGAGAGAACCAAGGGGA	338	UCCCCUUGGUUCUCUCAUC	1076
GGAGCAGCAGGAAGCACUA	339	GGAGCAGCAGGAAGCACUA	339	UAGUGCUUCCUGCGCUCC	1077
UCUCUCGACGCCAGCUCG	340	UCUCUCGACGCCAGCUCG	340	CGAGUCUCUGCGUCCGAGAGA	1078
UCCCCUACAAUCCCCAAAGU	341	UCCCCUACAAUCCCCAAAGU	341	ACUUUUGGGAUUGUAGGGA	1079
UGGGAGGUUUUAUCAAAGU	342	UGGGAGGUUUUAUCAAAGU	342	ACUUUUGAUAAAACUCCAA	1080
ACUGUACCAAGAAAAUAAA	343	ACUGUACCAAGAAAAUAAA	343	UUUUUUUACUGGUACAGU	1081
AUGGCAGGUGAUGAUUGUG	344	AUGGCAGGUGAUGAUUGUG	344	CACAAUCACUCCUGCCAU	1082
GAGGAAAGUAACAGUAGA	345	GAGGAAAGUAACAGUAGA	345	UCUACUGUUCAUUUCUC	1083
AGACAAUAAJAGCAACAGAC	346	AGACAAUAAJAGCAACAGAC	346	GUCUGUUCUUAUGUCU	1084
AAAUIUAGCAGGAAGAUGGC	347	AAAUIUAGCAGGAAGAUGGC	347	GCCAUCUUCCUGCUAAUU	1085
UUGGAGAAUGUAAUUAU	348	UUGGAGAAUGUAAUUAU	348	AUUAUAAUCUUUCUC	1086
UCGACGCAGGACUCGGCUU	349	UCGACGCAGGACUCGGCUU	349	AAGCCGAGUCCUGCGUCGA	1087
AAAAUUUCAAAUUUUCGGG	350	AAAAUUUCAAAUUUUCGGG	350	CCCGAAAAUUUUGAUUUU	1088
CAGGCCAGAUGAGAACC	351	CAGGCCAGAUGAGAACC	351	GGUUCUCUCAUCUGGCCUG	1089
UACCCAUUGUUUCAGCAU	352	UACCCAUUGUUUCAGCAU	352	AAUGCUGAAAACAUUGGU	1090
ACACAUUGCCUGGUACCCA	353	ACACAUUGCCUGGUACCCA	353	UGGGUACACAGGOAUUGUG	1091
GGCCAUUUGACAGAAGAAA	354	GGCCAUUUGACAGAAGAAA	354	UUUUCUUCUGUCAAUGGCC	1092

GAGCAGCAGGAAGCACUAU	355	GAGCAGCAGGAAGCACUAU	355	AUAGUGCUUCCUGCUC	1093
CUGUACCAAGUAAAUA	356	CUGUACCAAGUAAAUA	356	UUAAAUUUACUGGUACAG	1094
GAAAUGAUGACAGCAUGUC	357	GAAAUGAUGACAGCAUGUC	357	GACAUUGCUGUCAUCAUUUC	1095
CAUUGACAGAAGAAAAAU	358	CAUUGACAGAAGAAAAAU	358	AUUUUUCUJCUGUCAAUG	1096
AAAUGAUGACAGCAUGUCA	359	AAAUGAUGACAGCAUGUCA	359	UGACAUUGCUGUCAUCAUU	1097
GCUAGAAGGGAGAGGAUGG	360	GCUAGAAGGGAGAGGAUGG	360	CCAUCUCUCUCCUUCUAGC	1098
UAGGGAUJAUGGAAAACAG	361	UAGGGAUJAUGGAAAACAG	361	CUGUUUUCCAUAAUCCCUA	1099
AAAAAAUAGUAGAUUCAG	362	AAAAAAUAGUAGAUUCAG	362	CUGAAAUUCUCAUAAUUUC	1100
CUACACCUGUCAACAUAAU	363	CUACACCUGUCAACAUAAU	363	AUUAUGUUGACAGGUAG	1101
ACAGAUGGCGAGGUGAUGAU	364	ACAGAUGGCGAGGUGAUGAU	364	AUCAUACACCUGCAUCUGU	1102
CCACAGGGAUJGGAAGGAGAU	365	CCACAGGGAUJGGAAGGAGAU	365	AUCCUUCCAUCCUGUGG	1103
UJAGGGAUJAUGGAAAACA	366	UJAGGGAUJAUGGAAAACA	366	UGUUUUCCAUAAUCCCUA	1104
AGAUGCUGCAUUAAGCAG	367	AGAUGCUGCAUUAAGCAG	367	CUGCUUUAUAGCAGCAUCU	1105
AAUAGCAACAGACAUACAA	368	AAUAGCAACAGACAUACAA	368	UUGUAUGUCUGUUGCUAUU	1106
AAUUCAAAUUCGGGUU	369	AAUUCAAAUUCGGGUU	369	AACCCGAAAAUUGGAAUU	1107
CAGACUCACAAUAGCAUU	370	CAGACUCACAAUAGCAUU	370	AAUGCAUAAUUGGAGUCUG	1108
UAUGCAUJAGGAACAUUC	371	UAUGCAUJAGGAACAUUC	371	GAAUGAUUCCUAAUGCAUA	1109
UACACCUGUCAACAUAAU	372	UACACCUGUCAACAUAAU	372	AAUUAUUGUUGACAGGUGUA	1110
UGGAGGAAAGAACAAAGUA	373	UGGAGGAAAGAACAAAGUA	373	UACUUGUUCUAAUCCUCCA	1111
ACCAAGGGGAAGUGACAUAA	374	ACCAAGGGGAAGUGACAUAA	374	UAUGUCACUUCCCUJGGU	1112
GAGAUGGGUGCGAGGCGU	375	GAGAUGGGUGCGAGGCGU	375	ACGCUCUCUGCACCAUCUC	1113
UAUAGGUACAGUAUJAGUA	376	UAUAGGUACAGUAUJAGUA	376	UACUAAUACUGUACCUUA	1114
AUUAGGGAUUAUGGAAAC	377	AUUAGGGAUUAUGGAAAC	377	GUUUUCUAAUCCCUAAU	1115
UGGCUGUGGAAAGAUACCU	378	UGGCUGUGGAAAGAUACCU	378	AGGUACUUCUCCACGCCA	1116
GAGAGAUGGGUGCGAGGC	379	GAGAGAUGGGUGCGAGGC	379	GCUCUCGCACCCAUCCUC	1117
CCUACACCUGUCAACAUAA	380	CCUACACCUGUCAACAUAA	380	UUAUGUUGACAGGUAGG	1118
CAGCGAGUACAAUGGCAGU	381	CAGCGAGUACAAUGGCAGU	381	ACUGCCAUUUUGUACUGCUG	1119
GCGCUGUGGAAAGAUACCUA	382	GCGCUGUGGAAAGAUACCUA	382	UAGGUACUUCUCCACAGCC	1120
AGAAAAAUAGUAGUUUCA	383	AGAAAAAUAGUAGUUUCA	383	UAAAACUACUAAUUCU	1121
GCCACCUUUGCCUAGGUUU	384	GCCACCUUUGCCUAGGUUU	384	AACACUAGGCCAAAGGUGGC	1122
GAUGCUGCAUUAAGCAGC	385	GAUGCUGCAUUAAGCAGC	385	GCUGCUUUAUAGCAGCAUC	1123
GCUAUAGGUACAGUAUAG	386	GCUAUAGGUACAGUAUAG	386	CUAAUACGUACCUAUAGC	1124
AACAGAUGGCGAGGUGAUGA	387	AACAGAUGGCGAGGUGAUGA	387	UCAUCACCUGCCAUUCUGU	1125
AUCACUCUJUGGCAACGAC	388	AUCACUCUJUGGCAACGAC	388	GUCGUUGCCAAAGAGUGAU	1126
ACAUGGCCUGGUACCCACA	389	ACAUGGCCUGGUACCCACA	389	UGGGGUACACAGGCAUGU	1127
ACAGCAGUACAAUAGGCAG	390	ACAGCAGUACAAUAGGCAG	390	CUGCCAUUUUGUACUGCUGU	1128

AUGCAUUAGGAAUCAUUCA	391	AUGCAUJAGGAAUCAUUCA	391	UGAAUGAUUCCUAUGCAU	1129
AAUUGGGGUUUUAUCAAA	392	AAUUGGGAGGUUUUAUCAAA	392	UUGGAUAAAACCUCUCAAU	1130
UUGGAGGAAAGAACAAAGU	393	UUGGAGGAAAGAACAAAGU	393	ACUUGGUCAUUCUCCCAA	1131
AUUGGAGGAAAGAACAAAG	394	AUUGGAGGAAAGAACAAAG	394	CUUGGUCAUUCUCCCAAU	1132
AAAAAUUCAAAUUCGG	395	AAAAAUUCAAAUUCGG	395	CCGAAAUUUUUUAUUUUU	1133
AGGUGAAGGGCAGUAGUA	396	AGGUGAAGGGCAGUAGUA	396	UACUACUGCCCCUUCACCU	1134
CUAUAGGUACAGUUAUAGU	397	CUAUAGGUACAGUUAUAGU	397	ACUAAUACGUACCUUAUG	1135
AUAAAAGCCAGGAAUUGAU	398	AUAAAAGCCAGGAAUUGAU	398	AUCCAUUCCUGGUUUAU	1136
GGAGGAAAGUAACAGUAG	399	GGAGGAAAGUAACAGUAG	399	CUACUUGGUCAUUCUCCUCC	1137
AGCAGUACAAAUUGCAGUA	400	AGCAGUACAAAUUGCAGUA	400	UACUGCCAUUUGUACUGCU	1138
AUCAGUACAAAUUGCUIUC	401	AUCAGUACAAAUUGCUIUC	401	GGAGGACAUUUGUACUGAU	1139
UAUAGGGGUACCUGUGGGA	402	UAUAGGGGUACCUGUGGGA	402	UCCACACAGGUACCCCAUA	1140
AGAGAUGGGUGCGAGGCG	403	AGAGAUGGGUGCGAGGCG	403	CGCUCUCUGCACCACUUCU	1141
GGUGAAGGGCAGUAGUAA	404	GGUGAAGGGCAGUAGUAA	404	UUAUCUACUGCCCCUUCACC	1142
CUGAAGGGCCAGUAGUAAU	405	CUGAAGGGCCAGUAGUAAU	405	AUUAUCUACUGCCCCUUCAC	1143
CGCAGGACUCGGCUUGCUG	406	CGCAGGACUCGGCUUGCUG	406	CAGCAAGCCGAGUCCUGCG	1144
CACAUGCCUGUGUACCCAC	407	CACAUGCCUGUGUACCCAC	407	GUGGGUACACAGGCAUGUG	1145
GAGAGAGAUGGGUGGAGA	408	GAGAGAGAUGGGUGGAGA	408	UCUCGCACACCAUCUCUCUC	1146
UAGAAGGGAGAGAGAUGGGU	409	UAGAAGGGAGAGAGAUGGGU	409	ACCCAUCUCUCUCCUUCUA	1147
CACAGGGGAUGGAAAGGAUC	410	CACAGGGGAUGGAAAGGAUC	410	GAUCCUUUCCAUCCUGUG	1148
GCGAGGAAGAACGGGAGAC	411	GCGAGGAAGAACGGGAGAC	411	GUCUCGGCUUCCUCCUGCC	1149
UCCCCAAAGUCAAGGAGUA	412	UCCCCAAAGUCAAGGAGUA	412	UACUCCUUGACUUUGGGA	1150
CCUGUCAACAUAAUUGGAA	413	CCUGUCAACAUAAUUGGAA	413	UUCCAAUUAUGGUAGACAGG	1151
UAUCAGUACAAUGGUUC	414	UAUCAGUACAAUGGUUC	414	GAAGGCACAUUGUACUGAU	1152
UGAAGGGGCAGUAGUAAA	415	UGAAGGGGCAGUAGUAAA	415	UAUUAUCUACUGCCCCUUC	1153
CUCAGAUGCUGCAUUAAG	416	CUCAGAUGCUGCAUUAAG	416	CUUUAUGCAGCAUCUGAG	1154
ACAGGGGAUGGAAAGGAUCA	417	ACAGGGGAUGGAAAGGAUCA	417	UGAUCCUUUCCAUCCUGU	1155
AAGAAAAGGGGAUUGGG	418	AAGAAAAGGGGGAUUGGG	418	CCCAAUCCCCCUUUUCU	1156
UCAUUAGGGAUUAUUGGAA	419	UCAUUAGGGAUUAUUGGAA	419	UUCCAAUUAUCCUAAUGA	1157
GAAGGGAGAGAUGGGUGC	420	GAAGGGAGAGAUGGGUGC	420	GCACCCAUUCUCUCCUIC	1158
GUUAAAACAAUGGCCAUUGA	421	GUUAAAACAAUGGCCAUUGA	421	UCAAUGGCCAUUGUUUAC	1159
AUGGACAAGGUAGACUGUAG	422	AUGGACAAGGUAGACUGUAG	422	CUACAGUCUACUUGUCCAU	1160
UAGUAGAUUUUCAGGAACU	423	UAGUAGAUUUUCAGGAACU	423	AGUUCUCUGAAAUCUACUA	1161
CUGUCAACAUAAUUGGAAG	424	CUGUCAACAUAAUUGGAAG	424	CUUCCAAUUAUGGUAGACAG	1162
GGGGCAGUAGUAAUACAAG	425	GGGGCAGUAGUAAUACAAG	425	CUUGUAAUUAUCUGCCCC	1163
CAUJAGGGAUUAUUGGAAA	426	CAUJAGGGAUUAUUGGAAA	426	UUUCCAAUAAUCCUAAUG	1164

GAACUACUAGUACCUUCA	427	GAACUACUAGUACCUUCA	427	UGAAGGGGUACUAGUAGUUC	1165
GCAGGAAGCACUAGGGCG	428	GCAGGAAGCACUAGGGCG	428	CGCCCCAUAGGGCUUCCUGC	1166
AAGGAGAGAGAUGGGUGCG	429	AAGGAGAGAGAUGGGUGCG	429	CGCACCCAUACUCUCCUU	1167
CAGGAUAGGAUGGCCAAA	430	CAGGAUAGGAUGGCCAAA	430	UJUGGGCCAUCCAUUCUG	1168
GGAAAUGAACAGUAGAU	431	GGAAAUGAACAGUAGAU	431	UAUCUACUUGGUCAUUCU	1169
AAAAGACACCAAGGAAGCU	432	AAAAGACACCAAGGAAGCU	432	AGCUUCUUGGGUGGUUU	1170
AUCAUUCAAGCACACCAG	433	AUCAUUCAAGCACACCAG	433	CUGGUUGGGGUJGAAGUAU	1171
AACAAGUAGAUAAAUAAGU	434	AACAAGUAGAUAAAUAAGU	434	ACUAAUUAUCUACUUGUU	1172
AGGAAAUGAACAGUAGAU	435	AGGAAAUGAACAGUAGAU	435	AUCUACUUGGUCAUUCU	1173
GCAGGACUCGGCUUCCUGA	436	GCAGGACUCGGCUUCCUGA	436	UCAGGAAAGCCGAGGUCCUGC	1174
GAUCAUCAAGCACAAACC	437	GAUCAUCAAGCACAAACC	437	GGUUGUGGUJGAAGUAU	1175
CCUCAGAUGCUGCAUUA	438	CCUCAGAUGCUGCAUUA	438	UUUAUUGCAGCAUCUGAGG	1176
GAUGGAAAGGAUCACCAGC	439	GAUGGAAAGGAUCACCAGC	439	GCUGGGGAUCUUCUCAUC	1177
AGGAGAGAGAUGGGUGCGA	440	AGGAGAGAGAUGGGUGCGA	440	UGGCACCCAUUCUCUCCU	1178
CAUGGACAAGUAGACUGUA	441	CAUGGACAAGUAGACUGUA	441	UACAGUCUACUUGGUCAUG	1179
UCAGAUGCUGCAUUAAGC	442	UCAGAUGCUGCAUUAAGC	442	GCUUUAUUGCAGCAUCUGA	1180
AUGGAGAAAUAUAGUAGAU	443	AUGGAGAAAUAUAGUAGAU	443	AUCUACUAAUUUCUCCAU	1181
GAGAAAAAUAGUAGAUUUC	444	GAGAAAAAUAGUAGAUUUC	444	GAAAUUCUACUAAUUCUUC	1182
AUGACAGCAUGUCAGGGAG	445	AUGACAGCAUGUCAGGGAG	445	CUCCUGACAUUGGUCAU	1183
AGGCCAGAGAGAGAACCA	446	AGGCCAGAGAGAGAACCA	446	UGGUUCUCUCAUCUGGCCU	1184
AGAGAGAUGGGUGCGAGAG	447	AGAGAGAUGGGUGCGAGAG	447	CUCUCGACCCAUUCU	1185
ACCCAUGUUUCAGCAUUA	448	ACCCAUGUUUCAGCAUUA	448	UAAUGGUAAAACAUUGGU	1186
GAUGACAGCAUGUCAGGG	449	GAUGACAGCAUGUCAGGG	449	UCCUGACAUUGGUCAUC	1187
AGCCAGGAUGGGCCC	450	AGCCAGGAUGGAUGGGCCC	450	GGGCCAUCCAUUCUGGU	1188
UGAUGACAGCAUGUCAGGG	451	UGAUGACAGCAUGUCAGGG	451	CCUGACAUUGGUCAUCA	1189
CAGGAAGCACUAGGGCGC	452	CAGGAAGCACUAGGGCGC	452	GGGCCAUAGGUCCU	1190
ACAGACUACAAUAGCAU	453	ACAGACUACAAUAGCAU	453	AUGCAUAUUGGUCAUCU	1191
UGGAGGUUUUAUCAAGUA	454	UGGAGGUUUUAUCAAGUA	454	UACUUUAGAUAAAACUCA	1192
AAGCCAGGAUGGAUGGCC	455	AAGCCAGGAUGGAUGGCC	455	GGCCAUCCAUUCUGGCCU	1193
UUUUGACUAGGGAGGCCA	456	UUUUGACUAGGGAGGCCA	456	UAGCCUCCGGCUAGUAAA	1194
CAGAUGCUGCAUUAAGCA	457	CAGAUGCUGCAUUAAGCA	457	UGCUUUAUGCAGCAUCUG	1195
UGGGCCUGAAAUCCAA	458	UGGGCCUGAAAUCCAA	458	UAGGGAUUUUCAGGCCAA	1196
GCAUGGACAAGUAGACUGU	459	GCAUGGACAAGUAGACUGU	459	ACAGUCUACUUGGUCAUGC	1197
ACCUGUCAACAAUUJUGGA	460	ACCUGUCAACAAUUJUGGA	460	UCCAAUUAUGGUJACAGGU	1198
CAGGAACCUACUAGUACCCU	461	CAGGAACCUACUAGUACCCU	461	AGGGUACUACUAGUJUCCUG	1199
AUAGCAACAGACAAUACAAA	462	AUAGCAACAGACAAUACAAA	462	UUUGUAUGGUJUGGUCAU	1200

GGAGAGAGAUGGGUGCGAG	463	GGAGAGAGAUGGGUGCGAG	463	CUCGGCACCCAUUCUCUC	1201
ACACCUJGUCAACAUAAUG	464	ACACCUJGUCAACAUAAUG	464	CAAUUJAUUGGUJGACAGGUJU	1202
AGAAAUGAUGACAGCAUGU	465	AGAAAUGAUGACAGCAUGU	465	ACAUGUGUCUCAUCAUUUC	1203
AGAAGGGAGAGAGGGUG	466	AGAAGGGAGAGAGGGUG	466	CACCCAUUCUCUCUUCU	1204
AAUCAUJCAAGGACAACCA	467	AAUCAUJCAAGGACAACCA	467	UGGUJUGGUJUUGAAUGAUU	1205
CAAAAUUJGGGCCUGAAAA	468	CAAAAUUJGGGCCUGAAAA	468	UUUUCAGGGCCCAAUUUUUG	1206
GCAGUACAAAUGGAGUAU	469	GCAGUACAAAUGGAGUAU	469	AUACUGGCCAUUJGUACUGC	1207
GGGCAGUAGUAAAUCAGA	470	GGGCAGUAGUAAAUCAGA	470	UCUJGUAAUJACUACUGCCC	1208
UCAUUCAAGGACAACCCAGA	471	UCAUUCAAGGACAACCCAGA	471	UCUGGUJUGGUJUUGAAUGA	1209
AUGAUGACAGCAUGUCAGG	472	AUGAUGACAGCAUGUCAGG	472	CCUGACAUUCUGUCAUCAU	1210
GAACAAGGUAGUAAAUAUG	473	GAACAAGGUAGUAAAUAUG	473	CUAAUJUJAUUCUJGUUC	1211
UGACAGCAUGUCAGGGAGU	474	UGACAGCAUGUCAGGGAGU	474	ACUCCUGACAUUGCUGUCA	1212
GGAACUACUACGUACCCUUC	475	GGAACUACUACGUACCCUUC	475	GAAGGGUACUAGUAGUUC	1213
CACCUJGUCAACAUAAUUGG	476	CACCUJGUCAACAUAAUUGG	476	CCAAUJAUUGUJGACAGGUG	1214
GGCCAGAUGGAGAAACCA	477	GGCCAGAUGGAGAAACCA	477	UGGGUUCUCUCAUCUGGCC	1215
UGUGUACCCACAGACCCCA	478	UGUGUACCCACAGACCCCA	478	UGGGGUUCUGGGGUACACA	1216
GGAAAUCAUJCAAGGACAAC	479	GGAAUCAUJCAAGGACAAC	479	GUUGUGGUJUUGAAUGAUUCC	1217
CAGUACAAAUGGCAGUUU	480	CAGUACAAAUGGCAGUUU	480	AAUACUGGCCAUJUJGUACUG	1218
GCAGGAAGGAAAGGGAGACA	481	GCAGGAAGGAAAGGGAGACA	481	UGUCUCCGGCUUCUUCUGC	1219
AAAGGCCAGGAUGGAUGGC	482	AAAGGCCAGGAUGGAUGGC	482	GCCAUCCAUUCUCUGGCUUU	1220
UGAACACAAGGUAGUAAAUA	483	UGAACACAAGGUAGUAAAUA	483	UAUUUJAUUCUJGUUCA	1221
CAAAAUUCAAAUUJUCG	484	CAAAAUUCAAAUUJUCG	484	CGAAAAUUJUGAAUUUJUG	1222
UAGGACCUACACCUGUCAA	485	UAGGACCUACACCUGUCAA	485	UIGACAGGGGUAGGGGUCA	1223
GCCAGAUGAGAGAACCAAG	486	GCCAGAUGAGAGAACCAAG	486	CUUGGUJUCUCUCAUCUGGC	1224
GACAGCUGGGACUJCAUG	487	GACAGCUGGGACUJCAUG	487	CAUJGACAGGUCCAGCUGUC	1225
AAAGGCCACCUUJCCUAGU	488	AAAGGCCACCUUJCCUAGU	488	ACUAGGCCAAAGGGGUUU	1226
GAAAUGAACAAAGUAGUAAA	489	GAAAUGAACAAAGUAGUAAA	489	UUAUCUACUJGUCAUUC	1227
ACAAUJUUAAAAGAAAAGG	490	ACAAUJUUAAAAGAAAAGG	490	CCUUUUJCUUUJAAAUGU	1228
GCUGUGGAAAGAUACCUAA	491	GCUGUGGAAAGAUACCUAA	491	UAGGUUAUCUUCACAGC	1229
UGUCAACAAUJUGGAAGA	492	UGUCAACAAUJUGGAAGA	492	UCUJUCCAAUJUGGUJGACA	1230
UAAAAGAAAAGGGGGAUU	493	UAAAAGAAAAGGGGGAUU	493	AAUCCCCCUUUJCUUUJUA	1231
CAAUUUAAAAGAAAAGG	494	CAAUUUAAAAGAAAAGG	494	CCUUUUJCUUUJAAAUGU	1232
UJAGGUAGAUUUCAGAGAAC	495	UJAGGUAGAUUUCAGAGAAC	495	GUUCUCUGAAAUCUACUAA	1233
AUUUUAAAAGAAAAGGG	496	AUUUUAAAAGAAAAGGG	496	CCCUUUJCUUUJAAAUAU	1234
UAGCAACAGACAAUACAAAC	497	UAGCAACAGACAAUACAAAC	497	GUUUGUAUGGUJGUUGGUA	1235
UGGAACAAAGCCCCAGAAGA	498	UGGAACAAAGCCCCAGAAGA	498	UCUUCUGGGCUUGUCCAA	1236

AGGAUGAGGAUJAGAACAU	499	AGGAUGAGGAUJAGAACAU	499	AUGUUCUAAUCCUCAUCCU	1237
GACAAUUGGAGAAGUGAAU	500	GACAAUUGGAGAAGUGAAU	500	AUUCACUUUCUCCAAUJUGUC	1238
ACAGACCCAAACCCACAAG	501	ACAGACCCAAACCCACAAG	501	CUUGUGGGUJGGGUCCUGU	1239
CACCUAGAACUJUAAAUGC	502	CACCUAGAACUJUAAAUGC	502	GCAUAAAAGUUCUAGGGUG	1240
GAGCCAACAGGCCACCAG	503	GAGCCAACAGGCCACCAG	503	CUGGUGGGCUGUJGGCUC	1241
AGGACCUACCCUGUCAAC	504	AGGACCUACCCUGUCAAC	504	GUUGACAGGGGUAGGUCCU	1242
UUACAAAAAUUCAAAUJU	505	UUACAAAAAUUCAAAUJU	505	AAAUIJUGAAUJUJGUAA	1243
GGAGGUUUUUAUCAAGUAA	506	GGAGGUUUUUAUCAAGUAA	506	UUACUJUGAUAAAACCUC	1244
CUGGCUGJGGAAAGAUACC	507	CUGGCUGJGGAAAGAUACC	507	GGUAAUCUUCCACAGCCAG	1245
GGAGAAGUGAAUUAUAAA	508	GGAGAAGUGAAUUAUAAA	508	UUUAUAAAUCUUCUCCU	1246
AUGAUGACAGCAUGUCAG	509	AUGAUGACAGCAUGUCAG	509	CUGACAUJCGUGUCAUCAUJ	1247
AUCAUUAGGGAUJAUUGGAA	510	AUCAUUAGGGAUJAUUGGAA	510	UUCCAUAAAUCUCAUAGAU	1248
UCAAAAAAUJGGCCUGAAA	511	UCAAAAAAUJGGCCUGAAA	511	UUUCAGGCCCAAUJUJUGA	1249
ACCUACACCUGUCAACAU	512	ACCUACACCUGUCAACAU	512	UAUUGUJGACAGGGUAGGU	1250
GAUGAGGAUJAGAACAU	513	GAUGAGGAUJAGAACAU	513	CCAUGUUCUAAUCCUCAUC	1251
ACAGCUGGACUGUCAUAGA	514	ACAGCUGGACUGUCAUAGA	514	UCAUUGACAGGUCCAGCUGU	1252
CCCUCAGAUGCUGCAUAAU	515	CCCUCAGAUGCUGCAUAAU	515	UUAUAGCAGCAUCUGAGGG	1253
AUJAGUAGAUUUCAGAGAA	516	AUJAGUAGAUUUCAGAGAA	516	UUCUCUGAAAUCUACUAAU	1254
AGAAAAGGCCAGAACAGU	517	AGAAAAGGCCAGAACAGU	517	ACUGUCUUCUGCUUUUCU	1255
GACCUACACCUGUCAACAU	518	GACCUACACCUGUCAACAU	518	AUGUUGACAGGGGUAGGGC	1256
CACUCUUJGGCAACGACCC	519	CACUCUUJGGCAACGACCC	519	GGGUUCGUJGCCAAAGAGUG	1257
AUGAGGAUJAGAACAU	520	AUGAGGAUJAGAACAU	520	UCCAUUGUUCUAAUCCUCAU	1258
AUUUUAAAAGAAAAGGGGG	521	AUUUUAAAAGAAAAGGGGG	521	CCCCCUUUUCUJUJUAAA	1259
AGAACUJUAAAUGCAU	522	AGAACUJUAAAUGCAU	522	CCCAUGCAJUJUAGUUCU	1260
AUCUAUCAUACAU	523	AUCUAUCAUACAU	523	CAUCCAUJGUUJUGAUAGAU	1261
AUGGAACAAAGCCCCAGAAG	524	AUGGAACAAAGCCCCAGAAG	524	CUUCUGGGCUJGUUCCAU	1262
UUAUGACCCCAUCAAAAGAC	525	UUAUGACCCCAUCAAAAGAC	525	GUCUUJUGAUGGGGUCAUAA	1263
CACAAUJUAAAAGAAAAG	526	CACAAUJUAAAAGAAAAG	526	CUUUCUUJUAAAAGUUG	1264
GAACUUAAAUGCAU	527	GAACUUAAAUGCAU	527	ACCCAUJCGAUJUAAGUUC	1265
AAAAGAAAAGGGGAUJUG	528	AAAAGAAAAGGGGAUJUG	528	CAAUCCCCUUJUJU	1266
CGAUJGGAAAGGAUCACCG	529	CGAUJGGAAAGGAUCACCG	529	CUUGUGAUGGUJUCCAUCC	1267
AGGGCCAGUAAUACAA	530	AGGGCCAGUAAUACAA	530	UUGUAAUACUACUJGCCCU	1268
AAAGGGGGAUJGGGGU	531	AAAGGGGGAUJGGGGU	531	ACCCCCAAUCCCCCUU	1269
AGGGGGGGAUJGGGGU	532	AGGGGGGGAUJGGGGU	532	UACCCCCAAUCCCCCUU	1270
CAGGAUGAGGAUJAGAAC	533	CAGGAUGAGGAUJAGAAC	533	UGUUCUAAUCCUCAUCCUG	1271
AAAAUUAGUAGAUUCAGA	534	AAAAUUAGUAGAUUCAGA	534	UCUGAAAUCUACUJAAUUU	1272

(400/099)

GAUUGGAGGAAUGAAC	535	GAUUGGAGGAAUGAAC	535	UGUUCAUUUCCCAAUUC	1273
UACAAAAAUUCAAAUUU	536	UACAAAAAUUCAAAUUU	536	AAAAUUUUUGAAUJJUUGUA	1274
AGGAACUACUAGUACCCUU	537	AGGAACUACUAGUACCCUU	537	AAGGGGUACUAGUAGUCCU	1275
AAAGAAAAGGGGAUUGG	538	AAAGAAAAGGGGAUUGG	538	CCAAUCCCCCUUUCUUU	1276
AAAAAUUUGGAUGACAGAAA	539	AAAAAUUUGGAUGACAGAAA	539	UUCUGUCAUCCAAUUUUU	1277
ACAGGAUGAGGAUJAGAAC	540	ACAGGAUGAGGAUJAGAAC	540	GUUCUAUCCUCAUCCUGU	1278
ACAAUUGGAGAAGUGAAUU	541	ACAAUUGGAGAAGUGAAUU	541	AAUUCACUJUCUCCAAUUGU	1279
GGAUUGGAGAUJAGAAC	542	GGAUUGGAGAUJAGAAC	542	CAUGUUCUAUCCUCAUCC	1280
UCACCUAGAACUUAAAUG	543	UCACCUAGAACUUAAAUG	543	CAUUAAGUUCUAGGUGA	1281
AUUGGGCUCGAAAAAUCCAU	544	AUUGGGCUCGAAAAAUCCAU	544	AUGGAUUIUCAGGCCAAU	1282
AAUUGGGCCUCGAAAAUCCA	545	AAUUGGGCCUCGAAAAUCCA	545	UGGAUUIUCAGGCCAAU	1283
GGACCUACACCUGUCAACA	546	GGACCUACACCUGUCAACA	546	UGUUGACAGGGUAGGUCC	1284
GACAGGAUGGAGAUUAGAA	547	GACAGGAUGGAGGAUUAGAA	547	UUCUAAUCCUCAUCCUGUC	1285
UCUUAUCAAUJAGGAUGA	548	UCUUAUCAAUJAGGAUGA	548	UCAUCCAUAGUAUJAGUA	1286
GGAAUUGGAGGAUJAGAAC	549	GGAAUUGGAGGAUJAGAAC	549	GUCAUUIUCUCCAAUUC	1287
AAAAGGGGGAUJGGGGG	550	AAAAGGGGGAUJGGGGG	550	CCCCCAAUCCCCCUUJJU	1288
AAAAAUUGGAUGACGAAAC	551	AAAAAUUGGAUGACGAAAC	551	GUUUCUGUCAUCCAAUUU	1289
CAAUUGGAGAAGUGAAUUA	552	CAAUUGGAGAAGUGAAUUA	552	UAUUUCACUUCUCCAAUUG	1290
AUGACCCAUCAAAAGACUU	553	AUGACCCAUCAAAAGACUU	553	AAGCUUUJUGAGGGUCAU	1291
CUAAAGCCUCAAAAGCU	554	CUAAAGCCUCAAAAGCU	554	AGCUUUUJUGAGGCUUAG	1292
AGUACAUGGUUCCACAC	555	AGUACAUGGUUCCACAC	555	UGUGGAAGGCACAUJGUACU	1293
UUUCCGCUJGGGACUUUCC	556	UUUCCGCUJGGGACUUUCC	556	GGAAAGGUCCCCAGGGAAA	1294
CAGACAUACAACUAAAGA	557	CAGACAUACAACUAAAGA	557	UCUUUAGUJUGUAGUCUG	1295
UUAAGCCUCAAAAGCUU	558	UUAAGCCUCAAAAGCUU	558	AAGCUUUJUGAGGCUUAA	1296
GGACAAUUGGAGAAGUGAA	559	GGACAAUUGGAGAAGUGAA	559	UUCACUUCUCCAAUJGUCC	1297
GGAUUGGGGUACAGUGC	560	GGAUUGGGGUACAGUGC	560	GCACUGUACCCCCCAUCC	1298
AAAUUUGGCCUGAAAAUCC	561	AAAUUUGGCCUGAAAAUCC	561	GGAUUUUCAGGCCAAUJJU	1299
GGGGGAUJGGGGGUACAG	562	GGGGGAUJGGGGGUACAG	562	CUGUACCCCCCAAUCCCC	1300
GUGGGGGGACAUCAAGCAG	563	GUGGGGGGACAUCAAGCAG	563	CUGCUUJUGUCCCCCAG	1301
UCCUGGGJUGGGAAAGAU	564	UCCUGGGJUGGGAAAGAU	564	UACCUUJUCCACAGCCAGGA	1302
ACAAAAAUUJCAAAUJJUUC	565	ACAAAAAUUJCAAAUJJUUC	565	AAAAAUUJUGAAUUUUGU	1303
GGGGAUJGGGGGUACAGU	566	GGGGAUJGGGGGUACAGU	566	ACUGUACCCCCCAAUCCCC	1304
UAAACACAGUGGGGGACA	567	UAAACACAGUGGGGGACA	567	UGUCCCCCCCACUGGUUUA	1305
CAGACCCCAACCCACAAGA	568	CAGACCCCAACCCACAAGA	568	UCUUGUGGGGUJGGGGUCUG	1306
AGGGGCAAAUGGUACAUCA	569	AGGGGCAAAUGGUACAUCA	569	UGAUGUACCAUUGCCCCU	1307
AAUUGGAGGAAAGAACAA	570	AAUUGGAGGAAAGAACAA	570	UUGUUCAUUCCUCCAAU	1308

(400/099)

AAGCCACCUUUGCCUAGUG	571	AAGCCACCUUUGCCUAGUG	571	CACUAGGCAAAGGGGGCUU	1309
CCAUGUUUUCAGCAUUAUC	572	CCAUGUUUUCAGCAUUAUC	572	GAUAAUGCUGAAAACAUGG	1310
AAAGAAAAAAUCAGUAACA	573	AAAGAAAAAAUCAGUAACA	573	UGUUACUGAUUUUUUUUU	1311
AAAAAAUUGGAUGACAGAA	574	AAAAAAUUGGAUGACAGAA	574	UUCUGUCAUCCAUUUUUUU	1312
CAGUACAAUGUGGUUCCAC	575	CAGUACAAUGUGGUUCCAC	575	GUGGAAGGCACAUUGUACUG	1313
CUUCCCGUGGGACUUUC	576	CUUCCCGUGGGACUUUC	576	AAAAGUCCCCAGGGAAAG	1314
GCAACAGACAUAAACUA	577	GCAACAGACAUAAACUA	577	UAGUUUUGUAUGUCUGUUGC	1315
UAUCACCUAGAACUUIAAA	578	UAUCACCUAGAACUUIAAA	578	UUUAAAGUUCUAGGUGAU	1316
ACCCACAGACCCCAACCCA	579	ACCCACAGACCCCAACCCA	579	UGGGUJGGGUUCUGUGGGU	1317
GAUAGAUGGAACAAGCCCC	580	GAUAGAUGGAACAAGCCCC	580	GGGGCUJGUUCUCAUCUAUC	1318
GCUUAAAGCCUCAAUAAAAGC	581	GCUUAAAGCCUCAAUAAAAGC	581	GCUUUAAUUGAGGCUUAAAGC	1319
AUUGGGGGGUACAGUGCAG	582	AUUGGGGGGUACAGUGCAG	582	CUGCAUGUACCCCCCAAU	1320
CCACAGACCCCAACCCAC	583	CCACAGACCCCAACCCAC	583	GUGGGUJGGGUUCUGUGGG	1321
AAAAUUGGGCCUGAAAAAUC	584	AAAAUUGGGCCUGAAAAAUC	584	GAUUUUCAGGCCCAAUUUU	1322
CAUUCAGCACAACCAAGAU	585	CAUUCAGCACAACCAAGAU	585	AUCUGGUJUGGUJUGGUAAUG	1323
ACUUUUAAUGCAUGGGUAA	586	ACUUUUAAUGCAUGGGUAA	586	UUAACCOAUGCAUUAAGU	1324
UAGAACUJUAAAUGCAUGG	587	UAGAACUJUAAAUGCAUGG	587	CCAUGCAUAAAAGGUUCUA	1325
CUUAAAUGCAUGGGUAAA	588	CUUAAAUGCAUGGGUAAA	588	UUUACCCAUAGCAUJUAAAAG	1326
GGGAUUGGGGUACAGUG	589	GGGAUUGGGGUACAGUG	589	CACUGUACCCCCCAAUCCC	1327
UAUGACCCAUCAAAGACU	590	UAUGACCCAUCAAAGACU	590	AGUCUUUJUGAUGGGUCAUA	1328
GAAGAACGGGAGACAGCGA	591	GAAGAACGGGAGACAGCGA	591	UCCGCUJGUCCGGCUUUC	1329
CCCAUGUUUUCAGCAUUAU	592	CCCAUGUUUUCAGCAUUAU	592	AUAAGCUGAAAACAUGGG	1330
AGGAUUUGGAGGAAAGAA	593	AGGAUUUGGAGGAAAGAA	593	UUCAUUJUCCCAAUUCCU	1331
AGAGACAGGCCUAAUUUUU	594	AGAGACAGGCCUAAUUUUU	594	AAAAAAUUAUGCCUGUCU	1332
AAGUAGAUAUUAGUCAG	595	AAGUAGAUAUUAGUCAG	595	CUGACUJAAUUUACUACUU	1333
AUGUUUUAGCAUUAUCAG	596	AUGUUUUAGCAUUAUCAG	596	CUGAUUAUGCUGAAAACAU	1334
UUAUUUGCUGGUAGUGC	597	UUAUUUGCUGGUAGUGC	597	GCACUJAUACCAGACAAUAA	1335
AUUACAAAAAAUCAAAAUU	598	AUUACAAAAAAUCAAAAUU	598	AAUUUUGAAUUUJUGUAAU	1336
GCCAGGAUGGAUGGCCCA	599	GCCAGGAUGGAUGGCCCA	599	UGGGCCAUCCAUUCUGGC	1337
CCUGGCUGGGAAAGAUAC	600	CCUGGCUGGGAAAGAUAC	600	GUACUJUJUCCACAGCCAGG	1338
UGUIUUUCAGCAUUAUCAGA	601	UGUIUUUCAGCAUUAUCAGA	601	UCUGAUAAUGCUGAAAACA	1339
ACCUAGAACUUUAAAUGCA	602	ACCUAGAACUUUAAAUGCA	602	UGCAUJUAAAGUUCUAGGU	1340
GGGAUGGAAAGGAUCACCA	603	GGGAUGGAAAGGAUCACCA	603	UGGUGAUCCUUUCAUCCC	1341
AAUAAAAGCCAGGAUGGA	604	AAUAAAAGCCAGGAUGGA	604	UCCAUUJUCCGGUUUAUU	1342
AAAGGAAUUGGAGGAAAG	605	AAAGGAAUUGGAGGAAAG	605	CAUUCUCCUCAUUCUU	1343
ACUUUCGGCUGGGACUUU	606	ACUUUCGGCUGGGACUUU	606	AAAGGUCCCCAGGGAAAGU	1344

ACAGAAGAAAAAAAG	607	ACAGAAGAAAAAAAG	607	CUUUUUUUUUUUUCUGU	1345
AGCAACAGACAUACAAACU	608	AGCAACAGACAUACAAACU	608	AGUUUGUAUGUCUGUUGCU	1346
UAUUGUCUGGUUAUGUGCA	609	UAUUGUCUGGUUAUGUGCA	609	UGCACUUAUCCAGACAAUA	1347
UUAAAAGAAAAGGGGGAU	610	UUAAAAGAAAAGGGGGAU	610	AUCCCCCUUUUUUUUUUA	1348
UGCUUAGGCCUCAUAAAAG	611	UGCUUAGGCCUCAUAAAAG	611	CUUUAUUGGGCUUAAGCA	1349
CAGGAAGAUGGCCAGUAAA	612	CAGGAAGAUGGCCAGUAAA	612	UUACUGGCCAUUCUCCUG	1350
CCAGAUGAGAAGCAAGG	613	CCAGAUGAGAAGCAAGG	613	CCUUGGUUCUCUCAUCUGG	1351
GAUUGGGGGGUACAGUGCA	614	GAUUGGGGGGUACAGUGCA	614	UGCACUGUACCCCCCAAUC	1352
AAAUGAACAAAGUAGAUAAA	615	AAAUGAACAAAGUAGAUAAA	615	UUUAUUCUACUUUUCAUUUU	1353
AGCCACCUUUGCCUAGUGU	616	AGCCACCUUUGCCUAGUGU	616	ACACUAGGCAAAGGGGGCU	1354
GACUUUCCGCUGGGACUU	617	GACUUUCCGCUGGGACUU	617	AAGUCCCCAGGGGAAAGUC	1355
CCAGUAAAUAAGGCCAG	618	CCAGUAAAUAAGGCCAG	618	CUGGCUUUUUUUUUACUGG	1356
GCAAUGUAUGCCCCCUCCCA	619	GCAAUGUAUGCCCCCUCCCA	619	UGGAGGGGCAUACAUUGC	1357
AAUCUUAAAUGCAUGGGUA	620	AAUCUUAAAUGCAUGGGUA	620	UACCCAUUGCAUUUAAAAGUU	1358
UUGGGGGGUACAGUGCAGG	621	UUGGGGGGUACAGUGCAGG	621	CCUGCACUGUACCCCCCAA	1359
GGACUUUCCGCUGGGGACU	622	GGACUUUCCGCUGGGGACU	622	AGUCCOCAGGGAAAAGUCC	1360
CUAGAACUUAAAUGCAUG	623	CUAGAACUUAAAUGCAUG	623	CAUGCAUUUAAAAGUUCUAG	1361
UCAGUACAAUGGGCUUCCA	624	UCAGUACAAUGGGCUUCCA	624	UGGAAGCACAUUGGUACUGA	1362
AAGGAAAUUGGGAAAUGA	625	AAGGAAUUGGGAAAUGA	625	UCAUUUUCCUCAUUCCUU	1363
UACCCACAGACCCCAACCC	626	UACCCACAGACCCCAACCC	626	GGGUUGGGGUUGGGGUUA	1364
GAGACAGGCCAAUUUUUA	627	GAGACAGGCCAAUUUUUA	627	UAAAAAUUAGCCUGUCUC	1365
CUGCUUAGGCCUCAUAAA	628	CUGCUUAGGCCUCAUAAA	628	UUIAUUAGGGCUUJAAGCAG	1366
AGGAAGAUGGCCAGUAAA	629	AGGAAGAUGGCCAGUAAA	629	UUUUAUUGGCCAUUCUCCU	1367
AGACAUACAAACUAAAGAA	630	AGACAUACAAACUAAAGAA	630	UUCUUUAGUUUGGUAGUCU	1368
CAUGUUUUCAGCAUUAUCA	631	CAUGUUUUCAGCAUUAUCA	631	UGUAUAUGCUGAAAACAUG	1369
UUGGAAAGGACCAGCAAAG	632	UUGGAAAGGACCAGCAAAG	632	CUUJGCUUGGUCCUUUCCAA	1370
GGCUGUUGGAAAUGGGAA	633	GGCUGUUGGAAAUGGGAA	633	UCCACAUUUUCCAAAGCC	1371.
UUAAAUGGAGAAAAAUAGUA	634	UUAAAUGGAGAAAAAUAGUA	634	UACUAUUUUUCUCCAUUUA	1372
AGGAAGAAGGGAGACAGC	635	AGGAAGAAGGGAGACAGC	635	GCUGUCUCCGGCUUUCUCC	1373
AAAAAAAGAAAUAUCAGUA	636	AAAAAAAGAAAUAUCAGUA	636	UACUGAUUUUUUCUUUUUU	1374
AUCAGAAAGAACCUCCAUU	637	AUCAGAAAGAACCUCCAUU	637	AAUGGGGUUCUUCUJGAU	1375
AGACCCCAACCCACAAAGAA	638	AGACCCCAACCCACAAAGAA	638	UUCUJGUGGGGUUGGGGU	1376
CAAGUAGAUAAAUCAGUA	639	CAAGUAGAUAAAUCAGUA	639	UGACUAUUUAUCUACUJG	1377
AAAGCUUAGGUACAGUAU	640	AAAGCUUAGGUACAGUAU	640	AUACUGUACCUAUAGCJUU	1378
UGCUGCAUUAAGCAGCUG	641	UGCUGCAUUAAGCAGCUG	641	CAGCUGCUUUAUGGCAGCA	1379
UUAAAUGCAUGGGUAAA	642	UUAAAUGCAUGGGUAAA	642	UUUACCAUGCAUUAAA	1380

UUUCAGCAUUAUCAGAAG	643	UUUCAGCAUUAUCAGAAG	643	CUUCUGAUAAUGCUGAAAAA	1381
ACUGCUUAGCCUCAAUAA	644	ACUGCUUAGCCUCAAUAA	644	UUAUUGAGGCUUAGCAGU	1382
GGAAAGGACCAAGCAAGCU	645	GGAAAGGACCAAGCAAGCU	645	AGCUUUGCUGGUCCUUUCC	1383
UGUACCAGUAAAUAAG	646	UGUACCAGUAAAUAAG	646	CUUUAUUUUACUGGUACAA	1384
GAAGAAAAAAAAGCAU	647	GAAGAAAAAAAAGCAU	647	AUGCUUUUUUUUUUCUUC	1385
GUGUACCCACAGACCCCAA	648	GUGUACCCACAGACCCCAA	648	UGGGGGUUCUGGGGUACAC	1386
GGGGGAAUJGGGGUACAA	649	GGGGGAAUJGGGGUACAA	649	UGUACCCCCAAUCCCCCC	1387
GGAAAGAAGGGGAGACAGCG	650	GGAAAGAAGGGGAGACAGCG	650	CGCUGUCUCCGCUUCUUC	1388
GAAGCGGAGACAGCGACGA	651	GAAGCGGAGACAGCGACGA	651	UCGUCGUCUGCUCCGCUUC	1389
UJAAAUGCAUGGGUAAAAG	652	UJAAAUGCAUGGGUAAAAG	652	CUUUUACCCAUGCAUUAAA	1390
AAACCCACUGCUUAGCCUC	653	AAACCCACUGCUUAGCCUC	653	GAGGCUUAAAGCAGUGGGUU	1391
GUUUUCAGCAUUAUCAGAA	654	GUUUUCAGCAUUAUCAGAA	654	UUCUGAUAAUGCUGAAAAC	1392
GGAUUAAAUAUAGUAAA	655	GGAUUAAAUAUAGUAAA	655	UUACUAAUUAUUAUUAUCC	1393
GUACCCACAGACCCCAACC	656	GUACCCACAGACCCCAACC	656	GGUUGGGGUUCUGGGGUAC	1394
GAUUAAAUAUAGUAAAAG	657	GAUUAAAUAUAGUAAAAG	657	CUUACUAAUUAUUAUUAUUC	1395
AAGCCUCUAAAAGCUUUGC	658	AAGCCUCUAAAAGCUUUGC	658	GCAAGCUCUUAUUGAGGCUU	1396
GCAGGGACAUAAACAGGUAG	659	GCAGGGACAUAAACAGGUAG	659	CUACCUUGUUUAUGGUCCUGC	1397
CCCACUGCUUAGCCUCAA	660	CCCACUGCUUAGCCUCAA	660	UUGAGGCUUAAAGCAGUGGG	1398
GGGACUUCCGGCUGGGAC	661	GGGACUUCCGGCUGGGAC	661	GUCCCCAGCGGAAAGGUCCC	1399
AUCACCUAGAACUAAAUAU	662	AUCACCUAGAACUAAAUAU	662	AUUUAAAGUUCUAGGUGAU	1400
UAGAGCCUCGGAAAGCAUCC	663	UAGAGCCUCGGAAAGCAUCC	663	GGAUUGCUUCCAGGGCUCUA	1401
GGCGCUGUJGGAAAUGGGA	664	GGCGCUGUJGGAAAUGGGA	664	UCCACAUUUCCAACAGGCC	1402
UUUCAGCAUUAUCAGAAGG	665	UUUCAGCAUUAUCAGAAGG	665	CCUUCUGAUAAUGCUGAAA	1403
UGACCCAUCAAAAGCUUA	666	UGACCCAUCAAAAGCUUA	666	UAAGUUCUUUUGAUGGGUCA	1404
AGAAAAAAUAAAAGCAUUA	667	AGAAAAAAUAAAAGCAUUA	667	UAUUGCUUUUAUUUUUUCU	1405
AGAAAGGGAGACAGCGACG	668	AGAAAGGGAGACAGCGACG	668	CGUCGCUGUCUCCGCUUCU	1406
AGAAAAAAUAAAAGCAUUA	669	AGAAAAAAUAAAAGCAUUA	669	AAUGCUUUUAUUUUUUCU	1407
AUUGGAGAAAAUJGUAGA	670	AUUGGAGAAAAUJGUAGA	670	UCUACUAAUUUUCUCCAUU	1408
GCUGAACACAUUAAGACAG	671	GCUGAACACAUUAAGACAG	671	CUGUCUUAAGAUGGUUCAGC	1409
AAAAAGAAAAAUACAGUAA	672	AAAAAGAAAAAUACAGUAA	672	UUACUGAUUUUUUCUUUUU	1410
GAACAAGCCCCAGAAGACC	673	GAACAAGCCCCAGAAGACC	673	GGUCUUCUGGGGUUGGUUC	1411
GUGAUAAAUGUCAGCUAAA	674	GUGAUAAAUGUCAGCUAAA	674	UUUAGCUGACAUUAUCAC	1412
GAGCCCUUGGAAGCAUCCAG	675	GAGCCCUUGGAAGCAUCCAG	675	CUGGAUGCUUCCAGGGCUC	1413
AGUGGGGGGACAUCAAGCA	676	AGUGGGGGGACAUCAAGCA	676	UGCUUGAUUGUCCCCCACU	1414
GCCUGGGAGGCUCUCUGGCU	677	GCCUGGGAGGCUCUCUGGCU	677	AGCCAGAGAGCUCCAGGC	1415
UGGAAAGGACCAAGCAAGC	678	UGGAAAGGACCAAGCAAGC	678	GCUUUGCUGGUCCUUUCCA	1416

AGCAGGACAUAAACAAGGU	679	AGCAGGACAUAAACAAGGU	679	UACCUUUGUUUAUGUCCUGGU	1417
CCUAGAACUUAAUGCAU	680	CCUAGAACUUAAUGCAU	680	AUGCAUUAAAAGUUCUAGG	1418
AGUAGAUAAAUAUGCAGU	681	AGUAGAUAAAUAUGCAGU	681	ACUGACAUAAAUAUCUACU	1419
AAAUUAAAAGCCAGGAUGG	682	AAAUUAAAAGCCAGGAUGG	682	CCAUUCUGGUUUAUUUUU	1420
AGUAAAUAUAAAAGCAGGA	683	AGUAAAUAUAAAAGCAGGA	683	UCCUGGGUUUAUUUUUACU	1421
UGUGAUAAAUGUCAGCUAA	684	UGUGAUAAAUGUCAGCUAA	684	UUAGCGACAUAAAUCACAU	1422
AGCCUGGGAAGCAUCCAGG	685	AGCCUGGGAAGCAUCCAGG	685	CCUGGAUGGUUCCAGGGGU	1423
CACUGCUUAAGCCUCAAAU	686	CACUGCUUAAGCCUCAAAU	686	UAUUAGGGGUUAAAGCAGUG	1424
AAAAAAUUCAGUAACAGUAC	687	AAAAAAUUCAGUAACAGUAC	687	GUACUGGUUACGUUUUUU	1425
GAGCCUGGGGAGCUCUGG	688	GAGCCUGGGGAGCUCUGG	688	CCAGAGAGCUCCCAAGGGUC	1426
UUCGGCUGGGGACUUCCA	689	UUCGGCUGGGGACUUCCA	689	UGGAAAGUCCCCAGGGAA	1427
GAGAGACAGGGCUAAUUUU	690	GAGAGACAGGGCUAAUUUU	690	AAAAAUUJAGCCUGUCUC	1428
GCUGUGAUAAAUGUCAGCU	691	GCUGUGAUAAAUGUCAGCU	691	AGCGACAUAAAUCACAGC	1429
CCACAGACCCCAACCCACA	692	CCACAGACCCCAACCCACA	692	UGUGGGUUGGGGUUGUGGG	1430
CAGGAAGAAGGGAGACAG	693	CAGGAAGAAGGGAGACAG	693	CUGUCUCCGGCUUCUCCUG	1431
UAAGCCUCAAUAAAGCUUJG	694	UAAGCCUCAAUAAAGCUUJG	694	CAAGCUUUAUGAGGGCUUA	1432
UAAAAAAAGAAAAAAUCAGU	695	UAAAAAAAGAAAAAAUCAGU	695	ACUGAUUUUUUUUUUUA	1433
GACAGAAAGAAAAAAUAAA	696	GACAGAAAGAAAAAAUAAA	696	UUUUUUUUUUUUUUUUU	1434
GUACCGAGUAAAUAAGC	697	GUACCGAGUAAAUAAGC	697	GCUUUUAUUUUUACUGGUAC	1435
AAAAAGAAAAAAUCAGUAC	698	AAAAAGAAAAAAUCAGUAC	698	GUUACUGAUUUUUUUUUU	1436
AAAAAAUCAGUAACAGUACU	699	AAAAAAUCAGUAACAGUACU	699	AGUACUGUUACUGAUUUUU	1437
AGAGCCCCUGGAAGCAUCCA	700	AGAGCCCCUGGAAGCAUCCA	700	UGGAUGGUUCCAGGGGUU	1438
CAGGGGCAAAUGGGUACAU	701	CAGGGGCAAAUGGGUACAU	701	GAUGUACUUUGCCCCUG	1439
CUGCAUUAUACCAUACCUAG	702	CUGCAUUAUACCAUACCUAG	702	CUAGGUUAGGUAAAUGCAG	1440
UAAAUGCAUGGGUAAAAGU	703	UAAAUGCAUGGGUAAAAGU	703	ACUUUUACCCAUUGGUUUUA	1441
AAGUAAAACAUAGUAACAGA	704	AAGUAAAACAUAGUAACAGA	704	UCUGUUACGUUUACUJU	1442
CCACACAUUCCUGGUUACC	705	CCACACAUUCCUGGUUACC	705	GGUACACAGGGCAUGUGGG	1443
AGUAGAUUUCAGGAACUU	706	AGUAGAUUUCAGGAACUU	706	AAGUUUCUGGAAUACUACU	1444
CAUCAGAAAAGAACCUCAU	707	CAUCAGAAAAGAACCUCAU	707	AUGGAGGUUUCUUCUGUAG	1445
ACCAAGAAAUAUAAAAGCCA	708	ACCAAGAAAUAUAAAAGCCA	708	UGGCUUUUAUUUJACUGGU	1446
CACAGACCCCAACCCACAA	709	CACAGACCCCAACCCACAA	709	UUGGGGUUGGGGUUGGG	1447
AGGGGGGAUGGGGGUAC	710	AGGGGGGAUGGGGGUAC	710	GUACCCCCCACUCCCCU	1448
UGCAUUAUACCUACUAGU	711	UGCAUUAUACCUACUAGU	711	ACUAGGUUAGGUAAAUGCA	1449
CAAUGGACAUACAUAAUJU	712	CAAUGGACAUACAUAAUJU	712	AAAUUUAGAUAGGUCAUJG	1450
CUGAACAUUACUUAAGACAGC	713	CUGAACAUUACUUAAGACAGC	713	GCUGUCUUAGAUGUUCAG	1451
GCCUCAAUAAAAGCUUGCCU	714	GCCUCAAUAAAAGCUUGCCU	714	AGGCAAGGUUUUAUGAGGC	1452

(400/099)

UGUACCCACAGACCCAAC	715	UGUACCCACAGACCCAAC	715	GUUGGGGUCUGGGGUACA	1453
GAAGUAAAACAUAGUAACAG	716	GAAGUAAAACAUAGUAACAG	716	CUGUUACUAUGUUUACUUC	1454
GUAGGACCUACACCUGUCA	717	GUAGGACCUACACCUGUCA	717	UGACAGGUGUAGGUCCUAC	1455
CAGUGGGGGACAUCAAGC	718	CAGUGGGGGACAUCAAGC	718	GCUUUGAUUGUCCCCCACUG	1456
ACCCACACUGCUUAAGCCUCA	719	ACCCACACUGCUUAAGCCUCA	719	UGAGGGCUUAAGCAGUGGGU	1457
AAAAAAUUGGGCUGAAAAAU	720	AAAAAAUUGGGCUGAAAAAU	720	AUUUUCAGGCCAACUUUUU	1458
UGGGGGGACAUCAAGCAGC	721	UGGGGGGACAUCAAGCAGC	721	GCUGCUUGAUUGCCCCCA	1459
GUACAAAUGGCAGUAUUCAG	722	GUACAAAUGGCAGUAUUCAG	722	UGAAUACUGGCCAUJUGUAC	1460
AAGCUUAUAGGUACAGUAAU	723	AAGCUUAUAGGUACAGUAAU	723	AAUACUGUACCUAUAGCUU	1461
CAGAAGAAAAAAUAAAAGC	724	CAGAAGAAAAAAUAAAAGC	724	GCUUUUUUUCUUCUUCUG	1462
AAAUGGCAUGGGGUAAAAGUA	725	AAAUGGCAUGGGGUAAAAGUA	725	UACUUUUUACCCAUJGCAUU	1463
AGCCUCAAAUAAAAGCUUGCC	726	AGCCUCAAAUAAAAGCUUGCC	726	GGCAAGCUUUUUAGGGCU	1464
CCACUGCUUAAGCCUCUAAU	727	CCACUGCUUAAGCCUCUAAU	727	AUGAGGCUUAGCAGUGGG	1465
AAGAAGGGGAGACAGGCGAC	728	AAGAAGGGGAGACAGGCGAC	728	GUCCGUUGUCCGGCUUCU	1466
AAAUGGAGAAAAAUUAGUAG	729	AAAUGGAGAAAAAUUAGUAG	729	CUACUAAUUUUCCUAAUU	1467
AGCCUGGGAGGCUCUCUGGC	730	AGCCUGGGAGGCUCUCUGGC	730	GCCAGAGAGCUCCAGGCU	1468
AACAAGCCCCAGAAGACCA	731	AACAAGCCCCAGAAGACCA	731	UGGUCUUCUGGGCUUGUU	1469
UACCAAGUAAAUAAGCC	732	UACCAAGUAAAUAAGCC	732	GGCUUUUUUUACUGGUA	1470
UUCAAAAAAUUGGGCUGAA	733	UUCAAAAAAUUGGGCUGAA	733	UUCAGGGCCAAUUUUUGAA	1471
AGAAGAAAAAAUAAAAGCA	734	AGAAGAAAAAAUAAAAGCA	734	UGCUUUUUUUUUUCUUCU	1472
CUGUGUACCCACAGACCCC	735	CUGUGUACCCACAGACCCC	735	GGGGUCUGGGGUACACAG	1473
GCCUGUACUGGGGUUCUCU	736	GCCUGUACUGGGGUUCUCU	736	AGAGAGACCCAGUACAGGC	1474
CAGUAAAUAAGCCAGG	737	CAGUAAAUAAGCCAGG	737	CCUGGCCUUUUUUACUG	1475
UACAAAUGGCAGUAUUCAU	738	UACAAAUGGCAGUAUUCAU	738	AUGAAUACUGGCCAUUUUGUA	1476

The 3'-ends of the Upper sequence and the Lower sequence of the siNA construct can include an overhang sequence, for example about 1, 2, 3, or 4 nucleotides in length, wherein the overhanging sequence of the lower sequence is optionally complementary to a portion of the target sequence. The upper sequence is also referred to as the sense strand, whereas the lower sequence is also referred to as the antisense strand. The upper and lower sequences in the Table can further comprise a chemical modification having Formulae I-VII or any combination thereof.

Table III: HIV Synthetic Modified siRNA constructs

Target Pos	Target	Seq ID	RPI#	Aliases	Sequence	Seq ID
1399	ACCAUCAAUGAGGAAGCUG	36		HIV43:1399U21 siRNA sense	ACCAUCAAUGAGGAAGCUGTT	1483
2323	UAGAUACAGGAGCAGAUGA	8		HIV43:2323U21 siRNA sense	UAGAUACAGGAGCAGAUGATT	1484
2328	ACAGGAGCAGAUGAUACAG	5		HIV43:2328U21 siRNA sense	ACAGGAGCAGAUGAUACAGTT	1485
4930	UUUGGAAGGACCAAGCAA	1		HIV43:4930U21 siRNA sense	UUUGGAAGGACCAAGCAAATT	1486
5077	GUAGACAGGAUGAGGAUUA	4		HIV43:5077U21 siRNA sense	GUAGACAGGAUGAGGAUUAATT	1487
5955	CUUAGGCAUCUCCUAUGGC	99		HIV43:5955U21 siRNA sense	CUUAGGCAUCUCCUAUGGCTT	1488
5982	GGGGAGACAGCGGAAGAA	1477		HIV43:5982U21 siRNA sense	GGGGAGACAGCGGAAGAAATT	1489
8499	GCCUGUGGCCUUCUAGCUA	1478		HIV43:8499U21 siRNA sense	GCCUGUGGCCUUCUAGCUAATT	1490
1399	ACCAUCAAUGAGGAAGCUG	36		HIV43:1417L21 siRNA (1399C) antisense	CAGCUUCCUCAUUGAUGGUU	1491
2323	UAGAUACAGGAGCAGAUGA	8		HIV43:2341L21 siRNA (2323C) antisense	UCAUCUGGUCCUCCUACUATT	1492
2328	ACAGGAGCAGAUGAUACAG	5		HIV43:2346L21 siRNA (2328C) antisense	CUGUAUCAUCUGGUCCUUGUTT	1493
4930	UUUGGAAGGACCAAGCAA	1		HIV43:4948L21 siRNA (4930C) antisense	UUUGGUCCUUCUCCAAATT	1494
5077	GUAGACAGGAUGAGGAUUA	4		HIV43:5095L21 siRNA (5077C) antisense	UAAUCCUCAUCUGUACUACTT	1495
5955	CUUAGGCAUCUCCUAUGGC	99		HIV43:5973L21 siRNA (5955C) antisense	GCCAUAGGAGAUGCCUAAAGTT	1496
5982	GGGGAGACAGCGGAAGAA	1477		HIV43:6000L21 siRNA (5982C) antisense	UCUUUGUGCCUGUCUCCGCTT	1497
8499	GCCUGUGGCCUUCUAGCUA	1478		HIV43:8517L21 siRNA (8499C) antisense	UAGCUGAAAGGGACAGGCTT	1498
1399	ACCAUCAAUGAGGAAGCUG	36		HIV43:1399U21 siRNA stab04 sense	B AccAUAAUGAGGAAGCugTT B	1499
2323	UAGAUACAGGAGCAGAUGA	8		HIV43:2323U21 siRNA stab04 sense	B uAGAUAcAGGAAGCAGAUAGATT B	1500
2328	ACAGGAGCAGAUGAUACAG	5		HIV43:2328U21 siRNA stab04 sense	B AcAGGAGCAGAUGAUACAGTT B	1501
4930	UUUGGAAGGACCAAGCAA	1		HIV43:4930U21 siRNA stab04 sense	B uuUGGAAGGACCAAGCAAATT B	1502
5077	GUAGACAGGAUGAGGAUUA	4		HIV43:5077U21 siRNA stab04 sense	B GuAGAcAGGAUGAGGAuWATT B	1503
5955	CUUAGGCAUCUCCUAUGGC	99		HIV43:5955U21 siRNA stab04 sense	B cuuAGGcAucuccuAuGGcTT B	1504
5982	GCGGAGACAGCGGAAGAA	1477		HIV43:5982U21 siRNA stab04 sense	B GeGAGAcAGGcGAAAGATT B	1505
8499	GCCUGUGGCCUUCUAGCUA	1478		HIV43:8499U21 siRNA stab04 sense	B GcuGUGccuccuAGcuaATT B	1506
1399	ACCAUCAAUGAGGAAGCUG	36		HIV43:1417L21 siRNA (1399C) stab05 antisense	cAGcuccuAuGAuGGTtST	1507
2323	UAGAUACAGGAGCAGAUGA	8		HIV43:2341L21 siRNA (2323C) stab05 antisense	ucAucuGcucuGuAucuATtST	1508
2328	ACAGGAGCAGAUGAUACAG	5		HIV43:2346L21 siRNA (2328C) stab05 antisense	cugUAucAucuGcucuGuTtST	1509
4930	UUUGGAAGGACCAAGCAA	1		HIV43:4948L21 siRNA (4930C) stab05 antisense	uuuGcuGGuccuuuccAAATsT	1510
5077	GUAGACAGGAUGAGGAUUA	4		HIV43:5095L21 siRNA (5077C) stab05 antisense	uAAucucuAucuGuActsT	1511
5955	CUUAGGCAUCUCCUAUGGC	99		HIV43:5973L21 siRNA (5955C) stab05 antisense	GccAUAGGAGAUGccuAAAGTsT	1512
5982	GCGGAGACAGCGGAAGAA	1477	31236	HIV43:6000L21 siRNA (5982C) stab05 antisense	ucuucGcGcGcGucccGcTsT	1513
8499	GCCUGUGGCCUUCUAGCUA	1478	31237	HIV43:8517L21 siRNA (8499C) stab05 antisense	uAGcUGAAAGAGGcAcAGGcTsT	1514
1399	ACCAUCAAUGAGGAAGCUG	36		HIV43:1399U21 siRNA stab07 sense	B AccAuAAuGAGGAAGCugTT B	1515

2323	UAGAUACAGGAGCAUGA	8	HIV43:2323U21 siRNA stab07 sense	B uAGAUACAGGAGCAUGAATT B	1516
2328	ACAGGGAGCAGAUGAUACAG	5	HIV43:2328U21 siRNA stab07 sense	B AcAGGGAGCAGAUGAUACAGTT B	1517
4930	UUUGGAAAGGACCAAGCAA	1	HIV43:4930U21 siRNA stab07 sense	B uuUGGAAAGGACCAAGCAAATT B	1518
5077	GUAGACAGGAUGGGAUUA	4	HIV43:5077U21 siRNA stab07 sense	B GuAGACAGGAUGGGAUUAATT B	1519
5955	CUUAGGGCAUCUCCUAUGGC	99	HIV43:5955U21 siRNA stab07 sense	B cuuAGGGCAUCUCCUAUGGCATT B	1520
5982	GCGGAGGACAGCGACGAAGA	1477	HIV43:5982U21 siRNA stab07 sense	B GcGAGACAGCGACGAAGATT B	1521
8499	GCCUGUGGCCUCUAGCUA	1478	HIV43:8499U21 siRNA stab07 sense	B GccuGUCucuAGCuuATT B	1522
1399	ACCAUCAAUGAGGAAGCUG	36	HIV43:1417L21 siRNA (1399C) stab11 antisense	cAGuuuccuAUuGAuGGuTsT	1523
2323	UAGAUACAGGAGCAUGA	8	HIV43:2341L21 siRNA (2323C) stab11 antisense	ucAucuGcucuGuAucuATsT	1524
2328	ACAGGGAGCAGAUGAUACAG	5	HIV43:2346L21 siRNA (2328C) stab11 antisense	cuGuAucAucuGcucuGuTsT	1525
4930	UUUGGAAAGGACCAAGCAA	1	HIV43:4948L21 siRNA (4930C) stab11 antisense	uuuGcuGGuccuUuccAAATsT	1526
5077	GUAGACAGGAUGGGAUUA	4	HIV43:5095L21 siRNA (5077C) stab11 antisense	uAUuccuAUuccuGcucuAcTsT	1527
5955	CUUAGGGCAUCUCCUAUGGC	99	HIV43:5973L21 siRNA (5955C) stab11 antisense	GccAuAUGGAGAUGccuAAAGTsT	1528
5982	GCGGAGGACAGCGACGAAGA	1477	HIV43:6000L21 siRNA (5982C) stab11 antisense	ucuucGuccGcuGucccGcTsT	1529
8499	GCCUGUGGCCUCUAGCUA	1478	HIV43:8517L21 siRNA (8499C) stab11 antisense	uAGcuaGAAGAGGcAcAGGcTsT	1530
	AGGGGAAGUGACAUAGCAGGAAC	1479	HIV:1484U21 siRNA stab04 sense	B GGGAAAGuGAcAUAGcAGGATT B	1531
	CAGAGAUGAAAAAGGAAGGGAAA	1480	HIV:2666U21 siRNA stab04 sense	B GAGAUGGAAAAGGAAGGGATT B	1532
	CUUUGGAGGAGGAUAGGGGA	1481	HIV:7633U21 siRNA stab04 sense	B GGAGGGAGGAGAUAGGGTT B	1533
	CUGGGAAAAACAUGGGCAAAUCAC	1482	HIV:8906U21 siRNA stab04 sense	B GGAAAAAAACAuGGAGcAAuucTT B	1534
	AGGGGAAGUGACAUAGCAGGAAC	1479	HIV:1502L21 siRNA (1484C) stab05 antisense	uccuGcuAuGcucAcuucccTsT	1535
	CAGAGAUGAAAAAGGAAGGGAAA	1480	HIV:2684L21 siRNA (2666C) stab05 antisense	uccuuccuAUuccuAucuCTsT	1536
	CUUUGGAGGAGGAUAGGGGA	1481	HIV:7651L21 siRNA (7633C) stab05 antisense	cccuAuAucuccuucccATsT	1537
	CUGGGAAAAACAUGGGCAAAUCAC	1482	HIV:8924L21 siRNA (8906C) stab05 antisense	GauGcucuAUGuuuuuccTsT	1538
	ACCAUCAAUGAGGAAGCUG	36	HIV43:1399U21 siRNA stab09 sense	B CAGCUCUCCUCAUUGAUGGUUT B	1539
	UAGAUACAGGAGCAUGA	8	HIV43:2323U21 siRNA stab09 sense	B UCAUCUGCUCCUGUAUCUATT B	1540
	ACAGGGAGCAGAUGAUACAG	5	HIV43:2328U21 siRNA stab09 sense	B CUGUAUCAUCUGCUCCUGUTT B	1541
	UUUGGAAAGGACCAAGCAA	1	HIV43:4930U21 siRNA stab09 sense	B UUUGCUGGUCCUUUCCAAATT B	1542
	GUAGACAGGAUGGGAUUA	4	HIV43:5077U21 siRNA stab09 sense	B UAAUCUCAUCUJGUCUACUTT B	1543
	CUUAGGGCAUCUCCUAUGGC	99	HIV43:5955U21 siRNA stab09 sense	B GCCAUAGGGAGAUGCCUAGTT B	1544
	GCGGAGGACAGCGACGAAGA	1477	HIV43:5982U21 siRNA stab09 sense	B UCUUUCGUCGCGUCUCCGCTT B	1545
	GCCUGUGGCCUCUAGCUA	1478	HIV43:8499U21 siRNA stab09 sense	B UAGCUGAAAGGGACAGGCCTT B	1546
	ACCAUCAAUGAGGAAGCUG	36	HIV43:1417L21 siRNA (1399C) stab10 antisense	CAGCUCUCCUCAUUGAUGGUUT	1547
	UAGAUACAGGAGCAUGA	8	HIV43:2341L21 siRNA (2323C) stab10 antisense	UCAUCUGCUCCUGUAUCUATsT	1548
	ACAGGGAGCAGAUGAUACAG	5	HIV43:2346L21 siRNA (2328C) stab10 antisense	CUGUAUCAUCUGCUCCUGUTsT	1549
	UUUGGAAAGGACCAAGCAA	1	HIV43:4948L21 siRNA (4930C) stab10 antisense	UUUGCUGGUCCUUUCCAAATsT	1550
	GUAGACAGGAUGGGAUUA	4	HIV43:5095L21 siRNA (5077C) stab10 antisense	UAAUCCUCAUCUGCUUACTsT	1551
	CUUAGGGCAUCUCCUAUGGC	99	HIV43:5973L21 siRNA (5955C) stab10 antisense	GCCAUAAGGAGAUGGCCUAAAGTsT	1552
	GCGGAGGACAGCGACGAAGA	1477	HIV43:6000L21 siRNA (5982C) stab10 antisense	UCUUCGUCGCGUCUCCGGCTsT	1553

CCUGUGCCUCUAGCUA	1478	31233	HIV43:8517L21 siRNA (8499C) stab10 antisense	UAGCUGAAGGGCACAGGCTsT	1554
GGGGAGACAGCAGAAGA	1477	31234	HIV43:5982U21 siRNA stab04 sense	B uuuucGuccGcuGuccGGCTT B	1555
CCUGUGCCUCUAGCUA	1478	31235	HIV43:8499U21 siRNA stab04 sense	B uAGcGAAAGGGAcAGGCTT B	1556
GGGGAGACAGCAGAAGA	1477	31238	HIV43:5982U21 siRNA stab07 antisense	B uuuucGuccGcuGuccGGCTT B	1557
CCUGUGCCUCUAGCUA	1478	31239	HIV43:8499U21 siRNA stab07 antisense	B uAGcGAAAGGGAcAGGCTT B	1558
ACCAUCAAUGAGGAAGCUG	36	31242	HIV43:1399U21 siRNA inv stab09 sense	B GUCCAGGGAGUAACUACCATT B	1559
UAGAUACAGGAGGAGAUGA	8	31243	HIV43:2323U21 siRNA inv stab09 sense	B AGUAGACGGAGACAUAGAUtt B	1560
ACAGGAGGAGAUGAUACAG	5	31244	HIV43:2328U21 siRNA inv stab09 sense	B GACAUAGUAGACGGAGACATT B	1561
UUUGGAAAGGACCAAGCAA	1	31245	HIV43:4930U21 siRNA inv stab09 sense	B AACCGACCAAGGAAAGGUUUTT B	1562
GUAGACAGGAUGAGGAUUA	4	31246	HIV43:5077U21 siRNA inv stab09 sense	B AUUAGGAGUAGGAGACAGAUGTT B	1563
CUUAGGCAUCUCCUAUGGC	99	31247	HIV43:5955U21 siRNA inv stab09 sense	B CGGUAAUCCUCUACGGAUUCTT B	1564
GGGGAGACAGCAGGAAGA	1477	31248	HIV43:5982U21 siRNA inv stab09 sense	B AGAAGGAGGACAGAGGGGTT B	1565
CCUGUGCCUCUAGCUA	1478	31249	HIV43:8499U21 siRNA inv stab09 sense	B AUCGACUUUCUCCGGUGUCCGGTT B	1566
ACCAUCAAUGAGGAAGCUG	36	31250	HIV43:1417L21 siRNA (1399C) inv stab10 antisense	UGGUAGUUAACUCCUUGGACTsT	1567
UAGAUACAGGAGGAGAUGA	8	31251	HIV43:2341L21 siRNA (2323C) inv stab10 antisense	AUCUAUGGUCCUGGUACUACUTsT	1568
ACAGGAGGAGAUGAUACAG	5	31252	HIV43:2346L21 siRNA (2328C) inv stab10 antisense	UGUCCUCGUACUAAUGUUCTsT	1569
UUUGGAAAGGACCAAGCAA	1	31253	HIV43:4948L21 siRNA (4930C) inv stab10 antisense	AAACCUUUCCUGGUCCUUIUTsT	1570
GUAGACAGGAUGAGGAUUA	4	31254	HIV43:5095L21 siRNA (5077C) inv stab10 antisense	CAUCUGUCCUACUCCUAAUTsT	1571
CUUAGGCAUCUCCUAUGGC	99	31255	HIV43:5973L21 siRNA (5955C) inv stab10 antisense	GAUUCGGUAGAGGAUACCGGTsT	1572
GGGGAGACAGCAGGAAGA	1477	31256	HIV43:6000L21 siRNA (5982C) inv stab10 antisense	CGCCUCUGUCCUGCUUCUTsT	1573
CCUGUGCCUCUUCAGCUA	1478	31257	HIV43:8517L21 siRNA (8499C) inv stab10 antisense	CGGACACGGAGAAGUGGAUTsT	1574
GGGGAGACAGCAGGAAGA	1477	31258	HIV43:5982U21 siRNA inv stab04 sense	B AGAACGAGCAGAGGGCTT B	1575
CCUGUGCCUCUUCAGCUA	1478	31259	HIV43:8499U21 siRNA inv stab04 sense	B AucGAcuuucuccGuGuccGTT B	1576
GGGGAGACAGCAGGAAGA	1477	31260	HIV43:6000L21 siRNA (5982C) inv stab05 antisense	cGccucuGuccGcuGuccuUTsT	1577
CCUGUGCCUCUUCAGCUA	1478	31261	HIV43:8517L21 siRNA (8499C) inv stab05 antisense	cGGACAcGGAGAAGGcAUtTsT	1578
GGGGAGACAGCAGGAAGA	1477	31262	HIV43:5982U21 siRNA inv stab07 sense	B AGAACGAGCAGAGGGCTT B	1579
CCUGUGCCUCUUCAGCUA	1478	31263	HIV43:8499U21 siRNA inv stab07 sense	B AucGAcuuucuccGuGuccGTT B	1580
GGGGAGACAGCAGGAAGA	1477	31264	HIV43:6000L21 siRNA (5982C) inv stab11 antisense	cGccucuGuccGcuGuccGAUtTsT	1581
CCUGUGCCUCUUCAGCUA	1478	31265	HIV43:8517L21 siRNA (8499C) inv stab11 antisense	cGGACAcGGAGAAGGcAUtTsT	1582

Uppercase = ribonucleotide
u,c = 2'-deoxy-2'-fluoro U, C

T = thymidine

B = inverted deoxy abasic

s = phosphorothioate linkage

A = deoxy Adenosine

G = deoxy Guanosine

Table IV

Non-limiting examples of Stabilization Chemistries for chemically modified siRNA constructs

Chemistry	Pyrimidine	Purine	Cap	p=S	Strand
“Stab 1”	Ribo	Ribo	-	5 at 5'-end 1 at 3'-end	S/AS
“Stab 2”	Ribo	Ribo	-	All linkages	Usually AS
“Stab 3”	2'-fluoro	Ribo	-	4 at 5'-end 4 at 3'-end	Usually S
“Stab 4”	2'-fluoro	Ribo	5' and 3'-ends	-	Usually S
“Stab 5”	2'-fluoro	Ribo	-	1 at 3'-end	Usually AS
“Stab 6”	2'-O-Methyl	Ribo	5' and 3'-ends	-	Usually S
“Stab 7”	2'-fluoro	2'-deoxy	5' and 3'-ends	-	Usually S
“Stab 8”	2'-fluoro	2'-O-Methyl	-	1 at 3'-end	Usually AS
“Stab 9”	Ribo	Ribo	5' and 3'-ends	-	Usually S
“Stab 10”	Ribo	Ribo	-	1 at 3'-end	Usually AS
“Stab 11”	2'-fluoro	2'-deoxy	-	1 at 3'-end	Usually AS

CAP = any terminal cap, see for example Figure 10.

All Stab 1-11 chemistries can comprise 3' -terminal thymidine (TT) residues

All Stab 1-11 chemistries typically comprise 21 nucleotides, but can vary as described herein.

S = sense strand

AS = antisense strand

Table VA. 2.5 μ mol Synthesis Cycle ABI 394 Instrument

Reagent	Equivalents	Amount	Wait Time* DNA	Wait Time* 2'-O-methyl	Wait Time*RNA
Phosphoramidites	6.5	163 μ L	45 sec	2.5 min	7.5 min
S-Ethyl Tetrazole	23.8	238 μ L	45 sec	2.5 min	7.5 min
Acetic Anhydride	100	233 μ L	5 sec	5 sec	5 sec
N-Methyl Imidazole	186	233 μ L	5 sec	5 sec	5 sec
TCA	176	2.3 mL	21 sec	21 sec	21 sec
Iodine	11.2	1.7 mL	45 sec	45 sec	45 sec
Beaucage	12.9	645 μ L	100 sec	300 sec	300 sec
Acetonitrile	NA	6.67 mL	NA	NA	NA

B. 0.2 μ mol Synthesis Cycle ABI 394 Instrument

Reagent	Equivalents	Amount	Wait Time* DNA	Wait Time* 2'-O-methyl	Wait Time*RNA
Phosphoramidites	15	31 μ L	45 sec	233 sec	465 sec
S-Ethyl Tetrazole	38.7	31 μ L	45 sec	233 min	465 sec
Acetic Anhydride	655	124 μ L	5 sec	5 sec	5 sec
N-Methyl Imidazole	1245	124 μ L	5 sec	5 sec	5 sec
TCA	700	732 μ L	10 sec	10 sec	10 sec
Iodine	20.6	244 μ L	15 sec	15 sec	15 sec
Beaucage	7.7	232 μ L	100 sec	300 sec	300 sec
Acetonitrile	NA	2.64 mL	NA	NA	NA

C. 0.2 μ mol Synthesis Cycle 96 well Instrument

Reagent	Equivalents:DNA/ 2'-O-methyl/Ribo	Amount: DNA/2'-O- methyl/Ribo	Wait Time* DNA	Wait Time* 2'-O- methyl	Wait Time* Ribo
Phosphoramidites	22/33/66	40/60/120 μ L	60 sec	180 sec	360sec
S-Ethyl Tetrazole	70/105/210	40/60/120 μ L	60 sec	180 min	360 sec
Acetic Anhydride	265/265/265	50/50/50 μ L	10 sec	10 sec	10 sec
N-Methyl Imidazole	502/502/502	50/50/50 μ L	10 sec	10 sec	10 sec
TCA	238/475/475	250/500/500 μ L	15 sec	15 sec	15 sec
Iodine	6.8/6.8/6.8	80/80/80 μ L	30 sec	30 sec	30 sec
Beaucage	34/51/51	80/120/120	100 sec	200 sec	200 sec
Acetonitrile	NA	1150/1150/1150 μ L	NA	NA	NA

- 5 • Wait time does not include contact time during delivery.
 • Tandem synthesis utilizes double coupling of linker molecule

CLAIMS

What we claim is:


1. A double-stranded short interfering nucleic acid (siNA) molecule that inhibits replication of a human immunodeficiency virus (HIV), wherein one of the strands of said double-stranded siNA molecule is an antisense strand which comprises a nucleotide sequence that is complementary to the nucleotide sequence of an HIV RNA or a portion thereof and the other strand is a sense strand which comprises a nucleotide sequence that is complementary to the nucleotide sequence of the antisense strand and wherein a majority of the pyrimidine nucleotides present in said double-stranded siNA molecule comprises a sugar modification.
5
2. The siNA molecule of claim 1, wherein the HIV RNA comprises HIV-1 RNA.
3. The siNA molecule of claim 1, wherein the HIV RNA comprises HIV-2 RNA.
4. The siNA molecule of claim 1, wherein the siNA molecule comprises no ribonucleotides.
15
5. The siNA molecule of claim 1, wherein the siNA molecule comprises ribonucleotides.
6. The siNA molecule of claim 1, wherein all the pyrimidine nucleotides in the siNA molecule comprise sugar modifications.
20
7. The siNA molecule of claim 6, wherein the modified pyrimidine nucleotides are selected from 2'-deoxy-pyrimidine, 2'-O-alkyl pyrimidine, 2'-C-alkyl pyrimidine, 2'-deoxy-2'-fluoro-pyrimidine, 2'-amino pyrimidine, 2'-methoxy-ethoxy pyrimidine, and 2'-O, 4'-C-methylene pyrimidine nucleotides, alone or in any combination thereof.
25
8. The siNA molecule of claim 7, wherein the 2'-O-alkyl pyrimidine nucleotide is 2'-O-methyl or 2'-O-allyl.
9. The siNA molecule of claim 1, wherein the nucleotide sequence of the antisense strand of the double-stranded siNA molecule is complementary to an RNA encoding an HIV protein or a fragment thereof.
30
10. The siNA molecule of claim 1, wherein each strand of the siNA molecule comprises about 19 to about 29 nucleotides, and wherein each strand comprises at least about 19 nucleotides that are complementary to the nucleotides of the other strand.

11. The siNA molecule of claim 1, wherein said siNA molecule is assembled from two oligonucleotide fragments, wherein one fragment comprises the nucleotide sequence of the antisense strand of the siNA molecule and the second fragment comprises the nucleotide sequence of the sense strand of the siNA molecule.
- 5 12. The siNA molecule of claim 1, wherein the sense strand is connected to the antisense strand via a linker molecule.
13. The siNA molecule of claim 12, wherein said linker molecule is a polynucleotide linker.
- 10 14. The siNA molecule of claim 12, wherein said linker molecule is a non-nucleotide linker.
15. The siNA molecule of claim 1, wherein any pyrimidine nucleotides present in the sense strand are 2'-deoxy-2'-fluoro pyrimidine nucleotides and wherein any purine nucleotides present in the sense region are 2'-deoxy purine nucleotides.
16. The siNA molecule of claim 1, wherein the sense strand comprises a 3'-end and a 5'-end, and wherein a terminal cap moiety is present at the 5'-end, the 3'-end, or both of the 5' and 3' ends of said sense strand.
- 15 17. The siNA molecule of claim 16, wherein said terminal cap moiety is an inverted deoxy abasic moiety.
- 20 18. The siNA molecule of claim 1, wherein the antisense strand comprises one or more 2'-deoxy-2'-fluoro pyrimidine nucleotides and one or more 2'-O-methyl purine nucleotides.
19. The siNA molecule of claim 1, wherein any pyrimidine nucleotides present in the antisense strand are 2'-deoxy-2'-fluoro pyrimidine nucleotides and wherein any purine nucleotides present in the antisense strand are 2'-O-methyl purine nucleotides.
- 25 20. The siNA molecule of claim 1, wherein the antisense strand comprises a phosphorothioate internucleotide linkage at the 3' end of said antisense strand.
21. The siNA molecule of claim 1, wherein the antisense strand comprises a glyceryl modification at the 3' end of said antisense strand.
22. The siNA molecule of claim 1, wherein each strand of the siNA molecule comprises 30 21 nucleotides.

23. The siNA molecule of claim 22, wherein about 19 nucleotides of each strand of the siNA molecule are base-paired to the complementary nucleotides of the other strand of the siNA molecule and wherein at least two 3' terminal nucleotides of each strand of the siNA molecule are not base-paired to the nucleotides of the other strand of the siNA molecule.
5
24. The siNA molecule of claim 23, wherein each of the two 3' terminal nucleotides of each fragment of the siNA molecule are 2'-deoxy-pyrimidines.
25. The siNA molecule of claim 24, wherein the 2'-deoxy-pyrimidine is 2'-deoxy-thymidine.
- 10 26. The siNA molecule of claim 22, wherein 21 nucleotides of each strand of the siNA molecule are base-paired to the complementary nucleotides of the other strand of the siNA molecule.
27. The siNA molecule of claim 22, wherein about 19 nucleotides of the antisense strand are base-paired to the nucleotide sequence of an HIV RNA or a portion thereof.
- 15 28. The siNA molecule of claim 22, wherein 21 nucleotides of the antisense strand are base-paired to the nucleotide sequence of an HIV RNA or a portion thereof.
29. The siNA molecule of claim 1, wherein the 5'-end of the antisense strand optionally includes a phosphate group.
30. The siNA molecule of claim 1, wherein the nucleotide sequence of the antisense strand or a portion thereof is complementary to the nucleotide sequence of the 5'-untranslated region of an HIV RNA or a portion thereof.
20
31. The siNA molecule of claim 1, wherein the nucleotide sequence of the antisense strand or a portion thereof is complementary to the nucleotide sequence of an HIV RNA or a portion thereof that is present in the RNA of all HIV.
- 25 32. A pharmaceutical composition comprising the siNA molecule of claim 1 in an acceptable carrier or diluent.
33. A medicament comprising the siNA molecule of claim 1.
34. An active ingredient comprising the siNA molecule of claim 1.
35. The use of a double-stranded short interfering nucleic acid (siNA) molecule that inhibits replication of a human immunodeficiency virus (HIV), wherein one of the
30

strands of the double-stranded siNA molecule is an antisense strand which comprises a nucleotide sequence that is complementary to the nucleotide sequence of an HIV RNA or a portion thereof and the other strand is a sense strand which comprises a nucleotide sequence that is complementary to the nucleotide sequence of the antisense strand and wherein a majority of the pyrimidine nucleotides present in the double-stranded siNA molecule comprises a sugar modification.

5

Figure 1

= SOLID SUPPORT

R = TERMINAL PROTECTING GROUP

FOR EXAMPLE:

DIMETHOXYTRITYL (DMT)

⁽¹⁾
~~~~~ = CLEAVABLE LINKER  
(FOR EXAMPLE: NUCLEOTIDE SUCCINATE OR  
INVERTED DEOXYABASIC SUCCINATE)

<sup>(2)</sup>  
~~~~~ = CLEAVABLE LINKER  
(FOR EXAMPLE: NUCLEOTIDE SUCCINATE OR
INVERTED DEOXYABASIC SUCCINATE)




Figure 2




Figure 3





Figure 4




POSITIONS (NN) CAN COMprise ANY NUCLEOTIDE, SUCH AS DEOXYNUCLEOTIDES (eg. THYMIDINE) OR UNIVERSAL BASES

B = ABASIC, INVERTED ABASIC, INVERTED NUCLEOTIDE OR OTHER TERMINAL CAP THAT IS OPTIONALLY PRESENT

L = GLYCERYL MOIETY THAT IS OPTIONALY PRESENT

**E = GETCERTE MOIETE HIER IS OF HONTELIJKE PRESENCE
S = PHOSPHOROTHIOATE OR PHOSPHORODITHIOATE**

Figure 5



lower case = 2'-O-Methyl or 2'-deoxy-2'-fluoro

italic lower case = 2'-deoxy-2'-fluoro

underline = 2'-O-methyl

ITALIC UPPER CASE = DEOXY

B = INVERTED DEOXYABASIC

L = GLYCERYL MOIETY OPTIONAL PRESENT

S = PHOSPHOROTHIOATE OR
PHOSPHORODITHIOATE


Figure 6

Figure 7




Figure 8




Figure 9: Target site Selection using siRNA





Figure 10

$\text{R} = \text{O, S, N, alkyl, substituted alkyl, O-alkyl, S-alkyl, alkaryl, or aralkyl}$
 $\text{B} = \text{Independently any nucleotide base, either naturally occurring or chemically modified, or optionally H (abasic).}$

Figure 11: Modification Strategy

